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Summary 
Sudden death and pump failure death are two major modes of death in patients 
with heart failure and reduced ejection fraction (HF-REF) and in patients with 
heart failure and preserved ejection fraction (HF-PEF). There have been 
advances in evidence-based treatments in patients with HF-REF over the last two 
decades, along with the changing patient characteristics in both HF-REF and HF-
PEF populations. It is of great interest and significance to discover if these 
changes have translated into temporal changes (and corresponding trends over 
time) in the risks of sudden death and pump failure death in both populations. 
Apart from examining any changes in the rates of mode-specific death in 
population level, it is also of interest and importance to estimate the risks for 
sudden death and pump failure death in individual patients. Accurate risk 
prediction can aid in better risk stratification. In patients with HF-REF, 
identifying high-risk subgroups would help target the device therapy to those 
most likely to benefit and identifying low-risk subgroups would avoid 
unnecessary implantation, thus improving the cost-effectiveness of the therapy. 
In patients with HF-PEF, identifying high-risk subgroups would enable further 
research into the efficacy of device therapy in this population. The aims of this 
work were to examine the trends in the rates of sudden death and pump failure 
death over time in patients with HF-REF and in patients with HF-PEF, and to 
separately develop validated models to predict sudden death and pump failure 
death in both populations.  
Given that there are limited data on mode-specific death from community-based 
studies, I used data from clinical trials which have more detailed and 
standardised sub-classification and adjudication of mortal events. Besides, 
compared to community-based studies, clinical trials have more detailed 
baseline characterisation, which allows more complete multivariable adjustment 
to account for confounding and between-study differences. Therefore, a cohort 
of 46,163 patients with HF-REF enrolled in 13 clinical trials conducted between 
1995-2015 and a cohort of 10,517 patients with HF-PEF in 3 clinical trials over 
the period 1999-2013 were included in this thesis. Multiple linear regression 
analysis was used to examine the trends in the rates of sudden death and pump 
failure death over time in both populations respectively. The cumulative 
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incidences for sudden death and pump failure death in each trial at different 
time points during follow-up were calculated with the cumulative incidence 
function method, counting the competing risk of death from other causes. The 
risk for each mode of death across trial arms and by HF duration was examined 
using the Cox regression models, with further adjustment for a number of 
confounding variables. The models to predict sudden death and pump failure 
death in patients with HF-REF were separately developed in PARADIGM-HF and 
validated in ATMOSPHERE. Models for both modes of death in HF-PEF were 
developed in I-PRESERVE and validated in CHARM-Preserved as well as TOPCAT. 
These models were constructed using a competing risk approach with the Fine-
Gray sub-distributional hazards regression analysis. Model performance was 
examined by assessing calibration (i.e. the agreement between the observed and 
predicted cumulative incidences over time) and discrimination (i.e. the ability to 
separate patients at higher risk from those at lower risk). 
I found that the risks of sudden death and pump failure death in patients with 
HF-REF have fallen across 13 clinical trials over the period 1995-2015, consistent 
with a cumulative use of evidence-based therapies in this population. The 
absolute rates of sudden death and pump failure death were very low in the 
early follow-up after randomisation in patients with HF-REF who received 
modern evidence-based treatment. Longer standing HF was associated with 
greater risks of sudden death and, particularly, pump failure death in HF-REF.  
The risks of sudden death and pump failure death were consistently low across 
the 3 largest clinical trials in patients with HF-PEF, with little difference by 
experimental treatment in any trial. There was a downward trend in the rates of 
sudden death and pump failure death across these trials over time, in parallel 
with a changing characteristic of patients enrolled in these trials. Nevertheless, 
sudden death and pump failure death remained the most common modes of 
death, altogether accounting for the majority of CV death. The absolute rates of 
sudden death and pump failure death in patients with HF-PEF were extremely 
low in the early follow-up after randomisation. Longer standing HF was 
associated with a slightly higher risk of sudden death and a substantially higher 
risk of pump failure death in HF-PEF. 
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The sudden death and pump failure death models in patients with HF-REF I 
developed in the largest and most contemporary cohort (PARADIGM-HF), 
included a number of variables collected in routine clinical practice, and 
accounted for the prognostic impact of the competing risk of death from other 
causes. The discriminating ability was modest for the sudden death model but 
excellent for the pump failure death model. Both models showed good 
calibration and were robust when externally validated in ATMOSPHERE.  
The prognostic models in patients with HF-PEF I developed in I-PRESERVE, using 
simple demographic and clinical variables, showed good discrimination and 
calibration for both sudden death and pump failure death, and were robust in 
external validation in CHARM-Preserved and TOPCAT. The performance of both 
models was further improved with the inclusion of NT-proBNP. 
In conclusion, I have found that the risks of sudden death and pump failure 
death have declined over time both in patients with HF-REF and in patients with 
HF-PEF based on clinical trial data. The patterns of change in the rates of both 
modes of death over time need to be examined in community-based populations. 
The prognostic models for both modes of death, showing reasonable 
performance, can be considered for use in risk stratification for mode-specific 
death in both populations, aiding in decision making in device therapy in similar 
patients in HF-REF and helping with patient selection for device interventions in 
future trials in HF-PEF.  
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Chapter 1 Introduction and literature review 
In this thesis, I will examine the risks of sudden death and pump failure death 
over time in patients with heart failure and reduced ejection fraction (HF-REF) 
and heart failure and preserved ejection fraction (HF-PEF). I will develop and 
validate models to predict sudden death and pump failure death separately in 
both populations. 
In the first chapter I will give an overview of heart failure (HF), and the two 
major modes of death, i.e. sudden death and pump failure death, in heart 
failure. Thereafter, I will review the literature on prognostic models that have 
been published for sudden death and pump failure death in heart failure. 
In the second chapter I will introduce and describe the datasets and study 
populations used to derive and validate the models before describing the 
statistical methods used for the analyses in this thesis. 
In Chapter 3 I will describe the risks of sudden death and pump failure death 
over time in patients with HF-REF enrolled in the major clinical trials of 
therapies for HF-REF. I will develop risk models to predict sudden death and 
pump failure death separately in patients with HF-REF in Chapter 4 and validate 
them in an independent cohort in Chapter 5. 
In Chapter 6 I will examine the risks of sudden death and pump failure death 
over time in patients with HF-PEF enrolled in the clinical trials in this 
population. I will construct models to predict sudden death and pump failure 
death separately in patients with HF-PEF, and externally validate them in 
independent cohorts in Chapter 7. 
Finally, I will discuss my findings and their implications in Chapter 8. 
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1.1 Overview of heart failure 
1.1.1 Definition and diagnosis of heart failure 
The European Society of Cardiology defines heart failure (HF) as “an abnormality 
of cardiac structure or function leading to failure of the heart to deliver oxygen 
at a rate commensurate with the requirements of the metabolizing tissues, 
despite normal filling pressures (or only at the expense of increased filling 
pressures)”,1 while the American College of Cardiology Foundation 
(ACCF)/American Heart Association (AHA) defines HF as “a complex clinical 
syndrome that results from any structural or functional impairment of 
ventricular filling or ejection of blood”.2 
Irrespective of the definition, clinically, HF is widely recognised as a syndrome 
with typical symptoms (e.g. dyspnoea, fatigue and exercise intolerance) and/or 
signs (e.g. peripheral oedema, elevated jugular venous pressure, pulmonary 
crackles) caused by an abnormality of cardiac structure and/or function.1-3 
These symptoms and signs can be identified based on medical history and 
physical examination, but many of them are non-specific and, therefore, are of 
limited diagnostic value; besides, before clinical symptoms/signs become 
apparent, patients can present with left ventricular dysfunction i.e. 
asymptomatic structural or functional cardiac abnormality, which is associated 
with increased risk of HF and death.4 Consequently, determination of an 
underlying cardiac cause is pivotal to the diagnosis of HF, and this evidence can 
be obtained from plasma natriuretic peptides (NPs) measurements, 
electrocardiographic (ECG) and echocardiographic evaluation.1-3 
1.1.2 Classification of heart failure  
The left ventricular ejection fraction (LVEF) is central to the classification of 
patients with HF, not only because of different underlying aetiologies, 
demographics, comorbidities, prognosis and response to treatment, but also 
because most clinical trials selected patients based on LVEF. Mathematically, 
LVEF is the stroke volume (the end-diastolic volume minus the end-systolic 
volume) divided by the end-diastolic volume in the left ventricle, which is 
usually measured using echocardiography, radionuclide techniques, ventricular 
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angiography or cardiac magnetic resonance imaging; a normal LVEF is generally 
considered to be >50%.  
Based on LVEF, HF is typically classified as HF with reduced ejection fraction 
(HF-REF), HF with preserved ejection fraction (HF-PEF), and HF with mid-range 
ejection fraction (HF-MREF), respectively.2, 3 HF-REF has been variably classified 
as LVEF ≤35%, ≤40%, and <40% in guidelines;1-3 randomised controlled trials 
(RCTs) in HF-REF have mainly enrolled patients with an LVEF ≤35%5, 6 or ≤40%.7, 8 
The diagnosis of HF-PEF requires LVEF ≥50% according to the latest guidelines,2, 3 
and patients with LVEF between 40% and 49% are considered to have HF-MREF.2, 3 
However, historically, the HF-PEF trials used different cut-off values of LVEF 
including >40%9, 10, ≥45%11, 12 and >45%,13 in other words, patients with HF-MREF 
have generally been included in the trials of HF-PEF. The diagnosis of HF-PEF is 
more difficult than the diagnosis of HF-REF because it is largely one of exclusion 
of other potential non-cardiac causes of symptoms suggestive of HF. Patients 
with HF-PEF generally do not have a dilated left ventricle or markedly reduced 
contractility (i.e. systolic dysfunction), but instead have an increase in left 
ventricular wall thickness and left atrial size (reflecting diastolic dysfunction). 
Patients with HF-PEF tend to be older, more often female and obese with a 
history of hypertension and are less likely to have coronary heart disease, 
compared to patients with HF-REF. Overall, prognosis is better in patients with 
HF-PEF than those with HF-REF, although it is only in patients with HF-REF that 
therapies have been shown to reduce morbidity and mortality; none of the 
experimental therapies from RCTs has been demonstrated efficacy in patients 
with HF-PEF to date.  
1.1.3 Incidence and prevalence of heart failure  
The incidence of HF varies largely across studies reflecting difference in the 
diagnostic criteria applied and population studied (demographic composition, 
geographic region and time frame); in general, the reported incidence ranges 
from 1 to 9 cases per 1000 person-years.14-18 Overall, HF occurs more frequently 
in the elderly than in a young population, and the incidence is higher in men 
than in women.19 Data on temporal trends suggest that the incidence of HF may 
have stabilised and possibly be declining over time in both Europe and the 
United states (US). A Swedish study, based on a health register in Stockholm 
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comprising 2.1 million people, reported an age- and sex-adjusted HF incidence 
of 3.8/1000 person-years in 2010 with a 24% decline compared to their national 
health data in 2006.17 This result was echoed by a Scottish national-level study 
based on 5.1 million people, which showed the age-standardised incidence of 
first HF hospitalisation declined from 1.62/1000 person-years in 1994 to 
1.05/1000 person-years in 2003 in men (a very similar trend for women).20 
Likewise, in the Olmsted County cohort from the US, the age- and sex-adjusted 
incidence of HF decreased substantially from 3.2 to 2.2 per 1000 person-years 
between 2000 and 2010, a 37.5% decrease over the decade.16 A decline in the 
incidence was observed both for HF-REF and HF-PEF, but less pronounced in HF-
PEF.16  
HF affects about 1-3% of the adult population in the developed countries: an 
estimated 900,000 people live with HF in the United Kingdom (UK),21 and this 
figure is about 6.5 million (2.5%) in the US.22 Similarly, the estimated prevalence 
of HF is 2.2% in Sweden.17 Overall, the estimated prevalence of HF is over 37.7 
million worldwide.14 The prevalence of HF increases with age, rising from 1.4-
1.9% among those aged 40-59 years to 13.4-14.1% among those ≥80 years of age 
based on the 2011-2014 US National Health and Nutrition Examination Survey.22 
These numbers are commensurate with the previous data from the Rotterdam 
study.23 Despite promising data suggesting the HF incidence is possibly 
decreasing, the prevalence of HF continues to rise, probably driven by the aging 
population, better prognosis of coronary heart disease, and improved survival as 
a result of better treatment and management of this disease.2, 3, 22 The reported 
prevalence of HF-PEF varies from 22% to 73% of all HF cases, depending partly on 
the definition used and population studied, and based on the available data. 
Studies have reported that the proportion of patients with HF-PEF is increasing 
over time.16, 24, 25 
1.1.4 Treatment of heart failure 
The goals of treatment in patients with HF are to relieve symptoms, improve 
functional capacity and quality of life, prevent hospital admission and improve 
survival.  
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Some pharmacological therapies have proven to reduce hospitalisation and 
mortality in patients with symptomatic [New York Heart Association (NYHA) 
functional class II-IV] HF-REF. These include three pivotal neurohumoral 
antagonists, that is, angiotensin converting enzyme inhibitors (ACEI) [or an 
angiotensin receptor blocker (ARB)], a beta-blocker and a mineralocorticoid 
receptor antagonist (MRA), which can modify HF progression and have been 
recommended for treatment in every patient with HF-REF, unless not tolerated 
or contraindicated.1-3 Very recently, in the Prospective comparison of ARNI with 
ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure 
(PARADIGM-HF), LCZ696 or sacubitril/valsartan, a combination of a neprilysin 
inhibitor and an ARB, has demonstrated superiority over enalapril (an ACEI) in 
reducing the risks of both mortality and HF hospitalisation, and is recommended 
as a replacement of ACEIs or ARBs in patients who remain symptomatic despite 
optimal medical therapy and who meet the trial criteria.3, 26, 27 Ivabradine, a 
sinoatrial node modulator, reduces heart rate and has been shown to reduce the 
risk of cardiovascular (CV) death or HF hospitalisation, and has been 
recommended in selected patients with HF-REF in sinus rhythm with a resting 
heart rate ≥70 beats/min.3, 26, 28 In conjunction with these evidence-based 
medications, diuretics are recommended and commonly used to alleviate the 
symptoms of congestion,2, 3 although the effect of diuretics on morbidity and 
long-term survival in patients with HF has yet to be examined. 
For device therapies, cardiac resynchronisation therapy (CRT) has been 
demonstrated to reduce all-cause mortality and hospitalisation for CV causes, 
and relieve symptoms and improve quality of life in selected patients with HF-
REF.29, 30 Accordingly, CRT is recommended in patients with HF-REF and QRS 
duration ≥130 ms and more specific indications are noted in the guidelines.2, 3  
Implantable cardioverter defibrillators (ICDs) are highly effective in correcting 
lethal ventricular tachyarrhythmias. Two landmark trials have provided data on 
the primary prevention of sudden death by an ICD in patients with HF-REF, i.e. 
the Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) in 2002 
and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) in 2005.31, 32 In 
detail, MADIT-II included 1232 patients with a prior myocardial infarction and a 
LVEF ≤30%, and use of an ICD was associated with a 31% reduced risk of overall 
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mortality [Hazard ratio (HR) 0.69, 95% confidence interval (CI) 0.51-0.93, 
p=0.016] and an absolute decrease in the mortality rate of 9% after 3 years (from 
31% to 22%).31 In SCD-HeFT, ICD treatment reduced all-cause death by 23% (HR 
0.77, 95% CI 0.62-0.96, p=0.007) in patients with NYHA class II-III HF and a LVEF 
≤35%, with an absolute reduction in the mortality rate of 7% in 5 years (from 36% 
to 29%).32 The effect on all-cause death did not vary according to the cause of 
HF (p value for interaction 0.68), but there was only a trend in the reduction of 
all-cause death either in the ischaemic (HR 0.79, 97.5% CI 0.60-1.04, p=0.05) or 
non-ischaemic (HR 0.73, 97.5% CI 0.50-1.07, p=0.06) subgroup.32 One year before 
the publication of SCD-HeFT, the Defibrillators in Non-Ischemic Cardiomyopathy 
Treatment Evaluation (DEFINITE) study did not find a significant survival benefit 
of ICD (HR 0.65, 95% CI 0.40-1.06, p=0.08) in 458 patients with non-ischaemic 
cardiomyopathy who had a LVEF <36% and NYHA class I-III symptoms.33 
Nevertheless, in a meta-analysis by Desai et al. of 5 trials including 1854 
patients with non-ischaemic HF, use of an ICD was associated with a 31% 
decreased risk of all-cause death (HR 0.69, 95% CI 0.55-0.87, p=0.002).34 These 
decade-old studies are the basis of the evidence for the recommendations of ICD 
implantation in the current guidelines.2, 3 However, there is an inconsistency in 
the level of evidence for non-ischaemic cardiomyopathy between the current 
American and European guidelines.2, 3 In the American guidelines, the findings 
from the SCD-HeFT and MADIT-II led to class IA recommendations of ICD 
implantation for primary prevention of sudden death in patients with NYHA class 
II-III symptomatic HF and a LVEF ≤35%, with no difference between patients with 
ischaemic and non-ischaemic causes.2 By contrast, in the European guidelines, 
findings from the DEFINITE trial, the subgroup analysis of the SCD-HeFT and the 
meta-analysis by Desai et al. altogether led to class IB recommendation for 
patients with non-ischaemic HF, as opposed to class IA recommendation for 
patients with ischaemic HF.3  
It is worth to mention that since the publication of SCD-HeFT, there has been an 
increasing use of evidence-based therapies including beta-blockers, MRAs and 
CRT. In SCD-HeFT, only 69% of patients received a beta-blocker at baseline, and 
19% received a MRA and none received CRT.32 Very recently, in the DANish study 
to assess the efficacy of ICDs in patients with non-ischemic Systolic Heart failure 
on mortality (DANISH), more than 90% of patients received a beta-blocker at 
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baseline and nearly 60% received a MRA and 58% received CRT.35 After a median 
67.6 months of follow-up, the study did not find a significant survival benefit of 
ICD (HR 0.87, 95% CI 0.68-1.12, p=0.28). However, there was an interaction 
between the ICD effect and age (p value for interaction 0.009). Use of an ICD 
was associated with a 36% lower risk of all-cause death in patients younger than 
68 years (HR 0.64, 95% CI 0.45-0.90, p=0.01), but not in patients ≥68 years (HR 
1.19, 95% CI 0.81-1.73, p=0.38). The effect of ICD treatment on all-cause death 
was the same regardless of CRT status (p value for interaction 0.73). In the 
subgroup of patients without CRT, ICD did not reduce the risk of all-cause 
mortality, and this was also the case in the CRT subgroup. In patients who 
received a CRT defibrillator (CRT-D) there was no difference in survival 
compared to patients who received a CRT pacemaker alone (CRT-P) (HR 0.91, 
95% CI 0.64-1.29, p=0.59).35 Likewise, in the Comparison of Medical Therapy, 
Pacing, and Defibrillation in Heart Failure (COMPANION) study,30 CRT-D was not 
superior to CRT-P (p =0.12) in reducing the risk of all-cause death in later 
analyses of the data by independent authors,36 although both reduced the risk of 
mortality compared to optimal medical therapy.30 
In patients with HF-PEF, none of the medical treatments tested, including 
candesartan, irbesartan, perindopril and spironolactone, have been shown to 
reduce morbidity and mortality,9-12 and the efficacy of device therapies has yet 
to be examined. Diuretics are used to relieve symptoms of congestion as in HF-
REF. Adequate management of comorbidities, such as atrial fibrillation, 
hypertension, myocardial ischaemia and dysglycaemia, is considered important 
in HF-PEF, though there is limited evidence in guide what specific treatment 
approaches are most effective.2, 3 On the basis of the favourable effects in 
PARADIGM-HF in HF-REF and in a phase II trial in HF-PEF,27, 37 sacubitril/valsartan 
is under examination in the ongoing Prospective Comparison of ARNI with ARB 
Global Outcomes in HF With Preserved Ejection Fraction (PARAGON-HF) trial.38 
There is another ongoing trial to evaluate the benefit of ICD therapy in patients 
with relatively preserved ejection fraction (LVEF 36-50%) and the presence of 
late gadolinium enhancement on cardiovascular magnetic resonance (CMR) 
imaging (CMR-Guide trial, ClincalTrial.gov number NCT01918215).2, 3 
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Ventricular assist devices (VADs) have emerged as a viable therapeutic option for 
patients with end-stage HF who are refractory to optimal medical therapy. VADs 
are typically used as a bridge to recovery or a bridge to transplantation, and are 
increasingly used as destination therapy.2, 3 Bridge to recovery is for patients 
who only need temporary support after which the heart recovers and the VAD is 
then removed. Bridge to transplantation is for patients who are eligible for heart 
transplantation and to keep them alive until a donor heart becomes available. 
Destination therapy is for patients with end-stage HF who are ineligible for 
transplantation, or as a permanent alternative for heart transplantation for 
patients long-term waiting for transplant.2, 3 Heart transplantation is the gold 
standard treatment in carefully selected patients with refractory end-stage HF, 
which has been shown to improve long term survival and increase functional 
status and quality of life.2, 3 Nevertheless, heart transplantation is a limited 
treatment option for patients with end-stage HF, given that the number of 
patients on the transplant waiting list exceeds the availability of donor hearts. 
Besides, issues with rejection and the consequences of long-term 
immunosuppressive therapy after transplant remain problematic.2, 3 Accordingly, 
for patients eligible for transplantation, VADs, initially used as a short-term 
bridge to transplant, have increasingly been used as a permanent alternative to 
heart transplant. 
1.1.5 Prognosis of heart failure  
Although community-based studies suggest that overall survival in patients with 
HF has improved over time, prognosis remains poor with a mortality rate of 40-
60% within 5 years of diagnosis.19, 39 Survival is generally better in patents with 
HF-PEF than in HF-REF,25, 40 but the trend in improvement of survival has been 
primarily observed in those with HF-REF but not in HF-PEF,25 which has been 
attributed to the advances in therapies and their implementation in the HF-REF 
population.2, 3 
The majority of patients with HF die from CV causes, and the proportion varies 
with study design (trial or population-based), study population and time period 
of study; 3, 41 in general, deaths attributed to non-CV causes are proportionally 
higher in community-based studies and among patients with HF-PEF, and there 
has been an increase in the proportion of non-CV deaths over time both in HF-
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REF and HF-PEF.16, 42, 43 The shift in the distribution of death toward non-CV 
causes may reflect the cumulative benefit of HF therapies in reducing CV death 
in HF-REF, and the increasing comorbidity burden due to the elderly nature in 
HF-PEF. The risk of CV death is generally decreasing but remains significant, and 
sudden death and pump failure death account for the majority of CV death in 
HF.3, 41, 44 I will summarise the definitions, incidences and treatment available 
for both modes of death in the next section. 
1.2 Sudden death and pump failure death in heart failure 
1.2.1 Classification of mode-specific death 
Historically, there has existed heterogeneity in the definitions of sudden death 
and a lack of reporting or detailed information on the definitions of pump failure 
death in HF studies before mid-1990s.45 Thereafter, a framework was proposed 
for classification of mode of death in HF, calling for recording detailed 
information on (A) activity and place of death, (C) cause of death, (M) mode of 
death and (E) events associated with death.45 Despite its anticipated value in 
characterising death events, systematically collecting this information would be 
resource intensive and hard to achieve. Consequently, over the last two 
decades, definitions for each mode of death used among HF studies were 
broadly similar, but not uniform in terms of details regarding timing of the 
event, presence of a witness and clinical conditions before death. More recently, 
consensus efforts have been made by the ACCF and AHA in collaboration with 
the US Food and Drug Administration (FDA) to standardise definitions of 
cardiovascular endpoint events used in clinical trials.46 Sudden death has been 
defined in a more detailed way: “death that occurs unexpectedly, not following 
an acute MI; death witnessed and occurring without new or worsening symptoms; 
death witnessed within 60 minutes of the onset of new or worsening cardiac 
symptoms, unless the symptoms suggest acute MI; death witnessed and 
attributed to an identified arrhythmia (e.g., captured on an ECG recording, 
witnessed on a monitor, or unwitnessed but found on ICD review); death after 
unsuccessful resuscitation from cardiac arrest; death after successful 
resuscitation from cardiac arrest and without identification of a specific cardiac 
or non-cardiac aetiology; or unwitnessed death in a subject seen alive and 
clinically stable ≤24 hours prior to being found dead without any evidence 
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supporting a specific non-CV cause of death (information regarding the patient’s 
clinical status preceding death should be provided, if available)”. Pump failure 
death has been defined as “death associated with clinically worsening symptoms 
and/or signs of HF, regardless of HF aetiology (deaths due to HF can have various 
aetiologies, including single or recurrent myocardial infarctions, ischaemic or 
non-ischaemic cardiomyopathy, hypertension, or valvular disease)”. Worsening 
symptoms due to HF include dyspnoea, decreased exercise tolerance, fatigue, 
worsened end-organ perfusion and volume overload. And worsening signs of HF 
include peripheral oedema, increasing abdominal distention or ascites, 
pulmonary rales/crackles/crepitations, increased jugular venous pressure and/or 
hepatojugular reflux, S3 gallop, and clinical significant or rapid weight gain 
thought to be related to fluid retention.   
Standardisation of endpoint definitions is of great importance to achieve uniform 
event reporting and data collection. It should help reduce the bias of event 
adjudication within a trial between central endpoint committee members, and 
enhance the event consistency across trials and across health care systems thus 
facilitating combined or comparative analyses.  
1.2.2 Risk of mode-specific death in heart failure 
The rates of mode-specific death have varied across studies in terms of study 
design, study population (e.g. HF type, disease severity, demographics, 
comorbidity burden), classification of mortal events (definition and case 
ascertainment) and time (the calendar year of study and the duration of follow-
up).  
Looking at study design, compared to clinical trials, population-based studies, 
generally, are less likely to present specific breakdown of death events from CV 
and non-CV causes, and if provided, death events were less often adjudicated by 
a central endpoint committee. Besides, population-based studies are highly 
variable in terms of setting of enrolment (e.g. primary care, outpatient clinic, 
hospital discharge/admission), study sample size (and events), and follow-up 
duration. Accordingly, data on mode-specific death from population-based 
studies are scarce and variable. Among patients with HF-REF, a Japanese cardiac 
register study reported that 23% of total mortality among the hospitalised HF 
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patients was attributed to sudden death, and 37% due to pump failure and 18% 
due to non-CV causes.47 Rather consistent rates of sudden death (18% and 20%) 
and pump failure death (34% and 33%) were reported from another two cohort 
studies, although the contribution of non-CV death to the overall mortality was 
variable (47% and 28%).48, 49 In patients with HF-PEF, sudden death accounted for 
about 7-15% of total mortality, whereas the proportions of deaths attributed to 
pump failure and non-CV causes varied widely, ranging from 17% to 60% and from 
17% to 86% respectively.44 Based on clinical trial studies, in patients with HF-
REF, sudden death was reported to account for average 42% (range 23-58%) of 
total mortality, followed by pump failure death at 36% (range 27-56%), whereas 
non-CV death accounted for a smaller proportion at 14% (range 4-20%).50 In 
patients with HF-PEF, sudden death accounted for average 25% (range 21-28%) of 
overall mortality, pump failure death at 15% (range 13-21%) and non-CV death at 
32% (29-37%).50  
There are several observational studies that have performed point-to-point 
comparisons of the risks of mode-specific death in patients with HF between 
different therapeutic periods. Cubbon R et al. reported a significant reduction in 
sudden death (from 34% to 13%) and a concomitant increase in non-CV death 
(11% to 41%), with negligible change in pump failure death (41% to 37%) as a 
proportion of total mortality among patients with ambulant HF-REF recruited 
between 1993-1995 and 2006-2009 in the same geographic region in the UK.51 
Similarly, a decrease in the contribution of sudden death and an increase in non-
CV death to overall mortality was also observed among patients with severe HF 
awaiting heart transplantation in a single centre in the US and among patients 
with HF with mixed LVEF in the Tohoku district of Japan.52, 53 However, the 
temporal trends in rates of mode-specific death over time have yet to be 
examined, in particular with adjustment for detailed patient characteristics at 
baseline. 
1.2.3 Effects of heart failure treatment on mode-specific death 
The currently recommended neurohumoral therapies for HF-REF, including ACEIs 
or ARBs,54, 55 beta-blockers,56 and MRAs,57 all reduce the risk of sudden death. 
Evidence from meta-analyses of RCTs demonstrated that, compared to placebo, 
ACEIs reduced the risk of sudden death by 20% (odds ratio 0.80, 95% CI 0.70-
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0.92, p≤0.001),54 beta-blockers by 31% (odds ratio 0.69, 95% CI 0.62-0.77, 
p<0.00001) and MRAs by 23% (odds ratio 0.77, 95% CI 0.66-0.89, p=0.001).56, 57 A 
study of Candesartan in Heart failure Assessment of Reduction in Mortality and 
morbidity (CHARM) programs showed that candesartan (an ARB) reduced sudden 
death by 15% compared to placebo (HR 0.85, 95% CI 0.73-0.99, p=0.036).55 In the 
PARADIGM-HF, sacubitril/valsartan reduced the risk of sudden death by 20% 
compared with enalapril (HR 0.80, 95% CI 0.68-0.94, P=0.008) in patients who 
were receiving guideline recommended medications including a beta-blocker and 
a MRA.58 Ivabradine did not reduce the risk of sudden death.28 
With the cumulative use of these neurohumoral therapies, the residual risk of 
sudden death may be decreasing, and the overall survival benefit of ICD may 
have diminished to non-significant levels. However, ICDs have been shown to be 
effective in reducing the risk of sudden death in HF-REF, irrespective of 
aetiology. Use of an ICD led to a 67% reduction in sudden death (HR 0.33, 95% CI 
0.20-0.59, p<0.001) in patients with ischaemic HF in MADIT-II,59 and a 80% 
reduction (HR 0.20, 95% CI 0.06-0.71, p=0.006) in patients with non-ischaemic 
cardiomyopathy in DEFINITE, although in the latter trial this effect was based 
upon a tiny number of events.33 Likewise, in SCD-HeFT an ICD reduced the risk of 
sudden death in the ischaemic (HR 0.43, 95% CI 0.27-0.67) and non-ischaemic 
(HR 0.34, 95% CI 0.17-0.70) causes of HF.60 In the very recent DANISH study, ICD 
treatment reduced sudden death by 50% in patients with non-ischaemic 
cardiomyopathy (HR 0.50, 95% CI 0.31-0.82, p=0.005).  
CRT had a neutral effect on sudden death compared to optimal medical therapy 
(HR 1.04, 95% CI 0.73-1.46, p=0.84) based on the evidence from a meta-analysis 
of 5 RCTs,61 although individual trials had mixed results. In an extended report 
from the Cardiac REsynchronization-Heart Failure (CARE-HF) trial, CRT-P 
reduced sudden death by 46% (HR 0.54, 95% CI 0.35-0.84, p=0.006),62 while in 
the COMPANION trial CRT-P had no effect on sudden death (HR 1.21, 95% CI 
0.70-2.07, p=0.485), but CRT-D reduced sudden death by 56% (HR 0.44, 95% CI 
0.23-0.86, p=0.02).63 This may reflect that CRTs modify left ventricular 
remodelling and improve cardiac function which may have the paradoxical effect 
of appearing to increase death due to arrhythmia. Beneficial left ventricular 
remodelling can reduce the arrhythmia burden, but can also lead to greater 
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exposure to the risk of sudden death by reducing the rate of pump failure 
death.3 It is unclear if the reduction in sudden death with an ICD is independent 
of CRT status. Although in the DANISH there was no difference in the overall 
survival benefit of an ICD between patients with and without an CRT, the 
interaction was not reported for mode-specific death.35 
Based on individual studies, both enalapril and candesartan reduced the risk of 
pump failure death by 22% compared to placebo (HR 0.78, 95% CI 0.65-0.94, p 
<0.01).55, 64 In PARADIGM-HF, sacubitril/valsartan reduced the risk of pump 
failure death by 21% compared to enalapril (HR 0.79, 95% CI 0.64-0.98, 
p=0.034).58 The effect of beta-blockers on pump failure death had mixed results 
from individual studies and no meta-analysis is yet available to provide a 
synthesised estimate.65 This is also the case for the effect of MRAs on pump 
failure death: spironolactone reduced pump failure death by 36% compared to 
placebo (HR 0.64, 95% CI 0.51-0.80, p<0.001) in patients with severe HF, while 
eplerenone only showed a trend in reduction (HR 0.77, 95% CI 0.55-1.08, p=0.12) 
in patients with mild symptomatic HF who were already receiving an ACEI/ARB 
and a beta-blocker.66, 67 Ivabradine reduced the risk of pump failure death by 
26% compared to placebo (HR 0.74, 95% CI 0.58-0.94, p=0.014).28 CRT, either 
alone or in combination with an ICD, reduced the risk of pump failure death 
compared to optimal medical therapy.62, 63 In a meta-analysis of 5 RCTs, use of 
CRT led to a 38% reduction of pump failure death (HR 0.62, 95% CI 0.46-0.85, 
p=0.003).61 ICD treatment alone had no effect on the risk of pump failure death 
in SCD-HeFT,60 and the effect of ICDs on pump failure death was not reported in 
the other ICD trials (of course, an ICD would not be expected to reduce pump 
failure death).33, 35, 59 
In HF-PEF, none of the examined neurohumoral therapies, including ARBs50, 55 
and MRAs,12 reduced the risk of sudden death or pump failure death. The effect 
of a beta-blocker on either mode of death was not reported, probably due to 
small study size and few events.10 Device therapies have yet to be examined in 
this population. 
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1.2.4 Summary 
The last two decades have witnessed advances in, and implementation of 
evidence-based therapies in patients with HF-REF, along with the changing risk 
profiles and comorbidities in both HF-REF and HF-PEF populations. It is of great 
interest and importance to discover if these changes have translated into 
temporal changes (and corresponding trends over time) in the risks of sudden 
death and pump failure death in both populations. There are limited data on 
mode-specific death from population-based studies which tend to vary greatly in 
terms of study participants, study size and follow-up duration, and which have 
relatively sparse patient characterisation at baseline. By contrast, cohorts from 
clinical trials have more detailed baseline characterisation, which allows more 
complete multivariable adjustment, and more standardised follow-up and event 
sub-classification and adjudication, which may reduce the bias and variation 
within a study. Accordingly, I will examine the trends in the risks of sudden 
death and pump failure death over time in patients with HF-REF enrolled in 13 
clinical trials conducted between 1995-2015 and in patients with HF-PEF from 3 
clinical trials over the period 1999-2013 respectively. 
Apart from examining the rate of mode-specific death in population level, it 
would be of interest and importance to predict the risk of mode-specific death 
in individual patients. Accurate risk prediction for mode-specific death in 
individual patients can help with better risk stratification and aid clinicians and 
patients in decision making. Among patients with HF-REF, identification of high-
risk subgroups would help target costly interventions, such as ICDs and LVADs, to 
those most in need, and identifying low-risk subgroups would avoid unnecessary 
treatment and improve the cost-effectiveness of these interventions. Among 
patients with HF-PEF, knowledge of prognosis would facilitate further research 
into the efficacy of specific interventions in this population, e.g. designing 
randomised controlled trials in selected patients with high risks. Existing risk 
stratification models focus on predicting all-cause mortality in HF patients, 
which have been systematically reviewed.68-70 Fewer models have been 
developed to predict mode-specific death, i.e. sudden death and pump failure 
death, and their characteristics and performance have not been appraised. 
Therefore, in the next section I will perform a systematic review to identify 
published models to predict sudden death and pump failure death in patients 
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with chronic ambulatory HF, to summarise and compare their characteristics and 
performance, and to evaluate their clinical utility.  
1.3 Prognostic models for sudden death and pump 
failure death in heart failure 
1.3.1 Methods 
1.3.1.1 Search strategy 
A systematic search was performed in the electronic databases MEDLINE and 
Embase, limited to adult human subjects and English language. Relevant key 
search terms were combined including “heart failure” and “ambulatory” and 
“mortality” or “survival” or “sudden death” or “pump failure death” and 
“model” or “predict”. The search terms and search strategy in detail are 
presented in Appendix Table 1 and Appendix Table 2. The search was last 
updated on 17 April 2017. Bibliographic references of eligible studies and 
relevant reviews were hand searched to identify additional studies. 
1.3.1.2 Review methods and selection criteria 
Retrieved articles from MEDLINE and Embase databases were combined in the 
reference manager Endnote (Version X7). After eliminating duplicate papers, I 
screened the titles and abstracts of the retrieved publications, and then 
examined full-text versions of all publications considered potentially relevant. 
Studies were eligible if they enrolled adult (≥18 years) patients with chronic 
ambulatory HF, reported multivariable analysis (≥2 predictors) to predict sudden 
death, pump failure death or both. There were no restrictions on study design, 
LVEF or geographic regions. Studies were excluded if they enrolled patients 
exclusively during a hospital admission, i.e. patients with acutely 
decompensated heart failure. For studies based on the same study cohorts, 
those with shorter follow-up or smaller sample size were excluded if they 
provided no additional information.  
1.3.1.3 Data extraction and data analysis 
Data extraction was undertaken by outcome (i.e. sudden death or pump failure 
death). For each included study, the information collected is outlined in detail 
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in Appendix Table 3, which mainly included the aspects of study characteristics, 
patient characteristics, outcome of interest, model construction, model validity, 
model performance and handling of missing data. Data were summarised and 
analysed according to these elements, with a focus on model construction 
(modelling approach, model assumption, individual predictors and the ratio of 
number of predictors and number of events) and model performance 
(discrimination, calibration and validation).  
Overfitting refers to a scenario of having too many variables relative to the 
number of observations/events in a regression model, which may lead to random 
error or noise. To avoid overfitting, there is a rule of thumb that there should be 
at least 10 events for each final prediction variable of a multivariable model.71 
Model discrimination, known as “separation”, refers to the ability to distinguish 
individuals who develop an event from those who do not, and is commonly 
examined using C statistics, e.g. ROC AUC (area under the curve of receiver 
operating characteristic curve) or Harrell’s C statistic.72 C statistics generally 
range from 0.5 (random concordance) to 1 (perfect concordance), the higher the 
C statistic, the better the model discrimination. Model calibration is also known 
as ‘prediction accuracy’, refers to the magnitude of agreement between 
predicted and observed event rates at a population level.72 Model validation 
examines the reliability of model performance when a model is applied to 
another cohort.73 These three aspects are indispensable in evaluating a model. I 
will explain these concepts in detail in the Chapter 2 Methods. Finally, I will 
select the best existing models for mode-specific death and point out their 
limitations if any. 
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1.3.2 Results 
A total of 2046 citations were identified from MEDLINE and 2650 from Embase. 
After removing duplicate records, the titles and abstracts of 3378 citations were 
screened, and 143 full-text articles were further assessed for eligibility with 
additional 14 publications identified through references. In total, 27 studies 
were finally included in this analysis,74-100 comprising 22 models to predict 
sudden death74-82, 84-86, 89, 91-93, 95-100 and 16 models for pump failure death,75, 78-80, 
82-85, 87, 88, 90, 91, 94, 98-100 all of which were published between 1994 and 2015. The 
diagram of study selection process is displayed in Figure 1-1.  
Figure 1-1 Diagram of study selection process in the literature review 
 
 
 
1.3.2.1 Study characteristics 
For the models that predicted sudden death, the majority, 11 (50%) studies, 
were based on prospective cohort data, 6 (27%) from clinical trial databases, 2 
(9%) from the combination of trial databases and registry data, 1 (5%) from 
retrospective patient records and 2 (9%) were unspecified (Table 1-1). Most 
studies, 12 (55%), developed models that used data collected from European 
cohorts, only 1 (5%) used data from North America, 4 (18%) were derived from 
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data from Japan and the remaining 5 (23%) used clinical trial databases that 
randomised patients across the world. Of these clinical trial databases most 
randomised patients were from North America and Europe. The sample size of 
the studies varied largely: 11 (50%) studies included <500 participants, and only 
7 (32%) studies had a sample size of ≥1000 patients. Of the 16 (73%) studies 
reporting the calendar time of data collection, most, 10 (67%) studies, used data 
collected by the year 2000, before the broad use of modern guideline-
recommended treatments such as beta-blockers and MRAs. The average duration 
of follow-up ranged from 6.1 months to 11.7 years, with the majority in the 
range of 2 to 4 years. 
Of the models to predict pump failure death, most, 10 (63%) studies, were based 
on prospective cohort data, 3 (19%) used clinical trial databases, and 1 (6%) was 
based on the combination of registry data and trial databases, leaving 2 (12%) 
unspecified (Table 1-2). 9 (56%) studies used data collected from European 
cohorts, 3 (19%) from Japanese cohorts, only 1 (6%) from the US and the 
remaining 3 (19%) used data from clinical trials that randomised patients 
worldwide but most from Europe and North America. The majority, 10 (63%) 
studies, had a sample size of <500 participants, and only 3 (19%) studies included 
over 1000 participants. 11 (69%) studies reported data collection time, about 
half (45%) of which were collected by the year 2000. The average duration of 
follow-up ranged from 6 months to 6.9 years, and the majority were within the 
range of 2-4 years. 
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Table 1-1 Study and patient characteristics for sudden death models 
Publication Study characteristics Patient characteristics 
 Data source 
Country 
(No. 
centres) 
Sample 
size 
Study 
period 
Follow-up 
duration 
HF 
subtype 
Patient population  
(age, sex, LVEF, and NYHA class III-IV) 
Baseline 
medication 
Kawai,75 2015 Prospective cohort study Japan (1) 81 NR Mean 6.9 
years 
HF-REF Mean age 63 years, men (77%), LVEF<35% 
and mean LVEF 26%, NYHA class III-IV 
(26%) 
ACEI/ARB (85%), 
beta-blocker (67%), 
MRA (64%) 
Shadman,74 
2015 
Registry + trial database (PRAISE, 
Val-HeFT, COMET, Italian HF 
Registry, University of Washington 
cohort) 
International 
(NR) 
9885 NR Mean 28 
months 
Mixed Median age 64 years, men (79%), median 
LVEF 27%, NYHA class III-IV (49%) 
ACEI/ARB (96%), 
beta-blocker (47%), 
MRA (6%) 
Adabag,76 2014 Trial database (I-PRESERVE) International 
(293) 
4128 2002-2008 Mean 49.5 
months 
HF-PEF Age >60 years and mean age 72 years, men 
(40%), LVEF ≥45% and mean LVEF 60%, 
NYHA class III-IV (79%) 
ACEI (25%), beta-
blocker (58%), MRA 
(15%) 
Furukawa,77 
2013 
Patient records (retrospective) Japan (1) 132 1995-2002 Mean 6.7 
years 
HF-REF Mean age 63 years, men (80%), LVEF <40% 
and mean LVEF 30%, NYHA class III-IV 
(18%) 
ACEI/ARB (85%), 
beta-blocker (69%), 
MRA (56%) 
Smilde,81 2009 Trial database (Dutch ibopamine 
multicenter trial) 
Netherlands 
(NR) 
90 1989-2002 Mean 11.7 
years 
HF-REF Mean age 60 years, men (85%), LVEF <45% 
and mean LVEF 29%, NYHA class III-IV 
(20%) 
NR 
Tamaki,80 2009 Prospective cohort study Japan (1) 106 NR Mean 65 
months 
HF-REF Mean age 64 years, men (76%), LVEF <40% 
and mean LVEF 30%, NYHA class III-IV 
(22%) 
ACEI (70%), beta-
blocker (75%), MRA 
(NR) 
Vazquez,79 2009 Prospective cohort study (MUSIC 
study)  
Spain (8) 992 2003-2007 Median 44 
months 
Mixed  
EF>45% 
(25%) 
Mean age 65 years, men (72%), LVEF 10-
70% and mean LVEF 37%, NYHA class III-IV 
(22%) 
ACEI/ARB 
(74/17%), beta-
blocker (68%), MRA 
(38%)  
Wedel,78 2009 Trial database (CORONA) International 
(371) 
3342 2003-2007 Median 
32.8 
months 
HF-REF Age ≥60 years and mean age 73 years, men 
(75%), LVEF≤40% (≤35% if NYHA class II) 
and mean LVEF 31%, NYHA class III-IV 
(63%), ischaemic aetiology (100%) 
ACEI/ARB (92%), 
beta-blocker (77%), 
MRA (39%), ICD 
(2.3%) 
Uretsky,82 2008 Trial database (CARE-HF) Europe (82) 813 2001-2005 Mean 36.4 
months 
HF-REF Median age 67 years, men (74%), 
LVEF≤35% and mean LVEF 25%, NYHA 
class III-IV (100%), cardiac dyssynchrony 
(100%) 
ACEI/ARB (95%), 
beta-blocker (72%), 
MRA (56%) 
Guazzi,85 2007 NR Italy (NR) 156 NR Mean 23.6 
months 
Unspecified Mean age 61 years, men (80%), mean LVEF 
35%, NYHA class III-IV (29%) 
ACEI (76%), beta-
blocker (46%), MRA 
(39%) 
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Mozaffarian,84 
2007 
Registry + trial database (PRAISE, 
ELITE2, Val-HeFT, RENAISSANCE, 
Italian HF Registry, University of 
Washington cohort) 
International 
(NR) 
10538 NR Mean 1.6 
years 
Mixed Mean age 65 years, men (76%), mean LVEF 
28%, NYHA class III-IV (51%) 
ACEI/ARB 
(80/39%), beta-
blocker (31%), MRA 
(NR) 
Watanabe,86 
2006 
Prospective cohort study (CHART 
study) 
Japan (26) 680 2000-2004 Mean 26 
months 
HF-REF Mean age 66 years, men (69%), LVEF <50% 
and mean LVEF 42%, NYHA class III-IV 
(19%) 
ACEI/ARB (71%), 
beta-blocker (39%), 
MRA (20%) 
Kearney,89 2004 Prospective cohort study  
(UK-HEART study) 
UK (8) 553 1993-2000 5 years Mixed Mean age 63 years, men (76%), mean LVEF 
42% and LVEF >45% (36%), NYHA class III-
IV (39%) 
ACEI/ARB (81%), 
beta-blocker (8%), 
MRA (NR) 
Isnard,93 2003 Prospective cohort study France (1) 250 1996-2000 Median 
584 days 
HF-REF Mean age 54 years, men (NR), LVEF <45% 
and mean LVEF 29%, NYHA class III-IV 
(55%) 
ACEI (89%), beta-
blocker (21%), MRA 
(14%) 
La Rovere MT,92 
2003 
Prospective cohort study Italy (NR) 202 1991-1995  Mean 3 
years 
HF-REF Mean age 54 years, men (87%), LVEF 23%, 
NYHA Class II-III (88%) 
ACEI/ARB (90%), 
beta-blocker (6%), 
MRA (NR) 
Poole-Wilson,91 
2003 
Trial database (ATLAS) International 
(287) 
3164 1992-1997 Median 46 
months 
HF-REF Mean age 64 years, men (80%), LVEF ≤30% 
and mean LVEF 23%, NYHA class III-IV 
(84%) 
ACEI/ARB (100%), 
beta-blocker (11%), 
MRA (NR) 
Baldasseroni,96 
2002 
Prospective cohort study Italy (150) 5517 1995-2000 1 year Unspecified Mean age 63 years, men (76%), LVEF (NR), 
NYHA class III-IV (28%) 
ACEI/ARB (84%), 
beta-blocker (18%), 
MRA (NR) 
Berger,95 2002 Prospective cohort study Austria (1) 452 1995-2000 Mean 592 
days 
HF-REF Mean age 54 years, men (87%), LVEF ≤35% 
and mean LVEF 20%, NYHA class III-IV 
(54%) 
ACEI/ARB (89/5%), 
beta-blocker (30%), 
MRA (NR) 
Teerlink,97 2000 Trial database (PROMISE) The US and 
Canada 
(119) 
1080 1989-1990 6.1 months HF-REF Mean age 64 years, men (78%), LVEF ≤35% 
and mean LVEF 21%, NYHA class III-IV 
(100%) 
ACEI/ARB (100%), 
beta-blocker (NR), 
MRA (NR) 
Madsen,99 1997 Prospective cohort study Denmark (1) 190 1988-1990 Median 
24.5 
months 
Unspecified Mean age 66 years, men (72%), median 
LVEF 30%, NYHA class III-IV (46%) 
ACEI/ARB (33%), 
beta-blocker (4%), 
MRA (NR) 
Szabo,98 1997 NR Netherlands 
(1) 
159 NR Mean 23 
months 
HF-REF Mean age 60 years, men (NR), LVEF <40% 
and mean LVEF 27%, NYHA class III-IV 
(38%) 
NR 
Szabo,100 1994 Prospective cohort study Netherlands 
(1) 
211 1988-1992 Mean 21 
months 
HF-REF Mean age 63 years, men (76%), LVEF <45% 
and mean LVEF 26%, NYHA class III-IV 
(NR) 
ACEI (42%), beta-
blocker (15%), MRA 
(NR) 
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CARE-HF, Cardiac Resynchronization in Heart Failure; CHART, Chronic Heart failure Analysis and Registry in Tohoku district; ELITE2, Evaluation of Losartan in the 
Elderly; NR, not reported; PRAISE, Prospective Randomized Amlodipine Survival Evaluation; PROMISE, Prospective Randomized Milrinone Survival Evaluation; 
RENAISSANCE, Randomized Enbrel North American Strategy to Study Antagonism of Cytokines. 
Table 1-2 Study and patient characteristics for pump failure death models 
Publication Study characteristics Patient characteristics 
 Data source 
Country (No. 
centres) 
Sample 
size 
Study 
period 
Follow-up 
duration 
HF subtype Patient population 
Baseline 
medication 
Kawai,75 2015 Prospective cohort study Japan (1) 81 NR Mean 6.9 
years 
HF-REF Mean age 63 years, men (77%), 
LVEF<35% and mean LVEF 26%, NYHA 
class III-IV (26%) 
ACEI/ARB (85%), 
beta-blocker (67%), 
MRA (64%) 
Tamaki,80 2009 Prospective cohort study Japan (1) 106 NR Mean 65 
months 
HF-REF Mean age 64 years, men (76%), LVEF 
<40% and mean LVEF 30%, NYHA class 
III-IV (22%) 
ACEI (70%), beta-
blocker (75%), MRA 
(NR) 
Vazquez,79 2009 Prospective cohort study 
(MUSIC study) 
Spain (8) 992 2003-2007 Median 44 
months 
Mixed Mean age 65 years, men (72%), LVEF 10-
70% and mean LVEF 37% and LVEF 
>45% (25%), NYHA class III-IV (22%) 
ACEI/ARB (74/17%), 
beta-blocker (68%), 
MRA (38%)  
Wedel,78 2009 Trial database (CORONA) International 
(371) 
3342 2003-2007 Median 32.8 
months 
HF-REF Age ≥60 years and mean age 73 years, 
men (75%), LVEF≤40% (≤35% if NYHA 
class II) and mean LVEF 31%, NYHA 
class III-IV (63%), ischaemic aetiology 
(100%) 
ACEI/ARB (92%), 
beta-blocker (77%), 
MRA (39%) 
Mehta,83 2008 Prospective cohort study UK (2) 396 2004-2006 Median 370 
days 
Mixed Median age 75 years, men (61%), mean 
LVEF 38%, NYHA class III-IV (88%) 
ACEI/ARB (72/7%), 
beta-blocker (31%), 
MRA (20%) 
Uretsky,82 2008 Trial database (CARE-HF) Europe (82) 813 2001-2005 Mean 36.4 
months 
HF-REF Median age 67 years, men (74%), 
LVEF≤35% and mean LVEF 25%, NYHA 
class III-IV (100%), cardiac dyssynchrony 
(100%) 
ACEI/ARB (95%), 
beta-blocker (72%), 
MRA (56%) 
Guazzi,85 2007 NR Italy (NR) 156 NR Mean 23.6 
months 
Unspecified Mean age 61 years, men (80%), mean 
LVEF 35%, NYHA class III-IV (29%) 
ACEI (76%), beta-
blocker (46%), MRA 
(39%) 
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Mozaffarian,84 
2007 
Registry + trial database 
(PRAISE, RENAISSANCE, 
ELITE2, Val-HeFT, Italian HF 
Registry, University of 
Washington cohort) 
International 
(NR) 
10538 NR Mean 1.6 
years 
Mixed Mean age 65 years, men (76%), mean 
LVEF 28%, NYHA class III-IV (51%) 
ACEI/ARB (80/39%), 
beta-blocker (31%), 
MRA (NR) 
Berger,87 2005 Prospective cohort study Austria (1) 452 1995-2000 Mean 592 
days 
HF-REF Mean age 54 years, men (87%), LVEF 
≤35% and mean LVEF 20%, NYHA class 
III-IV (54%) 
ACEI/ARB (89/5%), 
beta-blocker (30%), 
MRA (NR) 
Kyuma,88 2004 Prospective cohort study Japan (1) 158 1999-2001 16 months Mixed Mean age 64 years, men (70%), mean 
LVEF 41% and LVEF ≥50% (20%), NYHA 
class III-IV (39%) 
ACEI/ARB (64%), 
beta-blocker (55%), 
MRA (39%), ICD 
(8%) 
Poole-Wilson,91 
2003 
Trial database (ATLAS) International 
(287) 
3164 1992-1997 Median 46 
months 
HF-REF Mean age 64 years, men (80%), LVEF 
≤30% and mean LVEF 23%, NYHA class 
III-IV (84%) 
ACEI/ARB (100%), 
beta-blocker (11%), 
MRA (NR) 
Vrtovec,90 2003 Prospective cohort study US (1) 241 2001 6 months HF-REF Mean age 67 years, men (59%), mean 
LVEF 27%, NYHA class III-IV (100%) 
ACEI (87%), beta-
blocker (73%), MRA 
(NR) 
Kearney,89 2002 Prospective cohort study  
(UK-HEART study) 
UK (8) 553 1993-2000 5 years Mixed Mean age 63 years, men (76%), mean 
LVEF 42% and LVEF >45% (36%), NYHA 
class III-IV (39%) 
ACEI/ARB (81%), 
beta-blocker (8%), 
MRA (NR) 
Madsen,99 1997 Prospective cohort study Denmark (1) 190 1988-1990 Median 24.5 
months 
Unspecified Mean age 66 years, men (72%), median 
LVEF 30%, NYHA class III-IV (46%) 
ACEI/ARB (33%), 
beta-blocker (4%), 
MRA (NR) 
Szabo,98 1997 NR Netherlands 
(1) 
159 NR Mean 23 
months 
HF-REF Mean age 60 years, men (NR), LVEF 
<40% and mean LVEF 27%, NYHA class 
III-IV (38%) 
NR 
Szabo,100 1994 Prospective cohort study Netherlands 
(1) 
211 1988-1992 Mean 21 
months 
HF-REF Mean age 63 years, men (76%), LVEF 
<45% and mean LVEF 26%, NYHA class 
III-IV (NR) 
ACEI (42%), beta-
blocker (15%), MRA 
(NR) 
Abbreviations are same as Table 1-1. 
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1.3.2.2 Patient characteristics 
For sudden death, 14 (64%) models were derived from patients with HF-REF and 
only 1 (5%) model from patients with HF-PEF;76 the remaining 7 (32%) studies 
included all HF patients regardless of LVEF or did not specify the left ventricular 
systolic function further (Table 1-1). The average age of the patients in these 
studies ranged from 54 to 73 years, with the majority at about 64 years. The 
predominance of men (≥70%) was observed in all studies, except the model in 
the HF-PEF patients in which the proportion of men was 40%.76 The proportion of 
patients with NYHA class III or IV symptoms varied greatly across these studies 
ranging from 18% to 100%. There were 2 (9%) studies that did not report the use 
of ACEIs/ARBs,81, 98 of the remaining studies the use of ACEIs/ARBs was 
consistently high, except 2 studies in which data were collected before 199299, 
100 and 1 study in patients with HF-PEF.76 The use of beta-blockers was not 
reported in 3 (14%) studies,81, 97, 98 and only 7 (32%) studies had over 50% of 
patients treated with beta-blockers, and the proportion was below 50% in 12 
(55%) studies. The use of MRAs was not reported in 12 (55%) studies, and only 3 
(14%) studies had over 50% of patients having received MRAs,75, 77, 82 leaving 7 
(32%) studies with the proportion below 50%. Of the studies with the use of beta-
blockers and MRAs below 50% or not reported, most had collected data before 
the year 2000. 
For pump failure death models, 9 (56%) studies included HF patients with 
reduced EF, and the remainder either included HF patients with a full range of 
LVEFs or made no reference to LVEF; none of the models were developed 
specifically in patients with HF-PEF (Table 1-2). Patients in all studies were 
predominantly male. The distributions of the average age and the proportion of 
patients with NYHA class III-IV across the studies for pump failure death models 
was similar to those for sudden death models. The use of ACEIs/ARBs and beta-
blockers was not reported in one study,98 in the rest of the studies, the use of 
ACEIs/ARBs was consistently high, except 2 studies in which data were collected 
before 1992;99, 100 the use of beta-blockers was over 50% of patients in 7 (44%) 
studies and below 50% in 8 (50%) studies. The use of MRAs was not reported in 9 
(56%) studies, and only 2 (13%) studies had over 50% of patients having received 
MRAs,75, 82 leaving 5 (31%) studies with the proportion below 50%. Likewise, in 
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the studies with the use of beta-blockers and MRAs below 50% or not reported, 
data collection was mainly performed before the year 2000. 
1.3.2.3 Outcomes of interest 
The definitions of sudden death were broadly similar across these studies, 
despite 6 (27%) studies having included witnessed cardiac arrest75, 77, 80, 85, 93, 95 
and 1 further (5%) study included appropriate ICD discharge for ventricular 
tachycardia or fibrillation92 (Table 1-3). The sudden death events were 
adjudicated by an endpoint committee in 10 (45%) studies, most of which were 
derived from clinical trials except 3 from observational studies, i.e., the MUSIC 
(MUerte Subita en Insuficiencia Cardiaca) study,79 the UK-HEART (United 
Kingdom-heart failure evaluation and assessment of risk trial) study,89 and one 
cohort from Italy;85 the remaining 12 (55%) studies either included investigator-
reported events or did not specify this further. Most, 12 (55%) studies, had less 
than 50 sudden death events; only 7 studies had over 100 events, most of which 
were based on trial databases, except one based on the Italian Network on HF 
Registry cohort.96 
The definition for pump failure death used was generally similar across the 
studies, whereas 2 studies, i.e. the MUSIC study79 and the ATLAS (assessment of 
treatment with lisinopril and survival) trial,91 also included heart transplantation 
as a pump failure death, which contributed to 16% (N=20) and 9% (N=39) of the 
overall pump failure deaths respectively (Table 1-4). Half of the models were 
based on endpoint-committee adjudicated events, the Seattle HF model (SHFM) 
study, based on multiple cohorts, used a mix of adjudicated and investigator-
report events,84 and the remaining studies either used investigator-reported 
events or made no reference to event identification. Over two thirds of the 
studies had less than 50 pump failure death events, and only 5 studies had over 
100 events, all of which were from clinical trials except the one based on the 
MUSIC study.79 
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Table 1-3 Event number and definition, and model construction and performance for sudden death models 
 Outcome of interest Model construction Model performance 
Publication Number and definition for SD (Event 
adjudication) 
No. final/candidate variables (final 
in bold) 
Analytic 
method 
Over-
fitting 
Model 
assumption 
Missing data Discrimination Calibration Validation 
Kawai,75 2015 (N=16 including witnessed cardiac arrest) 
Witnessed cardiac arrest or death within 1 
hr of the onset of acute symptoms, 
unexpected or unwitnessed death in a 
patient known to have been well within the 
previous 24 hrs. (NR) 
2/6 MIBG score, washout rate of 
cardiac MIBG, heart to mediastinum 
MIBG uptake ratio on delayed image, 
uric acid, norepinephrine, LVEDD. 
Cox regression Yes NR NR Sensitivity, 
specificity, 
predictive 
accuracy 
NR No 
Shadman,74 
2015 
(SPRM) 
(N=1225) Unexpected death in a clinically 
stable patient or death from documented 
or presumed cardiac arrhythmia without a 
clear non-CV cause.  
(Investigator report or endpoint committee 
adjudication) 
10/17 Sex, age, ischaemic aetiology, 
diabetes, LVEF, LVEDD, SBP, 
creatinine, serum sodium, log NT-
proBNP, NYHA class, BMI, diuretic 
dose, statin, beta-blocker, ACEI/ARB, 
digoxin. 
multinomial 
logistic 
regression 
No No NR NR NR No 
Adabag,76 
2014 
(I-PRESERVE) 
(N=231) Unexpected death in a previously 
clinically stable patient and included 
patients who had an unsuccessful 
attempted resuscitation, all having a 
human contact within 24 hrs before the 
event. (Endpoint committee adjudication) 
6/18 Age, sex, LVEF, BMI, ischaemic 
aetiology, history of ischaemic heart 
disease, diabetes, MI, AF, chronic 
kidney disease, LBBB on ECG, 
pulmonary congestion on chest X-ray, 
creatinine, albumin, neutrophil count, 
ln NT-proBNP, loop diuretic, ACEI. 
Cox regression 
with stepwise 
selection 
No PH 
assumption 
examined 
NR Harrell's C 
(0.75) 
observed 
vs. 
predicted 
plot 
No 
Furukawa,77 
2013 
(N=26 including witnessed cardiac arrest) 
Witnessed cardiac arrest or death within 1 
hr of the onset of acute symptoms, 
unexpected or unwitnessed death in a 
patient who was known to have been well 
within the previous 24 hrs. (NR) 
3/14 Early repolarization pattern, 
LVEF, QRS duration, ventricular late 
potential, duration of filtered QRS 
complex, age, sex, aetiology, NYHA 
class, heart rate, SBP, DBP, LVEDD, 
total counts of VPBs on Holter 
monitoring. 
Cox regression 
with stepwise 
selection 
Yes NR NR Sensitivity, 
specificity, 
predictive 
accuracy 
NR No 
Smilde,81 2009 (N=28) Unexpected death that occurred 
within 1 hr of new or more serious 
symptoms, or during sleep or while 
unobserved, in the absence of increasing 
angina or progressive HF. (Investigator 
report) 
2/13 LVEF <30%, VPBs >20/h, sex, 
VT, mean NN <750ms, SDNN 
<110ms, SDNN <50ms, SDANN 
<100ms, RMSSD <25ms, TP <2500 
ms2, VLFP <1500 ms2, LFP <300 ms2 
and HFP <100 ms2. 
Cox regression No NR NR NR NR No 
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Tamaki,80 2009 (N=18 including witnessed cardiac arrest) 
Witnessed cardiac arrest or death within 1 
hr of the onset of acute symptoms, 
unexpected or unwitnessed death in a 
patient known to have been well within the 
previous 24 hrs. (NR) 
2/6 Washout rate of cardiac MIBG, 
heart to mediastinum MIBG uptake 
ratio on delayed image, uric acid, 
norepinephrine, LVEF, heart to 
mediastinum MIBG uptake ratio on 
early image. 
Cox regression 
with stepwise 
selection 
Yes NR NR Sensitivity, 
specificity, 
predictive 
accuracy 
NR No 
Vazquez,79 
2009 
(MUSIC) 
(N=90) A witnessed death occurring within 
1 hr from onset of new symptoms, unless 
a cause other than cardiac was obvious, 
or an unwitnessed death (<24 hrs) in the 
absence of pre-existing progressive 
circulatory failure or other causes of death, 
or a death during attempted resuscitation. 
(Endpoint committee adjudication) 
5/12 Prior AVE, Echo (LA size >26 
mm, LVEDD ≥33mm, MR grade 3/4, 
LVEF≤35%, restrictive filling pattern), 
ECG & Holter (AF, LBBB/IVCD, 
NSVT + frequent VPBs), eGFR<60 
ml/min/1.73 m2, NT-proBNP >1000 
pg/ml, Troponin positive. (AVE 
denotes atherosclerotic vascular 
event, which included previous MI, 
stroke or lower limb ischemia). 
Cox regression 
with stepwise 
selection 
No NR >5% 
excluded; 
<5% median 
imputation 
Harrell's C 
statistic (0.77) 
Predicted 
vs. 
observed 
survival in 
deciles of 
their risk 
scores 
Bootstrap 
resampling 
Wedel,78 2009 
(CORONA) 
(N=407) Witnessed instantaneous death in 
the absence of any acute symptoms, and 
also in the absence of progressive 
circulatory failure, the latter lasting for ≥60 
min; unwitnessed death in the absence of 
pre-existing progressive circulatory failure 
or other modes of death; patients 
resuscitated from a cardiac arrest in the 
absence of pre-existing circulatory failure 
or other modes of death and who die 
within 28 days without a non-CV cause 
being identified; or a similar patient who 
dies during an attempted resuscitation; 
death within 60 min from the onset of new 
symptoms unless other cause than 
cardiac is obvious. (Endpoint committee 
adjudication) 
8/29 Log NT-proBNP, LVEF, age, 
Apo A-I, CABG, diabetes, AF, sex, 
NYHA class, creatinine, SBP, 
pacemaker, intermittent claudication, 
stroke, CK, PTCA/PCI, BMI, MI, 
ALAT, hsCRP, ICD, Apo B, aortic 
aneurysm, hypertension, angina, 
smoking, heart rate, TSH, 
triglycerides. 
Cox regression No NR Complete 
case analysis 
ROC AUC 
(NR) 
NR No 
Uretsky,82 
2008 
(CARE-HF) 
(N=71) Witnessed sudden unexpected 
collapse with or without documented 
arrhythmia, or unwitnessed sudden 
unexpected death in the CV category. 
(Endpoint committee adjudication) 
2/8 Index of MR severity*, CRT, log 
BNP*, end-diastolic volume index*, 
SBP*, IDC, EQ-5D*, interventricular 
mechanical delay*. (*Included time-
dependent covariates with the values 
measured at 3 months replacing the 
Cox regression 
with stepwise 
selection 
No PH 
assumption 
examined 
NR NR NR No 
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baseline value in the model for those 
still at risk after 3 months). 
Guazzi,85 2007 
 
(N=17 including witnessed cardiac arrest) 
A witnessed cardiac arrest or death within 
1 hr of the onset of acute symptoms, or an 
unexpected unwitnessed death in a 
patient known to have been well within the 
previous 24 hrs. (Adjudication from a 
panel of 3 physicians) 
2/6 Peak VO2, VE/VCO2 slope, 
exercise oscillatory breathing, LV 
mass, left ventricular end-systolic 
volume, LVEF. 
Cox regression 
with stepwise 
selection 
Yes NR NR NR NR No 
Mozaffarian,84 
2007 
(SHFM) 
(N=1014) Unexpected death in a clinically 
stable patient or death from documented 
or presumed cardiac arrhythmia without a 
clear non-CV cause.  
(Investigator report or endpoint committee 
adjudication) 
14/17 Age, sex, BMI, NYHA class, 
LVEF, ischaemic aetiology, SBP, 
diuretic dose, allopurinol, statin, 
sodium, creatinine, cholesterol, 
white blood cell, haemoglobin, 
lymphocytes, uric acid. 
Cox regression 
with stepwise 
selection 
No NR Complete 
case analysis 
ROC AUC 
(0.68) 
NR No 
Watanabe,86 
2006 
(CHART) 
(N=36) Sudden, unexpected death without 
worsening HF. It included witnessed 
sudden collapse and death, and 
unwitnessed deaths which were 
unexpected and which could not be 
explained by non-cardiac causes. 
(Investigator report) 
5/16 Age, sex, prior HF 
hospitalisation, underlying heart 
diseases, NYHA class, diabetes, 
hypertension, NSVT, AF, ACEI/ARB, 
beta-blocker, digitalis, spironolactone, 
BNP >200 pg/ml, LVEF <30%, and 
LVEDD>60 mm. (After including the 
number of risk markers as a 
covariate, only number of risk 
markers ≥3 included) 
Cox regression 
with stepwise 
selection 
Yes NR NR Sensitivity, 
specificity 
NR No 
Kearney,89 
2004 
(UK-HEART) 
(N=67) Death occurred within 1 hr of a 
change in symptoms or during sleep or 
while the patient was unobserved and had 
previously been clinically stable. (Endpoint 
committee adjudication) 
4/16 Age, sex, NSVT, LVH, LVEDD, 
LVSDD, LVEF, sodium, potassium, 
urea, creatinine, log cardiothoracic 
ratio, ln QTc dispersion, QTc 
dispersion across leads V1-V6, 
maximum QTc interval, and QRS 
dispersion across leads V1-V6. 
Cox regression 
with stepwise 
selection 
No NR Multiple 
imputation  
ROC AUC 
(0.71) 
NR Bootstrap 
resampling 
Isnard,93 2003 (N=19 including witnessed cardiac arrest) 
Witnessed cardiac arrest, a death within 1 
hr of worsening symptoms, or an 
1/13 NYHA class, heart rate, SBP, 
LVEDD, LVEF, sodium, ANP, NT-
ANP, BNP, norepinephrine, 
Cox regression 
with stepwise 
selection 
No NR NR NR NR No 
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unexpected death during sleep without 
worsening symptoms the day before. (NR) 
endothelin, peak VO2, and percent 
predicted VO2 consumption. 
La Rovere 
MT,92 2003 
(N=19 including ICD discharge for VT/VF) 
Death occurring within 1 hr of onset of 
symptoms in a medically stable patient, 
death during sleep, unwitnessed death 
occurring within 1 hr of the patient last 
being seen alive, or appropriate and 
documented ICD discharge for fast VT/ 
VF. (NR) 
2/9 LVEF ≤21%, LVEDD ≥77 mm, 
VPBs ≥86/h, BUN ≥57 mg/dl, Bilirubin 
≥1.03 mg/dl, HRV (Baseline SDNN 
≤21 ms, Baseline LFP ≤11 ms2, 
Baseline LFP/HFP ≤0.37, 
Controlled-breathing LFP ≤13 ms2).   
Cox regression Yes NR NR NR NR Run a new 
model in 
an 
external 
cohort 
Poole-
Wilson,91 2003 
(ATLAS) 
(N=589) Observed arrhythmic deaths and 
sudden deaths not attributable to 
intractable MI or any other identifiable 
cause. These deaths were also recorded 
as “witnessed” or “unwitnessed”. Patients 
with sudden loss of consciousness who 
were resuscitated but later died. (Endpoint 
committee adjudication) 
8/22 Lisinopril treatment, age, sex, 
ischaemic heart disease, LVEF, 
NYHA, SBP, DBP, heart rate, sodium, 
potassium, creatinine, 
haemoglobin, antidiabetic agent, 
aspirin, beta-blocker, long acting 
nitrates, short acting nitrates, 
previous ACEI, anti-arrhythmic 
agent, calcium channel blocker, 
anticoagulant/warfarin. 
competing risk 
Cox regression 
No NR NR NR NR No 
Baldasseroni,96 
2002 
(N=306) NR. (NR) 10/23 age, ischaemic heart disease, 
prior HF hospitalisation, NYHA 
class, SBP, 3rd heart sound, 
chronic AF, VT, beta-blocker, 
LBBB, sex, cardiothoracic ratio, 
LVEF, heart rate, renal failure, ACEI, 
diuretic, digoxin, nitrates, 
amiodarone, calcium antagonist, 
other antiarrhythmic agent and 
antiplatelet. 
Cox regression No NR NR NR NR No 
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Berger,95 2002 (N=44 including witnessed cardiac arrest) 
Witnessed cardiac arrest or death within 1 
hr of the onset of acute symptoms or 
unexpected, unwitnessed death (i.e. 
during sleep) in a patient known to have 
been well within previous 24 hrs. 
(Investigator report) 
1/16 log BNP, log NT-ANP, LVEF, 
log NT-BNP, SBP, big endothelin, 
NYHA class, ARB, beta-blocker, 
rhythm, amiodarone, heart rate, 
ACEI, diabetes, CAD, hypertension. 
Cox regression 
with stepwise 
selection 
No NR NR ROC AUC 
(0.66) 
NR No 
Teerlink,97 
2000 
(PROMISE) 
(N=139) Unexpected circulatory collapse 
resulting in death within 1 hr in a previous 
clinically stable patient. (Endpoint 
committee adjudication) 
4/10 LVEF, NYHA class, CAD, age, 
milrinone, SBP, NSVT episodes, 
PVBs, NSVT, NSVT beats. 
Cox regression 
with stepwise 
selection 
No NR NR ROC AUC 
(0.69) 
NR No 
Madsen,99 
1997 
(N=20) Death within 1 hr of the onset of 
new symptoms or unobserved but 
assumed based on the clinical setting. 
(Investigator report) 
5/8 VT ≥4 beats, sodium ≤137 
mmol/L, magnesium ≤0.8 mmol/L, 
creatinine ≥121 umol/L, the 
increase in heart rate during 
exercise ≤35 beats/min, LVEF, 
noradrenaline, serum urea >7.6 
mmol/L. 
Cox regression 
with stepwise 
selection 
Yes NR NR NR NR No 
Szabo,98 1997 (N=16) Death that occurred within 1 hr of 
onset of symptoms or during sleep in the 
absence of increasing angina or acute 
worsening of HF. (Investigator report) 
1/3 LVEF <27%, SDNN <108 ms, 
percent difference between 
successive normal to normal NN 
intervals >50ms. 
Cox regression No NR NR NR NR No 
Szabo,100 1994 (N=23) Unexpected death within 1 hr of 
the onset of new signs/symptoms or 
during sleep, in the absence of increasing 
angina or overt HF. 
(Investigator report) 
2/4 LVEF ≤27%, presence of VT, 
Frequency VT ≥144 beats/min, length 
VT ≥2s. 
Cox regression No NR NR NR NR No 
AF, atrial fibrillation; ALAT, Alanine transaminase; ANP, atrial natriuretic peptide; Apo A-I, Apolipoprotein A-I; Apo B, Apolipoprotein B; CK, creatine kinase; DBP, 
diastolic blood pressure; FS, fractional shortening; GGT, gamma-glutamyl transpeptidase; EQ-5D, EuroQol five dimensions questionnaire; HFP, high frequency 
power; HRV, heart rate variability; hsCRP, high-sensitivity C-reactive protein; IDC, idiopathic dilated cardiomyopathy; IVCD, intraventricular conduction defect; LA, 
left atrial; LFP, low frequency power; LV, left ventricular; LVEDD, left ventricular end diastolic diameter;  LVSD, left ventricular systolic dysfunction; MI, myocardial 
infarction; MIBG, metaiodobenzylguanidine; MR, mitral regurgitation; NR, not reported; NSVT, nonsustained ventricular tachycardia; PTCA, percutaneous 
transluminal coronary angioplasty; SBP, systolic blood pressure; SDNN, standard deviation of all normal-to-normal RR intervals; TP, all frequencies total power; 
TSH, thyroid-stimulating hormone; VLFP, very low frequency power; VPB, ventricular premature beat; VT, ventricular tachycardia; VF, ventricular fibrillation.   
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Table 1-4 Event number and definition, and model construction and performance for pump failure death models 
 Outcome of interest Model construction Model performance 
Publication Number and definition for PFD 
(Event adjudication) 
No. final/candidate variables (final in 
bold) 
Analytic 
method 
Over-
fitting 
Model 
assumption 
Missing 
data 
Discrimination Calibration Validation 
Kawai,75 2015 (N=11) Death because of 
progressively reduced cardiac 
output and failed organ perfusion. 
(NR) 
3/6 MIBG score, washout rate of cardiac 
MIBG, creatinine, uric acid, LVEDD, LVEF 
Cox regression Yes NR NR sensitivity, 
specificity, 
predictive 
accuracy 
NR No 
Tamaki,80 
2009 
(N=11) NR. (NR) 4/7 LVEDD, washout rate of cardiac 
MIBG, LVEF, creatinine, uric acid, heart to 
mediastinum MIBG uptake ratio on delayed 
image, left atrial dimension 
Cox regression 
with stepwise 
selection 
Yes NR NR sensitivity, 
specificity, 
predictive 
accuracy 
NR No 
Vazquez,79 
2009 
(MUSIC) 
(N=123 including 20 heart 
transplant) Death occurring in 
hospitals as a result of refractory 
progressive end-stage HF or heart 
transplantation. (Endpoint 
committee adjudication) 
6/18 Age ≥65, BMI <25, Echo (LA size >26 
mm, LVEDD ≥33 mm, MR grade 3/4, LVEF 
≤35%, restrictive filling pattern), ECG & 
Holter (AF, heart rate >80 beats/min, QRS 
duration >120 ms, LBBB/IVCD, NSVT + 
frequent VPBs), eGFR <60 ml/min/1.73 m2, 
hyponatremia ≤138 mmol/L, NT-proBNP 
>1000 pg/ml, troponin-positive, 
haemoglobin <120 g/L, GGT >50 IU/L 
Cox regression 
with stepwise 
selection 
No NR >5% 
excluded; 
<5% 
median 
imputation 
Harrell's C 
(0.80) 
Predicted 
versus 
observed 
survival in 
deciles of 
their risk 
scores 
Bootstrap 
resampling 
Wedel,78 2009 
(CORONA) 
(N=230) Cardiogenic shock; 
pulmonary oedema sufficient to 
cause tachypnoea and distress. HF 
symptoms or signs requiring 
intravenous therapy or oxygen 
administration. Confinement to bed 
but only if this is due to HF 
10/29 Log NT-proBNP, age, diabetes, 
CABG, NYHA class, heart rate, AF, SBP, 
LVEF, intermittent claudication, BMI, 
smoking, creatinine, hypertension, CK, 
angina, stroke, Apo A-I, sex, PTCA/PCI, 
pacemaker, aortic aneurysm, ICD, ALAT, 
triglyceride, Apo B, TSH, MI, hsCRP 
Cox regression No NR Complete 
case 
analysis 
ROC AUC 
(0.80) 
Predicted 
versus 
observed  
No 
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symptoms. Sudden death during 
hospitalisation for aggravated HF. 
(Endpoint committee adjudication) 
Uretsky,82 
2008 
(CARE-HF) 
(N=102) Death due to progressive 
failure of the heart to pump 
adequately to sustain life. (Endpoint 
committee adjudication) 
3/8 Log BNP, SBP, CRT, interventricular 
mechanical delay, end-diastolic volume 
index, index of MR severity, EQ-5D, IDC 
Cox regression 
with stepwise 
selection 
No PH 
assumption 
examined 
NR NR NR No 
Mehta,83 2008 (N=31) Worsening HF, manifest by 
an increase in symptoms and HF 
medications and usually including 
hospitalization, in the week 
preceding death (including 
cardiogenic shock, pulmonary 
oedema, HF symptoms/signs 
requiring intravenous therapy or O2, 
confinement at home due to HF, 
cases described as end stage HF in 
which therapy was felt to be futile 
and progressive HF cases in which 
terminal arrhythmias were 
documented). (Adjudication from a 
panel of 3 cardiologists) 
5/28 Age, sex, race, CAD aetiology, acute 
MI aetiology, NYHA class, outpatient vs. 
inpatient assessment, SBP <115 mmHg, 
heart rate, AF history, QRS duration >100 
ms, lung crackles beyond bases, 
cardiothoracic ratio, sodium, urea ≥10 
mmol/L, creatinine ≥100 umol/L, 
haemoglobin, Troponin T, LVEDD, LVESD, 
FS, LVEF, global left ventricular systolic 
function, ACEI*, ACEI/ARB*, beta-blocker*, 
beta-blocker and ACEI or ARB*, MRA*. 
(*drug therapy at the time of discharge or 
death) 
Cox regression 
with stepwise 
selection 
Yes NR NR NR NR No 
Guazzi,85 
2007 
(N=17) Deaths resulting from HF 
deterioration with progression of 
congestive symptoms. (Adjudication 
from a panel of 3 physicians) 
3/6 LV mass, left ventricular end-systolic 
volume, VE/VCO2 slope, peak VO2, 
exercise oscillatory breathing, LVEF. 
Cox regression 
with stepwise 
selection 
Yes NR NR NR NR No 
Mozaffarian,84 
2007 
(SHFM) 
(N=684) Death due to progressively 
reduced cardiac output and failure 
of organ perfusion. (Investigator 
report or endpoint committee 
adjudication) 
14/17 Age, male sex, BMI, NYHA class, 
LVEF, ischaemic aetiology, SBP, diuretic 
dose, allopurinol, statin, sodium, 
creatinine, cholesterol, white blood cell, 
haemoglobin, lymphocytes, uric acid. 
Cox regression 
with stepwise 
selection 
No No Complete 
case 
analysis 
ROC AUC 
(0.85) 
NR No 
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Berger,87 2005 (N=31) Death due to pump failure 
owing to progressive deterioration of 
ventricular function with worsening 
HF symptoms even if the terminal 
episode was an arrhythmia. 
(Investigator report) 
3/16 Log NT-ANP, big endothelin, log BNP, 
log NT-BNP, NYHA class, diabetes, CAD, 
ACEI, LVEF, SBP, heart rate, rhythm, 
amiodarone, beta-blocker, ARB, 
hypertension. 
Cox regression 
with stepwise 
selection 
No NR NR ROC AUC 
(0.88) 
NR No 
Kyuma,88 
2004 
(N=15) Death due to deterioration of 
congestive HF. (NR) 
1/6 BNP, age, cardiac 123I-MIBG activity 
(late heart to mediastinum ratio), nitrate, 
diabetes, chronic renal dysfunction. 
Cox regression No NR NR NR NR No 
Poole-
Wilson,91 2003 
(ATLAS) 
(N=445 including 39 heart 
transplant) Patients with intractable 
HF, even if the terminal event was 
an arrhythmia; heart transplantation 
was included. (Endpoint committee 
adjudication) 
10/22 Lisinopril treatment, age, sex, 
ischaemic heart disease, LVEF, NYHA 
class, SBP, DBP, heart rate, sodium, 
potassium, creatinine, haemoglobin, 
antidiabetic agent, aspirin, beta-blocker, 
long acting nitrates, short acting nitrates, 
previous ACEI, anti-arrhythmic agent, 
calcium channel blocker, 
anticoagulant/warfarin 
Competing risk 
Cox regression 
No NR NR NR NR No 
Vrtovec,90 
2003 
(N=24) Death resulting from 
multiorgan failure caused by HF 
progression. (NR) 
2/21 QTc interval >440ms, 
BNP>1000pg/ml, BNP<700pg/ml, BNP 701-
1000 pg/ml, QRS >120ms, age, sex, 
ischaemic aetiology, NYHA class, heart rate, 
SBP, DBP, LVEF, LVEDD, sodium, 
creatinine, inotropes, diuretic, digoxin, ACEI, 
beta-blocker. 
Cox regression 
with stepwise 
selection 
No NR NR NR NR No 
Kearney,89 
2002 
(UK-HEART) 
(N=76) Death occurred after a 
documented period of symptomatic 
or hemodynamic deterioration. 
(Endpoint committee adjudication) 
3/17 Age, sex, NSVT, LVH, LVEDD, 
LVSDD, LVEF, sodium, potassium, urea, 
creatinine, ln cardiothoracic ratio, ln SDNN, 
ln VLEP, ln LFP, ln HFP and ln TP. 
Cox regression 
with stepwise 
selection 
No NR NR ROC AUC 
(0.77) 
NR No 
Madsen,99 
1997 
(N=29) Death due to progressive 
pump failure after a period of severe 
HF even if the terminal episode was 
an arrhythmia. (Investigator report) 
7/9 Sodium≤137 mmol/L, the increase in 
heart rate during exercise≤35 beats/min, 
NYHA class, maximal heart rate 
difference during 24h ≤50, LVEF, plasma 
noradrenaline, potassium, urea, exercise 
time ≤4 min. 
Cox regression 
with stepwise 
selection 
Yes NR NR NR NR No 
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Szabo,98 1997 (N=14) Death due to progressive 
pump failure included all fatalities 
occurring after a period of 
deterioration of HF symptoms. 
(Investigator report) 
3/4 LVEF <27%, SDNN <108 ms, percent 
differences between successive normal 
to normal NN intervals >50ms, 
LFP>14ms2. 
Cox regression Yes NR NR NR NR No 
Szabo,100 
1994 
(N=22) Death occurring in the 
presence of progressively 
worsening pump function despite 
maximal treatment. (Investigator 
report) 
2/3 LVEF ≤27%, presence of VT, VPB 
≥353/24hrs. 
Cox regression  No NR NR NR NR No 
Abbreviations are same as Table 1-3. 
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1.3.2.4 Model construction 
Apart from one study using logistic regression,74 all sudden death models were 
developed using Cox regression analysis. Only 2 studies examined the 
proportional hazards assumptions76, 82 (Table 1-3). All models for pump failure 
death used the Cox regression analysis, with only one study examining the 
proportional hazards assumption82 (Table 1-4).  
Overall, most studies considered routinely obtained variables for risk prediction 
including demographics, clinical assessments, comorbidities, treatment, and 12-
lead ECG, echocardiography, chest X-ray, routine laboratory measures, as well 
as natriuretic peptides. Some studies further incorporated other measures that 
are not routinely collected such as data from signal-averaged ECGs,77, 80 24h 
ambulatory ECGs (including heart rate variability parameters),75, 77, 79, 81, 89, 92, 94, 
96-100 cardiac Iodine-123 meta-iodobenzylguanidine (123I-MIBG) imaging,75, 80, 88 
cardiopulmonary exercise testing,85, 93, 99 quality of life82 and other 
neurohormonal tests (e.g. noradrenaline, endothelin).80, 87, 93, 95, 99 The number of 
candidate predictors varied generally from 3 to 29 for both the sudden death 
and pump failure death models (Table 1-3 and 1-4).  
Accordingly, the final models showed a great variety in number and type of 
prediction variables across these studies (Table 1-3 and 1-4). The number of 
final predictors for the sudden death models ranged from 1 to 14 (median 3.5); 
nearly identical findings were observed for the pump failure death models. Of 
note, overfitting (i.e. one predictive variable is studied for less than 10 events) 
was observed in 7 sudden death models and 6 pump failure death models, 
respectively. A few variables have emerged as the most consistent predictors for 
sudden death across these studies: LVEF was included in 11 models, in 7 of which 
LVEF was used as a continuous variable74, 77, 78, 80, 84, 91, 97 and in 4 of which LVEF 
was categorised by the value of 30%81, 86 or 27%98, 100 respectively; age was 
included in 7 studies as a continuous variable;74, 76, 78, 84, 91, 96, 97 B-type natriuretic 
peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 
included in 6 studies and in 1 as a continuous variable,93 3 as a continuous 
variable with log transformation,76, 78, 95 and 2 as a categorical variable;79, 86 
sex74, 76, 78, 84 and a history of diabetes74, 76, 78, 86 were included in 4 studies. 
Likewise, a few predictors for pump failure death emerged consistently: LVEF 
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was included in 9 studies, in 6 of which LVEF was used as a continuous variable75, 
78, 80, 84, 91, 99 and in 3 studies LVEF was categorised by the value of 27%98, 100 or 
35%;79 BNP or NT-proBNP was included in 6 studies with 1 using it as a continuous 
variable,88 3 as a continuous variable with log transformation,78, 82, 87 and 2 using 
categories;79, 90 and systolic blood pressure was included in 4 studies as a 
continuous variable78, 82, 84, 91 and in one study with the categorisation at 115 
mmHg;83 serum sodium was included in 4 studies as a continuous variable83, 84, 91, 
94 and in one study with the categorisation at 138 mmol/L;79 age 78, 83, 84, 91 and 
serum creatinine75, 80, 91, 94 were included in 4 studies as a continuous variable. 
1.3.2.5 Model performance 
Model discrimination was examined only in 7 (32%) models for sudden death 
using C statistics (i.e. ROC AUC and Harrell’s C),76, 78, 79, 84, 89, 95, 97 ranging from 
0.66 to 0.77 (Table 1-3); similarly, C statistics were only evaluated in 5 (31%) 
models for pump failure death,78, 79, 84, 87, 94 which were consistently high ranging 
from 0.77 to 0.88 (Table 1-4). In the remaining studies for sudden death or pump 
failure death, model discrimination was either unspecified or examined with the 
use of the measures of sensitivity and specificity which subjectivity involved in 
the selection of the cut-off values and were typically used in diagnostic tests. 
Model calibration was largely unexamined, except 2 sudden death models76, 79 
and 2 pump failure death models.78, 79 In general, model validation was poorly 
performed across these studies. For sudden death models only 2 had internal 
validation using bootstrap resampling method,79, 89 and one had ‘external 
validation’92 which involved developing a new model in another cohort rather 
than external validation (Table 1-3). Only one pump failure death model had 
internal validation79 (Table 1-4).  
1.3.2.6 The best existing models and their limitations 
In patients with HF-REF, the SHFM, originally designed to predict all-cause 
death,101 was reported to have good discrimination when applied to predict 
sudden death (ROC AUC 0.68) and, particularly, pump failure death (ROC AUC 
0.85).84 However, the SHFM was significantly less discriminatory for both sudden 
death and pump failure death in patients who had receiving beta-blockers than 
those did not.84 Besides, the predictive variables in the SHFM may more reflect 
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overall survival, and lack specificity for mode-specific death. Based on the same 
population, the SHFM authors recently developed the Seattle Proportional Risk 
Model (SPRM) to predict the proportion of deaths due to sudden death rather 
than the absolute risk.74 However, data were collected in the study cohorts 
before the widespread use of beta-blockers and MRAs. It is unclear whether 
these models still perform well when applied to a contemporary cohort receiving 
modern guideline recommended therapies. Models developed in the CORONA 
(the Controlled Rosuvastatin Multinational Trial in Heart Failure) trial showed 
good discrimination and calibration in predicting sudden death as well as pump 
failure death.78 Most patients had received guideline recommended therapies, 
but this cohort had exclusive ischaemic cause of HF. Besides, some routine 
biochemical measurements, such as serum chloride and albumin, were not 
considered in the model construction. Models developed in the MUSIC study also 
showed good calibration and discrimination to predict sudden death and pump 
failure death with C statistics of 0.77 and 0.80, respectively.79 Although a 
substantial number of patients in this study had received current guideline 
recommended therapies, this cohort included HF patients with full range of 
LVEFs, and about 25% had a LVEF ≥45%, i.e., they are not exclusively HF-REF 
patients. Besides, despite the mortality events having been adjudicated by an 
endpoint committee, which is unusual in prospective cohort studies, the number 
of events was relatively small, i.e. 90 sudden deaths and 123 pump failure 
deaths including 20 heart transplantations. More importantly, none of the 
models abovementioned have been validated in other independent cohorts, or 
has taken into account the competing risk of death from other causes (which is 
frequent). 
In patients with HF-PEF, no models have been developed to predict pump failure 
death, and there is only one model available to predict sudden death, which was 
based on the I-PRESERVE (the Irbesartan in Heart Failure with Preserved Ejection 
Fraction Study) trial,76 the largest trial in HF-PEF by far. All sudden death events 
were adjudicated by a central endpoint committee and the large number of 
events avoided model overfitting. The model simply consisted of 6 variables 
including age, male sex, history of diabetes, history of myocardial infarction, 
LBBB on ECG and natural log transformed NT-proBNP, and showed good 
discrimination (Harrell’s C 0.75) and calibration. Nevertheless, the model has 
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not been validated in an independent cohort. Moreover, the modelling approach 
did not consider the competing risk of death from other causes, which was large 
accounting for 74% of total mortality. 
1.3.3 Summary 
I have summarised separately the published models to predict sudden death and 
pump failure death in patients with HF, and undertook a critical appraisal of the 
available models in the aspects of study and patient characteristics, the number 
and adjudication of events, and model construction and model performance (i.e. 
discrimination, calibration and validation).  
These existing models are mainly developed in patients with HF-REF or in 
patients with HF where the LVEF was not specified; only one model has been 
developed to predict sudden death in patients with HF-PEF and none for pump 
failure death. These models all have some features that would limit the 
consideration of their use in clinical practice: many models were developed 
before the wide use of modern guideline-recommended medications, including 
beta-blockers and MRAs; most were based on a relatively small study size and 
few events, commonly leading to model overfitting; about half of the models 
used the individual investigator-reported events, in which inter-investigator bias 
may arise; more importantly, model performance, in particular model 
calibration and model validation, were largely unexamined. In other words, most 
models terminated at the phase of model construction, leaving the model 
quality and robustness unevaluated and unknown. These limitations may in part 
explain the reality that none of these models have been used in routine clinical 
practice.  
Consequently, there is a need to develop models to predict sudden death and 
pump failure death in patients with HF-REF and HF-PEF separately based on a 
large cohort with a great use of modern guideline recommended therapies, 
which account for the prognostic influence of the competing risk of death from 
other causes, and more importantly, to examine the discrimination and 
calibration ability of the developed models, and to examine the model 
robustness by validating in an independent cohort. I will develop models that 
meet these requirements in this thesis. In addition, I will examine if the classic 
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SHFM and the new SPRM still perform well in contemporary cohorts on optimal 
medical therapies. 
This will be achieved through the aims and objectives outlined in the next 
chapter.  
Aims and Objectives 
Aims 
Following introduction and the results of the literature review the following aims 
of this thesis were developed: 
• To describe the trends in the rates of sudden death and pump failure death 
over time in patients with HF-REF and in patients with HF-PEF. 
• To develop and validate models to predict sudden death and pump failure 
death in patients with HF-REF and in patients with HF-PEF. 
These aims were translated into the following objectives: 
Objectives 
• To describe the rates of sudden death and pump failure death in patients 
with HF-REF enrolled in 13 clinical trials over the period 1995-2015.  
• To examine how the risks of sudden death and pump failure death have 
changed between 1995 and 2015, with the cumulative introduction of 
disease modifying medications in patients with HF-REF enrolled in 13 clinical 
trials. 
• To calculate the cumulative incidences of sudden death and pump failure 
death during follow-up, particularly early after randomisation, in patients 
with HF-REF enrolled in 13 clinical trials. 
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• To examine if the risks of sudden death and pump failure death differ by the 
length of time between HF diagnosis and randomisation in patients with HF-
REF enrolled in 13 clinical trials. 
• To develop models to predict sudden death and pump failure death in a 
large contemporary cohort of patients with HF-REF enrolled in PARADIGM-
HF, accounting for the competing risk of death from other causes. 
• To validate the models developed in this thesis in another modern cohort of 
patients with HF-REF enrolled in ATMOSPHERE. 
• To validate the existing SHFM for predicting sudden death and pump failure 
death and the SPRM for predicting sudden death in the contemporary 
PARADIGM-HF and ATMOSPHERE cohorts. 
• To describe the rates of sudden death and pump failure death in patients 
with HF-PEF enrolled in 3 clinical trials over the period 1999-2013.  
• To examine how the risks of sudden death and pump failure death have 
changed over 1999-2013 in patients with HF-PEF enrolled in 3 clinical trials. 
• To calculate the cumulative incidences of sudden death and pump failure 
death during follow-up, particularly early after randomisation, in patients 
with HF-PEF enrolled in 3 clinical trials. 
• To examine if the risks of sudden death and pump failure death differ by the 
length of time between HF diagnosis and randomisation in patients with HF-
PEF enrolled in 3 clinical trials. 
• To develop models to predict sudden death and pump failure death in a 
large cohort of patients with HF-PEF enrolled in I-PRESERVE, accounting for 
the competing risk of death from other causes. 
• To validate the models for sudden death and pump failure death developed 
in this thesis in other two cohorts of patients with HF-PEF enrolled in 
CHARM-Preserved and TOPCAT.  
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Chapter 2 Methods 
2.1 Study population 
I will perform the analyses based on the individual patient-level data from 16 
RCTs in patients with chronic HF. Thirteen of these trials enrolled patients with 
HF-REF, which included the Randomized Aldactone Evaluation Study (RALES),66 
the Beta-blocker Evaluation of Survival (BEST) trial,102 the Cardiac Insufficiency 
Bisoprolol Study II (CIBIS-II),5 the Metoprolol CR/XL Randomised Intervention 
Trial in Congestive Heart Failure (MERIT-HF),7 the Valsartan Heart Failure (Val-
HeFT) trial,103 the SCD-HeFT trial,32 the Alternative trial and the Added trial of 
the CHARM programme,104, 105 the CORONA trial,8 the Gruppo Italiano per lo 
studio della sopravvivenza nell’Insufficienza cardiaca Heart failure (GISSI-HF) 
trial,106 the Eplerenone in Mild Patients Hospitalization and Survival Study in 
Heart Failure (EMPHASIS-HF),67 the PARADIGM-HF trial,27 and the Aliskiren Trial 
to Minimize OutcomeS in Patients with HEart failure (ATMOSPHERE) trial.6 The 
remaining 3 trials were conducted in patients with HF-PEF including the 
preserved trial of the CHARM programme (CHARM-Preserved),9 the Irbesartan in 
Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE),11 and the 
Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist (TOPCAT) trial.12 
All trials were approved by the institutional review boards or ethic committees 
at each of the participating centres and all patients provided written informed 
consent for participation in these trials. The design and results of these trials 
have been published and their main characteristics are summarised in Table 2-1 
and Table 2-2. 
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Table 2-1 Design of the included clinical trials in HF-REF   
RALES 
(N=1663) 
BEST 
(N=2708) 
CIBIS-II 
(N=2647) 
MERIT-HF 
(N=3991) 
Val-HeFT 
(N=5010) 
SCD-HeFT 
(N=2521) 
CHARM-Alternative 
(N=2028) 
Comparison Spironolactone  
25mg o.d. 
Bucindolol 
100mg b.i.d. 
Bisoprolol 10mg o.d. Metoprolol CR/XL  
200mg o.d. 
Valsartan  
160mg b.i.d. 
Shock-only,  
single-lead ICD 
Candesartan 
32mg o.d. 
 
Placebo Placebo Placebo Placebo Placebo Amiodarone  
400 mg o.d. 
Placebo 
      
Placebo 
 
Study period 1995-1998 1995-1999 1995-1998 1997-1998 1997-2000 1997-2003 1999-2003 
Follow-up duration  Mean 24 months Mean 2.0 years Mean 1.3 years Mean 1.0 year Mean 23 months Median 45.5 months Median 33.7 months 
Site distribution 195 centres in 15 
countries 
90 centres in the 
US and Canada 
274 hospitals in 18 
countries in western 
and eastern Europe 
313 sites in 13 
European countries 
and in the US 
302 centres in 16 
countries 
95 centres in the US 618 centres in 26 
countries 
Inclusion criteria 
       
Age -years - ≥18 18-80 40-80 ≥18 ≥18 ≥18 
NYHA class III-IV III-IV III-IV II-IV II-IV II-III II-IV 
LVEF-% ≤35 ≤35 ≤35 ≤40 (max walking 
distance ≤450m for 
6 min walk test if 
36-40) 
<40 with 
LVIDD/BSA >2.9 
cm/m2 
≤35 ≤40 
Prior HF hospitalisation No No No No No  No Hospitalisation for a 
cardiac reason within the 
previous 6 months if 
NYHA class II 
Exclusion criteria 
       
BP -mmHg - Systolic BP <80 Uncontrolled 
hypertension,  
systolic BP <100  
Systolic BP <100  - - Symptomatic 
hypotension 
Potassium -mmol/L >5.0  - - - - - ≥5.5  
Serum creatinine >221umol/L  ≥265 umol/L  ≥300 umol/L  - >221umol/L  >221umol/L  ≥265 umol/L  
Others - Heart rate <50 
beats/min 
Heart rate <60 
beats/min 
- - Pacemaker implanted Intolerance to ACEIs 
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CHARM-Added 
(N=2548) 
CORONA 
(N=5011) 
GISSI-HF 
(N=4574) 
EMPHASIS-HF 
(N=2737) 
PARADIGM-HF 
(N=8399) 
ATMOSPHERE 
(N=7016) 
Comparison Candesartan  
32mg o.d. 
Rosuvastatin  
10mg o.d. 
Rosuvastatin  
10mg o.d. 
Eplerenone 50mg o.d. Sacubitril/valsartan 
(LCZ696) 200mg b.i.d. 
Aliskiren/enalapril 
 
Placebo Placebo Placebo Placebo Enalapril 10mg b.i.d. Aliskiren 300mg o.d. 
      
Enalapril 5-10mg b.i.d. 
Study period 1999-2003 2003-2007 2002-2008 2006-2010 2009-2014 2009-2015 
Follow-up duration  Median 41 months Median 32.8 months Median 3.9 years Median 21 months Median 27 months Median 36.6 months 
Site distribution 618 centres in 26 
countries 
371 sites in 19 
European countries, 
Russia, and South 
Africa 
357 centres in Italy 278 centres in 29 countries 1043 centres in 47 
countries 
789 centres in 43 
countries 
Inclusion criteria 
      
Age -years ≥18 ≥60 ≥18 ≥55 ≥18 ≥18 
NYHA class II-IV II-IV II-IV II II-IV II-IV 
LVEF-% ≤40 ≤40 (≤35 if NYHA 
class II) 
≤40, or >40 if 
hospitalised for HF in 
the previous year 
≤30 (30-35 if QRS 
duration >130 ms) 
≤40/≤35 (since December 
2012) 
≤35 
Prior HF hospitalisation Hospitalisation for a 
cardiac reason within 
previous 6 months if 
NYHA class II 
No HF hospitalisation 
within previous 12 
months if LVEF >40%    
Cardiovascular 
hospitalisation within prior 6 
months; if not, BNP 
≥250pg/ml or NT-proBNP 
≥500pg/ml in men and 
≥750pg/ml in women. 
If HF hospitalisation 
within prior 12 months, 
BNP ≥100 pg/ml or NT-
proBNP ≥400pg/ml; if not, 
BNP ≥150pg/ml or NT-
proBNP ≥600pg/ml 
If HF hospitalisation 
within prior 12 months, 
BNP ≥100 pg/ml or NT-
proBNP ≥400pg/ml; if 
not, BNP ≥150pg/ml or 
NT-proBNP ≥600pg/ml 
Exclusion criteria 
      
BP -mmHg Symptomatic 
hypotension 
- - Uncontrolled hypertension or 
symptomatic hypotension, or 
systolic BP <85 
Symptomatic 
hypotension, systolic BP 
<100 at screening or <95 
at randomisation 
Symptomatic 
hypotension, systolic BP 
<95 at visit 1 or <90 at 
randomisation 
Potassium -mmol/L ≥5.5 - - >5.0 within 24 hours prior to 
randomisation 
>5.2 at screening, or >5.4 
at randomisation 
≥5.0 at screening, or 
≥5.2 at randomisation 
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Renal function 
Serum creatinine -
umol/L 
eGFR -ml/min/1.73m2 
 
Creatinine ≥265 Creatinine >221 Creatinine >221  eGFR <30 at randomisation eGFR <30 at screening, 
or <35 at randomisation 
eGFR <40 at screening, 
or <35 at randomisation, 
or eGFR decrease >25% 
from screening to 
randomisation 
Others - Ischaemic aetiology - Haemoglobin <10 g/dl A history of angioedema, 
or intolerant of ACEIs or 
ARBs 
A history of inability to 
take ACEIs 
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Table 2-2 Design of the included clinical trials in HF-PEF   
CHARM-Preserved 
(N=3023) 
I-PRESERVE 
(N=4128) 
TOPCAT 
(N=3445) 
Comparison Candesartan 32 mg 
o.d. 
Irbesartan 300 mg o.d. Spironolactone 15-45 mg o.d. 
 
Placebo Placebo Placebo 
Study period 1999-2003 2002-2008 2006-2013 
Follow-up duration Median 36.6 months Mean 49.5 months Mean 3.3 years 
Site distribution 618 centres in 26 
countries 
293 sites in 25 countries 233 sites in 6 countries 
Inclusion criteria 
   
Age -years ≥18 ≥60 ≥50 
NYHA class II-IV II-IV - 
LVEF-% >40 ≥45 ≥45 
Prior HF 
hospitalisation 
Hospitalisation for a 
cardiac reason within 
previous 6 months if 
NYHA class II 
HF hospitalisation within 
previous 6 months; if not, 
ongoing class III or IV 
symptoms with 
corresponding evidence 
HF hospitalisation within prior 
12 months; if not, a BNP ≥100 
pg/ml or NT-proBNP ≥360 
pg/ml within 60 days before 
randomisation 
Exclusion criteria 
   
BP -mmHg Symptomatic 
hypotension 
Systolic BP <100, or systolic 
BP >160 or diastolic BP >95 
despite antihypertensive 
therapy 
Systolic BP >160 
Renal function Serum creatinine  
≥265 umol/L  
Serum creatinine  
>221 umol/L 
Serum creatinine ≥221 
umol/L, or eGFR <30 
ml/min/1.73m2 
Potassium -mmol/L ≥5.5 - ≥5.0 
Others - Intolerant of ARBs, previous 
LVEF <40%, haemoglobin 
<11 g/dl 
- 
 
 
2.2 Outcomes of interest 
In this thesis, sudden death and pump failure death are the outcomes of 
interest. Adjudication of these events in each trial was carried out by an 
independent endpoint committee in a blinded fashion using pre-specified 
criteria. The definitions of both outcomes used in these trials are presented in 
Table 2-3. Similar, but not identical criteria, were used in most of these trials. 
To increase consistency across the trials, death occurring suddenly but 
accompanied by preceding HF worsening in BEST and Val-HeFT was considered as 
pump failure death rather than sudden death. 
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Table 2-3 Definitions of sudden death and pump failure death used in the included trials 
Trial Definition of sudden death  Definition of pump failure death  
RALES Witnessed death from cardiac causes heralded by abrupt loss of 
consciousness within 1 hour after the onset of symptoms in a patient in 
whom death was unexpected. 
Deaths due to worsening HF (defined as increasing symptoms or signs 
requiring an increase treatment). 
BEST Sudden death either with or without preceding changes in HF symptoms. Death due to pump failure with or without secondary arrhythmic death. 
CIBIS-II Death occurring within 1 hour without previous worsening of symptoms of 
HF, including unexpected deaths occurring during sleep to be sudden when 
patients were found dead by family members sharing the same room in the 
morning. 
Death occurred as a consequence of progressive deterioration of HF, acute 
pulmonary oedema, or cardiogenic shock. 
MERIT-HF Witnessed instantaneous death in the absence of progressive circulatory 
failure lasting for ≥60 minutes, unwitnessed death in the absence of pre-
existence progressive circulatory failure or other causes of death, death 
within 28 days after resuscitation from cardiac arrest in the absence of pre-
existing circulatory failure or other causes of death, death during attempted 
resuscitation, or death within 60 minutes from the onset of new symptoms 
unless a cause other than cardiac was obvious. 
Death from HF, which was any of cardiogenic shock, pulmonary edema, heart-
failure symptoms or signs requiring intravenous therapy or oxygen, 
confinement to bed because of HF symptoms, or sudden death during hospital 
stay for aggravated HF. 
Val-HeFT Observed or unobserved death that was apparently sudden and unexpected 
and usually out of the hospital. 
Deaths occurred in the setting of worsening symptoms of HF, usually in the 
hospital or after a recent hospitalization for worsening HF. 
SCD-HeFT Death occurred suddenly and presumed to cardiac causes including 
tachyarrhythmia, bradyarrhythmia and HF. 
Death occurring in a subject with progressively worsening HF over the 
preceding 3 to 4 months, in whom long-term survival was not expected, was 
considered to be due to HF even when death was sudden or associated with a 
terminal ventricular tachyarrhythmia event. This adjudication required the 
absence of evidence that the cause of progressive HF was not a sustained 
supraventricular or ventricular tachyarrhythmia. Events deemed related to HF 
therapy such as those triggered by digoxin toxicity or inotrope-related 
ventricular tachyarrhythmia were also characterized as being due to HF. 
CHARM-Alternative, 
CHARM-Added and 
CHARM-Preserved 
Death that occurred unexpectedly in an otherwise stable patient. Examples 
may include: the time of death is unknown; for identified arrhythmic death; in 
the absence of medical care; patient is unable to be resuscitated from 
cardiac arrest; and patient who later dies from an attempted resuscitation. 
Death occurring within the context of clinically worsening symptoms and/or 
signs of HF without evidence of another cause of death.  
If worsening HF is secondary to MI, then MI should be listed as the primary 
cause of death given that the patient suffered a MI within 14 days of death. 
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CORONA Sudden death refers to sudden cardiac death and includes the following 
deaths: 
1. Witnessed instantaneous death in the absence of any acute symptoms; 
and also in the absence of progressive circulatory failure, the latter lasting 
for 60 minutes or more. 
2. Unwitnessed death in the absence of pre-existing progressive circulatory 
failure or other modes of death. 
3. Patients resuscitated from a cardiac arrest in the absence of pre-existing 
circulatory failure; or other modes of death and who die within 28 days 
without a non-cardiovascular cause (e.g. suicide, accident) being identified; 
or a similar patient who dies during an attempted resuscitation. 
4. Death within 60 minutes from the onset of new symptoms unless other 
cause than cardiac is obvious. 
Pump failure death included the following deaths: 
Cardiogenic shock (defined as hypotension resulting in a failure to maintain 
normal renal or cerebral function for >60 minutes prior to death). 
Pulmonary oedema sufficient to cause tachypnoea and distress. 
HF symptoms or signs requiring iv therapy or oxygen administration. 
Confinement to bed but only if this is due to HF symptoms. 
Sudden death during hospitalisation for aggravated HF. 
 
GISSI-HF Sudden death from cardiac cause occurring within 1 hour from symptom 
onset. 
Not reported. 
EMPHASIS-HF Witnessed/unwitnessed instantaneous or near instantaneous death that 
occurred without warning, or within 24 hours of non-diagnostic symptoms. 
The cause of death has to be considered cardiac in origin and not due to 
another adjudicated cause including AMI, arrhythmias or progressive HF. 
No sudden symptoms: Patient was observed by anyone in his/her usual 
state of health within 24 hours of death. 
Sudden symptoms: Patient experienced abrupt loss of consciousness within 
1 hour of the onset of at least 1 of the following new or worsened symptoms: 
chest pain, dyspnoea at rest, dyspnoea with exertion, palpitations, 
syncope/near syncope, other. 
Diagnosis of HF by at least 1 of each of the following 2 criteria:  
1. Symptoms: newly developed or worsening increasing dyspnoea at rest or 
with exertion, newly developed or worsening orthopnoea, or newly developed 
or worsening paroxysmal nocturnal dyspnoea. 
2. Signs: newly developed or worsening increasing peripheral oedema, newly 
developed or worsening pulmonary basilar crackles/post-tussive rales, newly 
developed or worsening jugular venous distension, newly developed or 
worsening third heart sound or gallop rhythm, chest x-ray evidence of 
pulmonary venous congestion, renal hypoperfusion (worsening renal function) 
with no other apparent cause, or pleural effusion.  
And if time allows, change in HF medication (new or additional oral diuretic, 
intravenous diuretic, intravenous vasodilator, intravenous inotrope, intravenous 
digitalis/digitoxin or other) or supportive measures (continuous positive airway 
pressure, mechanical ventilation, mechanical support, e.g. intra-aortic balloon 
pump and ventricular assist device or other). 
No evidence of other primary cause of death (e.g. AMI based on negative 
biochemical markers of cardiac myocyte necrosis). 
PARADIGM-HF and 
ATMOSPHERE 
Death occurring unexpectedly in an otherwise stable subject.  Further sub-
classification of sudden death is as follows: 
1. Death witnessed or subject last seen alive <1 hour previously or 
2. Subject last seen alive ≥1 hour and < 24 hours previously. 
Death occurring in the context of clinically worsening symptoms and/or signs of 
HF without evidence of another cause of death. Death occurring as a 
complication of the implantation of a ventricular assist device, cardiac 
transplant, or other surgery primarily for refractory HF. Death occurring after 
referral to hospice specifically for progressive HF. 
Chapter 2 69 
 
 
 
  
Note: If worsening HF is secondary to MI, then MI should be listed as the 
primary cause of death if the subject suffered an MI within 14 days of death. 
I-PRESERVE Unexpected death in a previously stable patient. This includes patients who 
were comatose then died after attempted resuscitation. Patients in this 
category should have had recent human contact before the event. Patients 
who die who have been out of contact for prolonged or unknown periods of 
time will be classified as unknown. 
Death from worsening/intractable HF which generally occur during 
hospitalization but can occur at home during hospice care. Terminal 
arrhythmias associated with pump failure deaths will be classified as a pump 
failure death. Pump failure secondary to a recent myocardial infarction will be 
classified as an MI death. 
TOPCAT Death that occurred unexpectedly in an otherwise stable subject. Further 
sub-classification of sudden death will be as follows: witnessed or last seen 
≥1 and <24 hours. 
Death occurring within the context of clinically worsening symptoms and/or 
signs of HF without evidence of another cause of death. If worsening HF is 
secondary to MI, then MI should be listed as the primary cause of death given 
that the subject had an MI within 14 days of death. 
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2.3 Statistical analyses 
I analysed the data in several ways, in line with the objectives of my thesis.  
2.3.1 Descriptive statistics 
I examined the baseline characteristics of the total population, patients with 
and without sudden death (i.e. those who died from other non-sudden causes 
and those alive) and patients with and without pump failure death (i.e. those 
who died from other causes than pump failure death and those alive) in each 
trial, respectively. These included patient demographics, clinical assessment, 
medical history, medical treatment and device, and 12-lead ECG findings and 
laboratory measurements if available. Continuous variables that were normally 
distributed (e.g. age, LVEF) were summarised as means and standard deviations 
and compared using Student’s t-test between 2 subgroups or one-way ANOVA 
among ≥3 subgroups. Continuous variables that were not normally distributed, 
e.g. NT-proBNP, were summarised using medians and interquartile ranges, and 
analysed using the non-parametric Mann-Whitney U test for comparison of 2 
subgroups or the Kruskal-Wallis test for comparison of ≥3 subgroups. Categorical 
variables were presented as numbers and percentages and analysed with a chi-
square test or the Fisher’s exact test if cells have an expected frequency of ≤5. 
2.3.2 Handling missing data 
Missing data occur when no data value is available for a variable in an 
observation. Rubin defined three main forms of missingness including missing 
completely at random (i.e. the probability of data being missing does not 
depend on the observed or unobserved data), missing at random (i.e. the 
probability of data being missing does not depend on the unobserved data, 
conditional on the observed data), and missing not at random (the probability of 
data being missing does depend on the unobserved data, conditional on the 
observed data).107 There are several methods to handle missing data.108 One is 
complete case analysis, i.e. to include only those patients for whom all variables 
involved in the analysis are observed, which is commonly used especially when 
the volume of missing is not large. Another popular method is the imputation 
technique, including simple imputation and multiple imputation, which is 
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appropriate when data are missing (completely) at random.109 The third is the 
missing-indicator method, which does not impute missing values, instead, 
missing observations are set to a certain value with an additional dummy 
variable to indicate these missing; this method allows all patients to be included 
in the analysis, thus maintaining statistical power. 
Analyses in this thesis were based on complete case analysis approach, except 
for the scenario described below. Estimated glomerular filtration rate (eGFR) 
and NT-proBNP are important prognostic factors but were not available in all 
patients. Measurements of eGFR were available in all trials except the CHARM 
programme, where it was only recorded in North American patients. NT-proBNP 
was recorded only in a subset of patients in Val-HeFT (81% available), CORONA 
(73%), GISSI-HF (15%), PARADIGM-HF (99.8%), ATMOSPHERE (91%), I-PRESERVE 
(84%) and TOPCAT (18%), and was not recorded in the rest of trials (i.e. 
completely missing). To examine the additional prognostic effect of eGFR and 
NT-proBNP on the risk of each mode of death, sensitivity analyses were 
performed using the missing-indicator method, in addition to the primary 
complete case analysis. Details were described in Chapter 3 and Chapter 6. 
2.3.3 Survival data and censoring  
In clinical research, it is very common that the outcome is the time from a 
defined point to the occurrence of a given event, e.g. time to CV death after 
some treatment intervention, or time to tumour recurrence after surgery. This 
type of outcome provides more information than simply whether or not an event 
has occurred. Data with time-to-event outcomes are known as survival data, or 
more precisely, time-to-event data.110 A distinctive feature of survival data is 
censoring, which refers to those subjects in whom an event is not observed 
within the follow-up and thus they provide only partial information on when the 
event would occur.111 There are three types of censoring: ‘left censoring’ where 
the event occurred prior to certain time but not exactly when, ‘interval 
censoring’ where the event occurred within some window of time, and most 
commonly, ‘right censoring’ where the event has yet to occur.110 In this thesis I 
focused on ‘right-censoring’ since all events are observed exactly or right 
censored. ‘Right censoring’ occurs when the follow-up of a subject ends before 
an event can be observed, which can be due to loss to follow-up (e.g. the 
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patient moves away), withdrawal due to a side effect, or the subject does not 
experience an event by the end of the study (administrative censoring) or the 
subject has another event that precludes the occurrence of the primary one (a 
competing risk). However, these censored subjects cannot be excluded in the 
analysis since the amount of time they go through without experiencing an event 
itself is informative and must be accounted for.   
2.3.4 Overview of survival analysis: conventional vs. competing 
risk methods 
Survival analysis refers to a set of statistical methods to analyse survival data 
and handle censoring, i.e. allowing censored subjects to contribute information 
until they leave the study for a variety of reasons.  
Conventional methods for analysing survival data make the important 
assumption of independent or non-informative censoring.112, 113 This means that 
censoring occurs randomly, and if these subjects could be followed beyond the 
time points they were censored, they would have the same future risk for the 
occurrence of a given event as the non-censored counterparts. These methods 
are appropriate when the outcome of interest is overall survival, but are 
problematic if the outcome of interest is mode-specific death or a non-fatal 
event since competing risks arise in this case.112, 113  
Specifically, a competing risk is an event whose occurrence precludes the 
occurrence of the outcome of primary interest. To illustrate this, assume that 
the outcome of interest is CV death, but clearly a subject could die from a non-
CV cause, in this case non-CV death serves as a competing risk. A subject who 
dies due to a non-CV cause is no longer at risk for CV death no matter how long 
the duration of follow-up is extended. This setting violates the assumption of 
‘independent censoring’, which assumes that a patient dying from a non-CV 
cause still has the same chance of having a CV death as those who remain alive. 
This only exists in an imaginary world where a subject could not die from other 
causes but a CV cause. In the example of non-fatal events, death serves as a 
competing risk which precludes the occurrence of non-fatal events.  
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In the presence of competing risks, censoring subjects when a competing event 
occurs, as conventional survival analysis does, is inappropriate. A more 
appropriate approach is to acknowledge the presence of competing risks and to 
make inference for the primary outcome accounting for competing risks; this 
method is known as competing risk analysis.112 
2.3.5 Estimation of the event probability (or cumulative incidence) 
The initial description of survival data is often to graphically present and 
estimate the probability (or risk) of a given event over a certain time interval. 
There are several fundamental concepts to define.114 One of the most important 
concepts is the survival function S(t), which is the probability of survival or 
remaining event free to a certain time t. Another important concept is the 
failure function F(t), which can be estimated by one minus the survival 
function, 1-S(t), estimating the probability of having an event by time t, given 
that a subject has not had an event just prior to that time. In the absence of 
competing risk, the Kaplan-Meier (KM) estimate is commonly used to estimate 
the survival function S(t).115 Using the product limit method, it computes the 
survival probability at a certain time interval multiplied by any earlier computed 
probabilities to get the final estimate, given that the probability of survival at 
the end of the interval on condition that the subject was a survivor at the 
beginning of the interval (conditional probability). The survival probability at 
any particular time t is calculated by the formula given below: 
𝑆(𝑡) =
number of subjects at risk prior to time t –  number of subjects having an event
number of subjects at risk prior to time t
 
Only those remaining event-free and uncensored at time t are counted as at risk, 
i.e. those censored by time t are not counted in the calculation. Under 
independent censoring, making inference on the completely observed population 
can be feasible, those at risk are representative for those censored, i.e. the 
censored subjects are not at high or low risk of having an event. However, 
censorings can also be caused by competing risks, and these censored subjects 
will certainly not experience the primary event any longer. Since subjects that 
will never fail are treated as if they could fail, the naïve estimate of event 
probability based on KM estimate is upwards biased, especially if the competing 
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risk is large.116 A more appropriate estimate takes into account the possibility 
that a subject is at risk for the primary outcome of interest, but can also be 
removed from the risk because of competing events. This estimate refers to the 
cumulative incidence function (CIF).114, 116 The CIF for kth cause is defined as 
CIFk(t), which denotes the probability of experiencing the kth event before time 
t and before the occurrence of other competing events. I omit the details here 
as they are not essential for a qualitative understanding of the CIF and have 
been described in many publications.114, 116   
In this thesis, sudden death and pump failure death are the outcomes of 
interest, and deaths from other causes, i.e. non-sudden deaths and deaths other 
than due to worsening HF, serve as competing risks respectively. I calculated the 
CIF for mode-specific death at different time points during follow-up and plotted 
the CIF curves over time, counting death from other causes as a competing risk. 
2.3.6 Regression models for survival data 
Another fundamental concept in survival analysis is hazard function h(t), which 
denotes the instantaneous rate of occurrence of the event at time t among 
subjects who are still at risk to time t.114 Hazard function regression models 
allow examination of the effect of a set of covariates on survival or the risk of a 
given event. Cox proportional hazards regression models are most popularly used 
in survival analysis and Fine-Gray sub-distribution proportional hazards 
regression models are increasingly used in the context of competing risks.112, 117, 
118  
2.3.6.1 Cox proportional hazards regression model 
Cox proportional hazards regression models are used with the assumption that 
the covariates have a multiplicative effect on the hazard and this effect is 
constant over time. This can be written as h(t)=h0(t)exp(Xβ), where h0(t) 
denotes the baseline hazard function (i.e. the hazard function when all 
covariates are set to zero), X denotes a set of covariates, and β denotes their 
corresponding coefficients; the exponentiation of a beta-coefficient for a certain 
covariate is the corresponding hazard ratio (HR), which denotes the relative 
change in the hazard function by increasing the covariate by one unit holding 
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other covariates constant. A hazard ratio reflects whether, and to what the 
extent, the rate of outcome of interest is affected by a certain covariate. A HR 
=1 implies no association between the covariate and the rate, a HR >1 implies 
that an increase in the covariate value is associated with a higher rate, whereas 
a HR <1 implies that an increase in the covariate value is associated with a lower 
rate. Moreover, the further away the HR is from 1, the larger the effect in that 
covariate. 
Under independent censoring, the cumulative hazard function H(t) can be 
estimated by ‘Nelson-Aalen estimate’, which is based on the same calculation 
information of the KM estimate.114 There is a ‘one-to-one’ relationship between 
the hazard function and incidence: a risk factor associated with a higher hazard 
of a given event is also associated with a higher incidence.114 The relation is:  
                       𝑆(𝑡) = 𝑒−𝐻(𝑡) or 𝐹(𝑡) = 1 − 𝑒−𝐻(𝑡) 𝑜𝑟 𝑆(𝑡) = 𝑆0(𝑡)exp (𝑋𝛽) 
However, in the presence of competing risks, there is no longer direct 
correspondence between the hazard of the event of interest and its cumulative 
incidence, as the cumulative incidence of a given event depends not only on the 
hazard itself but also on the hazard of competing events.114 Regression models in 
the context of competing risks are detailed below. 
2.3.6.2 Models in the presence of competing risks: cause-specific hazards 
and sub-distribution hazards 
To accommodate competing risks, there mainly exist two modelling methods: 
one models the association of covariates on the cause-specific hazard function, 
and the other models the association of covariates on the CIF.114 Both methods 
are valid and the choice of the appropriate approach depends on the research 
question: the former is preferred for aetiological questions and the latter is 
preferred for prognostic research.112  
Assuming the research question is to assess the effect of experimental treatment 
compared with placebo on sudden death, then non-sudden deaths serve as 
competing events. If the treatment reduced the rate of sudden death but did not 
affect the rate of non-sudden deaths, the treatment would reduce the absolute 
risk of sudden death, but this reduced risk would leave more patients at risk for 
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non-sudden death. Thus, although the treatment did not affect the rate of non-
sudden death, we would expect to observe an increase in the absolute risk of 
non-sudden death associated with the treatment. Similarly, if the treatment 
only modestly reduced the rate of sudden death but dramatically reduced the 
rate of non-sudden death, the absolute risk of sudden death would increase 
merely because the lowered incidence of non-sudden death leaves more patients 
vulnerable to sudden death. In this case, the over-compensation could conceal 
the moderate rate reduction of sudden death associated with the treatment. If 
it is an aetiological research question (e.g. does the treatment decrease the rate 
of the event of interest?), cause-specific hazards regression models are 
preferred, and if it is relevant to prognosis (e.g. does the treatment decrease 
the absolute risk of the event of interest?), models on CIF are recommended.112 
Regression on the cause-specific hazard function can be achieved by a Cox 
proportional cause-specific hazards regression model. This model assumes the 
same functional association between covariates and the cause-specific hazard 
function, as the popular Cox model for overall survival in the absence of 
competing risks does for the association between covariates and the overall 
hazard. It is technically valid that a cause-specific hazards model for a specific 
event can be fitted in a standard Cox regression treating competing events as if 
they were censored.  
Several models for regression on CIF have been introduced and the most popular 
model of this kind is the Fine-Gray sub-distribution proportional hazards 
model.116, 118 It builds a direct correspondence between covariates and 
cumulative incidence of a cause-specific event, as does the popular Cox model 
for the incidence of all-cause mortality.114 The resulting estimate for the effect 
of each covariate is known as sub-distribution hazard ratio (sHR). The numerical 
interpretation of sHR is same as the HR, and the difference is that the effect of 
the former is on CIF while the latter is on rate.114 
In this thesis, I used the Cox cause-specific hazards regression model to assess 
the rates of mode-specific death across trial arms and by HF duration, and used 
Fine-Gray sub-distribution hazards model for model development and validation. 
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2.3.7 Model validity assessment 
2.3.7.1 Overfitting 
Overfitting refers to a scenario that random error or noise is fitted in a 
regression model resulting in unstable coefficients and it occurs when a model is 
excessively complex, such as having too many parameters relative to the number 
of observations/events. To avoid overfitting, there is a rule of thumb that there 
should be at least 10 events for each final prediction variable of a multivariable 
model.71 
2.3.7.2 Linearity assumption for continuous variables 
The linearity assumption refers to an equal change of a continuous variable will 
have an equal effect on outcome. A variety of non-linear relationships are 
possible. It is inappropriate to put a continuous variable into a model without 
examining its linearity, since any non-linearity may lead to a loss of efficiency 
and introduce bias underlying the association.71 I used restricted cubic spline 
method with 5 knots to examine the linearity for a continuous variable with 
outcome.119, 120 If the relationship appears non-linear, certain cutoff values or 
mathematical transformation were applied based on the spline curves and 
clinical relevance.   
2.3.7.3 Distributional assumption 
For a certain regression analysis to be valid, the distributional assumption must 
be true. The Cox model makes a key assumption of proportional hazards, which 
refers to the survival functions for two strata must have hazards that are 
proportional over time, i.e. the relative hazard is constant. This assumption is 
commonly examined by testing Schoenfeld residuals with the null hypothesis of a 
zero slope in a generalised linear model on time, and by visually assessing the 
parallelism of curves from log-log survival plots.121 For the Fine-Gray model in 
the competing risk settings, an equivalent to the hazard for the Cox model is the 
sub-distribution hazard, which refers to the hazard for an individual who either 
fails from cause k or does not, and in the latter case has an infinite failure time 
for cause k, given that with mutually exclusive event types, those who fail from 
one cause are no longer at risk for failing from other causes. Like the Cox model, 
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the Fine-Gray model makes a proportional assumption for the sub-distribution 
hazards, i.e. they are constant over time or time-independent.118 The 
assumption can be examined by adding time varying terms of the covariates in 
the model. The proportional sub-distribution hazards assumption is valid if none 
of the time-dependent covariates are statistically significant.122  
2.3.8 Model performance assessment 
When developing, or validating a model, we need to quantify how good the 
prediction from a model is, that is model performance. There are two 
fundamental aspects of model performance: calibration and discrimination.123  
Calibration, sometimes known as ‘prediction accuracy’, is the magnitude of 
agreement between predicted and observed event rates at a population level, 
with better models having smaller differences in-between. Calibration can be 
assessed graphically with the prediction on the x-axis and observation on the y-
axis, and perfect prediction should be on the 45-degree line. For a binary 
outcome, the y-axis (observation) only contains 0 and 1 values, and thus 
smoothing techniques, e.g. loess algorithm, are routinely used to estimate the 
observed probabilities corresponding to the predicted probabilities. We can also 
plot the results for patients with similar predicted risks to identify mis-
calibration in certain risk subgroups. For example, we can plot the observed 
outcome by deciles of prediction risks, which is a graphical depiction of the 
Hosmer-Lemeshow goodness-of-fit test.124 For survival data, we can plot the 
observed vs. predicted probabilities of an event across different risk subgroups 
over certain time interval to identify mis-calibration in certain risk subgroups or 
at certain timepoints.72 
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Figure 2-1 Calibration graph - an example 
 
Each circle corresponds to observed risk based on data (x axis) and predicted risk from the model 
(y axis) in each risk subgroup. The dotted line is the 45-degree line which indicates perfect 
prediction. 
 
Discrimination, also known as ‘separation’, refers to the ability of a model to 
distinguish patients who develop an event (‘case’) from those who do not 
(‘control’). In time-to-event settings, discrimination is the ability to separate 
who will develop an event earlier from who will develop an event later or not at 
all.72, 123 The concordance (C) statistic is routinely used to quantify the 
discrimination ability of prognostic models with binary and survival outcomes. In 
general, C statistic ranges from 0.5 (random concordance) to 1 (perfect 
concordance). For a binary outcome, C statistic is identical to the area under 
the receiver operating characteristic curve (ROC AUC),125 which plots sensitivity 
(proportion of ‘cases’ for whom the model predicts are at high risk) against 1-
specificity (proportion of ‘controls’ for whom the model predicts are high risk) 
for consecutive cutoffs for the probability of an outcome. The area indicates an 
estimated probability that for any possible pair of ‘case’ and ‘control’, the 
‘case’ has a higher predicted risk than the ‘control’ (i.e. concordant pair).  For 
time-to-event outcomes, C statistic is a rank-order measure, in which a pair of 
patients is called concordant if the event occurs earlier in the patient who has 
the higher risk predicted by a model, or vice versa. In the presence of right 
censoring, a pair of patients cannot be ordered if both are event-free and which 
one will first develop an event is unknown. The C statistic proposed by Harrell, 
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known as Harrell’s C, ignores the pairs that cannot be ordered and only use 
‘orderable’ pairs to calculate the concordant pairs among them.126 Harrell’s C 
depends on the study-specific censoring distribution, to accommodate for this a 
modified C index is proposed using the inverse of the probability of censoring 
weighted estimator.127  
Figure 2-2 ROC curve - an example 
A point in the upper left corner or coordinate (0,1) of the ROC space indicates a perfect 
classification with an area under ROC curve of 1.0, which represents 100% sensitivity (no false 
negatives) and 100% specificity (no false positives). The dotted diagonal line gives an area 
under ROC curve of 0.5 which represents a random guess i.e. no-discrimination. The more the 
points move towards the upper left direction, the better the discrimination is. The example given 
here has an excellent discrimination with an area under the ROC curve of 0.89. 
 
It can be argued that discrimination ability is more important than calibration 
since inadequate calibration can be adjusted (i.e. re-calibrated) whereas poor 
discrimination cannot be altered.72 
2.3.9 Model validation 
Validation refers to the process of assessing the performance of a predefined 
model in new data. It is worth noting that there are two misconceptions of the 
validation practice including repeating the whole modelling process in the 
validation cohort (which leads to new predictors and their corresponding 
coefficients), and refitting to the validation cohort the predictors from the 
derivation model (same predictors but different coefficients), both of which will 
lead to a new model other than validating the existing model, and as such, 
would themselves need validation.72 In terms of the independence of the 
validation cohort, validation can be divided into two subtypes: internal 
validation, which reuses a subset or all of the cohort in which a model was 
developed, and external validation, which uses a different cohort from the one 
for model derivation. In general, internal validation is used to assess and correct 
for the sampling variation of the derivation model, and bootstrapping is the most 
commonly used technique;73 whereas, external validation examines the 
replicability or generalisability of a developed model to a different but plausibly 
related cohort, which is crucial and a first step towards the introduction of a 
new model for consideration to use in clinical practice.73  
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In this thesis, external validation was performed for all the derived models to 
predict sudden death and pump failure death in both the HF-REF and HF-PEF 
populations. The performances of the existing SHFM84 and SPRM74 were also 
examined externally in the contemporary PARADIGM-HF and ATMOSPHERE 
cohorts.6, 27 
2.3.10 Individual risk estimation 
To estimate the absolute risk (i.e. CIF) for mode-specific death in individual 
patients using the models to be developed, the risk score was first calculated as 
the sum of the products of each predictor coefficient from each model and the 
corresponding predictor value in an individual patient.101 The derived risk score 
was to compute the corresponding incidence of mode-specific death at a given 
follow-up time by using the formula below:  
Estimated CIF (t) =1 – [1 - CIF0 (t)]**exp(risk score) =1 - S0(t)**exp(risk score) 
2.3.11 Statistical software packages 
The cumulative incidence function and C index were achieved using the ‘cmprsk’ 
and ‘pec’ packages in R project (version 3.2.3). Other data analyses were 
performed using the Stata (version 14, Stata Corp, College Station, TX, US). All 
tests of statistical significance were two-tailed at a significant level of 0.05 (p 
<0.05).  
Chapter 3 Rates of sudden death and pump 
failure death over time in HF-REF 
In this chapter I will describe the rates of sudden death and pump failure death 
separately in patients with HF-REF enrolled in 13 clinical trials over the period 
1995-2015. I will examine how the risks of sudden death and pump failure death 
have changed over this period with the cumulative use of evidence based 
medications, the cumulative incidence of each mode of death during follow-up, 
particularly early after randomisation, and whether these risks differ by the 
length of time from HF diagnosis to randomisation. The cumulative incidence 
function method will be used to calculate the incidences of sudden death and 
pump failure death during follow-up counting the competing risk of death from 
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other causes, the linear regression analysis will be used to examine the rate of 
each mode of death with the calendar year, and the conventional Cox regression 
analysis will be used to compute the annual rates and hazard ratios for each 
mode of death across trial arms and by HF duration.   
 
3.1 Methods 
3.1.1 Study population 
I attempted to obtain all major randomised clinical trials which supported 
guideline recommendations in patients with stable chronic HF-REF (with a LVEF 
≤40% and NYHA class II-IV symptoms) conducted over the last two decades. 
Among the 43 trials identified, 21 trials were excluded as the reasons indicated 
in Figure 3-1. A total of 22 trials were eligible for this analysis, but data were 
not obtained in 9 trials, and their characteristics are summarised in Appendix 
Table 4. Therefore, 13 RCTs available were included in the analysis, namely, 
RALES, BEST, CIBIS-II, MERIT-HF, Val-HeFT, SCD-HeFT, CHARM-Alternative, 
CHARM-Added, CORONA, GISSI-HF, EMPHASIS-HF, PARADIGM-HF and 
ATMOSPHERE.5-8, 27, 32, 66, 67, 102-106 The design and results of these trials have been 
reported in detail and their main characteristics are outlined in Table 2-1.  
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Figure 3-1 CONSORT diagram for trial selection in HF-REF 
 
3.1.2 Outcomes of interest 
I examined the annual rates and the proportions of sudden death and pump 
failure death separately in each trial, the cumulative incidences of each mode of 
death at different time points from randomisation (30 days, 60 days, 90 days, 
180 days, 1 year, 2 years and 3 years), and the risks of each mode of death 
according to the length of time between diagnosis of HF and randomisation (≤3 
months, >3-6 months, >6-12 months, >1-2 years, >2-5 years, and >5 years). In 
each trial, an independent endpoint committee blindly adjudicated death events 
using pre-specified criteria. Similar but not identical criteria were used in these 
trials (Table 2-2). In BEST and Val-HeFT, sudden death events included those 
with preceding HF symptoms, and to ensure consistency these events were 
counted as pump failure death other than sudden death in this analysis. 
 
3.1.3 Adjustment for potential confounding variables 
The confounding effect of a number of variables on the risks of sudden death 
and pump failure death was examined including age, sex, LVEF, NYHA class, 
ischaemic aetiology, and a history of myocardial infarction, hypertension and 
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diabetes, which had been collected in all trials. The measurements of eGFR 
were available in all trials except CHARM (measured only in North American 
patients). Plasma NT-proBNP levels were measured only in Val-HeFT, CORONA, 
GISSI-HF, PARADIGM-HF and ATMOSPHERE. The additional prognostic influence of 
eGFR and NT-proBNP on each mode of death was examined in patients with full 
data and after missing data imputation. 
 
3.1.4 Statistical analyses 
Baseline characteristics of all patients in each trial were summarised as means 
with standard deviations for continuous variables and percentages for 
categorical variables. Baseline characteristics of patients having a sudden death 
and the remaining patients (i.e. those alive and those dying non-suddenly) in 
each trial were also summarised and compared using Student’s t-test for 
continuous variables and chi square test for categorical variables. Likewise, 
baseline characteristics in patients with pump failure death and the rest (i.e. 
those survived and those died without worsening HF) in each trial were 
summarised and compared. NT-proBNP was presented as median and 
interquartile range and analysed using the Mann-Whitney U test, because of 
violating the assumption of normal distribution.  
 
The cumulative incidences for sudden death and pump failure death in each trial 
were calculated separately at the time points of 30 days, 60 days, 90 days, 180 
days, 1 year, 2 years and 3 years from randomisation, counting death from other 
causes as a competing risk, and were also outlined using cumulative incidence 
curves. The annual rates of each mode of death in each trial and in each arm of 
each trial were calculated per 100 patient-years. The hazard ratio for each 
mode of death in each trial arm was calculated using cause-specific Cox 
proportional hazards model using the placebo arm of the earliest trial, RALES, as 
the reference. In a Cox model, the association between calendar year and the 
risk for each mode of death was then examined with adjustment for 
randomisation arm and with trial as a random effect. These models were then 
further adjusted for the confounding variables listed above. For models further 
adjusting for eGFR and NT-proBNP, complete case analysis was performed as the 
primary analysis, together with a sensitivity analysis based on the missing-
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indicator method using single imputation for a missing value in those trials 
where data were not completely missing with a further covariate indicating 
missing data.108 The associations between calendar year and the annual rates of 
sudden death and pump failure death were assessed separately in a multiple 
linear regression model with the randomisation year and randomisation arm as 
covariates, weighted by the inverse-variance of the annual rate with trial as a 
random effect. A multivariate linear regression analysis was also undertaken for 
all-cause death to assess whether apparent outliers from the overall trends may 
result from the patients themselves enrolled in a specific trial or the 
misclassification of death events.  
 
The duration between HF diagnosis and randomisation was collected in BEST, 
Val-HeFT, SCD-HeFT, CHARM-Alternative, CHARM-Added, CORONA, GISSI-HF, 
EMPHASIS-HF, PARADIGM-HF and ATMOSPHERE, but not in RALES, CIBIS-II or 
MERIT-HF. To assess the effect of HF duration on the risk of each mode of death, 
patients with data available were merged and further divided into 6 groups: 
diagnosis within 3 months, >3-6 months, >6-12 months, >1-2 years, >2-5 years, 
and >5 years. According to these duration groups, cumulative incidence curves 
for each mode of death were produced and were compared using the Gray’s 
test,128 and hazard ratios for each mode of death were calculated employing 
patients with new-onset HF (within 3 months of diagnosis before randomisation) 
as reference, with adjustment for the confounding variables listed above and 
counting within-trial clustering.   
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3.2 Results 
This analysis consisted of 46,163 patients randomised in the 13 clinical trials 
conducted in patients with HF-REF over the past two decades (1995-2015), after 
excluding patients having an ICD or CRT-D (N=4228) at baseline and patients with 
a LVEF greater than 40% in GISSI-HF (N=461). Of the analysable patients, 10,857 
(23.5% of total population) died during follow-up, and 4190 (9.1%) were 
attributed to sudden death and 2973 (6.4%) were due to pump failure death. 
The levels of eGFR were measured in 43,060 (93%) patients and both eGFR and 
plasma NT-proBNP were available in 20,730 (45%) patients.   
 
3.2.1 Baseline characteristics of study population 
The key characteristics of patients in each trial are summarised in Table 3-1. 
There was a higher mean age in CORONA (73 years) and EMPHASIS-HF (69 years) 
compared to the other trials, because both set a minimum age threshold for 
inclusion (60 and 55 years respectively). Most patients were men across the 
trials; the proportion was highest in CIBIS-II (81%) and lowest in CHARM-
Alternative (68%). By design, all patients had NYHA class III-IV (predominantly 
class III) symptoms in RALES, BEST and CIBIS-II; all were in class II-III in SCD-HeFT 
(mainly class II) and all were in class II in EMPHASIS-HF. The remaining trials 
enrolled patients mainly in NYHA class II and III. The mean LVEF varied greatly 
by trial, ranging from 23% in BEST to 32% in GISSI-HF. CORONA by design only 
enrolled patients with an ischaemic aetiology; ischaemic aetiology was 
predominant in the remaining trials except GISSI-HF (40%). The proportion of 
patients with a history of hypertension was much higher in the more recent trials 
and this was also the case but to a lesser extent for the prevalence of diabetes. 
The proportion of patients with renal dysfunction (defined as eGFR <60 
ml/min/1.73 m2) varied across the trials ranging from 25% in ATMOSPHERE to 
57% in CORONA. The use of ACEIs/ARBs was consistently high (over 90%) across 
these trials, except CHARM-Alternative in which all patients were intolerant to 
ACEIs. Rates of treatment with a beta-blocker and a MRA were substantially 
higher in the more contemporary trials.   
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Table 3-1 Baseline characteristics of patients in the included trials in HF-REF 
  
  
Missing data 
No. (%)  
RALES 
(N=1663) 
BEST 
(N=2617) 
CIBIS-II 
(N=2647) 
MERIT-HF 
(N=3991) 
Val-HeFT 
(N=5010) 
SCD-HeFT 
(N=1692)  
Age -years 0 65.2±11.9 60.2±12.4 60.9±10.5 63.3±9.7 62.7±11.1 58.9±11.9 
Male (%) 0 73.2 77.9 80.5 77.5 80.0 76.5 
Race (%) 3860 (8.4) 
      
White 
 
86.6 69.4 99.0 94.1 90.3 76.4 
Black 
 
7.2 23.5 0.3 5.2 6.9 16.2 
Asian 
 
1.9 - 0.6 0.4 - 1.2 
Other 
 
4.3 7.1 0.2 0.3 2.8 6.2 
LVEF -% 112 (0.2) 25.4±6.7 23.1±7.3 27.4±6.0 27.7±6.9 26.7±7.2 23.9±6.9 
NYHA class (%) 12 (<0.1) 
      
I 
 
0.1 0 0 0 0.1 0 
II 
 
0.4 0 0 41 61.8 70.6 
III 
 
70.5 91.7 83.2 55.4 36.2 29.4 
IV 
 
29.0 8.3 16.8 3.6 1.9 0 
Ischaemic aetiology (%) 8 (<0.1) 54.6 58.0 49.8 65.3 57.2 52.0 
Blood pressure -mmHg 
       
Systolic 20 (<0.1) 122.2±20.1 117.3±18.0 129.7±19.4 129.8±17.2 123.8±18.5 120.0±19.4 
Diastolic 29 (<0.1) 74.6±11.6 71.1±11.2 79.7±11.1 78.3±9.2 75.5±10.6 71.2±11.3 
Heart rate -beats/min 18 (<0.1) 80.9±14.2 81.7±13.2 80.5±15.0 82.5±10.2 73.4±12.6 74.6±13.9 
Body mass index 1810 (3.9) - 28.0±5.9 26.9±4.1 27.2±4.7 26.9±4.5 - 
Medical history (%) 
       
Current smoking 6677 (14.5) - 17.8 16.6 14.5 - 15.6 
Previous HF 
hospitalisation 
22498 (48.7) - - - - - - 
Angina  6641 (14.4) 6.7 51.7 - 39.7 21.2 30.5 
Myocardial infarction  4 (<0.1) 28.4 41.8 55.0 48.2 46.9 44.3 
PCI 10668 (23.1) - 15.2 4.4 8.0 - 21.1 
CABG 4314 (9.3) - 28.3 - 20.9 23.2 26.8 
Hypertension 1 (<0.1) 23.5 59.2 43.5 43.8 40.9 56.0 
Diabetes 0 22.2 36.1 11.7 24.7 25.5 30.4 
Atrial fibrillation 4315 (9.3) - 23.9 - 16.7 12.1 14.7 
Stroke  4308 (9.3) - - 7.4¶ 7.9 6.9 7.2 
Laboratory tests 
       
eGFR -ml/min/1.73m2 3103 (6.7) 64.9±23.0 70.1±24.7 77.5±31.3 66.6±19.6 61.4±15.6 70.9±22.2 
eGFR <60 
ml/min/1.73m2 (%) 
3086 (6.7) 47.8 35.7 31.6 36.8 46.9 32.3 
Creatinine -mg/dl 3084 (6.7) 1.24±0.36 1.24±0.41 1.18±0.33 1.21±0.37 1.28±0.31 1.21±0.74 
NT-proBNP -pg/ml 25419 (55.1) - - - - 901a  
[377-1990] 
- 
Treatment (%) 
       
Digitalis 14 (<0.1) 73.5 92.1 52.0 63.6 67.3 71.1 
Diuretics 14 (<0.1) 100 93.4 98.5 90.3 85.5 83.5 
ACEI 14 (<0.1) 94.5 91.4 96.0 89.5 92.7 85.6 
ARB 9199 (19.9) - 6.2 - 6.6 NA 14.8 
ACEI/ARB 2678 (5.8) - 96.6 - 95.7 96.4 97.5 
Beta-blocker 14 (<0.1) 10.6 NA NA NA 34.9 68.7 
MRA 9001 (19.5) NA 3.3 10.9 0.2 5.0 19.3 
Pacemaker 15008 (32.5) - 7.9 - 3.9                - 0 
CRT-P  30723 (66.6) - - - - - - 
Treatment arm 0 49.4 50.0 50.1 49.9 50.1 49.9 
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CHARM-
Alternative 
(N=1960) 
CHARM-
Added 
(N=2448) 
CORONA 
(N=4875) 
GISSI-HF 
(N=3820) 
EMPHASIS-
HF 
(N=2316) 
PARADIGM-
HF 
(N=7156) 
ATMOSPHERE 
(N=5968) 
Age -years 66.1±10.8 63.6±11.0 72.7±7.1 67.2±10.8 68.7±7.7 63.7±11.6 63.1±12.1 
Male (%) 67.6 78.4 76.0 79.0 76.1 76.7 76.5 
Race (%) 
       
White 88.4 90.5 98.6 - 81.2 62.6 61.7 
Black 3.7 5.0 0.3 - 2.2 4.8 1.6 
Asian 6.6 3.6 0.7 - 13.3 20.7 28.9 
Other 1.3 0.9 0.4 - 3.3 11.9 7.8 
LVEF -% 30.0±7.4 28.1±7.5 30.1± 6.4 31.6±6.2 26.4± 4.4 29.9±6.1 28.8±5.5 
NYHA class (%) 
       
I 0 0 0 0 0 4.9 0 
II 48.0 24.1 37.1 63.1 100 69.8 61.4 
III 48.5 72.9 61.5 34.8 0 24.6 36.4 
IV 3.5 2.9 1.5 2.2 0 0.8 2.2 
Ischaemic aetiology 
(%) 
67.8 62.5 100 40.1 68.1 58.7 54.2 
Blood pressure -
mmHg 
       
Systolic 130.4±18.7 125.6±18.6 129.5±16.4 126.5±18.0 125.0±16.8 122.0±15.4 124.4±18.2 
Diastolic 76.8±10.7 75.2±10.7 76.3±8.9 77.1±9.8 75.3±10.2 74.2±10.0 77.6±11.0 
Heart rate -beats/min 74.5±13.7 73.7±13.1 71.8±11.2 73.2±13.6 72.3±12.7 72.9±12.1 72.4±12.7 
Body mass index 27.4±4.8 27.8±5.3 27.2±4.6 27.0±4.5 27.5±4.9 27.9±5.5 27.2±5.3 
Medical history (%) 
       
Current smoking 13.7 17.1 8.7 14.9 10.7 14.1 12.4 
Previous HF 
hospitalisation 
68.2 77.0 - 44.4 51.2 62.3 58.5 
Angina  58.1 52.6 72.7 11.4 43.5 27.2 23.7 
Myocardial 
infarction  
61.0 55.2 59.4 32.9 48.2 40.8 37.3 
PCI 15.7 14.3 11.2 8.1 18.6 18.1 16.3 
CABG 24.5 24.1 16.5 13.9 15.6 13.2 11.6 
Hypertension 49.8 48.1 63.9 52.7 67.2 71.3 62.4 
Diabetes 27.0 30.2 29.5 25.9 31.6 33.6 27.3 
Atrial fibrillation 25.3 26.4 40.9 18.8 30.7 36.6 33.5 
Stroke  8.4 8.4 12.5 4.5 9.4 8.3 7.0 
Laboratory tests 
       
eGFR -
ml/min/1.73m2 
68.5±26.7b 73.3±26.9c 57.8±15.1 69.9±21.8 71.4±21.8 68.8±20.3 75.1±24.7 
eGFR <60 
ml/min/1.73m2 (%) 
41.5b  32.5c 57.0 33.9 32.1 34.4 24.6 
Creatinine -mg/dl 1.21±0.45b 1.16±0.40c 1.30±0.32 1.15±0.34 1.14±0.30 1.10±0.29 1.02±0.27 
NT-proBNP -pg/ml - - 1480d 
[618-3156] 
884e 
[381-1980]  
- 1640 
[888-3342] 
1204f 
[630-2285] 
Treatment (%) 
       
Digitalis 45.4 57.9 33.1 40.1 28.2 31.2 32.5 
Diuretics 85.3 90.0 88.2 81.5 86.4 79.8 79.0 
ACEI 0 100 80.2 78.1 78.5 77.2 66.9 
ARB NA NA 12.7 18.1 19.0 23.0 1.4 
ACEI/ARB NA NA 91.8 93.7 94.4 99.8 67.3 
Beta-blocker 54.2 54.7 75.0 63.3 86.0 92.4 90.9 
MRA 23.5 16.8 38.9 39.8 NA 55.5 35.3 
Pacemaker 8.0 7.9 10.6 10.4 8.4 7.2 4.1 
CRT-P  - - - - 2.3 1.9 1.8 
Treatment arm 49.6 50.2 50.1 50.0 50.3 49.8 66.6 
¶ Cerebrovascular diseases. 
The letters denote the number of patients available: a=4067(81%), b=618(32%), c=872(36%), d= 
3555(73%), e=570(15%), f=5408(91%). 
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3.2.2 Baseline characteristics of patients with sudden death 
There were some differences in baseline characteristics between patients with 
and without sudden death (Table 3-2). Overall, those who died suddenly were 
older, more often male, and were more likely to have worse HF symptoms, lower 
LVEF or an ischaemic aetiology than those who had not died suddenly. Patients 
with sudden death tended to have a lower blood pressure, a higher heart rate, 
and were more likely to have prior myocardial infarction, a history of diabetes 
and renal dysfunction, but were less likely to have undergone coronary 
revascularisation. The NT-proBNP levels were substantially higher in patients 
having a sudden death in the trials with data available. There was a less use of a 
beta-blocker but a greater use of a diuretic, digitalis or MRA in patients having a 
sudden death. 
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Table 3-2  Baseline characteristics of patients with and without sudden death in the 
included trials in HF-REF 
 RALES BEST CIBIS-II MERIT-HF 
  SD 
(N=192) 
Others 
(N=1471) 
SD 
(N=294) 
Others 
(N=2323) 
SD 
(N=131) 
Others 
(N=2516) 
SD 
(N=211)  
Others 
(N=3780) 
Age -years 66.5±10.1 65.1±12.1 61.0±12.2 60.1±12.4 61.1±10.0 60.9±10.6 63.3±9.9 63.3±9.7 
Male (%) 81.8** 72.1 79.3 77.7 83.2 80.4 83.4* 77.2 
LVEF-% 24.4±6.7* 25.5±6.7 21.3±7.0*** 23.3±7.3 26.2±6.3* 27.5±6.0 25.7±7.0*** 27.8±6.9 
NYHA class (%)   
 
  
 
  
 
* 
 
I 0 0.1 0 0 0 0 0 0 
II 0.5 0.3 0 0 0 0 31.3 41.5 
III 74.5 70.0 91.2 91.8 81.7 83.3 64.5 54.9 
IV 25.0 29.6 8.8 8.2 18.3 16.7 4.3 3.6 
Ischaemic aetiology 
(%) 
60.9 53.8 68.7*** 56.7 48.9 49.8 72.0* 64.9 
Race (%) * 
 
  
 
  
 
  
 
White 89.1 86.3 66.3 69.8 99.2 99 91.9 94.3 
Black 4.2 7.6 26.2 23.2 0 0.3 7.1 5.1 
Asian 4.2 1.6 0 0 0.8 0.6 0.5 0.4 
Other 2.6 4.5 7.5 7.0 0 0.2 0.5 0.2 
BP -mmHg   
 
  
 
  
 
  
 
Systolic 122.9±21.0 122.1±20.0 116.1±16.8 117.5±18.2 126.5±18.3 129.9±19.4 125.7±17.4*** 130.0±17.1 
Diastolic 74.3±12.3 74.6±11.5 69.8±11.0* 71.3±11.2 78.4±10.0 79.8±11.1 77.3±9.4 78.3±9.2 
Heart rate -beats/min 79.0±14.2 81.1±14.2 81.3±13.3 81.8±13.2 82.2±14.2 80.4±15.0 83.7±11.1 82.5±10.1 
BMI - - 27.8±5.8 28.0±5.9 26.4±3.8 26.9±4.1 26.7±4.9 27.3±4.7 
Medical history (%)   
 
  
 
  
 
  
 
Current smoking - - 13.3* 18.3 13.0 16.8 15.2 14.4 
HF hospitalisation - -   
 
- - - - 
Angina 8.3 6.5 53.7 51.4 - - - - 
Myocardial 
infarction 
32.3 27.9 48.6* 40.9 53.4 55.1 53.6 47.9 
PCI - - 15.6 15.2 3.1 4.5 - - 
CABG - - 29.9 28.1 - - 15.6 21.2 
Hypertension 32.3** 22.4 63.3 58.6 45.8 43.3 43.1 43.8 
Diabetes 25.0 21.8 38.4 35.9 13.0 11.7 24.2 24.7 
Atrial fibrillation - - 23.8 23.9 - - 21.8* 16.4 
Stroke - - - - 16.0¶*** 7.0¶ 10.9 7.7 
Laboratory tests   
 
  
 
  
 
  
 
eGFR – 
ml/min/1.73m2 
61.0±22.1* 65.4±23.0 66.2±21.3** 70.7±25.0 72.0±26.5* 77.7±31.5 65.2±20.9 66.7±19.5 
eGFR <60 
ml/min/1.73m2 (%) 
52.6 47.1 41.0* 35.1 35.1 31.5 40.3 36.4 
Creatinine -mg/dl 1.33±0.39*** 1.23±0.36 1.29±0.37* 1.23±0.41 1.23±0.31 1.17±0.33 1.26±0.37* 1.21±0.37 
NT-proBNP -pg/ml - - - - - - - - 
Treatment (%)   
 
  
 
  
 
  
 
Digitalis 74.0 73.0 95.9* 91.6 67.9*** 50.8 74.9*** 63.0 
Diuretics - - 96.3* 93.1 - - 93.8 90.1 
ACEI 95.3 93.4 92.9 91.3 97.7 94.6 89.6 89.5 
ARB - - 3.7 6.5 - - 6.2 6.6 
ACEI/ARB - - 96.3 96.7 - - 95.7 95.7 
Beta-blocker 8.3 10.9 NA NA NA NA NA NA 
MRA NA NA 4.8 3.1 12.2 10.8 - - 
Pacemaker - - 8.8 7.7 - - - - 
CRT-P - - - - - - - - 
Treatment arm 42.7* 50.3 44.6* 50.7 36.6** 50.8 37.4*** 50.6 
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Val-HeFT SCD-HeFT CHARM-Alternative 
 SD 
(N=442) 
Others 
(N=4568) 
SD 
(N=168) 
Others 
(N=1524) 
SD 
(N=186) 
Others 
(N=1774) 
Age -years 63.3±10.8 62.6±11.1 59.0±11.3 58.8±12.0 67.6±10.9 66.0±10.8 
Male (%) 86.7*** 79.3 83.3* 75.7 74.2* 66.9 
LVEF-% 24.8±7.2*** 26.9±7.1 23.0±6.5 24.0±6.9 28.4±7.7** 30.1±7.3 
NYHA class (%) ** 
 
* 
 
* 
 
I 0 0.1 0 0 0 0 
II 55.4 62.4 63.7 71.4 38.2 49.0 
III 41.0 35.7 36.3 28.6 56.5 47.6 
IV 3.6 1.8 0 0 5.4 3.3 
Ischaemic aetiology (%) 64.0** 56.5 64.3*** 50.6 77.4** 66.7 
Race (%)   
 
  
 
  
 
White 89.6 90.4 76.8 76.3 86.6 88.6 
Black 7.2 6.8 17.3 16.1 2.2 3.8 
Asian - - 1.2 1.2 9.1 6.3 
Other 3.2 2.8 4.8 6.4 2.2 1.2 
BP -mmHg   
 
  
 
  
 
Systolic 123.2±18.6 123.8±18.5 118.5±19.6 120.1±19.4 128.5±18.9 130.6±18.7 
Diastolic 74.5±10.1* 75.6±10.6 69.7±11.2 71.4±11.3 76.0±11.2 76.9±10.6 
Heart rate -beats/min 74.7±13.4* 73.3±12.5 74.9±13.8 74.6±14.0 75.3±13.7 74.4±13.7 
BMI 26.9±4.6 27.0±4.5 - - 26.7±5.0* 27.5±4.8 
Medical history (%)   
 
  
 
  
 
Current smoking - - 13.1 15.9 15.6 13.5 
HF hospitalisation - -   
 
73.7 67.6 
Angina 22.4 21.1 38.7* 29.6 57.5 58.1 
Myocardial infarction 52.9** 46.3 60.1*** 42.6 69.4* 60.1 
PCI - - 22.6 20.9 14.5 15.8 
CABG 25.3 23.0 30.4 26.4 24.2 24.6 
Hypertension 43.9 40.6 60.7 55.4 50.5 49.8 
Diabetes 27.8 25.2 39.3** 29.4 33.9* 26.3 
Atrial fibrillation 14.5 11.9 16.1 14.6 31.7* 24.6 
Stroke 6.8 6.9 8.3 7.1 7.5 8.5 
Laboratory tests   
 
  
 
  
 
eGFR - 
ml/min/1.73m2 
61.0±16.0 61.4±15.6 69.9±21.9 71.0±22.2 59.1±20.8**c 69.4±27.0d 
eGFR <60 
ml/min/1.73m2 (%) 
46.9 46.8 31.0 32.4 58.5**c 39.8d 
Creatinine -mg/dl 1.31±0.31* 1.28±0.31 1.23±0.38 1.21±0.77 1.34±0.36*c 1.20±0.45d 
NT-proBNP -pg/ml 1335***a 
[571-3034] 
867b 
[363-1909] 
- - - - 
Treatment (%)   
 
  
 
  
 
Digitalis 73.8** 66.7 78.0* 70.3 57.5*** 44.1 
Diuretics 90.7*** 85.0 92.3** 82.5 91.9** 84.6 
ACEI 93.4 92.6 85.1 85.7 0 0.2 
ARB NA NA 17.9 14.4 NA NA 
ACEI/ARB 96.4 96.4 98.8 97.3 NA NA 
Beta-blocker 31.0 35.3 72.0 68.3 50.5 54.6 
MRA - - 17.9 19.5 29.0 22.9 
Pacemaker - - - - 9.7 7.8 
CRT-P - - - - - - 
Treatment arm 52.0 49.9 45.2 50.5 40.9* 50.6 
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CHARM-Added CORONA GISSI-HF 
  SD 
(N=311) 
Others 
(N=2137) 
SD 
(N=631)  
Others 
(N=4244) 
SD 
(N=367) 
Others 
(N=3453) 
Age -years 65.8±10.4*** 63.3±11.1 73.7±7.6*** 72.6±7.0 70.2±9.2*** 66.9±10.9 
Male (%) 81.0 78.1 82.6*** 75.1 80.4 78.9 
LVEF-% 26.6±7.3*** 28.3±7.5 29.3±6.7*** 31.2±6.4 30.5±6.1*** 31.7±6.2 
NYHA class (%) * 
 
** 
 
*** 
 
I 0 0 0 0 0 0 
II 18.3 25.0 33.6 37.6 52.9 64.2 
III 77.8 72.2 63.7 61.1 43.3 33.9 
IV 3.9 2.8 2.7 1.3 3.8 2.0 
Ischaemic aetiology (%) 67.2 61.8 100 100 50.4*** 39.0 
Race (%)   
 
  
 
  
 
White 90.7 90.5 98.1 98.7 - - 
Black 3.2 5.2 0 0.3 - - 
Asian 4.8 3.5 1.1 0.7 - - 
Other 1.3 0.8 0.8 0.4 - - 
BP -mmHg   
 
  
 
  
 
Systolic 123.7±17.1 125.9±18.8 127.1±17.5*** 129.8±16.3 126.9±18.8 126.5±18.0 
Diastolic 74.4±10.7 75.4±10.7 74.6±9.1*** 76.5±8.8 77.0±9.6 77.1± 9.8 
Heart rate -beats/min 74.0±13.2 73.6±13.1 72.5±11.1 71.7±11.2 73.7±12.7 73.1±13.7 
BMI 27.5±5.2 27.9±5.3 26.5±4.5*** 27.3±4.6 26.8±4.4 27.1±4.5 
Medical history (%)   
 
  
 
  
 
Current smoking 17.7 17.0 7.8 8.8 11.7 15.3 
HF hospitalisation 77.2 76.9 - - 47.4 44.1 
Angina 53.7 52.4 71.6 72.8 14.7* 11.0 
Myocardial infarction 59.2 54.7 65.5*** 58.5 39.2** 32.2 
PCI 10.0* 14.9 9.7 11.5 6.5 8.2 
CABG 24.1 24.1 15.7 16.6 14.7 13.8 
Hypertension 48.2 48.1 61.2 64.3 52.9 52.7 
Diabetes 36.0* 29.3 32.5 29.1 29.2 25.5 
Atrial fibrillation 24.8 26.7 44.1 40.4 23.2* 18.3 
Stroke 9.3 8.2 13.5 12.3 5.7 4.4 
Laboratory tests   
 
  
 
  
 
eGFR - 
ml/min/1.73m2 
71.4±29.9e 73.5±26.5f 55.1±15.0*** 58.2±15.1 64.3±21.2*** 70.5±21.8 
eGFR <60 
ml/min/1.73m2 (%) 
38.8e 31.6f 64.1*** 55.6 43.6*** 32.9 
Creatinine -mg/dl 1.20±0.41e 1.15±0.40f 1.38±0.34*** 1.29±0.31 1.24±0.40*** 1.14±0.33 
NT-proBNP -pg/ml - - 2894***g 
[1263-5326] 
1352h 
[562-2803] 
1659***i 
[829-3092] 
840j 
[353-1767] 
Treatment (%)   
 
  
 
  
 
Digitalis 62.4 57.3 37.1* 32.5 51.5*** 38.8 
Diuretics 93.9* 89.5 92.1** 87.6 88.0*** 80.8 
ACEI 100 99.9 80.8 80.1 77.1 78.2 
ARB NA NA - - 17.7 18.2 
ACEI/ARB NA NA 90.8 91.9 92.4 93.9 
Beta-blocker 50.5 55.3 73.1 75.2 58.9 63.8 
MRA 18.0 16.6 43.9** 38.2 39.0 39.9 
Pacemaker 8.4 7.9 10.0 10.7 14.7** 9.9 
CRT-P - - - - - - 
Treatment arm 47.3 50.6 49.4 50.2 53.1 49.6 
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*P<0.05, **p<0.01, *** p<0.001 
The letters denote the number of patients available: a=352 (80%), b=3715(81%), c=53(28%), 
d=567(32%), e=103(33%), f=769(36%), g=422(67%), h=3133(74%), i=49 (13%), j=521 (15%), k 
=573 (94%), m=4835 (90%). 
SD denotes sudden death. 
  
EMPHASIS-HF PARADIGM-HF ATMOSPHERE 
  SD 
(N=125) 
Others 
(N=2191) 
SD 
(N=525) 
Others 
(N=6631) 
SD 
(N=607)  
Others 
(N=5361) 
Age -years 69.9±8.4 68.6±7.6 63.0±12.2 63.7±11.6 63.2±12.5 63.1±12.1 
Male (%) 80.8 75.9 82.9*** 76.3 84.0*** 75.6 
LVEF-% 25.8±5.0 26.4±4.4 29.1±6.5** 29.9±6.1 28.1±5.5** 28.8±5.5 
NYHA class (%)   
 
*** 
 
*** 
 
I 0 0 4.0 4.9 0 0 
II 100 100 63.0 70.3 50.6 62.6 
III 0 0 31.8 24.0 45.5 35.4 
IV 0 0 1.1 0.7 4.0 2.0 
Ischaemic aetiology (%) 78.2* 67.5 65.1** 58.2 57.5 53.8 
Race (%) * 
 
*** 
 
** 
 
White 73.6 81.6 54.1 63.3 55.8 62.4 
Black 2.4 2.2 6.1 4.7 1.7 1.6 
Asian 21.6 12.8 29.0 20.0 35.6 28.2 
Other 2.4 3.4 10.9 12.0 7.0 7.8 
BP -mmHg   
 
  
 
  
 
Systolic 123.3±16.4 125.1±16.8 120.8±15.7 122.1±15.3 121.3±16.9*** 124.7±18.3 
Diastolic 74.8±9.0 75.3±10.3 73.9±10.5 74.2±10.0 76.9±10.8 77.7±11.0 
Heart rate -beats/min 74.0±11.9 72.2±12.7 73.6±11.7 72.9±12.2 73.1±12.8 72.3±12.7 
BMI 26.7±5.3 27.5±4.9 27.2±5.7** 28.0±5.5 26.2±5.2*** 27.3±5.3 
Medical history (%)   
 
  
 
  
 
Current smoking 11.2 10.6 13.7 14.1 11.9 12.5 
HF hospitalisation 55.6 50.9 65.0 62.1 59.0 58.4 
Angina 45.2 43.4 30.5 26.9 24.7 23.6 
Myocardial infarction 56.5 47.8 48.2*** 40.2 38.4 37.2 
PCI 17.7 18.6 13.1** 18.5 13.5* 16.7 
CABG 15.3 15.6 12.0 13.3 11.4 11.7 
Hypertension 68.8 67.1 69.7 71.4 59.1 62.8 
Diabetes 36.8 31.3 35.4 33.5 22.7** 27.8 
Atrial fibrillation 35.5 30.4 32.8 36.9 31.6 33.8 
Stroke 16.3** 9.0 9.0 8.3 8.7 6.8 
Laboratory tests   
 
  
 
  
 
eGFR - 
ml/min/1.73m2 
69.6±21.3 71.5±21.8 68.6±19.8 68.8±20.3 75.4±22.1 75.0±24.9 
eGFR <60 
ml/min/1.73m2 (%) 
34.4 32.0 34.7 34.4 24.9 24.6 
Creatinine -mg/dl 1.18±0.31 1.14±0.30 1.13±0.29 1.10±0.29 1.03±0.27 1.02±0.27 
NT-proBNP -pg/ml - - 2444*** 
[1256-5198] 
1580 
[870-3133] 
1801***k 
[903-3183] 
1142m 
[607-2149] 
Treatment (%)   
 
  
 
  
 
Digitalis 41.1** 27.5 35.4* 30.9 42.0*** 31.4 
Diuretics 90.3 86.1 81.7 79.6 84.2*** 78.4 
ACEI 82.3 78.2 79.2 77.1 67.9 66.8 
ARB 13.7 19.3 21.0 23.2 1.6 1.4 
ACEI/ARB 94.4 94.4 100 100 68.5 67.2 
Beta-blocker 80.6 86.3 89.9* 92.6 89.5 91.0 
MRA NA NA 55.8 55.4 37.2 35.1 
Pacemaker 2.4* 8.7 5.3 7.3 4.0 4.2 
CRT-P 0.8 2.4 1.0 2.0 1.3 1.8 
Treatment arm 44.8 50.6 45.3 50.2 67.2 66.6 
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3.2.3 Baseline characteristics of patients with pump failure death 
The characteristics of patients with and without pump failure death in each trial 
are outlined in Table 3-3. In general, patients having a pump failure death 
tended to be older, have more severe HF symptoms, lower LVEF and blood 
pressure. They were more likely to have previous hospital admission for 
worsening HF, a history of diabetes, atrial fibrillation or renal dysfunction. 
Similar to patients dying suddenly, patients having a pump failure death were 
less likely to be treated with a beta-blocker, but were more likely to receive a 
diuretic, digitalis or MRA and have a pacemaker or CRT-P implantation. Likewise, 
NT-proBNP levels were substantially higher in patients with a pump failure death 
than in those without. 
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Table 3-3  Baseline characteristics of patients with and without pump failure death in the 
included trials in HF-REF  
RALES BEST CIBIS-II MERIT-HF 
  PFD 
(N=316) 
Others 
(N=1347) 
PFD 
(N=336) 
Others 
(N=2281) 
PFD 
(N=83)  
Others 
(N=2564) 
PFD 
(N=88) 
Others 
(N=3903) 
Age -years 67.3±11.9*** 64.7±11.8 63.7±11.8*** 59.6±12.4 64.0±11.7** 60.8±10.5 68.0±7.0*** 63.2±9.7 
Male (%) 72.8 73.3 83.3* 77.1 92.8** 80.1 83.0 77.4 
LVEF-% 24.1±6.9*** 25.7±6.6 20.6±7.4*** 23.4±7.2 25.4±6.8** 27.5±5.9 24.4±6.9*** 27.8±6.9 
NYHA class (%) *** 
 
*** 
 
*** 
 
*** 
 
I 0 0.1 0 0 0 0 0 0 
II 0 0.4 0 0 0 0 13.6 41.6 
III 53.2 74.6 83.3 92.9 65.1 83.8 69.3 55.1 
IV 46.8 24.9 16.7 7.1 34.9 16.2 17.0 3.3 
Ischaemic 
aetiology (%) 
54.7 54.6 70.5 56.2 51.8 49.7 73.9 65.1 
Race (%)   
 
  
 
  
 
  
 
White 87.0 86.5 72.6 69.0 100 98.9 96.6 94.1 
Black 8.2 7.0 22.3 23.7 0 0.3 2.3 5.3 
Asian 0.6 2.2 4.8 5.6 0 0.6 1.1 0.4 
Other 4.1 4.3 0.3 1.8 0 0.2 0 0.3 
BP -mmHg   
 
  
 
  
 
  
 
Systolic 113.8±17.0*** 124.2±20.2 111.0±16.9*** 118.3±18.0 119.8±15.9*** 130.0±19.4 118.5±13.3*** 130.0±17.1 
Diastolic 70.8±10.8*** 75.5±11.6 67.6±10.2*** 71.6±11.3 74.5±8.5*** 79.8±11.1 73.2±8.4*** 78.4±9.2 
Heart rate -
beats/min 
81.8±14.1 80.6±14.2 82.1±13.5 81.7±13.2 82.1±17.0 80.4±14.9 85.5±11.3** 82.5±10.2 
BMI - - 26.7±5.4*** 28.2±6.0 26.3±4.2 26.9±4.1 24.9±3.7*** 27.3±4.7 
Medical history (%)   
 
  
 
  
 
  
 
Current smoking - - 14.9 18.2 18.1 16.6 11.4 14.6 
HF hospitalisation - - - - - - - - 
Angina 6.0 6.8 57.1* 50.9 - - - - 
Myocardial 
infarction 
28.2 28.4 51.8*** 40.3 57.8 54.9 56.8 48.0 
PCI - - 15.2 5.2 7.2 4.3 - - 
CABG - - 34.8** 27.4 - - 25.0 20.8 
Hypertension 13.9*** 25.8 61.3 58.8 32.5* 43.8 40.9 43.8 
Diabetes 21.5 22.3 45.2*** 34.8 18.1 11.5 38.6** 24.3 
Atrial fibrillation - - 33.0*** 22.6 - - 18.2 16.6 
Stroke - - - - 10.8¶ 7.3¶ 8.0 7.9 
Laboratory tests   
 
  
 
  
 
  
 
eGFR - 
ml/min/1.73m2 
59.8±21.3*** 66.1±23.2 59.1±27.8*** 71.7±23.8 61.4±32.2*** 78.0±31.1 55.3±17.4*** 66.9±19.5 
eGFR <60 
ml/min/1.73m2 
(%) 
59.7*** 45.0 59.6*** 32.3 56.6*** 30.8 59.3*** 36.3 
Creatinine -mg/dl 1.32±0.37*** 1.22±0.36 1.47±0.49*** 1.21±0.38 1.48±0.49*** 1.17±0.32 1.48±0.77*** 1.20±0.36 
NT-proBNP -
pg/ml 
- - - - - - - - 
Treatment (%)   
 
  
 
  
 
  
 
Digitalis 81.0*** 71.3 95.2* 91.7 62.7* 51.3 77.3** 63.3 
Diuretics - - 98.2*** 92.7 - - 96.6* 90.2 
ACEI 93.0 93.2 89.9 91.7 91.6 94.8 89.8 89.5 
ARB - - 4.2 6.5 - - 3.4 6.6 
ACEI/ARB - - 93.8** 97.1 - - 93.2 95.7 
Beta-blocker 5.1*** 11.5 NA NA 43.4 50.4 NA NA 
MRA NA NA 4.5 3.2 20.5** 10.6 - - 
Pacemaker - - 10.4 7.5 - - - - 
CRT-P - - - - - - - - 
Treatment arm 40.2*** 51.6 49.4 50.1 43.4 50.4 34.1** 50.2 
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Val-HeFT SCD-HeFT CHARM-Alternative 
  PFD 
(N=321) 
Others 
(N=4689) 
PFD 
(N=125) 
Others 
(N=1567) 
PFD 
(N=151) 
Others 
(N=1809) 
Age -years 67.5±10.7*** 62.4±11.0 64.8±10.4*** 58.4±11.9 70.6±10.1*** 65.7±10.8 
Male (%) 80.4 80.0 83.2 75.9 66.2 67.7 
LVEF-% 24.5±6.9*** 26.9±7.1 22.2±6.0** 24.1±7.0 27.2±7.3*** 30.2±7.3 
NYHA class (%) *** 
 
*** 
 
*** 
 
I 0 0.1 0 0 0 0 
II 34.6 63.6 44.8 72.7 26.5 49.8 
III 59.5 34.6 55.2 27.3 61.6 47.4 
IV 5.9 1.7 0 0 11.9 2.8 
Ischaemic aetiology (%) 65.4** 56.6 68.0*** 50.7 69.5 67.6 
Race (%)   
 
  
 
  
 
White 92.5 90.2 78.4 76.2 88.1 88.4 
Black 4.7 7.0 14.4 16.3 3.3 3.7 
Asian - - 1.6 1.2 6.6 6.6 
Other 2.8 2.8 5.6 6.3 2.0 1.3 
BP -mmHg   
 
  
 
  
 
Systolic 117.2±17.9*** 124.2±18.5 114.5±18.8** 120.4±19.4 124.1±18.1*** 130.9±18.7 
Diastolic 71.3±10.2*** 75.8±10.6 65.8±10.7*** 71.7±11.3 72.6±10.7*** 77.2±10.6 
Heart rate -beats/min 75.1±12.1* 73.3±12.6 76.5±14.5 74.4±13.9 78.0±12.2** 74.2±13.8 
BMI 25.9±4.4*** 27.0±4.5 - - 26.5±5.5* 27.5±4.8 
Medical history (%)   
 
  
 
  
 
Current smoking - - 9.6 16.1 11.9 13.9 
HF hospitalisation - - - - 90.7*** 66.3 
Angina 28.3** 20.7 32.0 30.4 56.3 58.2 
Myocardial infarction 50.8 46.6 55.2* 43.5 66.2 60.6 
PCI - - 22.4 21.0 10.6 16.1 
CABG 29.6** 22.8 39.2** 25.8 21.2 24.8 
Hypertension 43.9 40.7 68.8** 54.9 47.7 50.0 
Diabetes 30.5* 25.1 46.4*** 29.1 43.7*** 25.6 
Atrial fibrillation 14.6 11.9 25.6*** 13.8 35.1** 24.4 
Stroke 10.3* 6.6 7.2 7.2 10.6 8.2 
Laboratory tests   
 
  
 
  
 
eGFR - ml/min/1.73m2 51.0±15.7*** 62.1±15.3 59.1±17.8*** 71.8±22.3 51.5±29.4***c 69.6±26.1d 
eGFR <60 
ml/min/1.73m2 (%) 
76.6*** 44.8 52.0*** 30.7 74.4***c 39.2d 
Creatinine -mg/dl 1.51±0.38*** 1.27±0.30 1.39±0.46** 1.19±0.75 1.63±0.58***c 1.18±0.42d 
NT-proBNP -pg/ml 2375a 
[1040-4366]  
843b 
[356-1849] 
- - - - 
Treatment (%)   
 
  
 
  
 
Digitalis 77.9*** 66.6 82.4** 70.2 57.0** 44.4 
Diuretics 96*** 84.8 95.2*** 82.5 98.7*** 84.2 
ACEI 90.3 92.9 86.4 85.6 0 0 
ARB NA NA 13.6 14.9 NA NA 
ACEI/ARB 93.8** 96.6 98.4 97.4 NA NA 
Beta-blocker 20.2*** 35.9 59.2* 69.4 37.1*** 55.6 
MRA - - 25.6 18.8 39.7*** 22.1 
Pacemaker - - - - 12.6* 7.6 
CRT-P - - - - - - 
Treatment arm 46.7 50.4 50.4 49.9 44.4 50.1 
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CHARM-Added CORONA GISSI-HF 
  PFD 
(N=200) 
Others 
(N=2248) 
PFD 
(N=372) 
Others 
(N=4503) 
PFD 
(N=321)  
Others 
(N=3499) 
Age -years 68.6±11.0*** 63.2±10.9 75.3±7.2*** 72.5±7.1 71.9±8.6*** 66.8±10.9 
Male (%) 80.5 78.2 76.3 76.0 81.6 78.8 
LVEF-% 25.3±7.3*** 28.4±7.4 29.0±6.9*** 31.1±6.4 29.2±6.9*** 31.8±6.1 
NYHA class (%) *** 
 
*** 
 
*** 
 
I 0 0 0 0 0 0 
II 15.0 25.0 26.3 38.0 41.4 65.1 
III 75.0 72.7 70.4 60.7 52.0 33.2 
IV 10.0 2.3 3.2 1.3 6.5 1.7 
Ischaemic aetiology (%) 66.0 62.2 100 100 49.2*** 39.3 
Race (%)   
 
  
 
  
 
White 92.0 90.3 98.4 98.6 - - 
Black 3.0 5.2 0 0.3 - - 
Asian 4.5 3.6 1.1 0.7 - - 
Other 0.5 0.9 0.5 0.4 - - 
BP -mmHg   
 
  
 
  
 
Systolic 121.0±18.0*** 126.0±18.6 123.4±16.3*** 130.0±16.4 120.9±17.1*** 127.0±18.0 
Diastolic 72.7±10.7*** 75.5±10.7 73.2±8.5*** 76.5±8.9 74.0±9.4*** 77.4±9.8 
Heart rate -beats/min 76.0±12.5** 73.4±13.2 74.8±11.7*** 71.5±11.1 75.0±13.1* 73.0±13.7 
BMI 26.3±5.0*** 27.9±5.3 26.1±4.4*** 27.3±4.6 25.7±4.4*** 27.1±4.5 
Medical history (%)   
 
  
 
  
 
Current smoking 14.5 17.3 4.8** 9.0 9.3** 15.4 
HF hospitalisation 85.5** 76.2 - - 61.1*** 42.9 
Angina 53.5 52.5 73.1 72.6 13.1 11.2 
Myocardial infarction 58.5 54.9 61.6 59.2 42.4*** 32.0 
PCI 7.5** 14.9 8.6 11.5 7.8 8.1 
CABG 25.5 23.9 14.0 16.7 20.6*** 13.3 
Hypertension 44.5 48.4 59.7 64.3 46.7* 53.3 
Diabetes 35.5 29.7 37.6*** 28.8 34.9*** 25.0 
Atrial fibrillation 37.5*** 25.5 48.9** 40.2 26.8*** 18.1 
Stroke 9.5 8.3 15.1 12.3 7.2* 4.3 
Laboratory tests   
 
  
 
  
 
eGFR - ml/min/1.73m2 55.4±18.9***e 74.9±27.0f 51.1±15.0*** 58.4±15.0 59.7±22.1*** 70.8±21.6 
eGFR <60 
ml/min/1.73m2 (%) 
62.5***e 29.8f 74.3*** 55.6 57.4*** 31.8 
Creatinine -mg/dl 1.43±0.43***e 1.14±0.39f 1.45±0.37*** 1.29±0.31 1.34±0.44*** 1.13±0.32 
NT-proBNP -pg/ml - - 3404g 
[1722-6753] 
1373h 
[579-2894] 
2035i 
[1170-4236] 
819j 
[347-1702] 
Treatment (%)   
 
  
 
  
 
Digitalis 72.5*** 56.6 47.0*** 32.0 59.2*** 38.3 
Diuretics 99.0*** 89.2 97.8*** 87.4 94.7*** 80.3 
ACEI 100 99.9 73.1*** 80.8 74.8 78.4 
ARB NA NA - - 19.9 17.9 
ACEI/ARB NA NA 87.1*** 92.2 91.9 93.9 
Beta-blocker 37.0*** 56.2 64.8*** 75.8 49.2*** 64.6 
MRA 24.5** 16.1 51.3*** 37.9 53.0*** 38.6 
Pacemaker 16.5*** 7.2 14.8** 10.3 19.9*** 9.5 
CRT-P - - - - - - 
Treatment arm 44.0 50.8 49.7 50.1 47.0 50.2 
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 EMPHASIS-HF PARADIGM-HF ATMOSPHERE 
 
PFD 
(N=94) 
Others 
(N=2222) 
PFD 
(N=261)  
Others 
(N=6895) 
PFD 
(N=305) 
Others 
(N=5663) 
Age -years 71.6±7.9*** 68.5±7.6 65.3±13.0* 63.6±11.6 65.4±13.4*** 63.0±12.0 
Male (%) 80.9 75.9 80.1 76.6 82.3* 76.2 
LVEF-% 24.9±4.5** 26.4±4.4 28.2±6.6*** 29.9±6.1 27.0±5.8*** 28.9±5.5 
NYHA class (%)   
 
** 
 
  
 
I 0 0 1.9 5.0 0 0 
II 100 100 63.6 70.0 55.1 61.8 
III 0 0 33.7 24.2 41.6 36.1 
IV 0 0 0.8 0.8 3.3 2.1 
Ischaemic aetiology (%) 74.2 67.8 49.0** 59.1 45.9** 54.6 
Race (%)   
 
  
 
*** 
 
White 71.3 81.6 57.9 62.8 63.8 61.6 
Black 4.3 2.2 3.8 4.8 4.9 1.4 
Asian 18.1 13.1 21.5 20.7 23.7 29.2 
Other 6.4 3.2 16.9 11.7 7.6 7.8 
BP -mmHg   
 
  
 
  
 
Systolic 117.6±16.3*** 125.3±16.7 118.0±14.8*** 122.1±15.4 118.8±18.3*** 124.7±18.2 
Diastolic 72.0±11.7** 75.4±10.1 71.5±9.9*** 74.3±10.0 73.8±10.8*** 77.8±11.0 
Heart rate -beats/min 75.3±13.9* 72.1±12.6 74.8±12.9* 72.9±12.1 73.5±13.7 72.3±12.6 
BMI 25.2±4.2*** 27.6±4.9 27.1±5.4** 28.0±5.5 26.6±5.4 27.2±5.3 
Medical history (%)   
 
  
 
  
 
Current smoking 11.7 10.6 9.6* 14.3 11.5 12.5 
HF hospitalisation 74.5*** 50.2 69.0* 62.1 71.8*** 57.8 
Angina 39.4 43.7 19.5** 27.5 20.3 23.9 
Myocardial infarction 63.8** 47.6 38.7 40.9 33.4 37.5 
PCI 14.9 18.8 13.4* 18.3 12.8 16.5 
CABG 16.0 15.6 12.3 13.2 11.5 11.7 
Hypertension 62.8 67.4 63.6** 71.6 57.7 62.7 
Diabetes 44.7** 31.1 39.5* 33.4 22.3* 27.6 
Atrial fibrillation 36.2 30.4 41.8 36.4 41.6** 33.1 
Stroke 11.7 9.3 12.3* 8.2 8.9 6.9 
Laboratory tests   
 
  
 
  
 
eGFR - ml/min/1.73m2 61.2±20.1*** 71.8±21.7 63.4±24.9*** 69.0±20.0 70.6±26.1** 75.3±24.5 
eGFR <60 
ml/min/1.73m2 (%) 
52.1*** 31.3 49.0*** 33.9 37.0*** 23.9 
Creatinine -mg/dl 1.26±0.32*** 1.13±0.30 1.22±0.35*** 1.10±0.29 1.11±0.32*** 1.02±0.26 
NT-proBNP -pg/ml - - 3645*** 
[1795-6704] 
1591 
[877-3157] 
2236***k 
[1081-4241] 
1168m 
[616-2174] 
Treatment (%)   
 
  
 
  
 
Digitalis 44.1*** 27.5 41.0*** 30.8 45.9*** 31.8 
Diuretics 95.7** 86.0 88.5*** 79.4 85.9** 78.6 
ACEI 72.0 78.7 72.4 77.4 63.0 67.1 
ARB 20.4 19.0 28.0 22.8 1.0 1.4 
ACEI/ARB 92.5 94.5 100 100 63.0 67.6 
Beta-blocker 79.6 86.3 88.9* 92.5 89.5 90.9 
MRA 43.6 50.6 59.4 55.3 42.0* 35.0 
Pacemaker 14.9* 8.1 14.6*** 6.9 6.9* 4.0 
CRT-P 5.3* 2.1 5.0*** 1.8 4.3*** 1.7 
Treatment arm 43.6 50.6 44.8 50.0 71.5 66.4 
*P<0.05, **p<0.01, *** p<0.001. 
a=258 (80%), b=3809 (81%), c=39(26%), d=581(32%), e=72(36%), f=800 (36%), g=256 (69%), 
h=3299 (73%), i=47 (15%), j=523 (15%), k=292 (96%), m=5116 (90%).  
PFD denotes pump failure death. 
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3.2.4 Sudden death rates in each trial and in each arm of each 
trial 
Compared to the earlier trials, the rate of sudden death was lower in the more 
recent trials which had a higher adoption of disease-modifying therapies, except 
for CORONA which enrolled patients aged ≥60 years with an ischaemic aetiology 
only (Figure 3-2 and Table 3-4). The annual rate of sudden death declined from 
6.5% in the oldest RALES to 3.3% in the latest ATMOSPHERE, although CORONA 
lay above the trend with a rate of 5.2%, p for trend=0.001 (Table 3-4 and Figure 
3-3). There was a similar pattern in the rates of death from any cause across the 
trials, suggesting that the higher sudden death rate in CORONA was likely to be 
due to the underlying risk of patients in the trial itself (Figure 3-4). 
Unsurprisingly, the proportion of sudden death relative to total mortality did not 
fall across trials, given that the downward trend in sudden death rates was in 
line with the falling overall mortality rates (Figure 3-5).   
 
Figure 3-2  Cumulative incidence curves for sudden death by trials in HF-REF 
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Table 3-4 Annual rates and cumulative incidences of sudden death at different time points in 
the included trials in HF-REF (treatment arms combined) 
  RALES BEST CIBIS-II MERIT-HF Val-HeFT 
  (N=1663) (N=2617) (N=2647) (N=3991) (N=5010) 
No. of sudden death 192 294 131 211 442 
Annual rate (95% CI) 6.5 (5.6-7.4) 5.6 (5.0-6.3) 3.8 (3.2-4.5) 5.3 (4.6-6.1) 4.7 (4.3-5.2) 
Cumulative incidence 
(95% CI) 
     
30 days 1.0 (0.5-1.5) 0.5 (0.2-0.8) 0.4 (0.1-0.6) 0.3 (0.1-0.5) 0.6 (0.4-0.8) 
60 days  1.5 (0.9-2.0) 1.1 (0.7-1.6) 0.9 (0.6-1.3) 0.7 (0.4-0.9) 1.0 (0.7-1.3) 
90 days 2.4 (1.6-3.1) 1.8 (1.3-2.3) 1.3 (0.9-1.7) 1.3 (0.9-1.6) 1.3 (1.0-1.7) 
180 days 4.2 (3.2-5.2) 3.1 (2.4-3.7) 2.0 (1.5-2.5) 2.5 (2.0-3.0) 2.6 (2.2-3.1) 
1 year 6.7 (5.5-7.9) 5.8 (4.9-6.7) 3.8 (3.0-4.5) 5.0 (4.3-5.7) 4.5 (3.9-5.1) 
2 years 10.9 (9.3-12.4) 9.7 (8.5-10.9) 6.8 (5.4-8.2) - 8.4 (7.5-9.2) 
3 years 13.4 (11.4-15.4) 13.5 (12.0-15.1) - - 12.2 (10.6-13.9) 
  SCD-HeFT CHARM-Alternative CHARM-Added CORONA 
  (N=1692) (N=1960) (N=2448) (N=4875) 
No. of sudden death 168 186 311 631 
Annual rate (95% CI) 3.0 (2.6-3.5) 3.7 (3.2-4.2) 4.3 (3.8-4.8) 5.2 (4.8-5.6) 
Cumulative incidence 
(95% CI) 
    
30 days 0.5 (0.2-0.9) 0.6 (0.2-0.9) 0.6 (0.3-0.9) 0.5 (0.3-0.7) 
60 days  0.9 (0.4-1.3) 1.1 (0.6-1.5) 1.0 (0.6-1.4) 0.9 (0.6-1.1) 
90 days 1.4 (0.9-2.0) 1.6 (1.1-2.2) 1.5 (1.0-1.9) 1.3 (1.0-1.7) 
180 days 2.5 (1.7-3.2) 2.5 (1.8-3.2) 2.5 (1.9-3.2) 2.6 (2.2-3.1) 
1 year 3.7 (2.8-4.6) 4.2 (3.3-5.1) 4.5 (3.7-5.3) 5.0 (4.4-5.6) 
2 years 6.4 (5.2-7.5) 6.7 (5.6-7.8) 8.2 (7.1-9.3) 9.1 (8.3-9.9) 
3 years 8.7 (7.4-10.1) 9.5 (8.1-10.8) 11.2 (9.9-12.4) 13.2 (12.2-14.2) 
  GISSI-HF EMPHASIS-HF PARADIGM-HF ATMOSPHERE 
  (N=3820) (N=2316) (N=7156) (N=5968) 
No. of sudden death 367 125 525 607 
Annual rate (95% CI) 2.7(2.5-3.0) 2.9 (2.4-3.4) 3.3 (3.1-3.6) 3.3 (3.1-3.6) 
Cumulative incidence 
(95% CI) 
    
30 days 0.3 (0.2-0.5) 0.3 (0.1-0.5) 0.4 (0.3-0.6) 0.3 (0.2-0.5) 
60 days  0.6 (0.3-0.8) 0.7 (0.3-1.0) 0.7 (0.5-0.9) 0.6 (0.4-0.8) 
90 days 1.0 (0.7-1.3) 1.0 (0.6-1.5) 1.0 (0.8-1.3) 1.0 (0.7-1.2) 
180 days 1.5 (1.2-1.9) 2.1 (1.5-2.7) 2.0 (1.7-2.3) 1.9 (1.6-2.3) 
1 year 3.2 (2.6-3.8) 3.0 (2.3-3.7) 3.7 (3.3-4.2) 3.9 (3.4-4.4) 
2 years 5.6 (4.9-6.4) 5.3 (4.3-6.4) 6.5 (5.9-7.1) 6.7 (6.0-7.3) 
3 years 7.6 (6.7-8.4) 7.4 (6.0-8.7) 8.8 (8.0-9.5) 9.3 (8.5-10.0) 
Annual rates are shown as sudden death per 100 patient-years. Cumulative incidences are 
presented as percent. ‘-’ denotes data not available. 
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Figure 3-3  Trends in the sudden death rate across trial arms over time in HF-REF 
 
Annual rates are shown as sudden death per 100 patient-years. The black dotted line is based on 
the multiple linear regression of the annual rate in each trial arm with the randomisation year 
and randomisation arm as covariates, weighted by its inverse-variance and with trial as a 
random effect. P for slope represents the p value for randomisation year based on the linear 
model. Each circle represents each trial arm as labelled, with the control arm in each trial 
illustrated in gray and the experimental arm in white. The centre of each circle corresponds to 
randomisation year (x axis) and the annual rate (y axis) in each arm, the error bars in each 
circle correspond to the 95% confidence interval of the annual rate. The area of each circle 
represents the sample size in each arm (reference size shown in the upper right corner). C 
denotes control arm; T, experimental treatment arm; P, placebo arm; A, amiodarone arm. 
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Figure 3-4  Trends in the all-cause death rate across trial arms over time in HF-REF 
 
Annual rates are shown as all-cause death per 100 patient-years. Other notes and abbreviations 
are same as those in Figure 3-3. 
 
Figure 3-5  Proportions of sudden death and pump failure death relative to overall mortality 
across the trials in HF-REF 
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The rate of sudden death was lower in the experimental therapy group in all 
trials, with the exceptions of Val-HeFT and GISSI-HF, where the opposite, albeit 
to a minimal extent, was true (Figure 3-3). Adjusting for randomisation 
treatment, with trial as a random effect, there was a 41% decline in the risk of 
sudden death over the past 20 years (HR 0.59, 95% CI 0.37-0.92, p=0.021). The 
fall in risk over time was attenuated when additionally adjusting for 
conventional confounding variables, but randomisation treatment remained 
significantly associated with a lower risk of sudden death (HR 0.87, 95% CI 0.82-
0.93, p <0.001). When examining the risk of sudden death by individual trial 
arm, compared to the placebo arm of RALES, the risks of sudden death were 59% 
and 54% lower in the treatment arm of PARADIGM-HF and in the combination 
therapy arm of ATMOSPHERE, respectively (Figure 3-6). These differences were 
attenuated somewhat but remained highly significant after adjustment for 
conventional confounding covariates (adjusted HR 0.65, 95% CI 0.51-0.83, 
p<0.001; 0.70, 0.55-0.89, p=0.004, respectively [Figure 3-7]). A similar result 
was observed with further adjustment for eGFR (Figure 3-8). In the subset of 
patients with both eGFR and NT-proBNP available, compared with the placebo 
arm of Val-HeFT, the risk of sudden death in the treatment arm of PARADIGM-HF 
and in the combination therapy arm of ATMOSPHERE were slightly lower (16% 
and 10% respectively) with adjustment for the conventional covariates but was 
markedly lower (43% and 25% respectively) further adjusting for NT-proBNP 
(Figure 3-9). Imputation of missing values made little change in these findings 
(Figure 3-8 and Figure 3-9). 
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Figure 3-6  Hazard ratio for sudden death across the trial arms in HF-REF with incremental 
use of evidence-based medications 
 
Annual rates are shown as sudden death per 100 patient-years. Hazard ratios shown are 
compared to the placebo arm of RALES (N=46,151). C denotes control arm; T, experimental 
treatment arm; P, placebo arm; A, amiodarone arm. 
 
Figure 3-7 Hazard ratio for sudden death across the trial arms in HF-REF with incremental 
use of evidence-based medications, with adjustment for 8 conventional covariates 
 
Annual rates are shown as sudden death per 100 patient-years. Hazard ratios are adjusted for 
conventional covariates including age, sex, NYHA class, LVEF, ischaemic aetiology, previous 
myocardial infarction, and a history of hypertension and diabetes (N= 46,019). Hazard ratios 
shown are compared to the placebo arm of RALES. C denotes control arm; T, experimental 
treatment arm; P, placebo arm; A, amiodarone arm. 
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Figure 3-8  Hazard ratio for sudden death across the trial arms in HF-REF with incremental 
use of evidence-based medications, with adjustment for 8 conventional covariates and 
eGFR 
 
Annual rates are shown as sudden death per 100 patient-years. Panel A, HRs are adjusted for 
conventional confounding variables in the subset of patients with eGFR measurements 
available (N=42,920); Panel B, adjustment for conventional covariates and eGFR in the subset 
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of patients with eGFR measurement available (N=42,920); Panel C, adjustment for conventional 
covariates and eGFR with simple imputation of eGFR levels (N=46,019). HRs shown are 
compared to the placebo arm of RALES. C denotes control arm; T, experimental treatment arm; 
P, placebo arm; A, amiodarone arm. 
 
Figure 3-9  Hazard ratio for sudden death across the trial arms in HF-REF with incremental 
use of evidence-based medications, with adjustment for 8 conventional covariates, eGFR 
and NT-proBNP 
 
Annual rates are shown as sudden death per 100 patient-years. Panel A, adjustment for 
conventional confounding variables in the subset of patients with NT-proBNP available 
[N=20,715]; Panel B, adjustment for conventional covariates and eGFR in the subset of patients 
with NT-proBNP available [N=20,715]; Panel C, adjustment for conventional covariates, eGFR 
and log transformed NT-proBNP in the subset of patients with NT-proBNP available [N=20,715]; 
Panel D, adjustment for conventional covariates, eGFR and log transformed NT-proBNP with 
simple imputation of eGFR and NT-proBNP in the trials with NT-proBNP collected (i.e. not 
complete missing) [N=26,809]. HRs shown are compared to the placebo arm of Val-HeFT. C 
denotes control arm; T, experimental treatment arm. 
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3.2.5 Pump failure death rates in each trial and in each arm of 
each trial 
Similar to the trend in the sudden death rates across trials, the rate of pump 
failure death was substantially lower in the more recent trials compared to the 
earlier trials (Table 3-5 and Figure 3-10). The annual rate of pump failure death 
was quite high at 10.6% in the oldest trial (RALES) and was 6.4% in BEST, but 
later seemed to be starting to plateau, with a rate of 1.7% in the latest trials 
(PARADIGM-HF and ATMOSPHERE) (Table 3-5 and Figure 3-11). Overall, there was 
a downward trend in the rate of pump failure death across these trials with a 
slope of 3.47% per decade, p for trend =0.027 (Figure 3-11). It seemed the 
downward trend was driven by the high rates in the earliest trials of RALES and 
BEST, which randomised patients with severe HF; in a sensitivity analysis with 
the exclusion of both trials, the falling trend was attenuated but remained 
significant, with a slope of 0.92% per decade, p for trend =0.004 (Figure 3-12). 
There was a smaller proportion of pump failure death relative to total mortality 
in more recent trials (Figure 3-5).    
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Table 3-5 Annual rates and cumulative incidences of pump failure death at different time 
points in the included trials in HF-REF (treatment arms combined) 
  RALES BEST CIBIS-II MERIT-HF Val-HeFT 
  (N=1663) (N=2617) (N=2647) (N=3991) (N=5010) 
No. of pump failure death 316 336 83 88 321 
Annual rate (95% CI) 10.6 (9.5-11.8) 6.4 (5.7-7.1) 2.4 (1.9-2.9) 2.2 (1.8-2.7) 3.4 (3.1-3.8) 
Cumulative incidence (95% CI) 
     
30 days 1.0 (0.5-1.4) 0.2 (0.0-0.4) 0.1 (0.0-0.2) 0.1 (0.0-0.2) 0.1 (0.0-0.2) 
60 days  2.7 (1.9-3.5) 0.6 (0.3-0.9) 0.4 (0.1-0.6) 0.3 (0.1-0.4) 0.3 (0.1-0.4) 
90 days 3.5 (2.6-4.4) 1.0 (0.6-1.4) 0.7 (0.4-1.0) 0.4 (0.2-0.6) 0.5 (0.3-0.7) 
180 days 5.6 (4.5-6.7) 2.4 (1.9-3.0) 1.1 (0.7-1.4) 1.0 (0.7-1.3) 1.1 (0.8-1.4) 
1 year 10.5 (9.0-12.0) 5.2 (4.4-6.1) 2.2 (1.6-2.7) 2.1 (1.7-2.6) 2.6 (2.2-3.0) 
2 years 17.8 (15.9-19.6) 10.9 (9.7-12.2) 4.4 (3.3-5.5)  - 6.0 (5.3-6.7) 
3 years 21.7 (19.3-24.0) 15.2 (13.6-16.8)  -  - 9.9 (8.1-11.7) 
  SCD-HeFT CHARM-Alternative CHARM-added CORONA 
  (N=1692) (N=1960) (N=2448) (N=4875) 
No. of pump failure death 125 151 200 372 
Annual rate (95% CI) 2.2 (1.9-2.6) 3.0 (2.5-3.5) 2.8 (2.4-3.2) 3.1 (2.8-3.4) 
Cumulative incidence (95% CI) 
    
30 days 0.0 0.5 (0.2-0.8) 0.1 (0.0-0.2) 0.1 (0.0-0.2) 
60 days  0.3 (0.0-0.6) 0.6 (0.3-1.0) 0.3 (0.1-0.5) 0.4 (0.2-0.5) 
90 days 0.3 (0.0-0.6) 0.8 (0.4-1.2) 0.6 (0.3-0.9) 0.6 (0.4-0.9) 
180 days 0.7 (0.3-1.0) 1.7 (1.2-2.3) 1.1 (0.7-1.5) 1.5 (1.2-1.9) 
1 year 1.4 (0.8-1.9) 3.0 (2.3-3.8) 2.5 (1.8-3.1) 2.5 (2.1-3.0) 
2 years 3.3 (2.5-4.2) 5.8 (4.7-6.8) 4.7 (3.9-5.6) 5.2 (4.6-5.8) 
3 years 5.4 (4.3-6.5) 7.2 (6.0-8.4) 7.3 (6.2-8.3) 7.7 (6.9-8.5) 
  GISSI-HF EMPHASIS-HF PARADIGM-HF ATMOSPHERE 
  (N=3820) (N=2316) (N=7156) (N=5968) 
No. of pump failure death 321 94 261 305 
Annual rate (95% CI) 2.4 (2.1-2.7) 2.2 (1.8-2.7) 1.7 (1.5-1.9) 1.7 (1.5-1.9) 
Cumulative incidence (95% CI) 
    
30 days 0.2 (0.0-0.3) 0.2 (0.0-0.3) 0.1 (0.0-0.1) 0.1 (0.0-0.1) 
60 days  0.2 (0.1-0.4) 0.3 (0.1-0.5) 0.1 (0.1-0.2) 0.1 (0.0-0.2) 
90 days 0.4 (0.2-0.7) 0.5 (0.2-0.8) 0.2 (0.1-0.3) 0.2 (0.1-0.3) 
180 days 1.0 (0.7-1.3) 1.1 (0.7-1.6) 0.5 (0.3-0.7) 0.5 (0.4-0.7) 
1 year 2.1 (1.6-2.6) 1.9 (1.3-2.5) 1.5 (1.2-1.8) 1.3 (1.0-1.6) 
2 years 4.4 (3.8-5.1) 3.5 (2.7-4.4) 3.0 (2.6-3.4) 2.7 (2.3-3.1) 
3 years 6.2 (5.5-7.0) 5.5 (4.3-6.7) 4.5 (3.9-5.0) 4.3 (3.7-4.8) 
Annual rates are shown as pump failure death per 100 patient-years. Cumulative incidences are 
presented as percent. ‘-’ denotes data not available. 
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Figure 3-10  Cumulative incidence curves for pump failure death by trials in HF-REF 
 
Figure 3-11 Trends in the pump failure death rate across trial arms over time in HF-REF 
 
Annual rates are shown as pump failure death per 100 patient-years. The black dotted line is based 
on the multiple linear regression of the annual rate in each trial arm with the randomisation year 
and randomisation arm as covariates, weighted by its inverse-variance and with trial as a 
random effect. P for slope represents the p value for randomisation year based on the linear 
model. Each circle represents each trial arm as labelled, with the control arm in each trial 
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illustrated in gray and the experimental arm in white. The centre of each circle corresponds to 
randomisation year (x axis) and the annual rate (y axis) in each arm, the error bars in each 
circle correspond to the 95% confidence interval of the annual rate. The area of each circle 
represents the sample size in each arm (reference size shown in the upper right corner). C 
denotes control arm; T, experimental treatment arm; P, placebo arm; A, amiodarone arm. 
 
Figure 3-12 Trends in the pump failure death rate across trial arms over time in HF-REF, with 
the exclusion of RALES and BEST 
 
Annual rates are shown as pump failure death per 100 patient-years. Other notes and 
abbreviations are same as those in Figure 3-11. 
 
The rate of pump failure death was lower in the experimental treatment group 
in all trials, with the exceptions of SCD-HeFT and ATMOSPHERE (Figure 3-11). 
There was a substantial decline in the risk of pump failure death of 80% over the 
past two decades (HR 0.20, 95% CI 0.09-0.47, p<0.001), adjusting for 
randomisation treatment with trial as a random effect. In a sensitivity analysis 
with the exclusion of RALES and BEST, the size of risk reduction of pump failure 
death over time was attenuated to 50% but remained significant (HR 0.50, 95% CI 
0.33-0.78, p=0.002). With further adjustment for conventional covariates, the 
risk reduction over time was attenuated in both primary and sensitivity analyses, 
but randomisation treatment remained significantly related to a lower risk of 
pump failure death (HR 0.84, 95% CI 0.78-0.91, p<0.001). When examining the 
risk of pump failure death by individual trial arm, compared to the placebo arm 
of RALES, the risk of pump failure death was 89% and 90% lower in the treatment 
arm of PARADIGM-HF and in the combination therapy arm of ATMOSPHERE, 
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respectively (Figure 3-13). These differences were slightly attenuated but 
remained pronounced after adjustment for conventional confounding covariates 
(adjusted HR 0.34, 95% CI 0.26-0.43, p<0.001; 0.27, 0.21-0.36, p<0.001, 
respectively [Figure 3-14]). Further adjustment for eGFR gave a similar result 
(Figure 3-15). In the cohort with both measurements available in eGFR and NT-
proBNP, compared to the placebo arm of Val-HeFT, the risk of pump failure 
death in the treatment arm of PARADIGM-HF and in the combination therapy arm 
of ATMOSPHERE were substantially lower (43% and 50% respectively) with 
adjustment for the conventional covariates, and continued to fall (63% and 53% 
respectively) with further adjustment for NT-proBNP (Figure 3-16). Imputation of 
missing values gave similar results (Figure 3-15 and Figure 3-16). 
 
Figure 3-13  Hazard ratio for pump failure death across the trial arms in HF-REF with 
incremental use of evidence-based medications 
 
Annual rates are shown as pump failure death per 100 patient-years. Hazard ratios shown are 
compared to the placebo arm of RALES (N=46,151). C denotes control arm; T, experimental 
treatment arm; P, placebo arm; A, amiodarone arm. 
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Figure 3-14  Hazard ratio for pump failure death across the trial arms in HF-REF with 
incremental use of evidence-based medications, with adjustment for 8 conventional 
covariates 
 
Annual rates are shown as pump failure death per 100 patient-years. Hazard ratios are adjusted for 
conventional covariates including age, sex, NYHA class, LVEF, ischaemic aetiology, previous 
myocardial infarction, and a history of hypertension and diabetes (N= 46019). Hazard ratios 
shown are compared to the placebo arm of RALES. C denotes control arm; T, experimental 
treatment arm; P, placebo arm; A, amiodarone arm. 
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Figure 3-15 Hazard ratio for pump failure death across the trial arms in HF-REF with 
incremental use of evidence-based medications, with adjustment for 8 conventional 
covariates and eGFR 
 
Annual rates are shown as pump failure death per 100 patient-years. Panel A, HRs are adjusted for 
conventional confounding variables in the subset of patients with eGFR measurements 
available (N=42,920); Panel B, adjustment for conventional covariates and eGFR in the subset 
of patients with eGFR measurements available (N=42,920); Panel C, adjustment for 
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conventional covariates and eGFR with simple imputation of eGFR levels (N=46,019). HRs 
shown are compared to the placebo arm of RALES. C denotes control arm; T, experimental 
treatment arm; P, placebo arm; A, amiodarone arm. 
 
Figure 3-16 Hazard ratio for pump failure death across the trial arms in HF-REF with 
incremental use of evidence-based medications, with adjustment for 8 conventional 
covariates, eGFR and NT-proBNP 
 
Annual rates are shown as pump failure death per 100 patient-years. Panel A, adjustment for 
conventional confounding variables in the subset of patients with NT-proBNP available 
[N=20,715]; Panel B, adjustment for conventional covariates and eGFR in the subset of patients 
with NT-proBNP available [N=20,715]; Panel C, adjustment for conventional covariates, eGFR 
and log transformed NT-proBNP in the subset of patients with NT-proBNP available [N=20,715]; 
Panel D, adjustment for conventional covariates, eGFR and log transformed NT-proBNP with 
simple imputation of eGFR and NT-proBNP in the trials with NT-proBNP collected (i.e. not 
complete missing) [N=26,809]. HRs shown are compared to the placebo arm of Val-HeFT. C 
denotes control arm; T, experimental treatment arm. 
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3.2.6 Sudden death at different time points during follow-up  
The cumulative incidences of sudden death at 90 days were consistently low 
across these trials ranging from 2.4% (95% CI 1.6-3.1%) in RALES to 1.0% (95% CI 
0.7-1.2%) in ATMOSPHERE (Table 3-4 and Figure 3-2). At 180 days, in general, 
the cumulative incidence of sudden death was nearly double that at 90 days in 
each trial, but it remained low in absolute terms, at around 2% in contemporary 
trials such as PARADIGM-HF and ATMOSPHERE. At 1 year, the cumulative 
incidence reached 6.7% in RALES and was 5.8% in BEST or lower in the other 
trials. At 3 years, the cumulative sudden death rate reached over 13% in RALES, 
BEST and CORONA (13.4%, 13.5% and 13.2% respectively), but was much lower in 
the more recent trials (around 7.4-9.3%). 
  
3.2.7 Pump failure death at different time points during follow-up  
The cumulative incidences of pump failure death at 90 days were consistently 
low at 1.0% or lower across these trials, except for RALES with a value of 3.5% 
(95% CI 2.6-4.4%) (Table 3-5 and Figure 3-10). At 180 days, the cumulative 
incidence of pump failure death was almost double that at 90 days in each trial, 
but it remained low in absolute terms at 0.5% in the contemporary PARADIGM-HF 
and ATMOSPHERE. At 1 year, the cumulative incidence reached 10.5% in RALES 
and 5.2% in BEST and was 3.0% in CHARM-Alternative or lower in the other trials. 
At 3 years, the cumulative incidence of pump failure death reached over 21% in 
RALES and 15% in BEST, but was substantially lower in the more recent trials 
(about 4.3-6.2%). 
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3.2.8 Sudden death according to HF duration 
The cumulative risk of sudden death during follow-up was plotted according to 
the length of time from the diagnosis of HF to randomisation based on the 
merged data from ten trials with this information available (Figure 3-17). There 
was a significant overall difference among patients with different HF durations 
(Gray’s test p<0.001), where longer history of HF carried higher risk of sudden 
death, especially in the later period of follow-up. There was no evidence that 
the risk of sudden death in patients with recent-onset HF (within 3 months 
before randomisation) was higher than those with longer-standing HF. 
 
Figure 3-17  Cumulative incidence curves for sudden death over time in HF-REF according 
to the length of time between diagnosis of HF and randomisation (trials with data available 
combined) 
 
Hazard ratios for sudden death are shown for patients diagnosed within 3 months compared to 
those diagnosed with HF for >3-6 months, >6-12 months, >1-2 years, >2-5 years and >5 years 
respectively. These hazard ratios are adjusted for age, sex, NYHA class, LVEF, ischaemic 
aetiology, previous myocardial infarction and a history of diabetes and hypertension and are 
counted for within-trial clustering (N=37,706). Data were available in BEST, Val-HeFT, SCD-
HeFT, CHARM-Alternative, CHARM-Added, CORONA, GISSI-HF, EMPHASIS-HF, 
PARADIGM-HF and ATMOSPHERE (N= 37,830).  
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3.2.9 Pump failure death according to HF duration 
As shown in Figure 3-18, the cumulative incidence curves for pump failure death 
during follow-up were outlined by HF duration. Overall, a significant difference 
in the risk of pump failure death was observed among patients with different HF 
durations (Gray’s test p<0.001). Patients with longer-standing HF carried a 
higher risk of pump failure death: compared to patients with recent-onset HF, 
the risk of pump failure death was about 90%, 120% and 170% higher in those 
with a diagnosis of HF of >1-2 years, >2-5 years and over 5 years respectively.   
 
Figure 3-18  Cumulative incidence curves for pump failure death over time in HF-REF 
according to the length of time between diagnosis of HF and randomisation (trials with data 
available combined) 
 
 
Hazard ratios for pump failure death are shown for patients diagnosed within 3 months compared 
to those diagnosed for >3-6 months, >6-12 months, >1-2 years, >2-5 years and >5 years 
respectively. These hazard ratios are adjusted for age, sex, NYHA class, LVEF, ischaemic 
aetiology, previous myocardial infarction and a history of diabetes and hypertension and are 
counted for within-trial clustering (N=37,706). Data were available in BEST, Val-HeFT, SCD-
HeFT, CHARM-Alternative, CHARM-Added, CORONA, GISSI-HF, EMPHASIS-HF, 
PARADIGM-HF and ATMOSPHERE (N= 37,830). 
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3.3 Discussion 
This analysis of individual patient-level data from 46,163 patients randomised in 
13 clinical trials showed that the rates of sudden death and pump failure death 
in patients with HF-REF have fallen by 41% and by 80% respectively over the last 
20 years between the start of RALES and the completion of ATMOSPHERE. The 
declining rates over this period are in parallel with a cumulative use of disease 
modifying therapies known to reduce both modes of death. Now in patients with 
a high adoption of modern disease-modifying treatment in HF-REF, the absolute 
rate is relatively low for sudden death at around 2% at 6 months and 9% by 3 
years, and is even lower for pump failure death with the corresponding rates of 
0.5% and 4.5% respectively. Of note, a longer history of HF was associated with 
higher risks of sudden death and, in particular, pump failure death, especially in 
the later period of follow-up. 
This analysis found that the risk of sudden death has declined across trials over 
the last two decades, and this was coincident with a cumulative use of disease 
modifying therapies including beta-blockers and MRAs over the same time frame. 
Concerns may arise that the falling risk may be driven by the diverse study 
design and different levels of comorbidity burden across these trials. For 
example, patients enrolled in the more recent trials were more likely to have a 
history of hypertension and diabetes, and tended to have a lower blood pressure 
and heart rate than those in the older trials. However, the downward trend 
persisted after adjustment for major difference across the trials and key 
prognostic factors. Besides, the estimate of the falling risk of sudden death over 
time may be conservative. The plasma NT-proBNP, an important prognostic 
factor, was only measured in a subset of patients, but based on the cohort with 
data available, additional adjustment for NT-proBNP gave a substantially lower 
risk of sudden death in the more recent trials and treatment arms. Reassuringly, 
the observation of the falling trend in the sudden death rate was echoed by the 
finding from a study based on less selected patients over a similar time span.52 
A more pronounced reduction was observed in the risk of pump failure death 
across the same period, compared to sudden death or death from any cause; 
accordingly, pump failure death made a smaller contribution to overall mortality 
over time. Although both risks of sudden death and pump failure death increased 
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with progression of HF, pump failure death was more common, as a proportion 
of total mortality, in patients with more advanced HF.7, 84 It is arguable that the 
falling trend in the rate of pump failure death may be due to an unfair 
comparison given that patients enrolled in the earlier trials, i.e. RALES and 
BEST, had more severe HF than those in the more recent trials. However, after 
excluding patients in RALES and BEST in a sensitivity analysis, the falling trend 
persisted, although attenuated, and this was also the case with adjustment for 
the severity of HF including NYHA class and LVEF and other prognostic factors. 
This may reflect the cumulative use of disease modifying therapies, given the 
evidence from individual clinical trials that pharmacotherapies including beta-
blockers and MRAs improved pump function and lowered the risk of pump failure 
death,7, 66, 67 which was reinforced by the observation in this analysis that 
randomisation treatment was significantly associated with a lower risk of pump 
failure death. Another possible reason could be the improved management of 
acute worsening of HF, which would otherwise have led to a mortal event. 
Nevertheless, the observation of a declining risk of pump failure death over time 
stands in contrast to some observational studies in which only a modest 
reduction or even an increase was observed in the risk of pump failure death 
over time.51, 52 The reason for the discrepancy is uncertain, but it may result 
from the difference in the study population, since patients in this analysis were 
selected for trial participation, who were more likely to be younger and stable 
or have less severe symptoms, and who were different from those with newly 
diagnosed HF or hospitalised patients in observational studies. Besides, patients 
enrolled in the clinical trials were more likely to have comprehensive health 
care involving more frequent patient contact and better and timely management 
of HF aggravation than those in observational studies.  
Encouragingly, the cumulative incidences of sudden death are low at 3 months, 
and even at 6 months, in the more recent trials, in concert with a recent report 
of the national experience of wearable cardioverter defibrillators in the United 
States.129 Current guidelines have recommended the use of evidence-based 
medications for at least 3 months before device implantation.3, 130 However, in 
newly diagnosed patients initiation and up-titration of three neurohumoral 
blockers may take many weeks and there is evidence that reverse-remodelling is 
both dose-dependent and greater with multiple drugs than one or two agents.131-
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135 Moreover, decreases in left ventricular volumes and increases in LVEF may 
still occur between 6 and 12 months after treatment initiation. Consequently, 3 
months may be too short a period to wait to see whether there is sufficient 
recovery of LVEF to obviate the need for an ICD. For example, in one study, 66% 
of potential ICD candidates demonstrated an increase in LVEF above the 
threshold for implantation after optimisation of medical therapy over an average 
of 5.4 months.136 This analysis has shown that the rate of sudden death remains 
low (≤2%) for at least 6 months after randomisation in the trials analysed. It is 
unlikely that a clinically meaningful mortality benefit will be obtained with an 
ICD in patients with a sudden death rate of 1-2%,137 especially over the first 6 
months after implantation, as the clinical trials showed no discernible benefit 
using ICDs in that period.31, 32 This view is reinforced by a recent study in which 
no reduction in overall mortality was observed in patients with non-ischemic 
cardiomyopathy with high adoption of modern pharmacological treatment and 
cardiac resynchronization therapy.35 Furthermore, in a recent nationwide 
analysis of complications after primary prevention ICD implantation in 
ambulatory patients in the US, the device-related mortality rate was reported to 
be 0.73% at 30 days (with a total serious complication rate of 8.4%).138 It seems 
unlikely from the present findings that the mortality related to device 
implantation could be offset by a reduction in sudden death within 6 months. 
This result, therefore, highlights the need for better risk stratification of sudden 
death to benefit from ICD therapy in a cost-effective manner.  
The mortality rates due to progressive heart failure were quite low at early 
follow-up in the contemporary trials, e.g. at about 0.5% and 1.0% at 3 and 6 
months respectively. A different picture was outlined in population-based 
studies, where a high rate of pump failure death at early follow-up was 
observed.83 This inconsistency was not surprising given that patients enrolled in 
clinical trials often have established HF, i.e. survivors of early high-risk phase of 
this disease, in which death due to worsening HF makes a greater contribution.  
Patients with newly diagnosed HF did not have a higher risk for sudden death 
than those with a longer history of HF, if anything, the opposite is true, 
especially at later periods of follow-up. The association of a longer history of HF 
with a higher risk was also observed for pump failure death, with a greater 
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magnitude of the association and a wider separation by HF duration. This 
observation may be due the fact that patients with a longer standing of HF more 
often have advanced HF, in whom death from worsening HF is more common 
than sudden death.7  
There are several limitations to this analysis. Firstly, the study is a post-hoc 
analysis based on clinical trial data rather than “real-world” cohorts in which 
patients tend to be older, have more co-morbidity and be treated with fewer 
and less optimal doses of guide recommended medications.139-141 However, 
compared to the “real-world” unselected cohorts, cohorts from clinical trials 
have detailed characterisation and follow-up, which allows more complete 
multivariable adjustment. Moreover, it is in patients similar to those in this 
analysis that ICDs are most clearly indicated. Secondly, the definitions for mode-
specific death were not uniform despite being broadly similar across these trials. 
This is not surprising given that there were no standardised definitions for mode-
specific death until very recently when the US ACCF and AHA in collaboration 
with the FDA made a consensus on the definitions of cardiovascular endpoint 
events used in clinical trials.46 Besides, accurate classification of modes of death 
not only requires specific and detailed definitions, but also needs to capture the 
specific characteristics surrounding death and collect this information in a 
standardised way. Use of clinical trials has another strength that mortality 
events are sub-classified and cause of death is adjudicated in a careful and 
standardised way, and this could reduce the bias and variation within a trial. 
Thirdly, in this analysis time since randomisation instead of time since HF 
diagnosis was used as the underlying time scale, in other words, the patients 
examined were the “natural survivors” by the time of randomisation. This may 
be less likely to reflect the risks of sudden death and pump failure death in the 
time course of HF progression. However, ten out of the 13 trials provided 
information on the length of time between diagnosis of HF and randomisation.  
3.4 Summary 
The risks of sudden death and pump failure death in patients with HF-REF 
enrolled in clinical trials have fallen over the last two decades, in parallel with a 
cumulative use of disease modifying therapies on both modes of death. The 
absolute rates of sudden death and pump failure death were particularly low in 
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the early follow-up after randomisation in pharmacologically well-treated 
patients in the contemporary trials. A longer standing HF was associated with 
greater risks of sudden death and, particularly, pump failure death.  
Given the falling risks of both modes of death, it is of great importance to 
identify a high-risk subgroup to target costly devices to those most in need and 
to identify a low-risk subgroup to avoid unnecessary treatment, thereby 
improving the cost effectiveness of device treatment. In the next chapter, I will 
develop prognostic models to estimate the individual risks for sudden death and 
pump failure death in patients with HF-REF.   
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Chapter 4 Developing models to predict sudden 
death and pump failure death in HF-REF 
In this chapter I will develop prognostic models for sudden death and pump 
failure death separately in patients with HF-REF enrolled in PARADIGM-HF using 
a competing risk approach with Fine-Gray sub-distributional hazards regression 
models, accounting for the prognostic influence of death from other causes.27, 118 
The performance of the derived models will be examined by assessing the 
calibration ability, i.e. the agreement between the predicted and observed 
cumulative incidences, and discrimination ability, i.e. separating patients with a 
higher risk from those with a lower risk, respectively. An individual’s risk score 
for each mode of death will be calculated and the corresponding cumulative 
incidence will be predicted.  
4.1 Methods 
4.1.1 Study population 
The models were developed in a subset of patients with HF-REF randomised in 
PARADIGM-HF who did not have an ICD or CRT-D implanted at baseline.27  
4.1.2 Candidate prediction variables 
A broad spectrum of baseline variables (N=58) were assessed to identify 
predictors for each mode of death separately; the variables included 
demographics, clinical feathures of HF, medical history, treatment, 12-lead ECG, 
routine biochemical tests and NT-proBNP (Appendix Table 5). A full set of 
baseline variables were collected in most patients, and patients with missing 
values (<5.0%) were excluded in this analysis (Appendix Table 5). No difference 
was observed between the cohort with all baseline variables available and the 
overall population (all p values >0.7).   
4.1.3 Statistical analysis 
The prognostic influence of each candidate predictor on the cumulative 
incidence of each mode of death was first assessed by a univariate Fine-Gray 
sub-distribution hazards regression analysis.118 For each continuous variable, 
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linearity was examined using the restricted cubic spline method. If the response 
appeared nonlinear, certain cut-off values or transformation were applied based 
on the spline curves and clinical relevance. For categorical variables, 
appropriate dummy variables were used. For each variable, the statistical 
strength for predicting each mode of death was quantified by Χ2 values with one 
degree of freedom (the larger X2, the more powerful the predictor). For each 
outcome, univariate predictors significant at a p <0.20 level were entered into a 
multivariable Fine-Gray model with a backward stepwise selection at the 
exclusion p value of 0.05. The proportional sub-distribution hazards assumption 
for the derived models was examined using time varying terms. 
For each mode of death, an individual’s risk score was calculated as the sum of 
each predictor value multiplied by its corresponding coefficient from the final 
multivariable model. Model calibration was assessed by comparing the predicted 
cumulative incidence curve with observed Aalen-Johansen estimator in each 
quartile of the risk score (the closer the better). Model discrimination was 
assessed by visually examining the distribution of each set of curves (the wider 
the better), together with by computing the Harrell’s C statistic and C index at 
1, 2, and 3 years counting for right censoring.127  
4.2 Results 
4.2.1 Patient characteristics and mortality events  
This analysis included 7156 patients with HF-REF enrolled in PARADIGM-HF after 
excluding 1243 patients with an ICD or CRT-D at baseline. The average age was 
63.7 years and 77% were men. The mean LVEF was 29.9%, most were in NYHA 
class II-III (predominantly in class II [69.8%]) and the majority had an ischaemic 
aetiology (58.7%). There was substantial use of guideline-recommended 
medications including beta-blockers (92.4%) and MRAs (55.5%). The baseline 
characteristics are shown in Table 4-1. 
During a median 27 months of follow-up, 1344 death events occurred including 
525 sudden deaths and 261 pump failure deaths. The corresponding annual rates 
for sudden death and pump failure death were 3.4 (95% CI 3.1-3.7) and 1.7 (95% 
CI 1.5-1.9) per 100 patient-years, respectively.  
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Table 4-1 Baseline characteristics in PARADIGM-HF and ATMOSPHERE 
  PARADIGM-HF ATMOSPHERE 
p value 
  (N=7156) N=5968  
Age -years 63.7±11.6 63.1±12.1 0.01 
Male sex - no. (%) 5492 (76.7) 4565 (76.5) 0.73 
Race - no. (%)   <0.001 
White 4480 (62.6) 3659 (61.7)   
Black 344 (4.8) 95 (1.6)   
Asian 1480 (20.7) 1716 (28.9)   
Other 852 (11.9) 460 (7.8)   
Region - no. (%)   <0.001 
North America 275 (3.8) 81 (1.4)   
Latin America 1372 (19.2) 1077 (18.0)   
Western Europe 1423 (19.9) 1225 (20.5)   
Central Europe 2625 (36.7) 1737 (29.1)   
Asia or Pacific region 1461 (20.4) 1848 (31.0)   
Body mass index 28.0±5.5 27.2±5.3 <0.001 
Blood pressure -mmHg    
Systolic 122.0±15.4 124.4±18.2 <0.001 
Diastolic 74.2±10.0 77.6±11.0 <0.001 
Heart rate -beats/min 72.9±12.1 72.4±12.7 0.008 
LVEF -% 29.9±6.1 28.8±5.5 <0.001 
NYHA class - no. (%)   <0.001 
II 4988 (69.8) 4030 (67.5)   
III 1756 (24.6) 1718 (28.8)   
IV 54 (0.8) 56 (0.9)   
Ischaemic aetiology - no. (%) 4204 (58.7) 3232 (54.2) <0.001 
HF duration - no. (%)   <0.001 
within 1 year 2391 (33.4) 2229 (37.4)   
>1-5 years 2781 (38.9) 2197 (36.8)   
>5 years 1984 (27.7) 1538 (25.8)   
Medical history - no. (%)    
Current smoking  1008 (14.1) 741 (12.4) 0.005 
Previous HF hospitalisation 4459 (62.3) 3490 (58.5) <0.001 
Myocardial infarction  2919 (40.8) 2228 (37.3) <0.001 
Angina 1944 (27.2) 1415 (23.7) <0.001 
CABG or PCI 1951 (27.3) 1475 (24.7) 0.001 
Hypertension 5101 (71.3) 3725 (62.4) <0.001 
Diabetes 2406 (33.6) 1629 (27.3) <0.001 
Atrial fibrillation 2621 (36.6) 2002 (33.5) <0.001 
Stroke 596 (8.3) 419 (7.0) 0.005 
Cancer 320 (4.5) 186 (3.1) <0.001 
Asthma 249 (3.5) 179 (3.0) 0.12 
COPD 876 (12.2) 625 (10.5) 0.002 
PAD 610 (8.5) 461 (7.7) 0.10 
Medication - no. (%)    
Digoxin 2232 (31.2) 1940 (32.5) 0.11 
Diuretics 5709 (79.8) 4713 (79.0) 0.25 
ACEI or ARB 7156 (100.0) 4019 (67.3) <0.001 
Beta-blocker 6610 (92.4) 5423 (90.9) 0.002 
MRA 3969 (55.5) 2109 (35.3) <0.001 
Any antiplatelet agent 3988 (55.7) 3251 (54.5) 0.15 
Aspirin 3653 (51.0) 3021 (50.6) 0.63 
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Anticoagulant 2173 (30.4) 1633 (27.4) <0.001 
Statin 3796 (53.0) 2893 (48.5) <0.001 
Pacemaker 513 (7.2) 358 (6.0) 0.007 
CRT-P 136 (1.9) 107 (1.8) 0.65 
12-lead ECG - no. (%)    
QRS duration -ms 114.3±31.6 114.5±31.6 0.78 
Atrial fibrillation  1866 (26.1) 1434 (24.3) 0.02 
Bundle branch block 1965 (27.5) 1659 (28.1) 0.43 
Left bundle branch block 1440 (20.1) 1245 (21.1) 0.18 
Right bundle branch block 552 (7.7) 441 (7.5) 0.59 
Q wave 1247 (17.4) 1108 (18.8) 0.05 
Left ventricular hypertrophy 1423 (19.9) 1189 (20.1) 0.73 
Laboratory measurement    
eGFR <60 ml/min/1.73 m2 - no. (%) 2462 (34.4) 1467 (24.6) <0.001 
eGFR -ml/min/1.73 m2  68.8±20.3 75.1±24.7 <0.001 
Creatinine -mg/dl 1.10±0.29 1.02±0.27 <0.001 
BUN -mmol/L 7.2±2.9 7.2±2.9 0.09 
Albumin -g/L 42.8±3.2 43.2±3.6 <0.001 
Haemoglobin -g/L 139.4±16.2 137.4±16.6 <0.001 
Potassium -mmol/L 4.51±0.48 4.46±0.47 <0.001 
Sodium -mmol/L 141.5±3.0 139.7±3.3 <0.001 
Chloride -mmol/L 103.9±3.4 103.8±3.6 0.24 
Calcium -mmol/L 2.32±0.11 2.33±0.12 0.06 
Total cholesterol -mmol/L 4.59±1.16 4.54±1.20 0.005 
HDL-C -mmol/L 1.24±0.37 1.24±0.38 0.50 
LDL-C -mmol/L 2.58±0.95 2.52±1.00 <0.001 
Triglyceride-mmol/L 1.71±1.18 1.75±1.21 0.077 
NT-proBNP -pg/ml¶ 1640 (888-3342) 1204 (630-2285) <0.001 
¶ NT-proBNP measurements were available in 5408 (90.6%) patients in ATMOSPHERE. 
 
4.2.2 Derivation of the model to predict sudden death  
Table 4-2 lists the 25 most powerful prediction variables for sudden death from 
the univariate analysis in a descending order of predictive strength, and the top 
5 variables were NT-proBNP, Asian race, LVEF, NYHA class and BMI. A total of 10 
variables were finally included in the multivariable model. Male sex, Asian race, 
advanced NYHA class (III-IV vs. I-II), ischaemic aetiology, lower systolic BP, left 
ventricular hypertrophy (LVH) on ECG, prolonged QRS duration and a higher NT-
proBNP level were independently associated with a higher risk of sudden death, 
while prior CABG or PCI and a history of cancer were associated with a lower risk 
of sudden death. There was no further trend for systolic BP with values >130 
mmHg, for QRS duration with values <90 ms or >120 ms, or for log transformed 
NT-proBNP with values <6 (equivalent to NT-proBNP around 400 pg/ml) (Figure 
4-1).  
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Table 4-2 Univariate and multivariable predictors for sudden death in PARADIGM-HF 
  Univariate analysis* Multivariable model 
  sHR (95% CI) p value X2 score sHR (95% CI) coefficient p value X2 score 
Log NT-proBNP -pg/mL (from 6), per 1 log unit increase 1.50 (1.38-1.62) <0.001 96.2 1.42 (1.31-1.54) 0.348 <0.001 70.4 
Asian race vs. Caucasian race 1.71 (1.40-2.08) <0.001 28.5 1.54 (1.26-1.89) 0.434 <0.001 17.7 
LVEF 25-35%, per 1% increase 0.95 (0.93-0.97) <0.001 19.5     
NYHA class III/IV vs. I/II 1.48 (1.23-1.77) <0.001 17.6 1.35 (1.12-1.64) 0.302 0.002 9.4 
BMI 17-28 kg/m2, per 1 kg/m2 increase 0.94 (0.92-0.97) <0.001 16.1     
QRS duration 90-120 ms, per 5 ms increase 1.07 (1.03-1.10) <0.001 14.0 1.07 (1.04-1.11) 0.069 <0.001 15.4 
Triglycerides up to 2.3 mmol/L, per 1 mol/L increase 0.74 (0.62-0.87) <0.001 14.0     
Myocardial infarction history (yes vs. no) 1.35 (1.14-1.61) 0.001 12.0     
CABG or PCI (yes vs. no) 0.70 (0.56-0.86) 0.001 11.5 0.64 (0.51-0.81) -0.444 <0.001 14.5 
Male vs. female sex 1.47 (1.18-1.85) 0.001 11.2 1.44 (1.14-1.81) 0.365 0.002 9.7 
Cancer history (yes vs. no) 0.31 (0.16-0.63) 0.001 10.6 0.36 (0.18-0.72) -1.033 0.004 8.3 
Left ventricular hypertrophy on ECG (yes vs. no) 1.36 (1.12-1.66) 0.002 9.5 1.29 (1.06-1.58) 0.257 0.013 6.2 
Ischaemic aetiology (yes vs. no) 1.30 (1.09-1.56) 0.004 8.4 1.58 (1.30-1.93) 0.460 <0.001 21.2 
Albumin 30-45 g/L, per 1 g/L increase 0.96 (0.92-0.99) 0.004 8.4     
Haemoglobin A1C 5.7-12.0%, per 1% increase 1.09 (1.03-1.16) 0.004 8.3     
Systolic BP up to 130 mmHg, per 5 mmHg increase 0.95 (0.91-0.98) 0.005 8.0 0.95 (0.91-0.99) -0.049 0.018 5.6 
Black race vs. Caucasian race 1.69 (1.17-2.44) 0.005 7.9     
Serum potassium up to 4.0 mmol/L, per 0.1mmol/L increase 0.92 (0.82-0.98) 0.006 7.4     
Bundle branch block on ECG (yes vs. no) 1.28 (1.06-1.53) 0.009 6.9     
Digoxin use (yes vs. no) 1.23 (1.03-1.47) 0.024 5.1     
Beta-blocker use (yes vs. no) 0.73 (0.55-0.97) 0.031 4.7     
LCZ696 vs. enalapril 0.83 (0.70-0.98) 0.032 4.6     
Asthma history (yes vs. no) 0.51 (0.28-0.95) 0.033 4.5     
Atrial fibrillation history (yes vs. no) 0.82 (0.68-0.98) 0.033 4.5     
Left bundle branch block on ECG (yes vs. no) 1.23 (1.01-1.50) 0.043 4.1         
*The 25 strongest prediction variables for sudden death from the univariate analysis are presented in a descending order of predictive strength. 
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Figure 4-1 Histograms of systolic BP (A), QRS duration (B) and log NT-proBNP (C) and the 
corresponding spline curves with the risk of sudden death in PARADIGM-HF 
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4.2.3 Derivation of the model to predict pump failure death 
Table 4-3 shows the 25 strongest prediction variables for pump failure death 
from the univariate analysis in a descending order of predictive strength, and 
the top 5 variables were NT-proBNP, serum albumin, BUN, creatinine and eGFR. 
A total of 11 variables were included in the multivariable model, that is, systolic 
BP, advanced NYHA class, LVEF, ischaemic aetiology, longer history of HF 
(diagnosed either >1-5 years or >5 years), bundle branch block on ECG, serum 
albumin, creatinine and chloride, and NT-proBNP (log transformed). No further 
trend was observed for systolic BP above 130 mmHg, albumin below 30 or above 
45 g/L, creatinine below 1.0 or above 2.5 mg/dl, chloride below 90 or above 106 
mmol/L, and log transformed NT-proBNP below 6 (equivalent to NT-proBNP 
around 400 pg/ml) (Figure 4-2). 
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Table 4-3 Univariate and multivariable predictors for pump failure death in PARADIGM-HF 
  Univariate analysis* Multivariable model 
  sHR (95% CI) p value X2 score sHR (95% CI) coefficient p value X2 score 
Log NT-proBNP -pg/ml (from 6), per 1 log unit increase 2.00 (1.78-2.24) <0.001 142.3 1.61 (1.41-1.84) 0.477 <0.001 49.4 
Albumin 30-45 g/L, per 1g/L decrease 1.16 (1.12-1.20) <0.001 62.7 1.10 (1.06-1.15) 0.100 <0.001 26.5 
BUN 6-16 mmol/L, per 1mmol/L increase 1.17 (1.12-1.22) <0.001 54.6     
Creatinine 1.0-2.5 mg/dL, per 0.1 mg/dL increase 1.15 (1.10-1.19) <0.001 48.9 1.08 (1.03-1.13) 0.075 0.001 11.4 
eGFR up to 60 ml/min/1.73 m2, per 1ml/min/1.73 m2 increase 0.96 (0.94-0.97) <0.001 42.1     
Serum chloride 90-106 mmol/L, per 1 mmol/L decrease 1.12 (1.08-1.16) <0.001 38.3 1.09 (1.06-1.13) 0.091 <0.001 24.3 
HF duration >5 years vs. ≤ 1 year  2.71 (1.94-3.80) <0.001 34.0 2.58 (1.81-3.68) 0.948 <0.001 27.5 
LVEF up to 40%, per 1% decrease 1.05 (1.03-1.07) <0.001 30.0 1.02 (1.00-1.04) 0.020 0.032 4.6 
Haemoglobin 90-140 g/L, per 1 g/L increase 0.97 (0.96-0.98) <0.001 26.9     
Systolic BP up to 130 mmHg, per 5 mmHg decrease 1.14 (1.08-1.21) <0.001 22.8 1.10 (1.04-1.17) 0.098 0.001 12.1 
QRS duration 90-220 ms, per 5 ms increase 1.05 (1.03-1.06) <0.001 22.8     
Pacemaker implanted (yes vs. no) 2.29 (1.62-3.23) <0.001 22.0     
Diastolic BP -mmHg, per 1 mmHg increase 0.97 (0.96-0.98) <0.001 19.7     
Bundle branch block on ECG (yes vs. no) 1.72 (1.34-2.21) <0.001 18.5 1.45 (1.12-1.87) 0.369 0.005 8.1 
Cardiac resynchronization therapy (yes vs. no) 2.96 (1.68-5.22) <0.001 14.1     
Age 70-96 years, per 1 year increase 1.05 (1.02-1.08) <0.001 14.1     
Serum sodium -mmol/L, per 1 mmol/L  0.93 (0.89-0.97) <0.001 12.8     
Digoxin use (yes vs. no) 1.56 (1.22-1.99) <0.001 12.4     
Diuretics use (yes vs. no) 1.97 (1.35-2.88) <0.001 12.3     
NYHA class III/IV vs. I/II 1.57 (1.22-2.03) 0.001 12.1 1.42 (1.08-1.86) 0.350 0.011 6.5 
Ischaemic aetiology (yes vs. no) 0.66 (0.52-0.84) 0.001 11.4 0.70 (0.54-0.90) -0.357 0.005 7.7 
Haemoglobin A1C -%, per 1% increase 1.11 (1.04-1.18) 0.001 10.4     
Right bundle branch block on ECG (yes vs. no) 1.81 (1.26-2.59) 0.001 10.3     
HF duration >1-5 years vs. ≤ 1 year 1.73 (1.23-2.43) 0.002 9.9 1.73 (1.21-2.47) 0.549 0.003 9.1 
Heart rate above 70 beats/min, per 1 beat/min increase 1.02 (1.01-1.03) 0.002 9.7         
*The 25 strongest variables for pump failure death from the univariate analysis are presented in a descending order of predictive strength. 
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Figure 4-2 Histograms of systolic BP (A), serum creatinine (B), serum albumin (C), serum 
chloride (D) and log NT-proBNP (E) and the corresponding spline curves with the risk of 
pump failure death in PARADIGM-HF 
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4.2.4 Performance of the models 
As can be seen from Figure 4-3 the sudden death model was well calibrated: the 
curves for observed Aalen-Johansen estimators and predicted cumulative 
incidences were almost identical in each quartile of the risk score over time 
based on the model. In addition, each set of the four curves were well 
separated, indicating good discrimination. This was confirmed by a reasonable 
value of Harrell’s C statistic of 0.68 (95% CI 0.66-0.70) and C index of 0.67, 0.68 
and 0.66 at 1, 2 and 3 years, respectively.   
Figure 4-3 Observed vs. predicted cumulative incidence curves for sudden death by 
quartiles of the risk score based on the sudden death model in PARADIGM-HF 
 
 
 
 
For the pump failure death model, the curves for the predicted cumulative 
incidence agreed well with the corresponding observed ones by quartiles of the 
risk score, suggesting good calibration (Figure 4-4). The model appeared less 
able to discriminate the lower two quartiles, but the model identified the 
highest and the second highest quartiles which exhibited over 10 times and 3 
times the risk of the lowest quartile at 3 years respectively. The excellent 
discrimination was also quantified by C statistics with Harrell’s C of 0.79 (95% CI 
0.76-0.82) and C index of 0.82, 0.79 and 0.76 at 1-, 2- and 3-year, respectively.  
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Figure 4-4 Observed vs. predicted cumulative incidence curves for pump failure death by 
quartiles of the risk score based on the pump failure death model in PARADIGM-HF 
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There was some violation of proportional sub-distribution hazards assumption for 
systolic BP (p=0.01) in sudden death model and for albumin (p=0.02) in pump 
failure death model. When graphically displaying the cumulative incidences by 
tertiles of each predictor, the curves do not cross over time, suggesting that 
while statistically significant this was not relevant to the performance of the 
model (Figure 4-5). 
Figure 4-5 Cumulative incidence curves for sudden death by tertiles of systolic BP (A) and 
for pump failure death by tertiles of serum albumin (B) in PARADIGM-HF 
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4.2.5 Predicting an individual’s risk  
The multivariable models presented in Table 4-2 and Table 4-3 can be used to 
calculate an individual’s risk score for sudden death and for pump failure death 
respectively, by summing the products of the value and their corresponding 
coefficient of each predictor from each model. Based on the obtained risk 
scores, the corresponding cumulative incidence for each mode of death within 3 
years can be estimated using the curves outlined in Figure 4-6 and Figure 4-7. 
These figures show the distribution of the risk scores for sudden death and pump 
failure death and its association with the corresponding predicted cumulative 
incidence by 3 years, respectively. 
Figure 4-6 Distribution of the risk score for sudden death and its relation to the cumulative 
incidence of sudden death within 3 years in PARADIGM-HF 
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Figure 4-7 Distribution of the risk score for pump failure death and its relation to the 
cumulative incidence of pump failure death within 3 years in PARADIGM-HF 
 
Given below is an example of using the derived models to calculate the 
individual’s risk scores and cumulative incidences for sudden death and pump 
failure death respectively. 
Consider a white male patient, who has been diagnosed with HF of an ischaemic 
cause for 2 years, with a LVEF of 30% and NYHA functional class II and a systolic 
blood pressure 125 mmHg, who has previous PCI intervention and no other 
comorbidities, with a QRS duration of 110 ms and no other abnormalities on 
ECG, and with serum levels of albumin 40 g/L, chloride 96 mmol/L, creatinine 
1.2 mg/dl, and NT-proBNP 750 pg/ml. 
Based on Table 4-2, the risk score for sudden death is 0.365 + 0.460 -0.444 + 
(125/5)*(-0.049)+ 110/5*0.069 +ln(750)*0.348 =2.978. Figure 4-6 indicates that 
this patient is at low risk for sudden death with a probability of 3.5% by 3 years. 
Based on Table 4-3, the risk score for pump failure death is (130-125)/5*(0.098) 
+(40-30)*0.020 -0.357 +0.549+1.2*10*0.075 +(45-40)*(0.100) +(106-96)*(0.091) 
+ln(750)*0.477 = 5.958. Based on Figure 4-7, this patient is at low risk for pump 
failure death with a probability of 2.6% by 3 years. 
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4.3 Discussion 
I developed prognostic models to predict the risks of sudden death and pump 
failure death separately, using a competing risk analysis approach, in patients 
with HF-REF enrolled in PARADIGM-HF, the largest and most contemporary 
positive trial in HF. Both derived models demonstrated good discrimination and 
calibration.  
The clinical benefits of quantifying the risk of mode-specific death in individual 
patients with HF-REF have been discussed, and there already exist several 
predictive models for sudden death and pump failure death in HF as summarised 
in the Chapter 1 Introduction and literature review. However, they all have 
limitations and none has gained widespread acceptance in current clinical 
practice. Earlier models were developed before the widespread use of modern 
guideline recommended therapies including beta-blockers and MRAs.89, 91, 94 More 
recently, separate risk models for mode-specific death were developed in 
patients with HF and unspecified left ventricular function in the MUSIC study.79 
Although the models exhibited excellent discrimination for both sudden death 
and pump failure death with C statistics of 0.77 and 0.80 respectively, they were 
based on few events (90 sudden deaths and 123 pump failure deaths) and narrow 
spectrum of candidate predictors. Predictive models for sudden death and pump 
failure death were also developed in the cohort randomised in CORONA, where 
only patients with an ischaemic aetiology were included;78 additionally, 
routinely collected variables such as serum chloride and albumin were not 
examined. Investigators of the HF-ACTION trial only evaluated the incremental 
prognostic values for mode-specific death gained from new biomarkers, i.e. NT-
proBNP, galectin-3 and soluble ST2, in addition to a clinical model for all-cause 
death in the same cohort developed previously.142, 143 No predictive model or risk 
score was provided and over 46% of the patients in HF-ACTION had an ICD at 
baseline. Importantly, none of these models aforementioned has accounted for 
the prognostic influence of the competing risk of death from other causes.   
The models I developed here have particular strengths. First, they were 
constructed in a large contemporary HF population with a great number of 
patients having received modern guideline-recommended medications. Besides, 
the cohort was geographically and ethnically diverse, indicating these models 
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potentially can be generalisable to a broad range of modern patients with HF-
REF. Secondly, a wide variety of candidate variables, which are currently 
assessed in clinical practice, were examined including demographics, clinical 
assessment, medical history, treatment, ECG, routine biochemical tests and NT-
proBNP. Thirdly, death from other causes was counted as a competing risk 
instead of non-informative censoring, which can diminish its bias on the 
prognosis of each mode of death.113  
Each model has included some variables that have been previously identified to 
estimate prognosis for sudden death, such as male sex,78 NYHA class,96, 144 
ischaemic aetiology,91, 96 systolic BP96 and NT-proBNP,78, 79 and for pump failure 
death such as LVEF,78, 79 NYHA class,78 systolic BP,78 creatinine,94 albumin145 and 
NT-proBNP,78, 79 respectively. Although LVEF is a well-known prognostic factor 
for sudden death and has been used as a key criterion for selecting ICD 
recipients,3, 146 it was not independently associated with the risk of sudden 
death. This observation may reflect the relatively narrow range of LVEF in 
patients enrolled in PARADIGM-HF and, possibly, the inclusion of NT-proBNP, a 
related and more powerful predictor. This analysis also showed that Asian race 
was associated with a 50% higher risk of sudden death compared to other 
ethnicities (predominantly white). The reason for this is unknown, and apart 
from the difference in the clusters of baseline prognostic factors, it is possible 
due to an underlying genetic predisposition across races (e.g. the prevalence of 
atrial fibrillation is lower among Asians than Western caucasians).147 LBBB has 
been reported as a risk factor of sudden death,79, 96 but I found other ECG 
parameters, i.e. LVH and prolonged QRS duration (within a cut-off value of 120 
milliseconds above which there was no further trend) were more powerful and 
thus included in the multivariable model. Findings from previous studies have 
shown that both LBBB and RBBB were associated with a higher risk of pump 
failure death (somewhat stronger with RBBB).148 This was also the case in this 
analysis. The combination of LBBB and RBBB (namely BBB) increased the 
prediction power and thus were included in the multivariable model. Serum 
chloride was identified as a more powerful predictor than sodium for pump 
failure death, standing in contrast to the SHFM and the MUSIC risk score in which 
hyponatremia was a key component.79, 101 Of note, serum chloride levels were 
not analysed in these models. When both being assessed simultaneously, the 
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superiority of serum chloride over sodium in prognosis prediction was observed 
as reported previously.149, 150 The mechanism of higher prognostic value of serum 
chloride than sodium in predicting pump failure death is uncertain, and one 
possible explanation is that decongestive therapies such as loop diuretics lead to 
electrolyte wasting, while may limit reabsorption of chloride more potently than 
sodium, in other words, serum chloride may serve as a better surrogate for 
decongestive therapy use and intensity. Besides, chloride also serves as one of 
the major charge-balancing anions in the serum along with bicarbonate and 
albumin, and hypochloraemia may be associated with the pathophysiological 
states of high serum bicarbonate, low potassium and albumin.151, 152 Surprisingly, 
neither model included age or diabetes, two well-established risk factors in HF. 
This may reflect that advanced age and diabetes are not exclusively related to 
sudden death and pump failure death, but also associated with death from other 
CV or non-CV causes, thus their prognostic value failed to maintain when using 
competing risk approach. 
There were some limitations in this analysis. First, these models were 
constructed in patients from a clinical trial rather than in a “real-world” cohort, 
in other words, patients tended to be healthier, have less co-morbidity and 
receive more and higher doses of evidence-based treatment. However, it is in 
patients similar to those in this analysis that ICDs are most clearly indicated. 
Secondly, in line with previous findings,79, 84 the sudden death model was less 
discriminative than the pump failure death model. This suggests that there is a 
need for improvement in the prediction of sudden death. Some variables had 
been identified predictive of sudden death, but were not available in most 
patients in PARADIGM-HF such as echocardiographic parameters, 24-h Holter 
monitoring,79 and other biomarkers, e.g. apolipoprotein A-1,78 ST2 and galectin-
3.143 The addition of these predictors may further improve the model 
discrimination ability. Nevertheless, these parameters are not available in 
routine clinical practice; therefore, even if their addition improves model 
discrimination, it remains to be examined if the addition would improve the 
decision making to a degree that would justify the additional costs and 
complexity. Thirdly, in a given patient, the mode of death can be changed by 
implanting a defibrillator. Although patients with a defibrillator at baseline were 
excluded, I cannot rule out the potential confounding influence of ICDs 
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implanted after randomisation, although there were few such cases (2.7%). 
Lastly, even if mode-specific death were appropriately classified and accurately 
estimated, a difference may still lie in between the predicted risk and the 
response to treatment.  
4.4 Summary 
The prognostic models developed can separately estimate the risks of sudden 
death and pump failure death with good discrimination and calibration in the 
derivation cohort of patients with HF-REF. In the next chapter, I will validate 
both models externally in ATMOSPHERE. If both models remain robust in 
validation, they may be useful in risk stratification for mode-specific death, 
which aid decision making in device therapies and help with the selection of 
patients for specific interventions in future trials.  
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Chapter 5 Validating models to predict sudden 
death and pump failure death in HF-REF 
In this chapter I will separately examine the performance of the prognostic 
models for sudden death and pump failure death derived from PARADIGM-HF by 
external validation in ATMOSPHERE. I will also examine the model performance 
of the Seattle Heart Failure Model (SHFM)84 and Seattle Proportional Risk Model 
(SPRM),74 developed in a historic population in which beta-blockers and MRAs 
were not widely used, in the contemporary PARADIGM-HF and ATMOSPHERE 
cohorts. Validation will be performed by fitting a univariate regression analysis 
on the risk score which is the sum of the products of predictor coefficients from 
the derivation model and its corresponding predictor values in the validation 
cohort. For consistency, the same regression approach (i.e. Fine-Gray competing 
risk, Cox proportional hazards or logistic regression) in the model derivation 
process will be correspondingly used in the validation process.  
5.1 Methods 
5.1.1 The prognostic models to be validated 
Validation was undertaken for the sudden death model derived from PARADIGM-
HF which consisted of 10 prediction variables including sex, Asian race, systolic 
BP, ischaemic aetiology, NYHA class, cancer history, prior CABG or PCI, left 
ventricular hypertrophy on ECG, QRS duration and NT-proBNP; for the pump 
failure death derived from PARADIGM-HF including systolic BP, NYHA class, LVEF, 
ischaemic aetiology, HF duration (>1-5 years and >5 years), bundle branch block 
on ECG, serum albumin, creatinine, chloride and NT-proBNP; for SHFM which 
included age, sex, NYHA class, 100/LVEF, ischaemic aetiology, systolic BP, 
weight-adjusted diuretic dose, allopurinol, statin, sodium, 100/cholesterol, 
haemoglobin, percent lymphocytes, uric acid, ACEIs, beta-blockers, ARBs, K-
sparing diuretics and devices; and for the SPRM which consisted of age, sex, 
LVEF, NYHA class, systolic BP, BMI, a history of diabetes, digoxin use, and serum 
creatinine and sodium (Appendix Table 6 and Appendix Table 7).74, 84  
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5.1.2 The validation cohorts 
After excluding patients with an ICD or CRT-D at baseline, patients enrolled in 
ATMOSPHERE (N=5968) and patients in PARADIGM-HF (N=7156) comprised the 
two validation cohorts.6, 27 The sudden death model and pump failure death 
model derived from PARADIGM-HF were validated in the ATMOSPHERE cohort. All 
predictive variables were available in most patients (missing observations <3%) 
except NT-proBNP (9.4% missing); accordingly, the sudden death and pump 
failure death models were validated in 5234 (87.7%) and 5356 (89.7%) patients in 
ATMOSPHERE respectively, using the complete case analysis approach (Appendix 
Table 6). The SHFM model was validated both in PARADIGM-HF and 
ATMOSPHERE, and all prediction variables were available in most patients 
(missing observations ≤5%) except weight-adjusted diuretic dose (21.1% missing 
in PARADIGM-HF and 22.8% missing in ATMOSPHERE), leaving 5320 (74.3%) 
patients in PARADIGM-HF and 4223 (74.1%) in ATMOSPHERE for validation. All 
prediction variables for the SPRM were available in most patients (missing 
observations <2%) in PARADIGM-HF and ATMOSPHERE, with corresponding 7007 
(98.9%) and 5951 (99.7%) patients with complete data included in the validation 
(Appendix Table 7).  
5.1.3 Statistical analysis 
For each model to be validated, an individual’s risk score was calculated as the 
sum of predictor coefficients from each derivation model multiplied by its 
corresponding predictor values in the validation cohort. The obtained risk score 
of each model was fitted into a regression model using the same approach as the 
model derivation procedure for consistency, and model performance was 
examined using the same approach as the derivation procedure for valid 
comparison.  
To validate the models to predict sudden death and pump failure death derived 
from PARADIGM-HF, the individual’s risk score for each mode of death was fitted 
into a univariate Fine-Gray regression analysis.118 Model calibration was 
examined by comparing the predicted and observed cumulative incidences over 
time in each quartile of the risk score. Model discrimination was examined by 
visually evaluating the distribution of each set of cumulative incidence curves, 
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as well as by calculating the Harrell’s C statistic and C index at 1-, 2-, and 3-
year accounting for right censoring.127  
To validate the SHFM, the same risk score was fitted into a Cox proportional 
hazards model for sudden death, pump failure death and all-cause death, 
respectively.84 The discrimination ability was examined using the Harrell’s C 
statistic, and the calibration was examined by comparing the observed Kaplan-
Meier survival estimator with the predicted event free probability (based on Cox 
model for consistency) in each quartile of the risk score.  
To validate the SPRM, a logistic regression analysis was fitted for sudden death 
and the discrimination was examined using the ROC AUC at 1 year, an equivalent 
to Harrell’s C.74 In the same paper, a bi-modal system was proposed to provide 
individual estimates of the proportion of mortality due to sudden death for any 
given SHFM estimated mortality rate, which intended to identify the subset of 
patients who were at a disproportionately higher risk of sudden death but a 
lower absolute rate of dying from other causes, i.e. presumably benefit most 
from an ICD.74 This bimodal system, which consisted of the SPRM for the 
proportion of sudden death relative to total mortality and the SHFM for the 
absolute 1-year all-cause mortality rate, was also validated in the PARADIGM-HF 
and ATMOSPHERE cohorts. 
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5.2 Results 
5.2.1 Patient characteristics and events in ATMOSPHERE (versus 
PARADIGM-HF) 
A total of 5968 patients with HF-REF in ATMOSPHERE comprised the validation 
cohort after excluding 1048 patients with an ICD or CRT-D at baseline. As can be 
seen from Table 4-1, the patient characteristics at baseline in ATMOSPHERE 
were similar, for the most part, to PARADIGM-HF: predominantly male, mean 
age of 63 years, similar pattern of NYHA class distribution (mainly class II), over 
half with an ischaemic cause of HF and a very high use rate of beta-blockers 
(>90%). However, some differences were also noted. Compared to PARADIGM-HF, 
ATMOSPHERE had a higher proportion of Asian patients (29% vs. 21%), but a 
smaller proportion of patients with a history of hypertension (62% vs. 71%) or 
diabetes (27% vs. 34%). Mean serum creatinine level was lower in ATMOSPHERE 
than in PARADIGM-HF (1.02 mg/dl vs. 1.10 mg/dl). Correspondingly, the 
proportion of patients with renal dysfunction (eGFR <60 mL/min/1.73m2) was 
lower in ATMOSPHERE than in PARADIGM-HF (25% vs. 35%). Notably, substantially 
fewer patients were treated with a MRA in ATMOSPHERE than in PARADIGM-HF 
(35% vs. 55%), and the median plasma NT-proBNP level was much lower in 
ATMOSPHERE compared to PARADIGM-HF (1204 pg/ml vs. 1640 pg/ml).   
In ATMOSPHERE, there were 1644 death events including 607 sudden deaths and 
305 pump failure deaths over a median 37.7 months of follow-up. The annual 
rate of mode-specific death was identical to PARADIGM-HF, at 3.4 (95% CI 3.1-
3.7) per 100 patient-years for sudden death and 1.7 (95% CI 1.5-1.9) per 100 
patient-years for pump failure death. 
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5.2.2 Validation of the models derived from PARADIGM-HF 
As shown in Figure 5-1, the distribution of the risk score for sudden death in 
ATMOSPHERE was almost identical to PARADIGM-HF, with a mean ± standard 
deviation of 3.4 ± 0.6 and 3.5 ± 0.6, respectively.  
Figure 5-1 Distribution of the individual risk score for sudden death in ATMOSPHERE (A) 
and PARADIGM-HF (B) 
 
 
Each figure shows the distribution of the risk score based on the box plot (the upper) and the 
histogram (the lower). 
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Likewise, the distribution of the risk score for pump failure death in 
ATMOSPHERE agreed well with that in PARADIGM-HF (5.6 ± 0.9 vs. 5.8 ± 0.9) 
(Figure 5-2). 
Figure 5-2 Distribution of the individual risk score for pump failure death in ATMOSPHERE 
(A) and PARADIGM-HF (B) 
 
 
Each figure shows the distribution of the risk score based on the box plot (the upper) and the 
histogram (the lower). 
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For the sudden death model, discrimination ability in ATMOSPHERE was equally 
good as in PARADIGM-HF with a Harrell’s C of 0.68 (95% CI 0.65-0.70) and C-index 
of 0.70, 0.69 and 0.68 at 1 year, 2 years and 3 years, respectively. Figure 5-3 
shows the predicted and observed cumulative incidence curves by quartiles of 
the risk score in ATMOSPHERE. Each set of the observed and predicted curves 
was well separated between the neighbouring quartiles, visually confirming the 
discrimination ability concluded above. Moreover, each pair of the observed and 
predicted cumulative incidences in each quartile was fairly close over time 
except in the highest one, where the validation model under-estimated the risk 
of sudden death consistently over time. 
Figure 5-3 Observed vs. predicted cumulative incidence curves for sudden death by 
quartiles of the risk score in ATMOSPHERE 
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For the pump failure death model, there was a slight decrease in discrimination 
ability when validated in ATMOSPHERE, but it remained excellent with a 
Harrell’s C of 0.75 (95% CI 0.72-0.78) and C-index of 0.78, 0.76 and 0.73 at 1-, 2- 
and 3-year respectively. As presented in Figure 5-4, both the observed and 
predicted cumulative incidence curves were widely separated by quartiles of the 
risk score in ATMOSPHERE. Besides, the figure shows that the model was well 
calibrated in validation: the predicted cumulative incidence curve agreed well 
with the observed one in each quartile of the risk score, apart from the highest 
quartile where an under-estimation for pump failure death was observed in the 
early period of follow-up. 
Figure 5-4 Observed vs. predicted cumulative incidence curves for pump failure death by 
quartiles of the risk score in ATMOSPHERE 
 
 
 
5.2.3 Validation of SHFM in ATMOSPHERE and PARADIGM-HF 
As can be seen from Table 5-1, there were some similarities in baseline 
characteristics between the SHFM cohort and the contemporary PARADIGM-HF 
and ATMOSPHERE cohorts including the proportion of men, the distributions of 
age, serum sodium, haemoglobin, uric acid and lymphocyte percent. However, 
some notable differences were also observed: the SHFM cohort included patients 
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with mixed left ventricular dysfunction, while the contemporary cohorts only 
included patients with HF-REF, although the average LVEF was similar; the 
proportion of patients with advanced NYHA class (III-IV) was higher in the SHFM 
cohort than the two contemporary cohorts, this was also the case for the 
proportion of patients with an ischaemic aetiology; the proportion of patients 
having received potassium sparing diuretics, statins or, in particular, beta-
blockers were much higher, while the average cholesterol and creatinine levels 
were somewhat lower in the contemporary cohorts, compared to the SHFM 
cohort. 
Table 5-1 Baseline characteristics in the SHFM cohort and in ATMOSPHERE and 
PARADIGM-HF 
 SHFM ATMOSPHERE PARADIGM-HF 
 (N=10538) (N=5968) (N=7156) 
Age -years 65 (18-96) 63 (19-95)    64 (18-96) 
Male sex (%) 76 76 77 
NYHA class (%)    
II 49 67 70 
III 37 29 25 
IV 14 1 1 
LVEF -% 28 (1-75) 29 (5-35)  30 (5-42) 
Ischaemic aetiology (%) 62 54 59 
Systolic BP -mmHg 125 (70-210) 124 (85-200) 122 (90-188)  
ACEI (%) 80 67 89 
ARB (%) 39 1 61 
Beta-blocker (%) 31 91 92 
K-Sparing diuretic (%) 13a 36 56 
Allopurinol (%) 8b 7 9 
Statin (%) 25 48 53 
Serum sodium -mmol/L 140 (120-175) 140 (110-154) 141 (116-159) 
Creatinine -mg/dl 1.3 (0.1-8.2) 1.02 (0.1-3.2)  1.10 (0.2-3.7)    
Cholesterol -mg/dl 201 (33-600) 175 (54-451)c 178 (65-572)f 
Uric acid -g/dl 7.3 (0.1-20) 7.4 (1.6-16.6)  6.8 (0.3-17.1)g    
Haemoglobin -g/dl 13.8 (5.0-21.1) 13.7 (5.6-22.9)d   13.9 (6-20.1) h  
Lymphocyte -% 25 (1-91) 27 (3-76)e 28 (3-87)i 
The letter denotes the number of patients with data available: a=9775 (92.8%), b=5617 (53.3%), 
c=5759 (96.5%), d=5928 (99.3%), e=5920 (99.2%), f=6995 (97.8%), g=6996 (97.8%), h=6927 
(96.8%), i=6800 (95.0%). Data were presented as mean (range) or proportion in consistent with 
the data shown in the SHFM cohort from the paper by Mozaffarian D et al 2007.84 
 
During a mean 1.6 years of follow up, there were 2014 death events including 
1014 sudden deaths with an annual rate of 6.1 per 100 patient-years and 684 
pump failure deaths with an annual rate of 4.1 per 100 patient-years in the SHFM 
cohort, nearly double those in the validation cohorts. 
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The SHFM had good discrimination for sudden death with a 1-year C statistic of 
0.68 (95% CI 0.65-0.70) in the original cohort. However, when using SHFM to 
predict sudden death in the contemporary cohorts, its discrimination ability 
decreased in ATMOSPHERE and particularly in PARADIGM-HF, with the 
corresponding C statistics of 0.62 (95% CI 0.58-0.66) and 0.55 (95% CI 0.51-0.59) 
at 1 year, respectively (Table 5-2). 
Table 5-2 Discrimination ability of SHFM in the validation cohorts (versus the derivation 
cohort) 
 Derivation cohort ATMOSPHERE PARADIGM-HF 
Sudden death 
1 year 0.68 (0.65-0.70) 0.62 (0.58-0.66) 0.55 (0.51-0.59) 
3 years - 0.63 (0.60-0.66) 0.57 (0.54-0.60)  
Overall  - 0.63 (0.60-0.65) 0.57 (0.54-0.60) 
Pump failure death 
1 year 0.85 (0.83-0.87) 0.69 (0.62-0.76) 0.70 (0.65-0.75) 
3 years - 0.64 (0.59-0.68)   0.67 (0.63-0.70)  
Overall  - 0.64 (0.60-0.67) 0.67 (0.63-0.70)  
All-cause death 
1 year 0.73 (0.71-0.74) 0.64 (0.61-0.67) 0.60 (0.58-0.63) 
3 years - 0.62 (0.60-0.64)  0.60 (0.59-0.62) 
Overall  - 0.62 (0.60-0.63) 0.60 (0.59-0.62) 
Results are presented as values of Harrell’s C (95% confidence interval). 
 
The SHFM had excellent discrimination for pump failure death with a 1-year C 
statistic of 0.85 (95% CI 0.83-0.87) in the original cohort. When it was used to 
predict pump failure death in ATMOSPHERE, its discriminative ability declined 
substantially by 0.16 with a 1-year C statistic of 0.69 (95% CI 0.62-0.76). A 
similar size of decrease in discrimination was also observed when validated in 
PARADIGM-HF (Table 5-2). 
Given that the SHFM was originally designed to predict all-cause mortality, I also 
examined its discrimination for all-cause death in ATMOSPHERE and PARADIGM-
HF. Compared to its derivation cohort (C statistic 0.73, 95% CI 0.71-0.74), the 
discrimination ability at 1 year was much lower either in ATMOSPHERE (0.64, 95% 
CI 0.61-0.67) or in PARADIGM-HF (0.60, 95% CI 0.58-0.63) (Table 5-2). 
Surprisingly, the calibration ability was good when predicting sudden death, 
pump failure death or all-cause death either in ATMOSPHERE (Figure 5-5) or in 
PARADIGM-HF (Figure 5-6). 
Chapter 5 152 
 
Figure 5-5 Observed vs. predicted probabilities for sudden death, pump failure death and all-cause death by quartiles of the SHFM risk score in 
ATMOSPHERE 
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Figure 5-6 Observed vs. predicted probabilities for sudden death, pump failure death and all-cause death by quartiles of the SHFM risk score in 
PARADIGM-HF 
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5.2.4 Validation of SPRM in ATMOSPHERE and PARADIGM-HF 
There were 9885 patients with HF in the cohort for the derivation of SPRM. 
Table 5-3 shows some baseline characteristics in the SPRM cohort and in the 
validation cohorts of ATMOSPHERE and PARADIGM-HF. The mean age, proportion 
of men, and proportions of patients with an ischaemic aetiology and a history of 
diabetes were largely similar across these cohorts, but some differences were 
observed. Compared to the two validation cohorts, the SPRM cohort tended to 
have worse cardiac function, i.e. lower mean LVEF and a higher proportion of 
patients with NYHA class III-IV symptoms, and worse renal function, but had a 
much lower average level of NT-proBNP. The rate of use of statins, and, in 
particular, beta-blockers was much lower while digoxin use was much higher in 
the SPRM cohort than in the validation cohorts.  
Table 5-3 Baseline characteristics in the SPRM cohort and in ATMOSPHERE and 
PARADIGM-HF 
 SPRM 
(N=9885) 
ATMOSPHERE 
(N=5968) 
PARADIGM-HF 
(N=7156) 
Age -years 64±15 63±12    64±12 
Male sex -no. (%) 7806 (79.0) 4565 (76.5)  5492 (76.7)  
BMI 26.5±5.3 27.2±5.3 28.0±5.5 
LVEF -% 27±11 29±6    30±6  
Systolic BP -mmHg 121±25 124±18  122±15 
NYHA class -no. (%)    
II 5071 (51.3) 4030 (67.5)  4988 (69.8)  
III 3436 (34.8) 1718 (28.8)  1756 (24.6)  
IV 1378 (13.9) 56 (0.9)  54 (0.8)  
Ischaemic aetiology -no. (%) 5512 (55.8) 3232 (54.2)  4204 (58.7)  
Diabetes -no. (%) 2591 (26.2) 1629 (27.3)  2406 (33.6)  
Digoxin -no. (%) 6627 (67.0) 1940 (32.5)  2232 (31.2)  
Statin -no. (%) 2464 (24.9) 2893 (48.5)  3796 (53.0)  
ACEI or ARB -no. (%) 9533 (96.4) 4019 (67.3) 7156 (100) 
Beta-blocker -no. (%) 4616 (46.7) 5423 (90.9)  6610 (92.4)  
Diuretic dose -mg/kg 0.50±0.83 0.62±0.57b  0.66±0.69d 
Serum sodium -mmol/L 140±3 140±3 142±3e 
Creatinine -mg/dl 1.21±0.3 1.02±0.27    1.10±0.29    
NT-proBNP -pg/ml 895±1616a 1934±2519c 2964±4121 
 The letters denote the number of patients with data available: a=4028 (40.7%), b=4606 (77.2%), 
c=5408 (90.6%), d=5652 (79%), e=7026 (98.2%). 
Data were presented as mean ± standard deviation or number (percent) in consistent with the data 
shown in the SPRM cohort from the paper by Shadman R et al 2015.74 
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There were 2552 death events during a mean 28 months of follow up in the SPRM 
derivation cohort, including 1225 sudden deaths with an annual rate of 4.2 per 
100 patient-years.  
The SPRM was designed to predict the proportion of sudden death relative to 
total mortality other than the absolute risk. Overall, the model over-estimated 
the proportion of deaths that were sudden in ATMOSPHERE (predicted vs. 
observed proportions were 53.6% vs. 36.9%) as well as in PARADIGM-HF (52.5% vs. 
39.1%). A decrease in discrimination ability was observed when applying it to 
ATMOSPHERE and PARADIGM-HF (1-year ROC AUC 0.54 and 0.57, respectively), 
compared to 0.64 in the derivation cohort of SPRM. As can be seen from Figure 
5-7, using a threshold of 42% of proportion of mortality due to sudden death and 
25% of 1-year mortality rate (used by the SPRM investigators to identify patients 
most likely to benefit from an ICD), this bimodal system allocated the majority 
patients to the upper left quadrant, low risk of mortality which was primarily 
attributable to sudden death, either in ATMOSPHERE (81.5%) or in PARADIGM-HF 
(79.5%). In other words, this model predicted that most patients would have an 
indication for ICD.  
Figure 5-7. Validation of Seattle Proportional Risk model in ATMOSPHERE (A) and in 
PARADIGM-HF (B). 
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An annual all-cause mortality rate of below 25% and a predicted proportion of mortality due to 
sudden death of over 42% were used to identify the subset of patients in the left upper quadrant 
who are assumed to benefit most from ICD (according to the Seattle Proportional Risk model). 
Data were available for calculating the risk scores of SHFM and SPRM in 4417 (74.0%) patients 
in ATMOSPHERE (Panel A) and 5320 (74.3%) patients in PARADIGM-HF (Panel B). 
 
 
 
 
 
 
 
 
 
5.3 Discussion 
I externally validated the prognostic models for sudden death and pump failure 
death derived from PARADIGM-HF in ATMOSPHERE. Generally, the discrimination 
and calibration ability of both models developed in PARADIGM-HF were good and 
robust in ATMOSPHERE. I also examined the model performance of the SHFM and 
SPRM in the contemporary PARADIGM-HF and ATMOSPHERE cohorts. Despite 
reasonable calibration, the SHFM had a large decrease in the discrimination 
ability to predict sudden death, pump failure death and even all-cause death in 
both modern cohorts. The SPRM showed poor discrimination and calibration, and 
assigned most patients into the category who had a low mortality but primarily 
due to sudden death, i.e. meriting ICD implantation, in both contemporary 
cohorts.    
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5.3.1 What is external validation? 
Validation refers to examining the performance of a predefined model (identical 
predictors and their coefficients) in an independent cohort, other than repeating 
the whole modelling process in new data, or re-estimating the effects of 
predictors from the original model in new data. The latter two approaches 
would lead to new models, and therefore, would themselves need external 
validation.72 It is noteworthy that external validation is not exclusive to newly 
developed models, but also can be carried out in existing models developed in a 
historic population since which treatment or prognosis has largely changed.153    
Discrimination and calibration are two key aspects of evaluating and thus 
validating model performance. Discrimination is the ability to separate patients 
with differing prognosis. Patients predicted to be at greater risk should have 
higher event rates than those estimated to be at lower risk. Calibration 
examines the prediction accuracy, i.e. the agreement between the predicted 
and observed risks. Sometimes a model may systematically over-/under-predict 
the risk (poor calibration), but it may separate well between patients with high 
and low risks (good discrimination). The model may be still useful in risk 
stratification if the incompetence in calibration can be improved by 
recalibration strategies.72, 154 On the other hand, a model with poor 
discrimination assigns patients to a high or low risk similar to a random guess: a 
low-risk patient may be predicted at high risk, leading to unnecessary 
treatment, and a high-risk patient may be predicted at low risk, which would 
result in missed treatment. Moreover, the poor discrimination cannot be altered 
with post-modelling techniques. Therefore, a model with poor discrimination 
would have little clinical value in risk stratification, regardless of its calibration 
ability.72  
5.3.2 Why is external validation necessary? 
The performance of a prognostic model is generally better in the derivation 
cohort than in a new cohort. It is possible that a promising prediction model 
performs poorly outside the derivation cohort. Therefore, it is of fundamental 
importance to verify the robustness and generalisability of a newly-developed 
model in one or more independent cohorts before it can be considered for use to 
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inform prognosis for a wide range of patients in clinical practice.155 In a way, 
external validation can be regarded as a pilot trial of applying a model to target 
populations, and good performance in validation may serve as a reassurance for 
the consideration of model use. On the other hand, a poor performance could 
suggest further means of improvement for a derived model. If a model appears 
poorly calibrated (under-/over-prediction) in the validation cohort, the model 
should be recalibrated before it can be considered for use in similar populations; 
otherwise, an under-prediction would lead to appropriate patients missing out 
on certain beneficial treatments, while an over-prediction would result in 
inappropriate patients receiving certain treatments which are unnecessary. If a 
model has poor discrimination in validation, further improvement in the original 
model should be made, such as adding potential interaction between predictors, 
including more advanced forms of association between continuous predictors and 
outcomes, and including more powerful predictors. If not, patients would be 
wrongly assigned to a high or low risk, and a poorly discriminatory model would 
have little clinical value in risk stratification.  
Due to a lack of cohorts besides those used for model derivation, internal 
validation has been commonly used as an alternative.153 However, internal 
validation is no substitute for external validation. Because this approach is 
neither statistically efficient since cross-validation and split-sampling techniques 
typically make a sacrifice of the cohort size for model derivation and use smaller 
cohorts (and numbers of events) for model validation, nor methodologically 
sound given that there is no material difference between derivation and 
validation cohorts other than randomly by chance, thus no guarantee for 
generalisability.155  
5.3.3 Validation of models for mode-specific death derived from 
PARADIGM-HF 
When validating in ATMOSPHERE, the discrimination ability maintained for the 
sudden death model but slightly decreased for the pump failure death model 
derived from PARADIGM-HF. Nevertheless, in absolute terms, the discrimination 
ability was moderate for the sudden death model with C-statistic slightly below 
0.7, but excellent for pump failure death model with C-statistic around 0.75. 
Although both models were well-calibrated in the validation cohort, there was a 
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slight under-prediction in the highest quartile. If the models were used to guide 
decision making in device therapy, it may lead to appropriate patients missing 
out on device therapy, since patients with a high risk may be predicted to have a 
lower risk below the threshold for the indication of device therapy. Although a 
decrease in performance in validation is conceivable, the reason for the 
decrease is uncertain. However, it is unlikely caused by the difference in the 
baseline risk between the derivation and validation cohorts, since both cohorts 
were from clinical trial setting with similar eligibility criteria and reflected 
similar treatment strategies within nearly overlapped study periods, and 
consequently the corresponding incidences for mode-specific death were almost 
identical. One possible explanation is the variation in the distribution of 
individual predictor values between cohorts. For example, compared to 
PARADIGM-HF, NT-proBNP, the most powerful predictor in both models, was 
systematically lower in ATMOSHERE, and this was also the case for serum 
creatinine, a predictor for pump failure death; while the prevalence of Asian 
race, a predictor for sudden death, was higher in ATMOSPHERE. This variation 
may result in a mixed contribution of individual predictors to the overall risk 
score, which may cumulatively lead to a difference in the model performance, 
even if the underlying predictor effects were consistent. Another possibility is 
the inconsistency in the underlying predictor effects between the derivation and 
validation cohorts, since I cannot rule out there may exist unexamined 
interactions between covariates or more complicated relationships between 
covariates and the outcome. Nevertheless, the sudden death and pump failure 
death models remained robust when externally validated in the similar 
population, and these models can be considered for use in risk stratification and 
aiding decision making in device therapy. 
5.3.4 Validation of SHFM in the modern cohorts  
The SHFM was reported to have good discrimination for sudden death and 
particularly for pump failure death comparable to the models I developed in 
PARADIGM-HF. When applied to the contemporary PARADIGM-HF and 
ATMOSPHERE cohorts, the SHFM was well-calibrated, but had a substantial 
decrease in discrimination in either cohort. The reason for the decrease in 
discrimination is unknown, and one possible explanation is that the baseline risks 
for mode-specific death in the contemporary cohorts were in the lower 
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spectrums of the risks in the SHFM derivation cohort, i.e. narrower but within 
the spectrums, leading to less separated prognosis but within the prediction 
range for the contemporary cohorts. As can be seen where the annual rates for 
sudden death and pump failure death were 3.4 and 1.7 per 100 patient-years 
respectively in the modern validation cohorts, and the corresponding rates were 
much higher as 6.1 and 4.1 per 100 patient-years respectively in the SHFM 
derivation cohort. The decrease in discrimination and maintenance in calibration 
were also observed in the original SHFM for all-cause death, in which good 
agreement between the observed and predicted mortality was observed in the 
derivation as well as 5 validation cohorts, but the 1-year ROC AUC ranged from 
0.68 to 0.81 across these cohorts with different case-mix variations.101 In the 
derivation cohort, the SHFM was significantly less discriminatory for both sudden 
death and pump failure death in patients who had received beta-blockers than 
those did not.84 Accordingly, another explanation for the decrease in 
discrimination can be due to a universal use of beta-blockers (over 90%) in both 
contemporary validation cohorts.6, 27 Consequently, the SHFM may have little 
clinical significance in risk stratification for mode-specific death in patients 
receiving contemporary evidence-based therapies. 
5.3.5 Validation of SPRM in the modern cohorts  
The SPRM was developed to predict the proportion of sudden death relative to 
total mortality rather than the absolute risk.74 With a combination of the 
predicted risk of annual total mortality derived from SHFM, the investigators 
attempted to identify a subset of patients who would benefit most from ICD: a 
high risk of sudden death but a low risk of dying from other causes. Applying this 
bi-modal system to PARADIGM-HF and ATMOSPHERE, it yielded poor 
discrimination and over-estimated the proportional risk of sudden death. 
Consequently, the bi-model system allocated majority patients in the category 
who had low mortality rate but disproportionally high risk of sudden death, in 
other words, the majority of patients in the modern cohorts were predicted to 
have indications for an ICD. The reason for the poor performance of the SPRM in 
the modern cohorts is uncertain, but this may reflect the heterogeneity in 
proportion of sudden death as to overall mortality between the validation 
cohorts (<40%) and the derivation cohort (48%), suggesting an underlying 
difference in the baseline risk across cohorts. Thus, the intercept from the 
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original SPRM may not be transportable, and a direct application may lead to the 
predicted proportional risk being systematically higher in the validation cohorts. 
In keeping with this observation, a study showed that the SPRM overestimated 
the proportional risk of sudden death in patients with an ICD (predicted vs. 
actual proportion of sudden death: 56% vs. 31%) in the HF-ACTION cohort, in 
which the baseline risk for sudden death was presumably lower compared to the 
derivation cohort.156  
Very recently, two studies have shown that the SPRM was able to classify 
different magnitudes of the survival benefit from ICD in the HF-ACTION cohort 
and in an observational cohort including patients from an ICD registry and HF 
registries/clinical trials, but neither was a randomised clinical trial for primary 
prevention ICDs and both shared great differences in the baseline characteristics 
between the ICD and non-ICD subgroups.156, 157 Moreover, the SPRM was used to 
estimate the relative risk of sudden death as a proportion of total mortality, 
other than the absolute risk (i.e. cumulative incidence) of sudden death. The 
proportional risk may be useful at a population level for policy making, but not 
at an individual level for decision making. 
5.4 Summary 
The sudden death and pump failure death models developed in PARADIGM-HF 
remained robust in ATMOSPHERE. These models can be considered for use in risk 
stratification for mode-specific death and aiding decision making in device 
therapy in similar populations. Despite good calibration, the SHFM had a 
substantial decrease in discrimination to predict sudden death, pump failure 
death and even all-cause death in the modern cohorts. Therefore, the SHFM may 
have limited clinical value in risk stratification for sudden death and pump 
failure death in contemporary patients if not modified and re-validated. The 
SPRM showed poor discrimination and over-estimated the actual proportional 
risk of sudden death, and consequently, together with the SHFM, the bimodal 
system assigned most patients into the category of meriting an ICD in both 
contemporary cohorts.  
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Chapter 6 Rates of sudden death and pump 
failure death over time in HF-PEF 
In this section I will describe the rates of sudden death and pump failure death 
in patients with HF-PEF enrolled in three clinical trials over the time period 
between 1999 and 2013. I will examine the rates of sudden death and pump 
failure death in each trial and the cumulative incidences of each mode of death 
at different time intervals during follow-up, and the cumulative incidences for 
each mode of death according to the duration between HF diagnosis and 
randomisation. The analyses will be undertaken using the conventional survival 
analysis to calculate the annual rates for mode-specific death, and using the 
cumulative incidence function method to calculate their cumulative incidences 
during follow-up counting death from other causes as a competing risk. The 
relationship between the rate of mode-specific death and the calendar year will 
be examined using the multivariable linear regression analysis. The risk of mode-
specific death with the calendar year, by trial arm and by HF duration will be 
examined using the cause-specific Cox regression analysis.  
 
6.1 Methods 
6.1.1 Study population 
I attempted to obtain all major clinical trials in patients with chronic HF-PEF 
conducted over the last two decades. The majority of clinical trials in HF-PEF 
enrolled cohorts with small sample sizes (ranging from 40 to 426 participants) 
and examined the structural and functional outcomes including exercise 
capacity, 6-min walking distance, quality of life, changes in echocardiographic 
parameters and plasma natriuretic peptides levels over a short period of follow-
up (ranging from 1 week to 12 months),37, 158-163 and the key characteristics and 
results of these trials have been summarised in a recent systematic review.164 
Among the 7 trials identified examining mortality outcomes, 4 trials were 
excluded, i.e. the Digitalis Investigation Group ancillary trial (DIG- ancillary) 
[N=988] given that the outcomes were not adjudicated by an endpoint 
committee and only pump failure death events were reported,13 the secondary 
analysis of the Study of Effects of Nebivolol Intervention on Outcomes and 
Rehospitalization in Seniors With Heart Failure (SENIORS) because of small 
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cohort size (N=752) with only sudden death (N=27) having been reported,165 and 
the Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) trial and 
the Japanese Diastolic Heart Failure Study (J-CHF) because of small cohort size 
(N=245 and N=850 respectively) with neither mode of death having been 
reported. Their design and main characteristics are summarised in Appendix 
Table 8.10, 166 Finally, 3 RCTs were included in the analysis, namely CHARM-
Preserved, I-PRESERVE and TOPCAT.9, 11, 12 The design and results of the included 
trials have been published previously and their main characteristics are 
summarised in Table 2-2.  
 
6.1.2 Outcomes of interest 
The outcomes of interest were the proportions and the rates of sudden death 
and pump failure death in each trial, and the cumulative incidences of each 
mode of death at different time intervals since randomisation (30 days, 60 days, 
90 days, 180 days, 1 year, 2 years and 3 years), and the risks of each mode of 
death according to the length of time between diagnosis of HF and 
randomisation (≤1 year, >1-5 years and >5 years). In each trial, all death events 
were blindly adjudicated by an independent endpoint committee using pre-
specified criteria, which were similar across the trials (Table 2-3).  
 
6.1.3 Adjustment for potential confounding variables 
I examined the confounding effects of conventional covariates on the risks of 
sudden death and pump failure death including age, sex, LVEF, NYHA class, 
systolic BP, HF hospitalisation within the past 6 months, and a history of 
myocardial infarction, hypertension or diabetes, which were available in all 
trials. The eGFR measurements were recorded in all trials, except CHARM-
Preserved in which eGFR was only available in North American patients. Plasma 
NT-proBNP was available only in the subset of patients in I-PRESERVE (84% 
available) and TOPCAT (18% available). The additional prognostic effects of 
eGFR and NT-proBNP on each mode of death was examined in patients with 
complete data and after imputation of missing values. 
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6.1.4 Statistical analyses 
Baseline characteristics of all patients in each trial were summarised as means 
with standard deviations for continuous variables and percentages for 
categorical variables. Baseline characteristics of patients with sudden death and 
without sudden death (i.e. those alive and those dying non-suddenly) in each 
trial were also summarised and compared using Student’s t-test for continuous 
variables and chi square test for categorical variables. Likewise, baseline 
characteristics in patients with and without pump failure death in each trial 
were summarised and compared. NT-proBNP was not normally distributed and 
thus was presented as median and interquartile range and analysed using the 
Mann-Whitney U test.  
 
The annual rates of sudden death and pump failure death in each trial and in 
each arm of each trial were calculated using conventional survival analysis as 
per 100 patient-years. The cumulative incidences for each mode of death at 
different time points of 30 days, 60 days, 90 days, 180 days, 1 year, 2 years and 
3 years from randomisation were calculated and plotted using the cumulative 
incidence function method counting death from other causes as a competing 
risk.118, 128 The hazard ratio for each mode of death in each trial arm was 
calculated using cause-specific Cox proportional hazards model using the 
placebo arm of CHARM-Preserved as the reference. In a Cox model, the 
association between calendar year and the risk for each mode of death was then 
examined with adjustment for randomisation arm and with trial as a random 
effect. These models were then further adjusted for the confounding variables 
listed above. For models further adjusting for eGFR and NT-proBNP, the 
complete case analysis was performed as the primary analysis, together with a 
sensitivity analysis based on missing-indicator method using single imputation for 
a missing value in those trials where data were not completely missing, i.e. I-
PRESERVE and TOPCAT, with a further covariate indicating missing data.108 The 
association between calendar year and the annual rate of each mode of death 
was examined in a multiple linear regression model with the randomisation year 
and randomisation arm as covariates, weighted by the inverse-variance of the 
annual rate with trial as a random effect. To account for the inconsistency in the 
threshold of LVEF used in CHARM-Preserved (>40%) and I-PRESERVE and TOPCAT 
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(both ≥45%), sensitivity analyses were performed after excluding patients with a 
LVEF below 45% in CHARM-Preserved. To examine the changes in risks of total 
mortality and death due to non-CV causes across these trials, annual rates for 
both outcomes in each trial and in each arm of each trial were also calculated, 
and their associations with the calendar year were examined using the multiple 
linear regression analysis as described above. 
 
The length of time between HF diagnosis and randomisation was collected in 
CHARM-Preserved and I-PRESERVE, but not in TOPCAT. To assess the effect of HF 
duration on the risk of each mode of death, patients with data available were 
merged and further divided into 3 groups (based on the collected data): 
diagnosis within 1 year, >1-5 years and >5 years. According to these duration 
groups, cumulative incidence curves for each mode of death were produced and 
were compared using the Gray’s test,128 and HRs for each mode of death were 
calculated using patients within 1-year diagnosis of HF as reference, adjusting 
for the confounding variables listed above and counting for within-trial 
clustering.   
6.2 Results 
There were only 3 large clinical trials in patients with HF-PEF, and all were 
included in this analysis, which consisted of 10,517 patients after excluding 
patients having an ICD or CRT-D at baseline (N=79). Of these patients, 1876 
(17.8% of total population) died during follow-up, including 474 (4.5%) having a 
sudden death, 288 (2.7%) dying from pump failure, and 598 (5.7%) dying from 
non-CV causes. 
There were 444 (14.8%) patients with a LVEF below 45% in CHARM-Preserved. 
The eGFR levels were measured in 8500 (81%) patients and both eGFR and 
plasma NT-proBNP were available in 4063 (39%) patients.    
6.2.1 Baseline characteristics of study population 
The key characteristics of patients at baseline in each trial are shown in Table 6-
1. The mean age was higher in I-PRESERVE and TOPCAT (72 and 69 years 
respectively) than in CHARM-Preserved (67 years), because I-PRESERVE and 
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TOPCAT set minimum age thresholds for inclusion (60 and 50 years respectively). 
Likewise, both set a higher LVEF threshold for inclusion (≥45%) compared to 
CHARM-Preserved (>40%), accordingly, the average LVEF was higher in I-
PRESERVE and TOPCAT (59% and 57% respectively) than in CHARM-Preserved 
(54%). There was a female predominance in TOPCAT (52%) and particularly in I-
PRESERVE (60%), but not in CHARM-Preserved (40%). All trials enrolled patients 
mainly with NYHA class II and III symptoms with a preponderance of class III in I-
PRESERVE and class II in CHARM-Preserved and TOPCAT. The patients were 
typically obese with a higher level of mean BMI in TOPCAT compared to I-
PRESERVE and CHARM-Preserved (32.1 kg/m2 versus 29.6 kg/m2 and 29.2 kg/m2). 
Comorbidities were common: about 30-40% of patients had diabetes, atrial 
fibrillation, or renal dysfunction (defined as an eGFR <60 ml/min/1.73m2), the 
prevalence of which were all higher in TOPCAT than in CHARM-Preserved and I-
PRESERVE. The majority had coronary artery disease and hypertension; the 
proportion of patients with coronary artery disease was much higher in CHARM-
Preserved than in I-PRESERVE and TOPCAT (72% versus 51% and 59%), but a 
substantially higher prevalence of hypertension was observed in TOPCAT and I-
PRESERVE compared to CHARM-Preserved (91% and 89% versus 64%). However, 
the mean systolic blood pressure was 7 mmHg lower in TOPCAT than the other 
two trials (129 mmHg versus 136 mmHg and 136 mmHg). There was a higher rate 
of treatment with an ACEI/ARB, a beta-blocker or MRA in TOPCAT. NT-proBNP 
measurements were available in a subset of patients in TOPCAT (18%) and I-
PRESERVE (84%), with substantially higher median levels in TOPCAT than in I-
PRESERVE (843 pg/ml versus 339 pg/ml). 
Table 6-1 Baseline characteristics of patients in the included trials in HF-PEF 
  
CHARM-Preserved 
(N=3000) 
I-PRESERVE 
(N=4116) 
TOPCAT 
(N=3401) 
Age -years 66.7±11.1   71.6±6.9    68.5±9.6   
Female sex (%) 1204 (40.1) 2485 (60.4) 1760 (51.8) 
Race (%) 
   
White 2745 (91.5)  3847 (93.5)  3028 (89.0)  
Black 125 (4.2)  82 (2.0)  294 (8.6)  
Asian 71 (2.4)  35 (0.9)  18 (0.5)  
Other 59 (2.0)  152 (3.7)  61 (1.8)  
Blood pressure -mmHg 
   
Systolic 136.2±18.4 136.4±15.0   129.3±13.9    
Diastolic 77.8±10.7    78.8±9.1    75.9±10.6    
Heart rate -beats/min 71.3±12.4 71.4±10.5    69.0±10.6    
Body mass index 29.2±5.8    29.6±5.3    32.1±7.1   
LVEF -% 54.1±9.4 59.4±9.2   57.1±7.4    
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NYHA class (%) 
   
I-II 1825 (60.8) 869 (21.1) 2282 (67.2) 
III-IV 1175 (39.2)  3246 (78.9)  1116 (32.8)  
Aetiology (%) 
   
Ischaemic 1692 (56.4)  1033 (25.1)  - 
Hypertensive 682 (22.7)  2616 (63.6)  - 
Others 626 (20.9)  467 (11.3)  - 
HF duration (%) 
   
≤1 year 1272 (42.4)  1991 (48.4)  - 
>1 and ≤ 5 years 1114 (37.1)  1504 (36.6)  - 
>5 years 613 (20.4)  617 (15.0)  - 
Medical history (%) 
   
Current smoking 406 (13.5)  - 357 (10.5)  
HF hospitalisation within the 
previous 6 months 
1063 (35.4)  1809 (44.0)  1787 (52.5)  
Myocardial infarction  1325 (44.2)  963 (23.4)  873 (25.7)  
Angina  1807 (60.2)  1773 (43.1)  1598 (47.0)  
CABG or PCI 994 (33.1)  542 (13.2)  791 (23.3)  
Coronary artery disease 2151 (71.7) 2087 (50.7) 1993 (58.6) 
Hypertension 1932 (64.4)  3645 (88.6)  3109 (91.5)  
Diabetes 851 (28.4)  1128 (27.4)  1096 (32.3)  
Atrial fibrillation 874 (29.1)  1199 (29.1)  1192 (35.1)  
Stroke  267 (8.9)  394 (9.6)  260 (7.7)  
Pacemaker 214 (7.1)  245 (6.0)  247 (7.3)  
COPD or asthma - 386 (9.4)  543 (16.0)  
Dyslipidaemia - 1801 (43.8)  2039 (60.0)  
Treatment (%) 
   
Digitalis 831 (27.7)  556 (13.5)  337 (9.9)  
Diuretic 2240 (74.7)  3407 (82.8)  2778 (81.9)  
Loop 1860 (62.0)  2140 (52.0)  1764 (52.0)  
Thiazide 410 (13.7)  1552 (37.7)  1394 (41.1)  
ACEI or ARB 1775 (59.2) 2572 (62.5) 2863 (84.2) 
ACEI 563 (18.8)  1048 (25.5)  2231 (65.8)  
ARB 1503 (50.1)  2062 (50.1)  680 (20.0)  
Beta-blocker 1668 (55.6)  2423 (58.9)  2637 (77.7)  
MRA 350 (11.7)  631 (15.3)  1698 (49.9)  
Calcium channel blocker 938 (31.3)  1634 (39.7)  1284 (37.8)  
Antiarrhythmic agent 291 (9.7)  355 (8.6)  289 (8.5)  
Antiplatelet 1849 (61.6)  2412 (58.6)  2292 (67.6)  
Aspirin 1752 (58.4)  2249 (54.7)  2220 (65.4)  
Oral anticoagulant 735 (24.5)  783 (19.0)  774 (22.8)  
Lipid lowering agent 1248 (41.6)  1272 (30.9)  1816 (53.5)  
Anti-diabetic agent - 922 (22.4)  943 (27.8)  
Laboratory tests 
   
Creatinine -mg/dl 1.12±0.41a    1.00±0.32b    1.09±0.30    
eGFR -ml/min/1.73m2 72.3±26.9a  72.6±22.5b  67.7±20.2  
eGFR <60 ml/min/1.73m2 (%) 370 (34.5)a 1239 (30.8)b 1307 (38.5)  
NT-proBNP -pg/ml - 339 [133-960]c 843 [463-1727]d 
The letters denote the number of patients available: a=1074 (36%), b=4027 (98%), c=3470 (84%), 
d=615 (18%). 
“-” denotes data having not been recorded. 
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6.2.2 Baseline characteristics of patients with sudden death 
The characteristics of patients with and without sudden death in each trial are 
shown in Table 6-2. Overall, patients with sudden death were more often 
elderly, male, had lower LVEF and more advanced HF symptoms. They were 
more likely to have previous hospital admission for HF worsening, a history of 
myocardial infarction, diabetes or atrial fibrillation, and have been treated with 
loop diuretics. The average level of eGFR was lower, and correspondingly the 
proportion of patients with renal dysfunction was higher in patients with sudden 
death. Compared to patients without sudden death, the median level of NT-
proBNP in patients with sudden death was substantially higher in I-PRESERVE, 
but slightly lower in TOPCAT.  
Table 6-2 Baseline characteristics of patients with and without sudden death in the included 
trials in HF-PEF 
 CHARM-Preserved I-PRESERVE TOPCAT 
  
SD 
(N=134) 
Others 
(N=2866) 
SD 
(N=230)  
Others 
(N=3886) 
SD 
(N=110) 
Others 
(N=3291) 
Age -years 70.0±10.5*** 66.5±11.1 73.7±7.4*** 71.5±6.9 68.6±9.0 68.5±9.6 
Male sex (%) 90 (67.2) 1706 (59.5) 127 (55.2)*** 1504 (38.7) 78 (70.9)*** 1563 (47.5) 
Race (%)   
 
  
 
  
 
White 117 (87.3)*** 2628 (91.7) 220 (95.7)  3627 (93.3) 96 (87.3)  2932 (89.1) 
Black 2 (1.5)  123 (4.3) 5 (2.2)  77 (2.0) 9 (8.2)  285 (8.7) 
Asian 8 (6.0)  63 (2.2) 0 (0.0)  35 (0.9) 0 (0.0)  18 (0.5) 
Other 7 (5.2)  52 (1.8) 5 (2.2)  147 (3.8) 5 (4.5)  56 (1.7) 
Blood pressure -mmHg   
 
  
 
  
 
Systolic 136.6±16.8 136.2±18.5 135.8±15.8 136.4±14.9 128.5±16.0 129.3±13.8 
Diastolic 77.9±10.1 77.8±10.7 77.9±8.3 78.8±9.1 73.6±12.5* 75.9±10.5 
Heart rate -beats/min 73.2±12.1 71.2±12.4 73.3±10.3** 71.3±10.4 69.6±10.7 69.0±10.6 
Body mass index 28.6±5.5 29.2±5.8 28.6±5.1** 29.7±5.3 32.7±7.7 32.0±7.1 
LVEF -% 52.9±9.3 54.1±9.4 56.7±9.2*** 59.6±9.1 54.0±7.4*** 57.2±7.4 
NYHA class III-IV (%) 57 (42.5) 1118 (39.0) 181 (78.7) 3065 (78.9) 38 (34.5) 1078 (32.8) 
Aetiology (%)   
 
  
 
  
 
Ischaemic 80 (59.7)  1612 (56.2) 88 (38.3)*** 945 (24.3) - - 
Hypertensive 27 (20.1)  655 (22.9) 115 (50.0)  2501 (64.4) - - 
Other 27 (20.1)  599 (20.9) 27 (11.7)  440 (11.3) - - 
HF duration (%)   
 
  
 
  
 
≤1 year 52 (38.8)  1220 (42.6) 107 (46.5)  1884 (48.5) - - 
>1 and ≤ 5 years 46 (34.3)  1068 (37.3) 81 (35.2)  1423 (36.7) - - 
>5 years 36 (26.9)  577 (20.1) 42 (18.3)  575 (14.8) - - 
Medical history (%)   
 
  
 
  
 
Current smoking 26 (19.4)* 380 (13.3) - - 14 (12.7) 343 (10.4) 
HF hospitalisation 
within the previous 6 
months 
57 (42.5) 1006 (35.1) 128 (55.7)*** 1681 (43.3) 59 (53.6) 1728 (52.5) 
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Coronary artery 
disease 
92 (68.7) 2059 (71.8) 143 (62.2) *** 1944 (50.0) 67 (60.9) 1926 (58.5) 
Myocardial infarction  63 (47.0) 1262 (44.0) 81 (35.2)*** 882 (22.7) 41 (37.3)** 832 (25.3) 
Angina  70 (52.2) 1737 (60.6) 110 (47.8) 1663 (42.8) 46 (41.8) 1552 (47.2) 
CABG or PCI 36 (26.9) 958 (33.4) 36 (15.7) 506 (13.0) 36 (32.7)* 755 (23.0) 
Hypertension 96 (71.6) 1836 (64.1) 199 (86.5) 3446 (88.7) 100 (90.9) 3009 (91.5) 
Diabetes 57 (42.5)*** 794 (27.7) 86 (37.4)*** 1042 (26.8) 43 (39.1) 1053 (32.0) 
Atrial fibrillation 47 (35.1) 827 (28.9) 85 (37.0)** 1114 (28.7) 39 (35.5) 1153 (35.1) 
Stroke  19 (14.2)* 248 (8.7) 26 (11.3) 368 (9.5) 9 (8.2) 251 (7.6) 
Pacemaker 11 (8.2) 203 (7.1) 19 (8.3) 226 (5.8) 6 (5.5) 241 (7.3) 
COPD or asthma - - 37 (16.1)*** 349 (9.0) 20 (18.2) 523 (15.9) 
Dyslipidaemia - - 87 (37.8) 1714 (44.1) 66 (60.0) 1973 (60.0) 
Treatment (%)   
 
  
 
  
 
Digitalis 51 (38.1)** 780 (27.2) 47 (20.4)** 509 (13.1) 12 (10.9) 325 (9.9) 
Diuretics 117 (87.3)*** 2123 (74.1) 200 (87.0) 3207 (82.6) 95 (86.4) 2683 (81.7) 
   Loop 101 (75.4)** 1759 (61.4) 146 (63.5)*** 1994 (51.4) 77 (70.0)*** 1687 (51.4) 
   Thiazide 19 (14.2) 391 (13.6) 73 (31.7) 1479 (38.1) 38 (34.5) 1356 (41.3) 
ACEI or ARB 85 (63.4) 1690 (59.0) 145 (63.0) 2427 (62.4) 94 (85.4) 2769 (84.1) 
   ACEI 35 (26.1)* 528 (18.4) 70 (30.4) 978 (25.2) 73 (66.4) 2158 (65.7) 
   ARB 69 (51.5) 1434 (50.0) 113 (49.1) 1949 (50.2) 24 (21.8) 656 (20.0) 
Beta-blocker 60 (44.8)** 1608 (56.1) 132 (57.4) 2291 (59.0) 89 (80.9) 2548 (77.6) 
MRA 15 (11.2) 335 (11.7) 51 (22.2)** 580 (14.9) 56 (50.9) 1642 (49.9) 
Calcium channel 
blocker 
42 (31.3) 896 (31.3) 72 (31.3)** 1562 (40.2) 38 (34.5) 1246 (38.0) 
Antiarrhythmic agent 7 (5.2) 284 (9.9) 28 (12.2)* 327 (8.4) 11 (10.0) 278 (8.5) 
Antiplatelet 74 (55.2) 1775 (61.9) 136 (59.1) 2276 (58.6) 73 (66.4) 2219 (67.6) 
Aspirin 70 (52.2) 1682 (58.7) 123 (53.5) 2126 (54.8) 71 (64.5) 2149 (65.5) 
Oral anticoagulant 32 (23.9) 703 (24.5) 53 (23.0) 730 (18.8) 22 (20.0) 752 (22.9) 
Lipid lowering agent 44 (32.8)* 1204 (42.0) 63 (27.4) 1209 (31.1) 57 (51.8) 1759 (53.6) 
Anti-diabetic agent - - 73 (31.7)*** 849 (21.9) 40 (36.4)* 903 (27.5) 
Laboratory tests   
 
  
 
  
 
Creatinine -mg/dl 1.19±0.38a 1.12±0.42b 1.09±0.38***c 0.99±0.31d 1.20±0.32*** 1.09±0.30 
eGFR -ml/min/1.73m2 66.6±22.2a 72.5±27.1b 69.8±23.9c 72.7±22.4d 65.0±21.0 67.8±20.2 
eGFR <60 
ml/min/1.73m2 
17 (42.5)a 353 (34.1)b 80 (34.9)c 1159 (30.5)d 54 (49.1)* 1253 (38.1) 
NT-proBNP -pg/ml - - 944e 
[353-2032]*** 
320f 
[130-908] 
659g 
[515-2582] 
844h 
[461-1708] 
*P<0.05, **p<0.01, *** p<0.001 
SD denotes sudden death, “-“ denotes data having not been collected. 
The letters denote the number of patients available: a=40 (30%), b=1034 (36%), c=229 (100%), 
d=3798 (98%), e=195 (85%), f=3275 (84%), g=22 (20%), h=593 (18%). 
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6.2.3 Baseline characteristics of patients with pump failure death 
There were some notable differences in baseline characteristics between 
patients with and without pump failure death (Table 6-3). In general, compared 
to patients without pump failure death, patients who died from progressive 
pump failure were more likely to be older, have worse HF symptoms, lower 
blood pressure or BMI, and have higher heart rate. These patients with pump 
failure death tended to have longer standing HF, and have more comorbidities 
including previous HF hospitalisation, diabetes, atrial fibrillation, COPD or 
asthma and renal dysfunction, but were less likely to have hypertension. There 
was a higher rate of the use of digitalis, loop diuretics, oral anticoagulants or 
pacemaker, but a lower rate of use of antiplatelets in patients with pump failure 
death. The average level of eGFR was substantially lower and the median plasma 
NT-proBNP concentration was substantially higher in patients with pump failure 
death than those without pump failure death.  
Table 6-3 Baseline characteristics of patients with and without pump failure death in the 
included trials in HF-PEF 
 CHARM-Preserved I-PRESERVE TOPCAT 
  
PFD 
(N=100) 
Others 
(N=2900) 
PFD 
(N=123) 
Others 
(N=3993) 
PFD 
(N=65)  
Others 
(N=3336) 
Age -years 75.8±8.2*** 66.4±11.0 75.5±7.0*** 71.5±6.9 75.3±8.8*** 68.4±9.5 
Male sex (%) 58 (58.0) 1738 (59.9) 62 (50.4)* 1569 (39.3) 32 (49.2) 1609 (48.2) 
Race (%)   
 
  
 
  
 
White 93 (93.0)  2652 (91.4) 115 (93.5)  3732 (93.5) 57 (87.7)  2971 (89.1) 
Black 2 (2.0)  123 (4.2) 4 (3.3)  78 (2.0) 5 (7.7)  289 (8.7) 
Asian 1 (1.0)  70 (2.4) 2 (1.6)  33 (0.8) 1 (1.5)  17 (0.5) 
Other 4 (4.0)  55 (1.9) 2 (1.6)  150 (3.8) 2 (3.1)  59 (1.8) 
Blood pressure -mmHg   
 
  
 
  
 
Systolic 134.4±20.4 136.3±18.4 134.6±19.6 136.4±14.8 125.2±15.9* 129.3±13.8 
Diastolic 72.4±11.5*** 78.0±10.6 75.2±9.4*** 78.9±9.0 70.4±10.3*** 76.0±10.6 
Heart rate -beats/min 72.8±10.9 71.3±12.4 74.2±11.1** 71.3±10.4 71.4±10.7 68.9±10.6 
Body mass index 26.9±5.0*** 29.3±5.8 29.1±6.4 29.7±5.2 30.2±6.5* 32.1±7.1 
LVEF -% 54.7±10.3 54.0±9.4 56.7±9.0*** 59.5±9.1 56.5±7.1 57.1±7.5 
NYHA class III-IV (%) 61 (61.0)*** 1114 (38.4) 97 (78.9) 3149 (78.9) 34 (52.3)*** 1082 (32.5) 
Aetiology (%)   
 
  
 
  
 
Ischaemic 50 (50.0)  1642 (56.6) 44 (35.8)** 989 (24.8) - - 
Hypertensive 21 (21.0)  661 (22.8) 59 (48.0)  2557 (64.0) - - 
Other 29 (29.0)  597 (20.6) 20 (16.3)  447 (11.2) - - 
HF duration (%)   
 
  
 
  
 
within 1 year 25 (25.0)*** 1247 (43.0) 46 (37.4)* 1945 (48.8) - - 
>1 and ≤5 years 36 (36.0)  1078 (37.2) 54 (43.9)  1450 (36.3) - - 
>5 years 39 (39.0)  574 (19.8) 23 (18.7)  594 (14.9) - - 
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Medical history (%)   
 
  
 
  
 
Current smoking 10 (10.0) 396 (13.7) - - 7 (10.8) 350 (10.5) 
HF hospitalisation within 
 the previous 6 months 
56 (56.0)*** 1007 (34.7) 73 (59.3)*** 1736 (43.5) 28 (43.1) 1759 (52.7) 
Coronary artery disease 69 (69.0) 2082 (71.8) 62 (50.4) 2025 (50.7) 31 (47.7) 1962 (58.8) 
Myocardial infarction  40 (40.0) 1285 (44.3) 33 (26.8) 930 (23.3) 10 (15.4) 863 (25.9) 
Angina  54 (54.0) 1753 (60.4) 52 (42.3) 1721 (43.1) 24 (36.9) 1574 (47.2) 
CABG or PCI 28 (28.0) 966 (33.3) 19 (15.4) 523 (13.1) 16 (24.6) 775 (23.3) 
Hypertension 54 (54.0)* 1878 (64.8) 100 (81.3)* 3545 (88.8) 55 (84.6)* 3054 (91.6) 
Diabetes 37 (37.0) 814 (28.1) 52 (42.3)*** 1076 (26.9) 28 (43.1) 1068 (32.0) 
Atrial fibrillation 41 (41.0)** 833 (28.7) 62 (50.4)*** 1137 (28.5) 39 (60.0)*** 1153 (34.6) 
Stroke  13 (13.0) 254 (8.8) 16 (13.0) 378 (9.5) 7 (10.8) 253 (7.6) 
Pacemaker 14 (14.0)** 200 (6.9) 15 (12.2)** 230 (5.8) 12 (18.5)*** 235 (7.1) 
COPD or asthma - - 18 (14.6)* 368 (9.2) 51 (78.5)** 1988 (59.6) 
Dyslipidaemia - - 36 (29.3)** 1765 (44.2) 14 (21.5) 529 (15.9) 
Treatment (%)   
 
  
 
  
 
Digitalis 41 (41.0)** 790 (27.2) 38 (30.9)*** 518 (13.0) 13 (20.0)** 324 (9.7) 
Diuretics 90 (90.0)** 2150 (74.1) 115 (93.5)** 3292 (82.5) 63 (96.9)** 2715 (81.6) 
Loop 86 (86.0)*** 1774 (61.2) 103 (83.7)*** 2037 (51.1) 59 (90.8)*** 1705 (51.2) 
Thiazide 12 (12.0) 398 (13.7) 22 (17.9)*** 1530 (38.3) 20 (30.8) 1374 (41.3) 
ACEI or ARB 54 (54.0) 1721 (59.3) 88 (71.5)* 2484 (62.2) 53 (81.5) 2810 (84.2) 
ACEI 17 (17.0) 546 (18.8) 39 (31.7) 1009 (25.3) 35 (53.8)* 2196 (66.0) 
ARB 47 (47.0) 1456 (50.2) 69 (56.1) 1993 (49.9) 20 (30.8)* 660 (19.8) 
Beta-blocker 36 (36.0)*** 1632 (56.3) 61 (49.6)* 2362 (59.2) 57 (87.7) 2580 (77.5) 
MRA 22 (22.0)** 328 (11.3) 33 (26.8)*** 598 (15.0) 26 (40.0) 1672 (50.1) 
Calcium channel blocker 31 (31.0) 907 (31.3) 45 (36.6) 1589 (39.8) 18 (27.7) 1266 (38.0) 
Antiarrhythmic agent 15 (15.0) 276 (9.5) 18 (14.6)* 337 (8.4) 3 (4.6) 286 (8.6) 
Antiplatelet 50 (50.0)* 1799 (62.0) 54 (43.9)*** 2358 (59.1) 41 (63.1) 2251 (67.6) 
Aspirin 48 (48.0)* 1704 (58.8) 51 (41.5)** 2198 (55.1) 38 (58.5) 2182 (65.6) 
Oral anticoagulant 32 (32.0) 703 (24.2) 42 (34.1)*** 741 (18.6) 27 (41.5)*** 747 (22.4) 
Lipid lowering agent 22 (22.0)*** 1226 (42.3) 30 (24.4) 1242 (31.1) 44 (67.7)* 1772 (53.2) 
Anti-diabetic agent - - 41 (33.3)** 881 (22.1) 24 (36.9) 919 (27.6) 
Laboratory tests   
 
  
 
  
 
Creatinine -mg/dl 1.43±0.66***a 1.11±0.40b 1.18±0.36***c 0.99±0.32d 1.22±0.34*** 1.09±0.30 
eGFR -ml/min/1.73m2 54.7±23.5***a 72.9±26.8b 62.1±21.9***c 72.9±22.4d 58.8±18.1*** 67.9±20.2 
eGFR <60 ml/min/1.73m2 23 (62.2)***a 347 (33.5)b 66 (55.0)***c 1173 
(30.0)d 
38 (58.5)*** 1269 (38.1) 
NT-proBNP -pg/ml - - 1231e  
[408-2790]*** 
327f  
[131-924] 
2932g  
[1455-6455]*** 
826h 
[460-1677] 
*P<0.05, **p<0.01, *** p<0.001. 
PFD denotes pump failure death, “-“ denotes data having not been collected. 
The letters denote the number of patients available: a=37 (37%), b=1037 (36%), c=120 (98%), 
d=3907 (98%), e=100 (81%), f=3370 (84%), g=12 (18%), h=603 (18%). 
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6.2.4 Sudden death rates in each trial and in each arm of each 
trial 
The annual rate for sudden death was 1.5 per 100 patient-years in the earliest 
CHARM-Preserved, 1.4 per 100 patient-years in I-PRESERVE and 1.0 per 100 
patient-years in the latest TOPCAT (Table 6-4 and Figure 6-1). There was a 
declining trend in the rate of sudden death across these trials over time (p 
=0.021) (Figure 6-2), and the trend was attenuated but remained significant in a 
sensitivity analysis after excluding patients with LVEF below 45% in CHARM-
Preserved (p=0.045) (Figure 6-3). A decrease in the rate was accompanied by a 
falling proportion of sudden death relative to total mortality across trials (Figure 
6-4). The rate of death from any cause also decreased across these trials over 
time (p=0.025), but the rate of non-CV death did not change over time (p=0.24), 
leading to an increase in proportion of death from non-CV causes in the later 
trial (Figure 6-4, Figure 6-5 and Figure 6-6).  
Table 6-4 Annual rates and cumulative incidences of sudden death at different time points in 
the included trials in HF-PEF (treatment arms combined) 
 CHARM-Preserved I-PRESERVE TOPCAT 
 (N=3000) (N=4116) (N=3401) 
Sudden death events 134 230 110 
Annual rate (95% CI) 1.5 (1.3-1.8) 1.4 (1.2-1.6) 1.0 (0.8-1.2) 
Cumulative incidence (95% CI)    
30 days 0.1 (0.0-0.2) 0.2 (0.0-0.3) 0.1 (0.0-0.2) 
60 days  0.1 (0.0-0.2) 0.2 (0.1-0.4) 0.1 (0.0-0.2) 
90 days 0.1 (0.0-0.3) 0.3 (0.1-0.5) 0.2 (0.0-0.3) 
180 days 0.5 (0.3-0.8) 0.6 (0.4-0.9) 0.5 (0.2-0.7) 
1 year 1.2 (0.8-1.6) 1.3 (1.0-1.7) 1.0 (0.6-1.3) 
2 years 2.9 (2.3-3.5) 2.5 (2.0-2.9) 1.7 (1.3-2.2) 
3 years 4.4 (3.6-5.1) 3.7 (3.1-4.2) 2.4 (1.8-2.9) 
Annual rates are shown as per 100 patient-years. Cumulative incidences are presented as percent. 
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Figure 6-1 Cumulative incidence curves for sudden death by trials in HF-PEF 
 
Figure 6-2 Trends in the sudden death rate across trial arms over time in HF-PEF 
 
Annual rates are shown as sudden death per 100 patient-years. The black dotted line is based on 
the multiple linear regression of the annual rate in each trial arm with the randomisation year 
and randomisation arm as covariates, weighted by its inverse-variance and with trial as a 
random effect. P for slope represents the p value for randomisation year based on the linear 
model. Each circle represents each trial arm as labelled, with the control arm in each trial 
illustrated in gray and the experimental arm in white. The centre of each circle corresponds to 
randomisation year (x axis) and the annual rate (y axis) in each arm, the error bars in each 
circle correspond to the 95% confidence interval of the annual rate. The area of each circle 
represents the sample size in each arm (reference size shown in the upper right corner). C 
denotes control arm; T, experimental treatment arm. 
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Figure 6-3 Trends in the sudden death rate across trial arms over time in HF-PEF with the 
exclusion of patients with a LVEF below 45% in CHARM-Preserved 
 
Annual rates are shown as sudden death per 100 patient-years. Other notes and abbreviations are 
same as those in Figure 6-2. 
 
Figure 6-4 Proportions of sudden death and pump failure death relative to overall mortality 
across the trials in HF-PEF 
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Figure 6-5 Trends in the all-cause death rate across trial arms over time in HF-PEF 
 
 
Annual rates are shown as all-cause death per 100 patient-years. The black dotted line is based on 
the multiple linear regression of the annual rate in each trial arm with the randomisation year 
and randomisation arm as covariates, weighted by its inverse-variance and with trial as a 
random effect. P for slope represents the p value for randomisation year based on the linear 
model. Each circle represents each trial arm as labelled, with the control arm in each trial 
illustrated in gray and the experimental arm in white. The centre of each circle corresponds to 
randomisation year (x axis) and the annual rate (y axis) in each arm, the error bars in each 
circle correspond to the 95% confidence interval of the annual rate. The area of each circle 
represents the sample size in each arm (reference size shown in the upper right corner). C 
denotes control arm; T, experimental treatment arm. 
 
Figure 6-6 Trends in the non-CV death rate across trial arms over time in HF-PEF 
 
Annual rates are shown as non-CV death per 100 patient-years. Other notes and abbreviations are 
same as those in Figure 6-5. 
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The rate of sudden death was quite similar between treatment arms in each trial 
(Figure 6-2). This was in line with the finding from a Cox regression analysis with 
randomisation treatment and randomisation year as covariates, in which the risk 
for sudden death was not significantly associated with randomisation treatment 
(HR 0.99, 95% CI 0.83-1.19, p=0.954) but with randomisation year (HR per 
decade 0.48, 95% CI 0.33-0.69, p<0.001). A nearly identical result was observed 
with adjustment for conventional confounding variables (HR for randomisation 
treatment 0.98, 95% CI 0.83-1.19, p=0.954; HR for randomisation year per 
decade 0.48, 95% CI 0.32-0.71, p<0.001).  
When examining the risk of sudden death across trial arms, generally, there was 
no difference in the risk of sudden death between treatment arms within a trial, 
and the risk was about 40% lower in either arm of TOPCAT than that in the 
placebo arm of CHARM-Preserved (HR 0.62, 95% CI 0.43-0.89, p=0.010) (Figure 6-
7). A similar result was observed with adjustment for conventional confounding 
covariates (Figure 6-8). The difference was attenuated and marginally significant 
after further adjustment for eGFR (HR 0.67, 95% CI 0.41-1.11, p=0.118), and the 
imputation of missing values gave similar results (Figure 6-9). When further 
adjusting for NT-proBNP, compared with the placebo arm of I-PRESERVE, the risk 
of sudden death in the treatment arm of TOPCAT was marginally lower using 
complete case analysis (HR 0.60, 95% CI 0.30-1.19, p=0.141), but was 
significantly lower with the imputation approach including all patients in I-
PRESERVE and TOPCAT (HR 0.65, 95% CI 0.44-0.97, p=0.033) (Figure 6-10). 
Figure 6-7 Hazard ratio for sudden death across the trial arms in HF-PEF 
 
Annual rates are shown as sudden death per 100 patient-years. Hazard ratios shown were 
compared to the placebo arm of CHARM-Preserved (N=10,515). C denotes control arm; T, 
experimental treatment arm.  
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Figure 6-8 Hazard ratio for sudden death across the trial arms in HF-PEF with adjustment for 
8 conventional covariates 
 
Annual rates are shown as sudden death per 100 patient-years. Hazard ratios were adjusted for 
conventional covariates including age, sex, NYHA class, LVEF, systolic blood pressure, HF 
hospitalisation within the last 6 months, and a history of myocardial infarction, hypertension and 
diabetes (N=10,506). Hazard ratios shown were compared to the placebo arm of CHARM-
Preserved. C denotes control arm; T, experimental treatment arm. 
 
Figure 6-9 Hazard ratio for sudden death across the trial arms in HF-PEF with adjustment for 
8 conventional covariates and eGFR 
 
Annual rates are shown as sudden death per 100 patient-years. 
Panel A, HRs were adjusted for conventional confounding variables in the subset of patients with 
eGFR measurements available (N=8492); Panel B, adjustment for conventional covariates and 
eGFR in the subset of patients with eGFR measurements available (N=8492); Panel C, 
adjustment for conventional covariates and eGFR with simple imputation of eGFR levels 
(N=10,506). HRs shown were compared to the placebo arm of CHARM-Preserved. C denotes 
control arm; T, experimental treatment arm. 
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Figure 6-10 Hazard ratio for sudden death across the trial arms in HF-PEF with adjustment 
for 8 conventional covariates, eGFR and NT-proBNP 
 
 
Annual rates are shown as sudden death per 100 patient-years. 
Panel A, adjustment for conventional confounding variables in the subset of patients with NT-
proBNP available [N=4059]; Panel B, adjustment for conventional covariates and eGFR in the 
subset of patients with NT-proBNP available [N=4059]; Panel C, adjustment for conventional 
covariates, eGFR and log transformed NT-proBNP in the subset of patients with NT-proBNP 
available [N=4059]; Panel D, adjustment for conventional covariates, eGFR and log transformed 
NT-proBNP with simple imputation of eGFR and NT-proBNP in the trials with NT-proBNP 
collected (i.e. not complete missing) [N=7507]. HRs shown were compared to the placebo arm 
of I-PRESERVE. C denotes control arm; T, experimental treatment arm.   
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6.2.5 Pump failure death rates in each trial and in each arm of 
each trial 
The annual rate of pump failure death was lower in the more recent trials: 1.1 
per 100 patient-years in CHARM-Preserved, 0.7 per 100 patient-years in I-
PRESERVE and 0.6 per 100 patient-years in TOPCAT (Table 6-5 and Figure 6-11). 
There was a borderline downward trend in the annual rate of pump failure death 
over time (p=0.05) (Figure 6-12), and a similar trend was observed in the 
sensitivity analysis after excluding patients with a LVEF below 45% in CHARM-
Preserved (Figure 6-13). There was a smaller proportion of pump failure death 
relative to total mortality in TOPCAT (13% of total mortality) and I-PRESERVE 
(14%) than in CHARM-Preserved (21%) (Figure 6-4). 
Table 6-5 Annual rates and cumulative incidences of pump failure death at different time 
points in the included trials in HF-PEF (treatment arms combined)  
CHARM-Preserved I-PRESERVE TOPCAT 
 (N=3000) (N=4116) (N=3401) 
Pump failure death events 100 123 65 
Annual rate (95% CI) 1.1 (0.9-1.4) 0.7 (0.6-0.9) 0.6 (0.4-0.7) 
Cumulative incidence (95% CI) 
  
 
30 days 0.0 (0.0-0.1) 0.0 (0.0-0.1) 0.1 (0.0-0.1) 
60 days  0.1 (0.0-0.2) 0.1 (0.0-0.2) 0.1 (0.0-0.2) 
90 days 0.2 (0.0-0.4) 0.1 (0.0-0.2) 0.1 (0.0-0.3) 
180 days 0.5 (0.2-0.8) 0.2 (0.1-0.4) 0.2 (0.0-0.3) 
1 year 1.0 (0.6-1.4) 0.7 (0.5-1.0) 0.4 (0.2-0.6) 
2 years 2.0 (1.5-2.5) 1.2 (0.9-1.5) 1.1 (0.7-1.4) 
3 years 3.0 (2.4-3.7) 2.1 (1.6-2.5) 1.4 (0.9-1.8) 
Annual rates are shown as per 100 patient-years. Cumulative incidences are presented as percent.  
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Figure 6-11 Cumulative incidence curves for pump failure death by trials in HF-PEF 
 
 
Figure 6-12 Trends in the pump failure death rate across trial arms over time in HF-PEF 
 
Annual rates are shown as pump failure death per 100 patient-years. The black dotted line is based 
on the multiple linear regression of the annual rate in each trial arm with the randomisation year 
and randomisation arm as covariates, weighted by its inverse-variance and with trial as a 
random effect. P for slope represents the p value for randomisation year based on the linear 
model. Each circle represents each trial arm as labelled, with the control arm in each trial 
illustrated in gray and the experimental arm in white. The centre of each circle corresponds to 
randomisation year (x axis) and the annual rate (y axis) in each arm, the error bars in each 
circle correspond to the 95% confidence interval of the annual rate. The area of each circle 
represents the sample size in each arm (reference size shown in the upper right corner). C 
denotes control arm; T, experimental treatment arm. 
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Figure 6-13 Trends in the pump failure death rate across trial arms over time in HF-PEF with 
the exclusion of patients with a LVEF below 45% in CHARM-Preserved 
 
Annual rates are shown as pump failure death per 100 patient-years. Other notes and 
abbreviations are same as those in Figure 6-12. 
 
Similar to that of sudden death, the rate of pump failure death was quite similar 
between treatment arms within each single trial (Figure 6-12). This observation 
was in concert with the finding from Cox regression analysis with randomisation 
treatment and randomisation year as covariates, in which the risk for pump 
failure death had no significant relationship with randomisation treatment (HR 
0.96, 95% CI 0.76-1.21, p=0.73), but significant with randomisation year (HR per 
decade 0.35, 95% CI 0.22-0.56, p<0.001). Adjusting for conventional confounding 
covariates made little difference (HR for randomisation treatment 0.94, 95% CI 
0.75-1.19, p=0.622; HR for randomisation year per decade 0.33, 95% CI 0.20-
0.57, p<0.001).  
When examining the risk of pump failure death across trial arms, overall, a 
decrease was observed with about 37% lower in treatment arm of I-PRESERVE 
and 64% lower in the treatment arm of TOPCAT, compared to the placebo arm of 
CHARM-Preserved (HR 0.63, 95% CI 0.44-0.92, p=0.015; HR 0.36, 95% CI 0.22-
0.58, p<0.001) (Figure 6-14). A similar result was observed with adjustment for 
conventional confounding variables and with additionally adjusting for eGFR 
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(Figure 6-15 and Figure 6-16). In the subset of patients with both eGFR and NT-
proBNP available, compared with the placebo arm of I-PRESERVE, the risk of 
pump failure death was marginally higher in placebo arm of TOPCAT (HR 1.73, 
95% CI 0.78-3.82, p=0.177), and the difference was attenuated with more 
covariates being adjusted for (HR 1.14, 95% CI 0.50-2.56, p=0.756 with 
adjustment for conventional covariates, eGFR and NT-proBNP); nevertheless, the 
risk was marginally lower in the treatment arm of TOPCAT irrespective of 
adjusted covariates (crude HR 0.69, 95% CI 0.24-1.98, p=0.489; HR 0.49, 95% CI 
0.17-1.44, p=0.196 with adjustment for conventional covariates, eGFR and NT-
proBNP) (Figure 6-17). Imputation of missing values made little change to these 
findings (Figure 6-16 and Figure 6-17). 
Figure 6-14 Hazard ratio for pump failure death across the trial arms in HF-PEF 
 
 
Annual rates are shown as pump failure death per 100 patient-years.  
Hazard ratios shown were compared to the placebo arm of CHARM-Preserved (N=10,515).  
C denotes control arm; T, experimental treatment arm. 
 
Figure 6-15 Hazard ratio for pump failure death across the trial arms in HF-PEF with 
adjustment for 8 conventional covariates 
 
Annual rates are shown as pump failure death per 100 patient-years.  
Hazard ratios were adjusted for conventional covariates including age, sex, NYHA class, LVEF, 
systolic blood pressure, HF hospitalisation within the last 6 months, and a history of myocardial 
infarction, hypertension and diabetes (N=10,506). Hazard ratios shown were compared to the 
placebo arm of CHARM-Preserved. C denotes control arm; T, experimental treatment arm.  
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Figure 6-16 Hazard ratio for pump failure death across the trial arms in HF-PEF with 
adjustment for 8 conventional covariates and eGFR 
 
Annual rates are shown as pump failure death per 100 patient-years.  
Panel A, HRs were adjusted for conventional confounding variables in the subset of patients with 
eGFR measurements available (N=8492); Panel B, adjustment for conventional covariates and 
eGFR in the subset of patients with eGFR measurements available (N=8492); Panel C, 
adjustment for conventional covariates and eGFR with simple imputation of eGFR levels 
(N=10,506). HRs shown were compared to the placebo arm of CHARM-Preserved. C denotes 
control arm; T, experimental treatment arm.  
 
Figure 6-17 Hazard ratio for pump failure death across the trial arms in HF-PEF with 
adjustment for 8 conventional covariates, eGFR and NT-proBNP 
 
Annual rates are shown as pump failure death per 100 patient-years.  
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Panel A, adjustment for conventional confounding variables in the subset of patients with NT-
proBNP available [N=4059]; Panel B, adjustment for conventional covariates and eGFR in the 
subset of patients with NT-proBNP available [N=4059]; Panel C, adjustment for conventional 
covariates, eGFR and log transformed NT-proBNP in the subset of patients with NT-proBNP 
available [N=4059]; Panel D, adjustment for conventional covariates, eGFR and log transformed 
NT-proBNP with simple imputation of eGFR and NT-proBNP in the trials with NT-proBNP 
collected (i.e. not complete missing) [N=7507]. HRs shown were compared to the placebo arm 
of I-PRESERVE. C denotes control arm; T, experimental treatment arm. 
 
6.2.6 Sudden death and pump failure death at different time 
points during follow-up  
As can be seen from Table 6-4 and Figure 6-1, the cumulative incidences of 
sudden death at 180 days were consistently low at around 0.5% across these 
trials. At 1 year, the cumulative incidence was almost double that at 180 days, 
but remained low in absolute terms at about 1.0-1.3%. At 3 years, the 
cumulative sudden death rate reached at 4.4% (95% CI 3.6-5.1%) in CHARM-
Preserved, 3.7% (95% CI 3.1-4.2%) in I-PRESERVE and remained low at 2.4% (95% 
CI 1.8-2.9%) in TOPCAT. 
The cumulative incidence for pump failure death at 180 days was 0.5% in 
CHARM-Preserved or lower at 0.2% in I-PRESERVE and TOPCAT (Table 6-5 and 
Figure 6-11). Similarly, a one-fold increase of the cumulative rates from 180 
days to 1 year was observed. Overall, the cumulative incidence of pump failure 
death at 3 years was quite low, at 3.0% (95% CI 2.4-3.7%) in CHARM-Preserved, 
2.1% (95% CI 1.6-2.5%) in I-PRESERVE and 1.4% (95% CI 0.9-1.8%) in TOPCAT. 
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6.2.7 Sudden death and pump failure death according to HF 
duration 
Figure 6-18 outlines the cumulative incidences of sudden death during follow-up 
according to the length of time between diagnosis of HF and randomisation 
based on the merged data from CHARM-Preserved and I-PRESERVE. Overall, 
there was no significant difference in the cumulative incidence for sudden death 
among patients with different HF durations (Gray’s test p >0.05). After adjusting 
for confounding variables, there was a trend that longer-standing HF carried a 
modest higher risk of sudden death: compared to patients diagnosed with HF 
within 1 year, patients having HF for >1-5 years and over 5 years had a 13% and 
37% higher risk for sudden death, respectively (HR 1.13, 95% CI 1.06-1.19, 
p<0.001; HR 1.37, 95% CI 1.12-1.68, p=0.002, respectively). 
Figure 6-18 Cumulative incidence curves for sudden death over time in HF-PEF according to 
the length of time between diagnosis of HF and randomisation (trials with data available 
combined) 
 
 
Data were available in CHARM-Preserved and I-PRESERVE (N=7107). 
Hazard ratios for sudden death are shown for patients diagnosed within 1 year compared to those 
diagnosed for >1-5 years and >5 years respectively. These hazard ratios were adjusted for age, 
sex, NYHA class, LVEF, systolic blood pressure, HF hospitalization with the last 6 months, a 
history of myocardial infarction, diabetes and hypertension and were counted for within-trial 
clustering.  
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The cumulative incidence curves for pump failure death during follow-up by HF 
duration are presented in Figure 6-19. In general, there was a significant 
difference in the risk of pump failure death in patients with different HF 
durations (Gray’s test p<0.001), where patients with a longer history of HF 
carried a much higher risk for pump failure death. Compared to patients 
diagnosed with HF within 1 year, the risk for pump failure death was around 
120% and 180% higher in those diagnosed with HF for >1-5 years and over 5 years 
respectively (HR 2.18, 95% CI 1.99-2.40, p<0.001; HR 2.82, 95% CI 1.34-5.93, 
p=0.006).  
Figure 6-19 Cumulative incidence curves for pump failure death over time in HF-PEF 
according to the length of time between diagnosis of HF and randomisation (trials with data 
available combined) 
 
 
Data were available in CHARM-Preserved and I-PRESERVE (N=7107). 
Hazard ratios for pump failure death are shown for patients diagnosed within 1 year compared to 
those diagnosed for >1-5 years and >5 years respectively. These hazard ratios were adjusted 
for age, sex, NYHA class, LVEF, systolic blood pressure, HF hospitalization with the last 6 
months, a history of myocardial infarction, diabetes and hypertension and were counted for 
within-trial clustering.  
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6.3 Discussion  
This analysis including the three largest clinical trials in patients with HF-PEF 
showed that the rates of sudden death and pump failure death were low across 
these trials especially in the most recent TOPCAT, and the rate of mode-specific 
death had negligible difference by treatment group within a trial. There was a 
temporal downward trend in the rates of sudden death and pump failure death 
across these trials, and both together led to a falling rate of all-cause death 
across these trials, whereas the rate of non-CV death remained constant over 
time. Accordingly, there was an increasing proportional contribution of non-CV 
death to total mortality across these trials; nevertheless, sudden death 
remained the most common mode of death, followed by pump failure death, 
both constituting the majority of CV death. The cumulative incidence was very 
low at around 0.5% for sudden death and 0.2-0.5% for pump failure death by 6 
months. A longer history of HF was associated with a modest higher risk of 
sudden death but a substantial higher risk of pump failure death. 
Despite broad similarities, some notable differences existed in baseline 
characteristics across these trials. For example, patients in the CHARM-
Preserved were more like “HF-REF” patients: more often male and less obese, 
and more of ischaemic cause and less hypertensive. This discrepancy may be 
attributable to the heterogenous inclusion criteria used in these trials. In I-
PRESERVE and TOPCAT, patients were required to have a higher entry threshold 
of LVEF (both ≥45%) and other evidence including previous hospital admission for 
HF, or at least NYHA class III symptoms with evidence of structural heart disease 
in I-PRESERVE and an elevated natriuretic peptide level (BNP ≥100 pg/ml or NT-
proBNP ≥360 pg/ml) in TOPCAT.11, 12 By contrast, for eligibility in CHARM-
Preserved, there was a lower entry threshold of LVEF (>40%) and less stringent 
requirements for demonstrating the presence of diastolic dysfunction, i.e. 
symptomatic HF or hospitalisation for, less specific, cardiac reasons if NYHA 
class II.9 It is possible that CHARM-Preserved had included a fraction of patients 
with left ventricular systolic dysfunction.167  
The average level of NT-proBNP was much higher in TOPCAT than in I-PRESERVE. 
The reason for this is probably the natriuretic peptide concentration for trial 
eligibility. Patients in TOPCAT with NT-proBNP available had met the inclusion 
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criteria of NT-proBNP ≥360 pg/ml,12 and a similar average level of NT-proBNP 
was reported in the Prospective comparison of ARNI with ARB on Management Of 
heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial in which a 
similar NT-proBNP inclusion threshold (>400 pg/ml) was applied.37 On the other 
hand, I-PRESERVE set no threshold of natriuretic peptides for inclusion,11 which 
was also the case for the PEP-CHF study,166 and these two trials had a similar 
average level of NT-proBNP. It is worth to mention that natriuretic peptides 
were highly affected by the comorbidities including obesity, atrial fibrillation 
and renal dysfunction: obesity was related to a lower level while the presence of 
atrial fibrillation and renal dysfunction were related to a higher level of 
natriuretic peptides.168-171 Compared to I-PRESERVE, patients in TOPCAT tended 
to be more obese, but were more likely to have a history of atrial fibrillation and 
renal dysfunction. I cannot rule out the possibility that the comorbidities and 
their interaction somehow contributed to the observed difference in the NT-
proBNP level between I-PRESERVE and TOPCAT.  
Of note, the NT-proBNP level was slightly lower in patients with sudden death 
than those without sudden death in TOPCAT, standing in contrast to the 
observation in I-PRESERVE and the established fact that NT-proBNP was a 
powerful prognostic factor for sudden death in HF-PEF.76, 172 The reason for this 
inconsistency is unknown, but one possible explanation is that patients with NT-
proBNP available was only a small subset of TOPCAT (18%), who were older, 
more likely to be enrolled from America (than eastern Europe), and had worse 
renal function and prognosis than patients with NT-proBNP missing.12 This non-
random cohort may not capture the whole picture of the association between 
NT-proBNP and the risk of sudden death in TOPCAT.  
There was a falling trend in the rates of sudden death and pump failure death 
across these trials over time. This observation was not attributable to the effect 
of experimental treatments, in agreement with the reality that no therapy has 
established overall survival benefit in patients with HF-PEF.9, 11, 12 One possible 
explanation is that the shifting mode of death was driven by the increasing 
proportional contribution of non-CV death across trials over time, given that 
patients in the later trials were older and were more likely to have non-CV 
comorbid conditions. This, in a way, reflected the background that the 
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understanding of HF-PEF as a disease syndrome has evolved and matured over 
time, and HF-PEF has been increasingly sophisticatedly defined, and better 
distinguished from HF-REF,164 as reflected by the discrepancy in trial inclusion 
criteria and accordingly the patient characteristics at baseline. On the other 
hand, the more stringent criteria for trial entry in the later trials may also 
reflect a desire to establish efficacy of therapy in HF-PEF population by 
minimising patient variability, given the repeated therapeutic failure in previous 
trials.  
Despite the falling risk, sudden death remained the most common mode of death 
in the HF-PEF population; besides, findings from observational studies showed 
that the majority of patients experiencing a sudden death did not have severe 
left ventricular dysfunction.173, 174 Therefore, sudden death is still an attractive 
target for intervention prevention in the HF-PEF population and there has been a 
recent call for definitive trials of ICD in patients with HF-PEF.175 Given the lower 
rate of sudden death and a relatively higher competing risk of death from other 
causes in HF-PEF than in HF-REF, it is of fundamental importance to identify an 
enriched subset of patients at high risk for sudden death in designing 
defibrillator trials in HF-PEF. There is only one prognostic model for sudden 
death in HF-PEF which did not take into account the prognostic influence of the 
competing risk of death from other causes and has not yet been validated in an 
independent cohort.76 Consequently, there is still an unmet need to develop 
validated models for sudden death accounting for the competing risk of death 
from other causes.  
Despite the low rate, pump failure death remains the second most common 
mode of death in HF-PEF. Besides, despite similar definitions used in HF-PEF as 
in HF-REF,12, 27 pump failure death may have different mechanisms in HF-PEF and 
HF-REF, given advanced cardiogenic shock and low cardiac output states are less 
frequently observed in HF-PEF; instead, patients in HF-PEF more often have 
terminal events related to progressive right ventricular failure, pulmonary 
hypertension, end-stage renal disease and multi-organ failure.44 It is possible 
that the rates of pump failure death may have been over-estimated, and the 
actual rates may be even lower than these reported here. On the other hand, it 
is of great interest and importance to develop prognostic models for pump 
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failure death in HF-PEF which have not been documented, to better understand 
the mechanism of pump failure death in this population, to aid in nuancing a 
specific definition tailored to this population, and to identify a high-risk 
subgroup for decision making in heart transplantation and ventricular assist 
device and for planning palliative and end-of-life care.  
Longer standing HF was associated with higher risks of sudden death and pump 
failure death alike, but a wider separation by HF duration was observed in the 
risk of pump failure death than sudden death, especially at the later period of 
follow-up, which was echoed with the association between HF duration and the 
risk for mode-specific death in patients with HF-REF in Chapter 3. The HF 
duration is presumably related to the severity of HF, and, accordingly, the 
prognosis of HF. There was evidence that the severity of HF better discriminated 
the risk of pump failure death than sudden death in patients with HF-REF,84 and 
the same mechanism may also underlie the observation in patients with HF-PEF, 
which is yet to be examined in the development of models for both modes of 
death in this population in the next Chapter. Besides, it is possible that the 
higher risk of pump failure death during follow-up, especially in the later 
periods, was mediated by a greater reduction of left ventricular function in 
patients with longer standing HF over time. However, this assumption cannot be 
examined here given repeated measurements of LVEF were not available during 
follow-up. 
There were some limitations in this analysis. First, the study was a post-hoc 
analysis based on clinical trial cohorts, which may be not well representative of 
“real-world” unselected patients. However, compared to the “real-world” 
cohorts, cohorts from clinical trials have detailed characterisation and follow-
up, which allows more complete multivariable adjustment. It is in patients 
similar to those in this analysis that device therapies are likely to be 
investigated. Secondly, in TOPCAT there was a substantial variation in the 
baseline characteristics and clinical outcomes between regions of enrolment 
(Americas vs. Russia and Georgia).176 Although the event rates such as CV death 
in the Americans were reflective of other clinical trial patients in HF-PEF,9, 11 
much lower event rates were observed in patients enrolled in Russia and Georgia 
which accounted for 49% of total enrolment.12 The exclusion of less HF-PEF like 
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patients from Russia and Georgia may lead to a difference in the rates of mode-
specific death. Thirdly, the definitions for mode-specific death were not 
consistent despite broadly similar across these trials. This is not surprising given 
that there are no standardised definitions for mode-specific death until very 
recently a consensus was made on the definitions of CV endpoint events used in 
clinical trials.46 Use of clinical trials has another strength that cause of death is 
adjudicated in a careful and standardised way, and this could reduce the bias 
and variation within a trial. In addition, although the definitions of pump failure 
death used in HF-PEF was similar to those in HF-REF, pump failure death in HF-
PEF may be not classic pump failure as in HF-REF which leads to low cardiac 
output states and advanced cardiogenic shock. Instead, pump failure in HF-PEF, 
in many cases, involves progressive right ventricular failure, pulmonary 
hypertension, end-stage renal disease and multi-organ failure. The rates and the 
corresponding trends in rates may be different if a more tailored definition had 
been used in HF-PEF. Finally, in this analysis, time since randomisation instead 
of time since HF diagnosis was used as the underlying time scale, in other words, 
the patients examined were the “natural survivors” by the time of 
randomisation. This may be less likely to reflect the risks of sudden death and 
pump failure death in the time course of HF progression. However, CHARM-
Preserved and I-PRESERVE provided information on the length of time between 
diagnosis of HF and randomisation.  
6.4 Summary 
The risks of sudden death and pump failure death were consistently low across 
the three largest clinical trials in patients with HF-PEF, with little difference by 
experimental treatment in any trial. There was a downward trend in the rates of 
sudden death and pump failure death across these trials over time, parallel with 
a changing characteristic of patients enrolled in these trials; nevertheless, 
sudden death and pump failure death remained the most common modes of 
death, altogether accounting for the majority of CV deaths. The absolute rates 
of sudden death and pump failure death were very low in the early follow-up 
after randomisation. Longer standing HF was associated with a mild higher risk 
of sudden death and a substantial higher risk of pump failure death. 
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Chapter 7 Developing and validating models to 
predict sudden death and pump failure death in 
HF-PEF 
Despite the declining rates in HF-PEF, sudden death and pump failure death 
remain the most common modes of death in patients with HF-PEF.177 Risk 
stratification of both modes of death would aid with designing trials in the 
enriched high-risk groups who would benefit most from the therapy under 
investigation. However, there is a paucity of data in the literature on predictive 
models for sudden death and, in particular, for pump failure death in patients 
with HF-PEF. Only one model has been developed to predict sudden death with 
good discriminatory ability with a C statistic of 0.75.76 Nevertheless, this model 
has not been validated in an independent cohort, and did not account for the 
prognostic influence of the competing risk of death from other causes, which is 
substantial among the HF-PEF population.112 No model has been developed to 
predict pump failure death in HF-PEF. Therefore, there is a need to develop and 
validate prognostic models for both modes of death in this population taking into 
account the competing risk of death from other causes.  
In this chapter I will develop models to predict sudden death and pump failure 
death separately in patients with HF-PEF who were enrolled in the I-PRESERVE 
trial with the use of Fine-Gray sub-distribution hazards models and accounting 
for the competing risk of death from other causes.11, 118 For each mode of death, 
a series of models will be built, first based on candidate variables of 
demographics, clinical features of HF and medical history, then with the 
addition of ECG parameters, next with the addition of routine biochemical tests, 
and finally with the addition of NT-proBNP. In each of the derived models, 
model performance will be examined by assessing calibration, i.e. the 
agreement between the observed and predicted cumulative incidences, and 
discrimination, i.e. the separation of patients at higher risk from those at lower 
risk, respectively. An individual’s risk score for each mode of death will be 
calculated based on the respective model and the corresponding cumulative 
incidence will be predicted. The derived models will be externally validated in 
CHARM-Preserved and in TOPCAT.9, 12 Validation will be performed by fitting a 
univariate regression analysis on the risk score which is the sum of the products 
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of predictor coefficients from the derivation model and its corresponding 
predictor values in the validation cohort. 
7.1 Methods 
7.1.1 The derivation cohort and candidate prediction variables 
Patients with HF-PEF enrolled in the I-PRESERVE trial were used for model 
derivation after excluding patients with an ICD or CRT-D at baseline.11  
A number of baseline variables (N=45) were assessed to identify predictors for 
sudden death and pump failure death separately in I-PRESERVE; these variables 
included demographics, clinical features of HF, medical history, ECG 
parameters, routine laboratory tests and NT-proBNP. These variables and their 
data completeness are shown in detail in Appendix Table 9. A full set of baseline 
variables was collected in most patients in I-PRESERVE (missing observations 
<5%), except for NT-proBNP which was measured in 84% of the cohort.  
7.1.2 The validation cohorts  
The CHARM-Preserved and TOPCAT trials were used for model validation, after 
excluding patients with an ICD or CRT-D at baseline.9, 12 Patients with a LVEF 
<45% in CHARM-Preserved were also excluded to ensure consistency of the LVEF 
entry threshold across trials. 
The clinical variables were available in most patients in both validation cohorts, 
but laboratory measurements were not recorded in CHARM-Preserved, except 
eGFR and serum creatinine which were available in the patients from North 
America (39% of the cohort). In TOPCAT, laboratory measurements were 
recorded in most patients (missing observations <5%), except blood urea nitrogen 
(available in 77% of the cohort) and NT-proBNP (available in 18%) (Appendix 
Table 9). 
7.1.3 Statistical analysis 
For each mode of death, the prognostic value of each candidate predictor on the 
cumulative incidence was first examined with the use of a univariate Fine-Gray 
regression model.118 For each continuous variable, its linear association with the 
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cumulative incidence of mode-specific death was examined graphically by means 
of the restricted cubic spline method, and if the response appeared non-linear, 
certain cut-off values or transformation were used based on the spline curves 
and clinical relevance. For each categorical variable, appropriate dummy 
variables were applied based on literature and data availability. For each mode 
of death, the statistical power for each candidate variable was quantified by X2 
values with one degree of freedom which was positively associated with 
prediction strength. For each outcome, univariate predictors significant at a p 
value <0.20 were included in multivariable Fine-Gray regression analyses with a 
backward stepwise selection at an exclusion p value of 0.05. Each model was 
developed with the use of the complete-case analysis method. The proportional 
sub-distribution hazards assumption was examined using time varying terms for 
the derived models. Specifically, a total of 4 multivariable models were 
developed for each mode of death: Model 1 was selected from candidate 
variables of demographics, clinical features and medical history, Model 2 was 
developed based on candidate variables for Model 1 with the addition of ECG 
parameters, Model 3 based on routine laboratory tests in addition to variables 
for Model 2, and Model 4 based on NT-proBNP in addition to variables for Model 3 
(Figure 7-1).  
Figure 7-1 Model construction steps in HF-PEF 
 
For each derived model, an individual’s risk score was calculated as the sum of 
each predictor value multiplied by its corresponding coefficient from the 
multivariable model. Model calibration was graphically examined by comparing 
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the predicted cumulative incidence with the observed Aalen-Johansen estimator 
in each tertile of risk scores (the closer the observed and predicted incidences 
the better the calibration is). Model discrimination was examined by visually 
assessing the separation of each set of 3 curves (the wider the separation 
between the tertiles the better the discrimination is) and by computing the 
Harrell’s C statistic.71  
External validation was performed in CHARM-Preserved as well as in TOPCAT. In 
CHARM-Preserved, only Model 1 and Model 2 for mode-specific death were 
validated, given the laboratory variables were not available in most patients. In 
TOPCAT the 4 derived models for each mode of death were validated. For each 
model to be validated, an individual’s risk score was calculated as the sum of 
predictor coefficients from each derivation model multiplied by its 
corresponding predictor values in the validation cohort. The obtained risk score 
for each model was then fitted into a univariate Fine-Gray regression analysis. 
Model performance was examined using the same approach as the derivation 
procedure. Given the small cohort size of patients with NT-proBNP 
measurements in TOPCAT, the risk score of Model 4 for each mode of death was 
categorised into two subgroups by which the observed and predicted cumulative 
incidences over time were curved and compared. 
7.2 Results 
7.2.1 Patient characteristics and events in the derivation cohort 
The derivation cohort included 4116 patients with HF-PEF enrolled in I-
PRESERVE, after excluding 12 patients with an ICD or CRT-D at baseline. The 
average age was 72 years and 60% were women. The mean LVEF was 59%, the 
vast majority (97%) were in NYHA class II-III (predominantly in class III [76%]) 
symptoms, and most had a hypertensive aetiology (64%). The patient 
characteristics at baseline are shown in Table 7-1. 
During a median 52.9 months of follow-up, 877 death events occurred including 
230 sudden deaths and 123 pump failure deaths. The corresponding annual rates 
for sudden death and pump failure death were 1.4 (95% CI 1.2-1.6) and 0.7 (95% 
CI 0.6-0.9) per 100 patient-years, respectively.  
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Table 7-1 Baseline characteristics of patients with HF-PEF in the derivation and validation 
cohorts 
 Derivation cohort Validation cohorts 
  I-PRESERVE CHARM-
Preserved 
TOPCAT 
  (N=4116) (N=2556) (N=3401) 
Age -years 71.6±6.9    66.9±11.0    68.5±9.6   
Female (%) 2485 (60.4) 1077 (42.1) 1760 (51.8) 
Race (%) 
   
White 3847 (93.5)  2337 (91.4)  3028 (89.0)  
Black 82 (2.0)  107 (4.2)  294 (8.6)  
Asian 35 (0.9)  64 (2.5)  18 (0.5)  
Other 152 (3.7)  48 (1.9)  61 (1.8)  
Blood pressure -mmHg 
   
Systolic 136.4±15.0   136.6±18.6 129.3±13.9    
Diastolic 78.8±9.1    77.8±10.7    75.9±10.6    
Heart rate -beats/min 71.4±10.5    71.4±12.4    69.0±10.6    
Body mass index 29.6±5.3    29.3±5.8 32.1±7.1   
LVEF -% 59.4±9.2   56.1±8.7    57.1±7.4    
NYHA class (%) 
   
I-II 869 (21.1) 1582 (61.9) 2282 (67.2) 
III-IV 3246 (78.9)  974 (38.1)  1116 (32.8)  
Aetiology (%) 
   
Ischaemic 1033 (25.1)  1378 (53.9)  - 
Hypertensive 2616 (63.6)  631 (24.7)  - 
Other 467 (11.3)  547 (21.4)  - 
Medical history (%) 
   
Current smoking - 328 (12.8)  357 (10.5)  
HF hospitalisation within the previous6 
months 
1809 (44.0)  935 (36.6)  1787 (52.5)  
Myocardial infarction  963 (23.4)  1046 (40.9)  873 (25.7)  
Angina  1773 (43.1)  1509 (59.0)  1598 (47.0)  
CABG or PCI 542 (13.2)  821 (32.1)  791 (23.3)  
Coronary artery disease 2087 (50.7) 1790 (70.0)  1993 (58.6) 
Hypertension 3645 (88.6)  1683 (65.8)  3109 (91.5)  
Diabetes 1128 (27.4)  727 (28.4)  1096 (32.3)  
Atrial fibrillation 1199 (29.1)  762 (29.8)  1192 (35.1)  
Stroke  394 (9.6)  222 (8.7)  260 (7.7)  
Pacemaker 245 (6.0)  183 (7.2)  247 (7.3)  
COPD or asthma 386 (9.4)  - 543 (16.0)  
Dyslipidaemia 1801 (43.8)  - 2039 (60.0)  
Treatment (%) 
   
Digitalis 556 (13.5)  680 (26.6)  337 (9.9)  
Diuretics 3407 (82.8)  1909 (74.7)  2778 (81.9)  
Loop 2140 (52.0)  1576 (61.7)  1764 (52.0)  
Thiazide 1552 (37.7)  355 (13.9)  1394 (41.1)  
ACEI or ARB 2572 (62.5) 1499 (58.6)  2863 (84.2) 
Beta-blocker 2423 (58.9)  1405 (55.0)  2637 (77.7)  
MRA 631 (15.3)  302 (11.8)  1698 (49.9)  
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Calcium channel blocker 1634 (39.7)  833 (32.6)  1284 (37.8)  
Antiarrhythmic agent 355 (8.6)  250 (9.8)  289 (8.5)  
Antiplatelet 2412 (58.6)  1562 (61.1)  2292 (67.6)  
Aspirin 2249 (54.7)  1476 (57.7)  2220 (65.4)  
Oral anticoagulant 783 (19.0)  625 (24.5)  774 (22.8)  
Lipid lowering agent 1272 (30.9)  1052 (41.2)  1816 (53.5)  
Anti-diabetic agent 922 (22.4)  - 943 (27.8)  
ECG  
   
QRS duration -ms 90 (80-106) 
 
92 (82-106) 
Atrial fibrillation or flutter (%) 694 (16.9) 421 (16.5)  689 (20.4) 
Bundle branch block (%) 613 (14.9) 346 (13.6)  589 (17.4) 
Left bundle branch block (%) 336 (8.2) - - 
Right bundle branch block (%) 283 (6.9) - - 
Left ventricular hypertrophy (%) 1257 (30.5) 373 (14.7)  738 (21.8) 
Laboratory tests 
   
Albumin -g/L 43.1±3.4 - 41.1±5.4 
Aspartate aminotransferase -U/L 23.7±10.5 - 25.4±12.6 
Alanine aminotransferase -U/L 23.3±15.2 - 25.1±14.3 
Bilirubin -mg/dl 0.65±0.29 - 0.73±0.66 
Potassium -mmol/L 4.44±0.47 - 4.25±0.45 
Sodium -mmol/L 139.5±3.0 - 141.2±4.2 
Haemoglobin -g/L 140.0±15.0 - 133.0±16.8 
Haematocrit -% 42.1±4.5 - 41.2±66.3 
Leukocyte -109/L 7.15±2.0 - 7.07±3.8 
Neutrophil -109/L 4.53±1.7 - - 
Platelet -109/L 233.8±66.8 - 231.6±66.6 
Blood urea nitrogen -mg/dl 21.3±9.3 - 21.2±11.3d 
Creatinine -mg/dl 1.00±0.32a    1.12±0.41c    1.09±0.30    
eGFR -ml/min/1.73m2 72.6±22.5a 72.2±27.1c   67.7±20.2  
eGFR <60 ml/min/1.73m2 1239 (30.8)a 322 (34.9)c 1307 (38.5)  
NT-proBNP -pg/ml 339 (133-960)b - 843 (463-1727)e 
The letters denote the number of patients available: a=4027 (98%), b=3470 (84%), c=922 (39%), 
d= 2630 (77%), e=615 (18%). 
“-” denotes data having not been recorded. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 200 
 
7.2.2 Derivation of the sudden death models  
As can be seen from Table 7-2, the 25 strongest prediction variables for sudden 
death were listed in a descending order of prediction strength from the 
univariate analysis in I-PRESERVE, and the 5 most powerful prognostic variables 
were NT-proBNP, LVEF, blood urea nitrogen, male sex and serum creatinine.  
 
Table 7-2 The 25 most powerful predictors for sudden death based on univariate analysis in 
I-PRESERVE 
Prediction variable sHR (95% CI) p value X2 score 
NT-proBNP up to 3000 pg/ml, per 100 pg/ml increase 1.06 (1.05-1.08) <0.001 96.0 
LVEF 45-60%, per 1% decrease 1.08 (1.05-1.10) <0.001 34.0 
Blood urea nitrogen 15-55 mg/dl, per 1 mg/dl increase 1.03 (1.02-1.05) <0.001 29.6 
Male sex 1.92 (1.48-2.49) <0.001 24.1 
Serum creatinine 0.8-2.5 mg/dl, per 0.1 mg/dl increase 1.09 (1.05-1.13) <0.001 22.9 
Ischaemic aetiology 1.89 (1.45-2.47) <0.001 22.2 
Age 60 years or above, per 1 year increase 1.05 (1.03-1.07) <0.001 22.1 
QRS duration 90-130 ms, per 5 ms increase 1.10 (1.05-1.14) <0.001 20.3 
History of myocardial infarction 1.82 (1.39-2.38) <0.001 18.7 
Albumin 35-45 g/L, per 1 g/L decrease 1.10 (1.05-1.15) <0.001 15.1 
Neutrophil -109/L, per 109/L increase 1.09 (1.04-1.14) <0.001 14.5 
Leukocyte 6-10 109/L, per 109/L increase 1.18 (1.08-1.29) <0.001 13.3 
History of diabetes 1.64 (1.26-2.14) <0.001 13.2 
History of COPD or asthma 1.91 (1.34-2.72) <0.001 13.0 
HF hospitalisation within the last 6 months 1.60 (1.23-2.07) <0.001 12.5 
Left bundle branch block on ECG 1.84 (1.27-2.68) 0.001 10.2 
Bundle branch block on ECG 1.61 (1.18-2.21) 0.003 8.9 
BMI 18-45 kg/m2, per 1 kg/m2 increase 0.96 (0.93-0.99) 0.004 8.5 
eGFR up to 60 ml/min/1.73m2, per 1 ml/min/1.73m2 increase 0.98 (0.96-0.99) 0.004 8.5 
Heart rate 50-100 beats/min, per 5 beats/min increase 1.09 (1.03-1.16) 0.004 8.1 
History of atrial fibrillation 1.46 (1.11-1.90) 0.006 7.6 
Potassium 4-6 mmol/L, per 1 mmol/L increase 1.49 (1.11-2.00) 0.008 6.9 
Left ventricular hypertrophy on ECG 1.29 (0.99-1.69) 0.061 3.5 
Atrial fibrillation or flutter on ECG 1.33 (0.97-1.83) 0.076 3.2 
History of dyslipidaemia 0.80 (0.61-1.04) 0.097 2.8 
 
The 4 multivariable models for sudden death derived from 4 sets of candidate 
variables are summarised in Table 7-3. Model 1 consisted of 7 prediction 
variables which were independently associated with a higher risk of sudden 
death including older age, male sex, lower LVEF, higher heart rate, history of 
diabetes, history of myocardial infarction and HF hospitalisation within the 
previous 6 months. Model 2 further included LVH and bundle branch block on 
ECG, and both were associated with a higher risk of sudden death, in addition to 
Chapter 7 201 
 
the predictive variables in Model 1. In Model 3 serum albumin entered the model 
and lower albumin were associated with a higher risk of sudden death, but heart 
rate and bundle branch block on ECG dropped out of the model. In Model 4 
albumin and HF hospitalisation in the previous 6 months fell out of the model 
once NT-proBNP was included with higher levels of NT-proBNP being associated 
with a higher risk of sudden death.  
 
For the continuous variables, there was no further trend in risk of sudden death 
for age with values of <60 years, for LVEF with values of >60%, for albumin with 
values of <35 g/L or >45 g/L, and for NT-proBNP with values of >3000 pg/ml 
(Figure 7-2). 
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Table 7-3 Multivariable models for sudden death in I-PRESERVE  
Model 1  Model 2  
Number of patients (number of events) 4109 (230) 4109 (230) 
C statistic 0.71 (95% CI 0.68-0.75) 0.72 (95% CI 0.69-0.75) 
Prediction variable coefficient sHR (95% CI) X2 score p value coefficient sHR (95% CI) X2 score p value 
Age 60 years or above, per 1 year increase 0.049 1.05 (1.03-1.07) 25.5 <0.001 0.050 1.05 (1.03-1.07) 24.8 <0.001 
Male sex 0.553 1.74 (1.33-2.27) 16.6 <0.001 0.551 1.74 (1.33-2.27) 16.3 <0.001 
LVEF 45-60%, per 1% decrease 0.053 1.05 (1.03-1.08) 15.7 <0.001 0.051 1.05 (1.02-1.08) 14.3 <0.001 
Heart rate 50-100 beats/min, per 5 beats/min increase 0.070 1.07 (1.01-1.14) 5.2 0.022 0.067 1.07 (1.01-1.13) 4.8 0.029 
History of diabetes 0.519 1.68 (1.28-2.20) 14.3 <0.001 0.531 1.70 (1.30-2.23) 14.7 <0.001 
History of myocardial infarction 0.419 1.52 (1.14-2.02) 8.3 0.004 0.435 1.54 (1.16-2.05) 9.0 0.003 
HF hospitalisation within the previous 6 months 0.364 1.44 (1.10-1.88) 7.1 0.007 0.373 1.45 (1.11-1.89) 7.5 0.006 
Bundle branch block on ECG 
    
0.327 1.39 (1.00-1.92) 3.9 0.049 
Left ventricular hypertrophy on ECG 
    
0.376 1.46 (1.11-1.92) 7.3 0.007 
 
Model 3  Model 4  
Number of patients (number of events) 4021 (228) 3467 (195) 
C statistic 0.71 (95% CI 0.68-0.75) 0.75 (95% CI 0.72-0.78) 
Prediction variable coefficient sHR (95% CI) X2 score p value coefficient sHR (95% CI) X2 score p value 
Age 60 years or above, per 1 year increase 0.046 1.05 (1.03-1.07) 21.0 <0.001 0.034 1.03 (1.01-1.06) 9.5 0.002 
Male sex 0.529 1.70 (1.30-2.22) 14.8 <0.001 0.506 1.66 (1.23-2.23) 11.3 0.001 
LVEF 45-60%, per 1% decrease 0.055 1.06 (1.03-1.08) 16.7 <0.001 0.036 1.04 (1.01-1.07) 5.8 0.017 
Heart rate 50-100 beats/min, per 5 beats/min increase 
        
History of diabetes 0.547 1.73 (1.32-2.27) 15.5 <0.001 0.568 1.76 (1.31-2.37) 14.2 <0.001 
History of myocardial infarction 0.415 1.51 (1.14-2.01) 8.2 0.004 0.463 1.59 (1.17-2.15) 9.0 0.003 
HF hospitalisation within the previous 6 months 0.336 1.40 (1.07-1.83) 6.0 0.014 
    
Bundle branch block on ECG 
        
Left ventricular hypertrophy on ECG 0.395 1.48 (1.13-1.95) 8.0 0.005 0.340 1.40 (1.04-1.90) 4.9 0.027 
Albumin 35-45 g/L, per 1 g/L decrease 0.065 1.07 (1.01-1.12) 6.2 0.013 
    
NT-proBNP up to 3000 pg/ml, per 100 pg/ml increase 
    
0.048 1.05 (1.03-1.06) 42.6 <0.001 
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Figure 7-2 Histograms of age (A), LVEF (B), serum albumin (C), and NT-proBNP (D) and the corresponding spline curves with the risks of sudden death in I-
PRESERVE 
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The columns are the histogram of a continuous variable, and the left axis shows the percent of patients in each column. The black solid line is the subdistribution 
hazard ratio (sHR) of sudden death with the corresponding continuous variable and the black dot lines are the 95% confidence intervals. The maroon dash-dot line 
is the reference line with a sHR of 1.0 (i.e. no association).
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7.2.3 Derivation of the pump failure death models 
The 25 most powerful prediction variables for pump failure death are shown in 
Table 7-4 in a descending order of prediction strength based on the univariate 
analysis, and the 5 strongest prediction variables were NT-proBNP, blood urea 
nitrogen, serum creatinine, age and eGFR.  
Table 7-4 The 25 most powerful predictors for pump failure death based on univariate 
analysis in I-PRESERVE 
Prediction variable sHR (95% CI) p value X2 score 
NT-proBNP up to 3000 pg/ml, per 100 pg/ml increase 1.08 (1.06-1.10) <0.001 81.7 
Blood urea nitrogen 15-55 mg/dl, per 1 mg/dl increase 1.06 (1.04-1.07) <0.001 62.7 
Serum creatinine 0.8-2.5 mg/dl, per 0.1 mg/dl increase 1.15 (1.11-1.19) <0.001 53.1 
Age 60 years or above, per 1 year increase 1.08 (1.06-1.11) <0.001 41.0 
eGFR up to 80 ml/min/1.73m2, per 1 ml/min/1.73m2 increase 0.97 (0.96-0.98) <0.001 39.3 
eGFR <60 ml/min/1.73m2 2.79 (1.95-4.00) <0.001 31.4 
Atrial fibrillation or flutter on ECG 2.74 (1.89-3.97) <0.001 28.4 
Neutrophil 4-10*109/L, per 109/L increase 1.34 (1.20-1.50) <0.001 26.3 
History of atrial fibrillation 2.52 (1.77-3.59) <0.001 26.3 
Albumin 35-45 g/L, per 1 g/L decrease 1.16 (1.10-1.24) <0.001 24.1 
Diastolic BP up to 80 mmHg, per 1 mmHg decrease 1.05 (1.03-1.07) <0.001 22.9 
Leukocyte 6-13*109/L, per 109/L increase 1.22 (1.10-1.35) <0.001 14.5 
History of diabetes 2.00 (1.40-2.85) <0.001 14.4 
LVEF 45-60%, per 1% decrease 1.06 (1.03-1.10) <0.001 12.3 
HF hospitalisation within the past 6 months 1.86 (1.29-2.66) 0.001 11.4 
QRS duration 90-130 ms, per 1 ms increase 1.02 (1.01-1.03) 0.001 11.0 
Potassium 4-5.5 mmol/L, per 1 mmol/L increase 2.01 (1.31-3.07) 0.001 10.4 
History of dyslipidaemia 0.54 (0.37-0.80) 0.002 9.5 
BMI up to 30 kg/m2, per 1 kg/m2 increase 0.91 (0.85-0.97) 0.003 8.9 
Pacemaker use 2.21 (1.29-3.79) 0.004 8.4 
Heart rate 50-100 beats/min, per 5 beats/min increase 1.13 (1.04-1.23) 0.004 8.1 
Ischaemic aetiology 1.69 (1.17-2.45) 0.005 7.8 
History of hypertension 0.56 (0.35-0.88) 0.012 6.4 
Male sex 1.57 (1.10-2.23) 0.013 6.3 
Bundle branch block on ECG 1.70 (1.12-2.60) 0.014 6.1 
 
The 4 multivariable models for pump failure death are presented in Table 7-5. 
Specifically, Model 1 included 8 variables, in which older age, male sex, lower 
LVEF or diastolic blood pressure, higher heart rate, and history of diabetes or 
atrial fibrillation were associated with a higher risk of pump failure death, while 
a history of dyslipidaemia was associated with a lower risk. None of the 
candidate variables of ECG parameters were further selected, i.e. Model 2 was 
identical to Model 1. Based on Model 1, Model 3 additionally selected serum 
albumin, potassium and creatinine, and a lower level of albumin and higher 
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levels of potassium and creatinine were associated with a higher risk of pump 
failure death. However, with the addition of these variables male sex and heart 
rate fell out of the model. Model 4 included NT-proBNP, and a higher level of 
NT-proBNP was associated with a higher risk of pump failure death while LVEF, 
potassium, albumin and a history of atrial fibrillation fell out of the model. 
 
For the continuous variables, there was no further trend in the risk of pump 
failure death for age with values of <60 years, for LVEF with values of >60%, for 
diastolic blood pressure with values of >80 mmHg, for potassium with values of 
<4 mmol/L or >5.5 mmol/L, for albumin with values of <35 g/L or >45 g/L, for 
creatinine with values of <0.8 mg/dl or >2.5 mg/dl, and for NT-proBNP with 
values of >3000 pg/ml (Figure 7-3). 
 
  
Chapter 7 207 
 
Table 7-5 Multivariable models for pump failure death in I-PRESERVE 
 Model 1  Model 2 
Number of patients (number of events) 4109 (123)  
C statistic 0.78 (95% CI 0.75-0.82)      
Prediction variable coefficient sHR (95% CI) X2 score p value     
Age 60 years or above, per 1 year increase 0.067 1.07 (1.04-1.10) 24.9 <0.001  Same as Model 1   
Male sex 0.395 1.48 (1.03-2.13) 4.6 0.032     
Heart rate 50-100 beats/min, per 5 beats/min increase 0.099 1.10 (1.02-1.20) 5.5 0.019     
LVEF 45-60%, per 1% decrease 0.052 1.05 (1.02-1.09) 8.6 0.003     
Diastolic BP up to 80 mmHg, per 1 mmHg decrease 0.041 1.04 (1.02-1.07) 11.3 0.001     
History of diabetes 0.839 2.31 (1.63-3.29) 21.7 <0.001     
History of dyslipidaemia -0.646 0.52 (0.36-0.77) 10.6 0.001     
History of atrial fibrillation 0.593 1.81 (1.25-2.62) 9.8 0.002     
 Model 3 Model 4 
Number of patients (number of events) 3993 (116) 3448 (98) 
C statistic 0.80 (95% CI 0.76-0.83)  0.80 (95% CI 0.76-0.84) 
Prediction variable coefficient sHR (95% CI) X2 score p value coefficient sHR (95% CI) X2 score p value 
Age 60 years or above, per 1 year increase 0.055 1.06 (1.03-1.09) 14.1 <0.001 0.044 1.05 (1.01-1.08) 8.5 0.004 
Male sex         
Heart rate 50-100 beats/min, per 5 beats/min increase         
LVEF 45-60%, per 1% decrease 0.052 1.05 (1.02-1.09) 7.8 0.005     
Diastolic BP up to 80 mmHg, per 1 mmHg decrease 0.028 1.03 (1.00-1.05) 5.2 0.022 0.028 1.03 (1.00-1.06) 4.0 0.044 
History of diabetes 0.718 2.05 (1.41-2.98) 14.1 <0.001 0.758 2.13 (1.45-3.15) 14.5 <0.001 
History of dyslipidaemia -0.656 0.52 (0.35-0.78) 10.2 0.001 -0.676 0.51 (0.33-0.79) 9.1 0.003 
History of atrial fibrillation 0.588 1.80 (1.23-2.63) 9.3 0.002     
Potassium 4-5.5 mmol/L, per 1 mmol/L increase 0.486 1.63 (1.06-2.50) 4.9 0.027     
Albumin 35-45 g/L, per 1 g/L decrease 0.096 1.10 (1.03-1.18) 7.6 0.006     
Serum creatinine 0.8-2.5 mg/dl, per 0.1 mg/dl increase 0.069 1.07 (1.02-1.12) 8.5 0.004 0.060 1.06 (1.01-1.11) 6.1 0.014 
NT-proBNP up to 3000 pg/ml, per 100 pg/ml increase     0.059 1.06 (1.04-1.08) 31.4 <0.001 
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Figure 7-3 Histograms of age (A), LVEF (B), diastolic BP (C), serum potassium (D), albumin (E), creatinine (F) and NT-proBNP (G) and the corresponding 
spline curves with the risks of pump failure death in I-PRESERVE 
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7.2.4 Performance of the derived models 
As can be seen from Figure 7-4, each sudden death model demonstrated 
excellent calibration: the predicted cumulative incidence curve was in good 
agreement with the corresponding observed one based on the Aalen-Johansen 
estimator in each tertile of the risk score over time. Both sets of three curves 
were well separated, suggesting good discrimination; in particular, Model 4 
identified the highest tertile with 7 times the risk of the lowest tertile. The 
discrimination was further quantified by the Harrell’s C statistic with values of 
0.71 (95% CI 0.68-0.75) in Model 1, 0.72 (95% CI 0.69-0.75) in Model 2, 0.71 (95% 
CI 0.68-0.75) in Model 3 and 0.75 (95% CI 0.72-0.78) in Model 4.   
 
For each of the pump failure death models, the predicted and observed 
cumulative incidences were almost identical in each tertile of the risk score over 
time, indicating good calibration (Figure 7-5). Compared to the lowest tertile, 
the risk for pump failure death was 12 times higher in the highest tertile in 
Model 1, and this figure was 13 in Model 3 and 20 in Model 4 respectively. The 
excellent discrimination was also confirmed by the Harrell’s C statistic with 
values of 0.78 (95% CI 0.75-0.82) in Model 1, 0.80 (95% CI 0.76-0.83) in Model 3 
and 0.80 (95% CI 0.76-0.84) in Model 4.   
 
Some violation of proportional sub-distribution hazards assumption was observed 
for creatinine (p=0.043) in the pump failure death models. When graphically 
displaying the cumulative incidences of pump failure death by tertiles of 
creatinine, the curves generally did not cross over time, suggesting this was 
statistically significant but not relevant to the performance of the model (Figure 
7-6). 
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Figure 7-4 Observed vs. predicted cumulative incidence curves for sudden death by tertiles of the risk scores based on the sudden death models in I-
PRESERVE 
 
Red solid lines are predicted cumulative incidence curves based the corresponding models, and black dotted lines are the observed cumulative incidence curves 
based on Aalen-Johansen estimators. 
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Figure 7-5 Observed vs. predicted cumulative incidence curves for pump failure death by tertiles of the risk scores based on the pump failure death models 
in I-PRESERVE 
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Red solid lines are predicted cumulative incidence curves based the corresponding models, and black dotted lines are the observed cumulative incidence curves 
based on Aalen-Johansen estimators.
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Figure 7-6 Cumulative incidence curves for pump failure death by tertiles of serum creatinine level in I-PRESERVE 
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7.2.5 External validation of the models in CHARM-Preserved 
External validation was performed in 2556 patients in CHARM-Preserved after 
excluding 23 patients with an ICD or CRT-D and 444 patients with a LVEF below 
45%. There were some differences in baseline characteristics between CHARM-
Preserved and I-PRESERVE. Patients in CHARM-Preserved tended to be younger 
and more often men with a lower mean LVEF, and were more likely to have an 
ischaemic aetiology and a history of myocardial infarction, but had a lower 
prevalence of previous HF hospitalisation and LVH on ECG. Patient 
characteristics at baseline are summarised in Table 7-1. 
 
During a median 36.6 months of follow-up, 409 death events were recorded in 
CHARM-Preserved including 110 sudden deaths and 82 pump failure deaths, with 
the corresponding annual rates of 1.5 (95% CI 1.2-1.8) and 1.1 (95% CI 0.9-1.4) 
per 100 patient-years, respectively. 
 
For the sudden death models, there was a marginal decrease in discrimination 
ability when validated in CHARM-Preserved, with a Harrell’s C statistic of 0.68 
(95% CI 0.64-0.73) for Model 1 and 0.69 (95% CI 0.65-0.74) for Model 2. For Model 
1 the predicted and observed cumulative incidences were broadly similar across 
tertiles and both set of curves were evenly distributed. However, Model 2 was 
less able to discriminate the higher two tertiles and slightly under-predicted the 
highest tertile but over-estimated the middle tertile in the middle period of 
follow-up (Figure 7-7). 
 
For the pump failure death Model 1 (or Model 2), history of dyslipidaemia was 
not recorded and treatment with lipid lowering agents was used instead. 
Discrimination remained excellent in CHARM-Preserved with a Harrell’s C 
statistic of 0.79 (95% CI 0.75-0.83), and calibration was generally reasonable 
over time (Figure 7-8). 
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Figure 7-7 Observed vs. predicted cumulative incidence curves for sudden death by tertiles 
of the risk scores in CHARM-Preserved 
 
Panel A. Validation of sudden death model 1 from I-PRESERVE in CHARM-Preserved; Panel B. 
Validation of sudden death model 2 from I-PRESERVE in CHARM-Preserved.  
Because laboratory measurements were not examined in the majority of patients in CHARM-
Preserved, sudden death model 3 and model 4 from I-PRESERVE were not validated in 
CHARM-Preserved.  
Red solid lines are predicted cumulative incidence curves based the corresponding models, and 
black dotted lines are the observed cumulative incidence curves based on Aalen-Johansen 
estimators. 
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Figure 7-8 Observed vs. predicted cumulative incidence curves for pump failure death by 
tertiles of the risk scores in CHARM-Preserved 
 
Validation of the pump failure death model 1 (or Model 2) from I-PRESERVE in CHARM-
Preserved. Because laboratory measurements were not examined in the majority of patients in 
CHARM-Preserved, sudden death model 3 and model 4 from I-PRESERVE were not validated 
in CHARM-Preserved.  
Red solid lines are predicted cumulative incidence curves based the corresponding models, and 
black dotted lines are the observed cumulative incidence curves based on Aalen-Johansen 
estimators. 
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7.2.6 External validation of the models in TOPCAT 
Models developed in I-PRESERVE were also externally validated in 3401 patients 
in TOPCAT after excluding 44 patients with an ICD or CRT-D. Baseline 
characteristics were broadly similar between I-PRESERVE and TOPCAT, but some 
difference was also noted. Patients in TOPCAT were slightly younger and more 
often men, and had a lower level of mean LVEF, blood pressure and serum 
albumin, but had a substantially higher level of median NT-proBNP among the 
615 patients (18%) with NT-proBNP available. Patients in TOPCAT had a higher 
average BMI and were more likely to have a history of dyslipidaemia, renal 
dysfunction or prior HF hospitalisation, but had a lower prevalence of LVH on 
ECG, compared to I-PRESERVE. Patient characteristics at baseline are shown in 
Table 7-1. 
 
There were 520 death events in TOPCAT over a median 41.1 months of follow-
up, including 110 sudden deaths and 65 pump failure deaths with the 
corresponding annual rates of 1.0 (95% CI 0.8-1.2) and 0.6 (95% CI 0.4-0.7) per 
100 patient-years, respectively. 
 
For the sudden death models, a modest decrease in discrimination ability was 
observed when validated in TOPCAT, with a Harrell’s C of 0.66 (95% CI 0.61-0.71) 
for Model 1, 0.65 (95% CI 0.60-0.70) for Model 2, 0.64 (95% CI 0.59-0.69) for 
Model 3, and 0.73 (95% CI 0.64-0.83) for Model 4. Despite some disagreement in 
the middle period of follow-up, the observed and predicted cumulative 
incidences were generally similar across subgroups except for Model 3 which 
failed to separate the higher two tertiles, and largely overestimated the highest 
tertile and underestimated the middle one (Figure 7-9). 
 
For the pump failure death models, discrimination considerably decreased but 
remained good in TOPCAT with a Harrell’s C of 0.72 (95% CI 0.65-0.79) for Model 
1, 0.71 (95% CI 0.63-0.78) for Model 3, and 0.80 (95% CI 0.68-0.92) for Model 4. 
In general, the calibration was reasonable in these models, except Model 1 
which did not separate the lower two tertiles (Figure 7-10). 
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Figure 7-9 Observed vs. predicted cumulative incidence curves for sudden death by subgroups of the risk scores in TOPCAT 
  
Panel A. Validation of sudden death model 1 from I-PRESERVE in TOPCAT; Panel B. Validation of sudden death model 2 from I-PRESERVE in TOPCAT; Panel C. 
Validation of sudden death model 3 from I-PRESERVE in TOPCAT; Panel D. Validation of sudden death model 4 from I-PRESERVE in TOPCAT.  
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*Given the small cohort size of patients with NT-proBNP measurements in TOPCAT (N=615 [18%]), the risk score of Model 4 was categorised into 2 rather than 3 
subgroups.  
Red solid lines are predicted cumulative incidence curves based the corresponding models, and black dotted lines are the observed cumulative incidence curves 
based on Aalen-Johansen estimators. 
 
Figure 7-10 Observed vs. predicted cumulative incidence curves for pump failure death by subgroup of the risk scores in TOPCAT 
 
Panel A. Validation of the pump failure death model 1 (or 2) from I-PRESERVE in TOPCAT; Panel B. Validation of the pump failure death model 3 from I-PRESERVE 
in TOPCAT; Panel C. Validation of the pump failure death model 4 from I-PRESERVE in TOPCAT. *Given the small cohort size of patients with NT-proBNP 
measurements in TOPCAT (N=615 [18%]), the risk score of Model 4 was categorised into 2 other than 3 subgroups. Red solid lines are predicted cumulative 
incidence curves based the corresponding models, and black dotted lines are the observed cumulative incidence curves based on Aalen-Johansen estimators. 
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7.2.7 Predicting an individual’s risk 
The multivariable models presented in Table 7-3 and Table 7-5 from I-PRESERVE 
can be used to calculate an individual’s risk score for sudden death and pump 
failure death respectively, by adding up the products of the value and their 
corresponding coefficient of each prediction variable from each model. Based on 
the obtained risk score, the corresponding cumulative incidence for each mode 
of death within 4 years can be estimated using the corresponding curves outlined 
in Figure 7-11 and Figure 7-12, which showed the distribution of the risk scores 
for each mode of death, based on the clinical model (Model 1) and the model 
with NT-proBNP (Model 4), and its association with the corresponding predicted 
cumulative incidence by 4 years in I-PRESERVE, separately. 
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Figure 7-11 Distribution of the risk scores for sudden death based on Model 1 (A) and Model 
4 (B) and its relation to cumulative incidences within 4 years in I-PRESERVE 
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Figure 7-12 Distribution of the risk scores for pump failure death Model 1 (A) and Model 4 
(B) and its relation to cumulative incidences within 4 years in I-PRESERVE 
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7.3 Discussion 
In this chapter, I developed a series of prognostic models to predict sudden 
death and pump failure death separately in the elderly patients with HF-PEF 
enrolled in I-PRESERVE, and these models were externally validated in CHARM-
Preserved and TOPCAT cohorts. The derived models for sudden death and pump 
failure death using simple demographic and clinical variables showed good 
discrimination and calibration, and were robust in validation. With the addition 
of ECG parameters and routine biochemical measurements model performance 
showed little improvement in the derivation cohort, but decreased in the 
validation cohorts. Inclusion of the biomarker NT-proBNP substantially increased 
the discrimination ability of sudden death model, and simplified the model for 
pump failure death with a marginal increase in discrimination.    
 
Risk stratification for mode-specific death has been studied in patients with HF-
REF but remains largely unexplored among HF-PEF population.78, 79, 84 
Identification of prognostic factors for mode-specific death may help with the 
understanding of the pathophysiological mechanisms underlying this cause of 
death. It may also allow better classification of risk in patients allowing high-risk 
subgroups to be enrolled in new trials of interventions or therapies. This in turn 
will allow adequately powered trials to be conducted with potentially fewer 
patients and in patients likely to benefit. There is one model published for 
predicting sudden death in HF-PEF patients, which was also developed in I-
PRESERVE.76 This prior model, using conventional Cox regression analysis, closely 
resembles the model including NT-proBNP that I developed here using competing 
risk analysis with equally good discrimination. There were some minor but 
potentially important differences. In the previously derived model LBBB on ECG 
was included in the Cox model whereas LVH on ECG was selected by the 
competing risk model I constructed. There may be a number of explanations for 
the inconsistency. One possible explanation is the difference in the modelling 
approaches, i.e. whether or not taking into account death from other causes, 
which would result in different rates of sudden death, and consequently its 
associations with prediction variables. Similarly, it was LVH rather than LBBB 
that was included in the sudden death model in HF-REF using the competing risk 
analysis in Chapter 3. It is significant that LVH was an independent predictor for 
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sudden death in HF-REF as well as HF-PEF patients.178 From a pathophysiological 
perspective, LVH is one of the structural hallmarks of HF-PEF. As it may result 
from excess collagen deposition and fibrosis which occur in hypertrophy, it may 
alter regional conduction patterns and serve as islands of re-entry and an 
arrhythmic substrate, increasing the risk of sudden death.179 On the other hand, 
LBBB is a surface marker of multiple underlying cardiac diseases such as 
ischaemic heart disease. LBBB itself also denotes intra- and inter-ventricular 
dyssynchrony, abnormal LV diastolic filling patterns and impaired LV systolic 
function, which may result in worsening cardiac function.180 It is likely LBBB may 
correlate with other variables with stronger prognostic effects, such as history of 
myocardial infarction and LVEF, and in turn LBBB failed to remain in the 
multivariable models. 
 
There is no prognostic model available specifically to predict pump failure death 
in HF-PEF patients; existing models focus on death from any cause or a 
composite of HF hospitalisation (predominantly) or pump failure death.172 
Nevertheless, a series of models for pump failure death developed here have 
included some variables that have been previously identified to predict death 
and HF events, such as age, heart rate, LVEF, history of diabetes or atrial 
fibrillation, creatinine and NT-proBNP.172 Of note, the presence of prior HF 
hospitalisation, which has been reported as a strong risk factor of subsequent 
mortality or HF events,172, 181 was not included in the models for pump failure 
death; however, it was included in the sudden death models. The reason for this 
is unknown, and one explanation could be the inclusion criteria of the trial. All 
patients in NYHA class II had to have a previous HF hospitalisation within past 6 
months to be eligible for enrolment in I-PRESERVE.11 Consequently, prior HF 
hospitalisation may be related to mild HF symptoms and less severe disease, in 
which pump failure death was less likely to occur than sudden death. 
Intriguingly, dyslipidaemia was independently associated with a lower risk of 
pump failure death. At face value, it possibly reflects the interaction between 
dyslipidaemia and natriuretic peptides, given the median level of NT-proBNP was 
much lower in patients with dyslipidaemia than those without (287 versus 386 
pg/ml respectively). However, if this was true, dyslipidaemia would have 
dropped out of the model when including NT-porBNP, but it was maintained. The 
mechanism underlying requires further exploration. 
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Overall, a series of models were developed for each mode of death with a broad 
spectrum of variables being examined and included in a stepwise manner. The 
derived models with the use of simple demographic and clinical variables (Model 
1) showed good calibration and discrimination, in particular for pump failure 
death, and remained robust despite a modest decrease in discrimination (C 
statistic decreased by 0.05) when validated in TOPCAT. Interestingly, further 
addition of ECG parameters alone (Model 2) and even in combination with 
routine laboratory measurements (Model 3) made little improvement in model 
performance in the derivation cohort, and led to a decrease in discrimination 
and poor calibration (particularly Model 3) in validation. By contrast, the 
inclusion of NT-proBNP (Model 4) increased the discriminative ability for sudden 
death, while simplifying the model for pump failure death with a marginal 
increase in discrimination; both models remained robust when validated in the 
subset of patients with NT-proBNP available in TOPCAT. These observations may 
reflect two things. First, in line with the findings in HF-REF, NT-proBNP was the 
most powerful prognostic factor for sudden death as well as pump failure death 
in HF-PEF. It is plausible from a pathophysiological perspective. The secretion of 
NT-proBNP increases in response to increased cardiac wall stress, which is 
related to volume overload, ventricular stretch and hypertrophy during the 
progression of HF.182 Aa a result, NT-proBNP serves as a proxy of severity of HF, 
the higher level the more likely the advanced HF is, in which pump failure death 
is more frequent.7 Also, NT-proBNP can be an indirect marker of ventricular 
stretch and fibrosis which can result in pro-arrhythmic electrophysiological 
changes that may lead to sudden death, including slowed intraventricular 
conduction and ventricular ectopic beats.183 Second, NT-proBNP may correlate to 
or share some underlying mechanisms with other predictors for mode-specific 
death. Thus, the inclusion of NT-proBNP may alter the strength of the 
associations of other predictors with mode-specific death, which in return could 
lead to the exclusion of these “weakened” predictors, such as LVEF and history 
of atrial fibrillation for pump failure death. 
 
There are some limitations in this analysis. First, validation of the models that 
included NT-proBNP was performed in a subset of the TOPCAT cohort (615 
patients with 22 sudden death and 12 pump failure death events), together with 
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a substantial difference in the distribution of NT-proBNP levels from the 
derivation cohort, the robust result in validation should be viewed with some 
caution. There is a need to re-validate these models in a similar population with 
more substantial cohort size when available in future. Secondly, in TOPCAT 
there was a substantial variation in the baseline characteristics and clinical 
outcomes between regions of enrolment (Americas vs. Russia and Georgia).176 
Although the event rates such as all-cause mortality and HF hospitalisation in the 
Americans were reflective of other clinical trial patients in HF-PEF,9, 11 multi-
fold lower event rates were observed in patients enrolled in Russia and Georgia 
which accounted for 49% of total enrolment.12 The exclusion of less HF-PEF like 
patients from Russia and Georgia may lead to a difference in model validation. 
In a sensitivity analysis, I validated the models in the American subgroup, and 
the sudden death model remained robust, but the pump failure model showed a 
decrease in discrimination, possibly due to small sample size and number of 
events (data not shown). Thirdly, these models were developed in a clinical trial 
cohort. Patients tended to be healthier than “real world” cohorts and the 
performance of the models in real world cohorts needs to be tested. 
Nevertheless, it is in patients similar to those in this analysis that device 
therapies are likely to be investigated and my results would help select patients 
for any such trial. Moreover, in line with the models in HF-REF, the sudden death 
model was less discriminative than the pump failure death model.78, 79 This 
suggests that there is a need to improve the prediction of sudden death. Recent 
studies have shown that late gadolinium enhancement (LGE) on cardiovascular 
magnetic resonance (CMR) is highly predictive of sudden death in patients with 
dilated cardiomyopathy with relatively preserved ejection fraction,184 and there 
is an ongoing trial examining the ICD efficacy in patients with LVEF 36 to 50% 
and LGE on CMR.185 However, CMR parameters were not collected in I-PRESERVE, 
and the prognostic value of LGE alone and its incremental value to the 
prognostic models are unable to be examined. Finally, the vast majority of trial 
participants were white in the derivation and validation populations. Therefore, 
these models need to be re-validated in more ethnically diverse cohorts before 
using them in clinical practice.  
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7.4 Summary 
The prognostic models developed using simple demographic and clinical 
variables can predict the risks of sudden death and pump failure death 
separately with good discrimination and calibration in patients with HF-PEF in I-
PRESERVE, and remain robust in external validation. Including NT-proBNP further 
improved the performance of both models. These models may have important 
clinical implications for identifying high-risk patients for specific interventions in 
future trials among HF-PEF population.   
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Chapter 8 Discussion  
8.1 Summary of findings 
The aims of the studies were to examine if and how the rates of sudden death 
and pump failure death have changed over time in patients with HF-REF and in 
patients with HF-PEF enrolled in clinical trials respectively, and to develop and 
validate prognostic models to predict mode-specific death in both populations.  
8.1.1 Rates of mode-specific death in HF-REF and HF-PEF 
The analysis of individual-level data from 46,163 patients randomised in 13 
clinical trials has shown that the rates of sudden death and pump failure death 
have fallen over the last 2 decades between the start of RALES and the 
completion of ATMOSPHERE, consistent with a cumulative use of evidence based 
medications known to reduce both modes of death. Based on the analysis of 
10,517 patients enrolled in the 3 largest clinical trials in patients with HF-PEF, a 
downward trend was also observed in the rates of sudden death and pump 
failure death across these trials over the last 15 years between the start of 
CHARM-Preserved and the completion of TOPCAT, parallel with a changing 
characteristic of patients enrolled in the HF-PEF trials. 
It would be of interest to understand if there is a similar pattern of change in 
the rates of sudden death and pump failure death in patients with HF, 
particularly according to LVEF, from community-based studies. By far, there are 
two observational studies having examined the change in the rate of mode-
specific death in HF-REF over time. One study was based on the prospective UK-
HEART 1 and 2 cohorts, which included 281 and 357 ambulatory patients who 
had HF-REF with a LVEF ≤45% from the same cardiology outpatient clinics of 8 
general hospitals in the UK in the therapeutic eras of 1993-1995 and 2006-2009 
respectively. It showed that the risk of sudden death was 77% lower in the 
contemporary cohort (2006-2009) than in the historic cohort (1993-1995), after 
adjusting for age, sex, ischaemic aetiology and LV end diastolic dimension.51 The 
other study examined the mortality rates in 2507 consecutive patients with a 
mean age of 53 years and severe HF with reduced left ventricular function (LVEF 
≤40%) referred to a University hospital in Los Angeles for heart 
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transplantation/VAD evaluation across three 6-year eras between 1993 and 2010. 
This study showed that the rate of sudden death was 6.9% in the earliest era 
between 1993 and 1998, and were substantially lower at 3.1% and 2.0% in the 
latter eras of 1999-2004 and 2005-2010 respectively, while the rate of pump 
failure death was considerably higher in the latest era (12.6%) compared to the 
earlier two eras (7.1% and 7.0% respectively).52 Nevertheless, the UK-HEART 
study was a comparison of two time-points, and may not capture the true 
picture of the temporal trend in the rate of mode-specific death.51 The second 
study reflected single centre experience and most patients were candidates for 
heart transplant/VAD, in other words, they were not well representative of the 
general patients living with HF.52 Unfortunately, no observational studies have 
examined the trend in the rates of mode-specific death over time in HF-PEF 
population. 
The paucity of data from the real-world population may be due to a number of 
factors. First, few observational studies have detailed classification of mode-
specific CV death and non-CV death. Unlike clinical trials, in which death events 
are typically reviewed and adjudicated by an independent event committee 
using multiple sources of information, observational studies commonly use 
investigator-reported events or are simply based on death certificates, which are 
largely inaccurate.186 Secondly, even if modes of death were carefully classified 
and adjudicated, observational studies are highly variable in the terms of setting 
of enrolment (outpatient vs. inpatient), disease stage (newly diagnosed vs. 
awaiting heart transplantation), HF type (LVEF-category specified vs. 
unspecified), study design (sample size, duration of follow-up). Moreover, 
observational studies tend to lack detailed baseline characterisation, which as a 
result provides limited opportunity for comprehensive covariate adjustment to 
account for the between-study difference and confounding factors.  
If the risks of sudden death and pump failure death had declined over time in 
HF-REF and HF-PEF populations, what would be the implications on specific 
device therapies (ICDs and VADs) that aim to prevent mode-specific deaths, such 
as clinical benefit and cost-effectiveness?  
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8.1.2 Clinical benefit, side effects and cost-effectiveness of ICD 
therapy 
ICDs are clearly effective in terminating life-threatening ventricular 
arrhythmias, and the overall survival benefit of ICD demonstrated by two 
landmark clinical trials, MADIT-II and SCD-HeFT, has translated into clinical 
guidelines and practice.31, 32 Prophylactic implantation of ICDs has been 
recommended in patients with HF who have NYHA class II-III symptoms and a 
LVEF ≤35%, irrespective of aetiology.1, 2, 187 It is noteworthy that the evidence of 
benefit is less robust for patients with non-ischaemic cardiomyopathy. The 
DEFINITE trial, the single largest trial in non-ischaemic cardiomyopathy before 
the DANISH trial, included 458 such patients who had a LVEF <36% (mean 21%) 
and NYHA class I-III (21.6% in class I) symptoms, and only found a trend in 
reduction in overall mortality by ICD treatment (HR 0.65, 95% CI 0.40-1.06, 
p=0.08).33 As a result, the current European guideline recommendations for non-
ischaemic cardiomyopathy are additionally based on a meta-analysis of 5 trials 
as well as the non-ischaemic cardiomyopathy subgroup in SCD-HeFT.32, 34  
Since the conduction of SCD-HeFT, there has been an increasing use of guideline 
recommended medications such as beta-blockers and MRAs. The proportion of 
patients having received a beta-blocker was over 90% in the contemporary trials 
such as PARADIGM-HF and DANISH compared to 69% in SCD-HeFT; the use of a 
MRA was much higher in PARADIGM-HF and DANISH (close to 60%) than SCD-HeFT 
(19%).27, 32, 35 Besides, there has been an introduction of novel therapies such as 
CRT and sacubitril/valsartan.35, 58 In contrast to ICDs which have no effects on 
ameliorating arrhythmic substrates or improving cardiac function, these HF 
medications and CRT can target upstream drivers of arrhythmic risk such as 
adverse left ventricular remodelling, and provide survival benefits for both 
arrhythmic and non-arrhythmic deaths.188, 189 Consequently, these advances in 
HF therapy has translated into falling risks of overall mortality and sudden death 
alike. As shown in Chapter 3, now the absolute risk of sudden death is relatively 
low at around 2% at 6 months and 9% by 3 years in patients who have been 
treated with current guideline-recommended medications.  
Doubt may arise that now the benefit of ICD therapy from reducing sudden death 
may not be large enough to translate into an overall survival benefit. This view is 
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further reinforced by the findings from the very recent DANISH trial,35 which 
showed no overall survival benefit of ICD treatment (HR 0.87, 95% CI 0.68-1.12, 
p=0.28) in patients with non-ischaemic cardiomyopathy with high use rates of 
evidence-based medications and CRT, although sudden death was reduced by a 
half (HR 0.50, 95% CI 0.31-0.82, p=0.005). Of note, an interaction between age 
and the survival benefit was observed, as in patients younger than 68 years there 
was a significant reduction in all-cause mortality with ICD therapy (HR 0.64, 95% 
CI 0.45-0.90, p=0.01). The findings reflect two features of the trial. First, the 
rates of sudden death and overall mortality were low, with annual rates of 1.8 
and 5.0 per 100 patient-years respectively in the control group. This is because 
patients with non-ischaemic cardiomyopathy in nature have lower risks of 
sudden death and all-cause death than do patients with an ischaemic cause of 
HF, and the low background risks were further reduced by comprehensive 
evidence-based treatment in the trial. Second, the competing risk of death from 
non-sudden causes was high, as 27% of all deaths in the control group were 
attributed to a non-CV cause, one of the highest proportions ever described in a 
HF trial.42 This is likely because the trial enrolled more elderly patients (mean 
age of 64 years) and had a longer follow-up (median 67.6 months) than did any 
previous ICD trial (taking SCD-HeFT for example, the figures were 60 years and 
45.5 months respectively). The competing risk of non-sudden deaths becomes 
more frequent with age and with an increasing number of comorbidities, and 
there is more likely to be a shift towards less sudden death (i.e. more non-
sudden CV deaths and non-CV deaths) along with follow-up as HF advances and 
patients age. This is echoed by the differential response by age as the overall 
survival benefit was not observed in the older but younger subgroup, and the 
convergence of the survival curves in the control and ICD arms at 6 years after 
randomisation. 
In patients with ischaemic cardiomyopathy who are treated with modern optimal 
therapies, will the overall survival benefit remain robust or become non-
significant? The answer may lie in the RESET-SCD (REevaluation of optimal 
treatment Strategies for prEvenTion of Sudden Cardiac Death in patients with 
ischemic cardiomyopathy) study, a trial similar to DANISH to explore the role of 
ICD in patients with ischaemic cardiomyopathy and who are treated with modern 
optimal therapy.190 
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Prophylactic implantation of an ICD is not like an “insurance policy”, as patients 
who do not benefit from device therapy are still exposed to procedural and 
device associated complications, such as infection early after insertion, and 
later adverse outcomes including inappropriate shocks and device malfunction 
leading, in some patients, to diminished quality of life.191 Inappropriate ICD 
activations, commonly caused by supraventricular tachycardia, sinus tachycardia 
or abnormal sensing, have adverse effects on psychological well-being, worsen 
quality of life, and even lead to lethal outcomes.192, 193 In old ICD trials, the 
reported inappropriate shocks were frequent, occurring in 10% to 24% of patients 
and accounting for 25% to 35% of all ICD shocks.194 Although advances in ICD 
programming have significantly reduced the risk of inappropriate therapy,195 
there were still about 6% of patients having inappropriate shocks after 
implantation in the contemporary trials.35, 195 Based on a recent nationwide 
analysis of complications after primary prevention ICD implantation in 
ambulatory patients with left ventricular dysfunction in the US,138 the device-
related mortality rate was reported to be 0.73% at 30 days, with a total serious 
complication rate of 8.4%. These figures are comparable to the sudden death 
rates in patients with HF-REF who had a high adoption of modern guideline 
recommended treatment shown in this thesis (about 0.4% at 30 days and around 
9% at 3 years). Therefore, there is a need for better risk stratification of sudden 
death and identify a high-risk subgroup in whom ICDs would confer greater 
benefit than harm to a patient. 
ICD therapies are costly, and the average cost for an ICD (CRT-D) device alone is 
estimated to be £9692 (£12,293) in the UK, not including other associated 
medical costs such as implant procedure, hospital admission, device-related 
complications and device replacement.196 Primary prevention ICD implantation 
can pose an immense economic burden on the healthcare systems, owing to the 
high cost of the device and the large patient population in which it can be 
applied. Therefore, the cost-effectiveness of this therapy must be considered.  
The estimate of cost-effectiveness of a therapy depends on the within-trial 
efficacy and costs, and the projected effectiveness and costs beyond trial 
follow-up. Based on the results from 6 clinical trials that showed survival benefit 
of ICD treatment, the projected life expectancy increment with an ICD ranged 
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from 1.01 quality-adjusted life years (QALY) in SCD-HeFT to 2.99 QALY in MUSTT 
(Multicenter Unsustained Tachycardia Trial), at a cost between $34,000 per 
QALY gained in MUSTT to $70,200 per QALY gained in SCD-HeFT.197 These 
estimates were based on a fundamental assumption that an ICD had a constant 
effect on survival after 7 years, which has not been supported by data.197 The 
survival curves for the ICD and control arms converged at 6 years in the DANISH 
trial,35 and this is conceivable given that with time patients aged and were more 
likely to be comorbid with other medical conditions and subsequently die from 
causes other than sudden death, leading to a diminished benefit of an ICD. 
Indeed, cost-effectiveness is not an inherent property of any particular therapy 
but depends on the patient population in which the therapy is used, as does the 
clinical effectiveness of a therapy. In SCD-HeFT, there was a significant 
interaction between NYHA class and the cost-effectiveness of ICD treatment: 
cost-effectiveness was only observed in patients in NYHA class II ($29872 per 
life-year gained), but not in patients in NYHA class III in whom there was no 
incremental benefit but higher costs.198 This is conceivable given that in the 
SCD-HeFT there was also a difference in efficacy of ICD according to NYHA class: 
use of an ICD was associated with a 46% decreased risk of death in NYHA class II 
(HR 0.54, 95% CI 0.40-0.74, p<0.001), but had no effect on mortality in class III 
(HR 1.16, 95% CI 0.84-1.61, p=0.30).32 Similarly, in another study CRT-D was only 
cost-effective (with a threshold of £20,000 per QALY gained) in patients who had 
NYHA class I/II symptoms with QRS duration ≥150 ms and LBBB,199 in whom the 
evidence of survival benefit was most robust.3 
Collectively, the effect of ICD treatment on reducing sudden death is convincing, 
but given the declining risk of sudden death, the continuing high costs, the 
invasive nature and potential complications for the device, and population-
dependent cost-effectiveness, it is of clinical and societal importance to target 
ICDs to patients most likely to benefit (and to avoid unnecessary placement to 
those unlikely to benefit). Therefore, it is desirable to identify patients who are 
still at high risk for sudden death but are less likely to die from other causes, 
despite receiving modern guideline recommended treatment.  
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8.1.3 Models to predict sudden death  
The decision to implant an ICD for primary prevention, currently, is primarily 
based on LVEF, the dichotomisation of which as a risk stratification tool lacks 
both specificity and sensitivity.200 A reduced LVEF is not only a risk factor for 
sudden death but also for non-sudden death such as pump failure death, and 
only a small proportion of patients who had implanted a defibrillator received 
ICD therapy, i.e. a considerable number of patients died from other causes not 
preventable by an ICD.32 On the other hand, the majority of patients who 
experienced sudden death do not have a reduced LVEF.173 Therefore, either 
from a therapeutic or health-economic perspective, there is an unmet need for 
better risk stratification of sudden death in HF-REF and HF-PEF populations. In 
patients with HF-REF, identification of high-risk subgroups would help target the 
device therapy to those most likely to benefit and identifying low-risk subgroups 
would avoid unnecessary implantation, thus improving the cost-effectiveness of 
the therapy. In patients with HF-PEF, identifying high-risk subgroups would 
enable further research into the efficacy of ICD therapy and optimise potential 
for therapeutic success in this population. 
A multivariable risk model can provide a more nuanced and reliable risk 
estimation than a single risk stratifier. There are few models available to predict 
mode-specific death, and the details of their characteristics have been 
summarised in the literature review; however, they all have major limitations 
for the consideration of use in clinical practice. Apart from statistical 
inadequacy such as having small number of events and no validation, most 
models were developed in historic cohorts with few patients having received 
modern guideline recommended therapies and did not consider the competing 
risk of death from non-sudden causes. Current guidelines recommend ICD 
implantation only if the LVEF fails to increase to >35% after a sufficient time (≥3 
months) of optimal medical therapy.3 The residual risk of sudden death is lower 
in patients who have received modern evidence-based medications than those 
have not. Consequently, the historic models based on cohorts with a few 
patients having received modern evidence-based therapies may discriminate 
poorly between high- and low-risk patients in a modern cohort, thus offering 
little aid in guiding ICD implantation. In keeping with this, the annual rate of 
sudden death was much lower in the contemporary PARADIGM-HF and 
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ATMOSPHERE trials than the SHFM cohort (3.4 vs. 6.1 per 100 patient-years), and 
conceivably, the SHFM had a substantial decrease in discrimination in both 
modern cohorts. 
Moreover, the prognostic influence of death from other causes can no longer be 
ignored, given that the residual risk of sudden death has declined along with the 
increasing use of modern evidence-based medications in HF-REF or the changing 
patient characteristics in HF-PEF, and consequently death from non-sudden 
causes has been making greater contribution to total mortality. This view was 
reinforced by the age variation of ICD benefit in the DANISH trial: ICDs were very 
effective in patients aged <68 years but had no effect on mortality in those aged 
≥68 years. This may reflect the higher competing risk of death from other causes 
in the older subgroup who were more likely to live with multiple comorbidities 
especially over long-term follow-up. In a sense, the models I developed have a 
unique strength to account for the competing risk of death from other causes.  
The purpose of risk prediction for sudden death is to aid in decision making in 
ICD use. It is noteworthy that a high absolute risk of sudden death does not 
necessarily translate into the survival benefit of an ICD, which can be offset by a 
high competing risk of non-sudden deaths.188 Accordingly, the concept of 
proportional risk (instead of absolute risk) of sudden death was proposed, and a 
bimodal system for risk prediction of sudden death was developed by coupling 
the proportion of sudden death to total mortality with the absolute risk of total 
mortality.74 This bimodal system has been shown to stratify patients with 
different sizes of benefit from ICDs: patients with lower risk of total mortality 
and higher proportional risk of sudden death showed the greatest benefit from 
ICDs, and patients with lower risk of total mortality and lower proportional risk 
of sudden death showed no benefit from ICDs; however, it is not intuitive to find 
that patients with higher risk of total mortality but low proportional risk of 
sudden death (i.e. absolute risk of sudden death remained high) were still 
predicted to benefit from ICDs.157 This may be explained by the finding from the 
same authors which showed that an increase in the risk of total mortality is 
associated with a decrease in the proportional risk but an increase in the 
absolute risk of sudden death.84 Therefore, it may provide greater clarity to 
directly model the absolute risk than the proportional risk of sudden death. 
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Although the sudden death model I developed in HF-REF showed good 
performance and had counted for the competing risks of non-sudden deaths, it 
needs to be examined if the risk model can stratify patients with different 
magnitudes of survival benefit from ICDs in existing ICD trials in HF-REF, and if 
ICDs can demonstrate survival benefit in the high-risk subgroup identified from 
the sudden death models in both HF-REF and HF-PEF populations in future trials.  
Decision making in ICD implantation involves not only estimating the predicted 
risk of sudden death and therefore the potential benefit from an ICD, but also 
the device-related harms including side-effects and costs. These estimates may 
all vary in importance between individual patients, their clinicians, and in 
different health care systems. Different weights of benefit and harm may be 
given to these risks by a specific decision maker (e.g. a patient and/or a clinical 
team, or policy makers).201 One patient may consider a sudden death to be 50 
times worse than the potential harms of an ICD, whereas another patient may 
rank these risks differently (e.g. 5 time worse). My model offers an alternative 
to the two extreme choices that can currently be made - a “treat all” strategy 
(for example in the US) where every patient with the indication is considered for 
an ICD versus a “treat none” strategy where no patient is treated because the 
cost of treating every patient with the indication is unaffordable for the health 
care system. To make an informed choice about ICD therapy, it is important to 
accurately estimate the predicted risk of sudden death and try and integrate this 
with the different assessments of benefit and harm. The results from these 
estimates can then be compared to a “treat all” and a “treat none” strategy. 
From there is then possible to assess the potential of a more targeted approach 
to ICD implantation and the benefits and harms versus a “treat none” strategy 
(no benefit and no harm) and a “treat all’ strategy (maximal benefit but 
maximal harm). These decisions are complex and difficult to integrate into a 
single measure. More recently decision curve analysis has been proposed as a 
method to integrate these different facets of decision making and I aim to assess 
these aspects of my model in future analyses using the decision curve analysis 
method.202, 203  
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8.1.4 VADs and heart transplantation, and models to predict 
pump failure death  
For patients with refractory end-stage HF, there is a consensus that heart 
transplantation is the gold standard treatment, which offers markedly improved 
long-term survival and increases functional status and quality of life.204 
Nevertheless, heart transplantation is a limited option, given the number of 
patients on the transplant waiting list far outnumber the heart donors. Besides, 
this operation is not without complications such as infection early after 
transplantation, and adverse effects of immunosuppressive therapy in the long 
term.2, 3, 204 VAD support was initially used as a short-term bridge to transplant, 
and recent data suggested that VADs may have improved the prognosis of 
patients on the transplant waiting list.205 Given the expanded waiting lists for 
heart transplant with prolonged waiting time, VADs have increasingly emerged as 
a permanent therapeutic option and an alternative to heart transplantation.2, 3 
Pump failure death increases with increasing severity of HF, and pump failure 
death is the predominant mode of death in patients with severe HF.7, 63 In a 
sense, assessing the risk for pump failure death is of clinical importance in 
helping with decision making in VAD therapy, heart transplantation, and 
planning palliative and end of life care. Besides, as the second most common 
mode of death, pump failure death can be regarded as the single largest 
competing risk for sudden death; therefore, understanding the risk of pump 
failure death may also help make decisions on ICD implantation or when to 
deactivate implanted ICDs.  
The models I developed here to predict the risks of pump failure death in HF-REF 
and HF-PEF showed excellent discrimination and calibration with robust results 
in external validation. These models can be considered for use in risk prediction 
in similar patients with ambulatory HF. If a patient were predicted at high risk 
for pump failure death, close monitoring of symptoms and signs of congestion 
and early management of comorbidities that contribute to worsening HF such as 
renal dysfunction can be implemented, relevant interventions such as VADs and 
heart transplantation can be considered and consulted, and supportive network 
and palliative options can be offered. On the other hand, if a patient were 
predicted at low risk of pump failure death, these specific medical attention and 
efforts and relevant medical resources may be saved.  
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8.2 Limitations of the studies 
As with all studies, there are limitations. Firstly, the results of these studies are 
based on clinical trial cohorts, in which patients have met specific eligibility 
criteria, and consequently tend to be younger, and have less comorbid 
conditions than the real-world unselected population. Besides, trial participants 
are more likely to receive optimal (i.e. class and dose) guideline recommended 
therapies, given that they have greater access to medical care, and undergo 
more frequent evaluation of medical compliance. Therefore, the results may not 
truly reflect the real-world scenario. However, few observational studies have 
sophisticated classification of mode-specific death to make these analyses 
possible, let alone detailed patient characterisation and follow-up to allow more 
complete multivariable adjustment. Besides, it is in patients similar to those 
included in these studies (younger, less comorbid and on optimal therapy) that 
ICDs are most clearly indicated or most likely to be investigated in trials.  
Secondly, the trials included in these analyses did not share a uniform definition 
of sudden death. This is not surprising given that these trials were conducted 
before the recent introduction of standardised definitions of endpoints used in 
clinical trials proposed by the ACCF/AHA in collaboration with the US FDA.46 
Additionally, sudden death is often solely attributed to lethal ventricular 
tachyarrhythmias but clearly some deaths that occur suddenly are caused by 
other cardiac and non-cardiac events, e.g. acute myocardial infarction, 
pulmonary embolism, aortic dissection or stroke. It remains challenging to 
ascertain cause-specific death in the absence of post-mortem examination and 
rhythm monitoring. Fortunately, all sudden death events in each included trial 
were adjudicated by an independent committee according to pre-specified 
criteria and this should have reduced bias and variation within and between 
trials. 
Thirdly, in my thesis time from randomisation instead of time since HF diagnosis 
was used as the underlying time scale, in other words, the patients examined 
were the “natural survivors” by the time of randomisation. This may be less 
likely to reflect the risks of sudden death and pump failure death in the time 
course of HF progression. Nevertheless, 12 out of the 16 trials provided 
information on the length of time between diagnosis of HF and randomisation, 
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by which the risk of mode-specific death from randomisation was further 
examined.  
Fourthly, models to predict sudden death remain less discriminative than models 
for pump failure death, in line with previous findings,78, 79 suggesting the risk 
stratification for sudden death is more difficult. This is plausible given that even 
when due to a ventricular tachyarrhythmia, sudden death can be the result of a 
various pathophysiological events, such as an acute ischaemic event caused by 
plaque rupture or a sudden change in repolarisation caused by electrolyte shifts, 
and these upstream events may be associated with heterogeneous risk factors, 
demonstrating the challenge of identifying uniform predictors of sudden death. 
This highlights an unmet need to further improve the risk stratification for 
sudden death. Some promising variables have been found predictive of sudden 
death, but were not collected in the trials included here such as cardiac imaging 
parameters, 24-h Holter monitoring, and other novel biomarkers. For example, 
studies have showed that the presence and volume of myocardial scar and 
fibrosis detected with late gadolinium enhancement on CMR is predictive of 
sudden death and appropriate ICD therapy in patients with left ventricular 
dysfunction.184, 206, 207 Similarly, abnormalities in cardiac sympathetic innervation 
detected by 123I-MIBG scintigraphy have also shown to be prognostic of sudden 
death.208, 209 The addition of these predictors may further improve the model 
performance. On the other hand, it needs to be examined if the addition would 
improve the decision making in ICD use to a degree that would justify the 
additional costs and complexity. 
Furthermore, the predictive models are derived and validated in predominantly 
white populations. Therefore, revalidation and further re-calibration strategies 
are necessary before it can be applied to other ethnic groups, as well as other 
cohorts with different characteristics and inherent risks.  
Finally, it must be acknowledged that even if mode-specific death were 
appropriately classified and accurately estimated, a gap may still lie in between 
the predicted risk and the response to device therapy. 
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8.3 Future areas of research  
The set-up and ongoing prospective, multicentre, international HF registries 
provide us an important step towards a better understanding of clinical 
presentation and prognosis of HF in the real-world patients, such as the 
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT-
R)210 and the Global Congestive Heart Failure Registry (G-CHF) (ClinicalTrials.gov 
Identifier: NCT03078166). In order to advance the research in the area of mode-
specific death, sophisticated reporting schema for mode-specific death needs to 
be widely introduced in observational studies and to be standardised across 
clinical trials. To accrue sufficient information for this purpose, wide-scale 
systematic autopsy, improved capture and surveillance surrounding death, and 
long-term rhythm monitoring may better clarify the underlying pathology and 
mechanisms driving mortal events. The emerging use of post-mortem imaging 
such as CT scanning and CT angiography may detect non-arrhythmic causes of 
death that occur suddenly such as myocardial infarction, cerebral events and 
pulmonary embolism, which may help identify sudden non-arrhythmic death.211, 
212 On the other hand, implantable loop recorders may help characterise the true 
burden of sudden death in HF that is caused by ventricular tachyarrhythmias 
amenable to ICD therapy, as is the objective of the ongoing Ventricular 
Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart 
Failure with Preserved Ejection Fraction (VIP-HF) trial (ClinicalTrials.gov 
Identifier NCT01989299). It would be of interest to compare the rates of sudden 
death in the HF-PEF trials I examined here with the incidence of ventricular 
tachyarrhythmia to be reported in the VIP-HF study.  
The prognostic models for sudden death I developed here have shown reasonable 
discrimination, good calibration, and robustness in external validation. 
Nevertheless, there is still room for further improvement in risk stratification, 
given the high costs and potential complications of ICD therapy. There have 
emerged some promising cardiac imaging parameters in risk classification of 
sudden death including late gadolinium enhancement on CMR and 123I-MIBG 
score. There are two ongoing clinical trials to examine their roles in guiding the 
decision of ICD implantation, i.e. the Cardiovascular magnetic resonance-GUIDEd 
management of mild to moderate left ventricular systolic dysfunction (CMR 
GUIDE) trial and the International Study to Determine if AdreView Heart 
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Function Scan Can be Used to Identify Patients With Mild or Moderate Heart 
Failure (HF) That Benefit From Implanted Medical Device (ADMIRE-ICD) (Clinical 
trials.gov identifier NCT01918215 and NCT02656329, respectively). However, 
these imaging techniques are expensive, especially considering repeated imaging 
for risk re-evaluation, and not without contraindications. It would be clinically 
important and economically sensible to examine their incremental prognostic 
value in addition to the sudden death models using routinely obtained variables.   
A high risk of sudden death does not necessarily translate into the survival 
benefit of ICD treatment. This highlights the need to examine the performance 
of the sudden death model in stratifying the survival benefit from ICD therapy. 
In the next step, I will apply the sudden death model to patients with HF-REF 
randomised in ICD trials, to examine its performance in risk classification of 
sudden death in the control groups (i.e. external validation) and to evaluate to 
what extent the correlation (if any) between the risk of sudden death predicted 
by the model and survival benefit of ICDs. Besides, there is a need for further 
exploration if ICDs can demonstrate survival benefit in the high-risk subgroup 
identified from the sudden death model in HF-PEF populations in future trials. 
The goal of developing risk models for sudden death in HF-REF is to personalise 
prophylactic use of ICD therapy for the benefit of patients and society, by 
targeting the device to those most likely to benefit and avoiding unnecessary 
placement thereby improving its cost-effectiveness. It is important to examine 
the likelihood of unnecessary implantation based on the risk estimation from the 
sudden death model I have developed compared to a “treat none” strategy 
regardless of the predicted risk, and the chance of missing out on the benefit of 
an ICD and then comparing this to a “treat all” strategy. I will examine these 
clinical aspects of the model in future study.   
In the digital era, mobile devices have become commonplace in health care 
settings. Developing software applications of the risk models for a range of 
platforms (e.g. iOS, Android, Windows Phone and Web) would simplify the use 
and promote the application of the prognostic models. 
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8.4 Conclusions 
The conclusions and outcomes of the analyses presented in this thesis can be 
summarised as follows: 
The risks of sudden death and pump failure death in patients with HF-REF have 
fallen across 13 clinical trials conducted over the period 1995-2015, in parallel 
with a cumulative use of evidence based therapies in this population.  
The absolute rates of sudden death and pump failure death were very low in the 
early follow-up after randomisation in patients with HF-REF receiving modern 
guideline recommended treatment.  
Longer standing HF was associated with greater risks of sudden death and, 
particularly, pump failure death in patients with HF-REF. 
The sudden death and pump failure death models in HF-REF developed in the 
largest and most contemporary cohort (PARADIGM-HF), included a number of 
variables collected in routine clinical practice, and accounted for the prognostic 
impact of the competing risk of death from other causes. Both models showed 
good calibration and were robust when externally validated in ATMOSPHERE; the 
discriminating ability was excellent for the pump failure death model but 
modest for the sudden death model, suggesting further effort is needed to 
improve the risk stratification of sudden death.  
The risks of sudden death and pump failure death were consistently low across 
the three largest clinical trials in patients with HF-PEF, with little difference by 
experimental treatment in any trial. There was a downward trend in the rates of 
sudden death and pump failure death across these trials over time, parallel with 
a changing characteristic of patients enrolled in these trials; nevertheless, 
sudden death and pump failure death remained the most common modes of 
death, altogether accounting for the majority of CV death. The absolute rates of 
sudden death and pump failure death in patients with HF-PEF were extremely 
low in the early follow-up after randomisation. Longer standing HF was 
associated with a slightly higher risk of sudden death and a substantially higher 
risk of pump failure death in HF-PEF. 
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The prognostic models in patients with HF-PEF enrolled in I-PRESERVE, using 
simple demographic and clinical variables showed good discrimination and 
calibration for both sudden death and pump failure death, and remained robust 
in external validation in CHARM-Preserved and TOPCAT. Including NT-proBNP 
further improved the performance of both models. 
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Appendices 
Appendix Table 1  Search strategy and result in MEDLINE 
No Search term Number of items 
1 exp Ambulatory Care/ 49727 
2 exp Outpatients/ 12797 
3 (ambulatory or stable or chronic or out-patient or outpatient).mp. 1609708 
4 1 or 2 or 3 1614062 
5 exp Heart Failure/ 104687 
6 ((heart or cardiac) adj2 failure).ti,ab. 131648 
7 5 or 6 164798 
8 exp Death/ 136807 
9 exp Mortality/ 333648 
10 exp Survival/ 4477 
11 (death or mortality or survival).ti,ab. 1483216 
12 (sudden death or sudden cardiac death or unexpected death or arrhythmi# 
death).mp. 
30715 
13 ((death or mortality or die) adj3 (heart failure or pump failure)).mp.  5293 
14 (mode adj2 (death or mortality)).mp. 780 
15 8 or 9 or 10 or 11 or 12 or 13 or 14 1679583 
16 ((predict* or prognos*) and (scor* or model*)).mp. 519590 
17 (risk stratif* or risk classif* or risk scor*).mp. 30117 
18 16 or 17 537771 
19 4 and 7 and 15 and 18 2424 
20 limit 19 to (english language and humans and "all adult (19 plus years)") 2046 
Footnote:  
Database: Ovid MEDLINE (R) 1946 to April week 1 2017  
Last update date: 17-04-2017 
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Appendix Table 2  Search strategy and result in Embase 
No. Search term Number of items 
1 exp Ambulatory Care/ 47720 
2 exp Outpatients/ 133284 
3 (ambulatory or stable or chronic or out-patient or outpatient).mp. 2520351 
4 1 or 2 or 3 2520351 
5 exp Heart Failure/ 442568 
6 ((heart or cardiac) adj2 failure).ti,ab. 234676 
7 5 or 6 470546 
8 exp Death/ 833765 
9 exp Mortality/ 1018689 
10 exp Survival/ 990656 
11 (death or mortality or survival).ti,ab. 2366925 
12 (sudden death or sudden cardiac death or unexpected death or arrhythmi# 
death).mp. 
67645 
13 ((death or mortality or die) adj3 (heart failure or pump failure)).mp. 10081 
14 (mode adj2 (death or mortality)).mp. 1215 
15 8 or 9 or 10 or 11 or 12 or 13 or 14 3046449 
16 ((predict* or prognos*) and (scor* or model*)).mp. 781626 
17 (risk stratif* or risk classif* or risk scor*).mp. 65813 
18 16 or 17 820548 
19 4 and 7 and 15 and 18 6642 
20 limit 19 to (human and English language and Embase and (adult <18 to 64 
years> or aged <65+ years>)) 
2650 
Footnote: 
Database: Ovid Embase 1947-Present, updated daily  
Last update date: 17-04-2017 
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Appendix Table 3  Data extract form 
Key aspects Description (if needed) 
Study characteristics 
 
❖ Source of data 
 
• Patient records (retrospective) 
 
• Prospective cohort study or registry data 
 
• Clinical trial database 
 
❖ Region of study and number of centres 
 
❖ Data collection period (average follow-up)  
❖ Sample size 
 
Patient characteristics 
 
❖ LVEF and NYHA class LVEF: reduced, preserved, mixed, unspecified 
❖ Mean age and proportion of men 
 
❖ Treatment ACEI/ARB, beta-blocker, MRA and device 
Outcomes 
 
❖ Number of events 
 
❖ Definition of outcomes  
 
❖ Event adjudication  Investigator reported or event committee adjudication 
Model construction 
 
❖ Regression model 
 
• Cox proportional hazards regression Dependent variable: time to event, treating death from 
other causes as independent (i.e. non-informative) 
censoring. 
• Logistic regression Dependent variable: event (yes/no) 
• Competing risk analysis Dependent variable: time to event, treating death from 
other causes as informative censoring. 
❖ Variable selection 
 
• Not parsimonious Inclusion of all variables achieving a cut-off p value at 
univariate analysis 
• Parsimonious  Stepwise selection 
❖ Candidate and final variables 
 
Model validity 
 
❖ Model over-fitting The number of events divided by the number of final 
predictors <10 
❖ Model assumption Proportional hazards for Cox regression 
Model performance 
 
❖ Discrimination  
 
• Harrell’s C statistic 
 
• ROC AUC 
 
❖ Calibration  
 
• Hosmer-Lemeshow test Goodness of fit test for logistic regression or at a 
certain time point for Cox regression 
• Calibration curve Graphical display of the observed vs. predicted 
incidence for specific ranges of risk over time 
❖ Validation  
 
• Internal Split study samples 
• External Independent populations 
Missing data 
 
❖ Complete case analysis Drop patients with incomplete data 
❖ Simple imputation Replace missing data with an average value  
❖ Multiple imputation Replace missing data with a plausible value derived 
from the distribution of the other ones 
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Appendix Table 4  Design and characteristics of the trials that were eligible but not obtained in HF-REF 
  
  
PRAISE 1 
(N=1153) 
ATLAS 
(N=3164) 
PRAISE 2 
(N=1654) 
COMET 
(N=3029) 
ELITE II 
(N=3152) 
COPERNICUS 
(N=2289) 
AF-CHF 
(N=1376) 
HEAAL 
(N=3846) 
STICH 
(N=1212) 
SHIFT 
(N=6505) 
Comparison Amlodipine Lisinopril high 
dose 
Amlodipine Carvedilol Losartan Carvedilol Rhythm 
control 
Losartan high 
dose 
CABG + medical 
therapy 
Ivabradine 
 
Placebo Lisinopril low 
dose 
Placebo Metoprolol Captopril Placebo Rate control Losartan low 
dose 
Medical therapy Placebo 
Study period 1992.03-
1994.12 
1992.10-
1997.09 
1995.12-
2000.01 
1996.12-
2002.11 
1997.06-
1999.07 
1997.10-
2000.03 
2001.05-
2007.06 
2001.11-
2009.03 
2002.07-
2010.11 
2006.10-
2010.03 
Average follow-up  13.8 months - 33 months 58 months 1.5 years 10.4 months 37 months 4.7 years 56 months 22.9 months 
Site distribution 105 sites 287 sites in 19 
countries 
- 317 sites in 15 
European 
countries 
289 sites in 
46 countries 
334 sites in 21 
countries 
123 sites in 
Canada, the 
US, Argentina, 
Brazil, Europe, 
and Israel 
255 sites in 30 
countries 
127 sites in 26 
countries 
677 sites in 
37 countries 
Inclusion criteria 
          
  Age -years ≥18 ≥18 ≥18 ≥18 ≥60 ≥18 ≥18 ≥18 ≥18 ≥18 
  NYHA class IIIB-IV II-IV III-IV II-IV II-IV III-IV I-IV II-IV I-IV II-IV 
  LVEF-% <30 ≤30 <30 ≤35  ≤40 <25 ≤35  ≤40 ≤35  ≤35  
  HF hospitalisation - ER visit or 
hospitalisation 
for HF within 
last 6 months if 
NYHA class II 
- - - - HF 
hospitalisation 
within last 6 
months if 
LVEF not 
≤25% 
- - HF 
hospitalisation 
within last 12 
months  
  Others - - non-ischaemic 
cardiomyopathy 
- - - a history of 
atrial 
fibrillation 
intolerance to 
ACEIs 
CAD suitable for 
revascularisation 
sinus rhythm 
with resting 
heart rate ≥70 
beats/min 
Exclusion criteria 
          
  Creatinine -umol/L >270 >220 >265 - >220 >247.5 - >220 - - 
  Systolic BP -mmHg <85 or >159 - <85 or >160 <85 <90 <85 - <90 - symptomatic 
hypotension 
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  Potassium -mmol/L <3.5 or >5.5 - <3.5 or >5.5 - - <3.5 or >5.2 - <3.5 or >5.7 - - 
  Heart rate -beats/min - - - <60  - <68  - - - - 
Baseline treatment (%) 
          
  ACEI 99 89 100 91 50 NR 86 0 82 79 
  ARB NR NR NR 7 50 NR 11 100 9 14 
  ACEI or ARB NR NR NR NR NR 97 NR NR 90 NR 
  Beta-blocker NR 11 NR 100 22 50 79 72 85 89 
  MRA NR NR NR 11 22 19 45 38 46 60 
  ICD NR NR NR NR NR NR 7 NR 2 3 
Mortality events           
No. of all-cause death 413 1383 540 1112 530 425 445 1300 462 1055 
No. of sudden death  185 589 NR 479 231 114 159 481 173 451 
Proportion of sudden 
death relative to total 
mortality (%) 
44.8 42.6 - 43.1 43.6 26.8 35.7 37.0 37.4 42.7 
No. of pump failure 
death 
165 445 NR 365 99 NR 130 314 82 264 
Proportion of pump 
failure death relative 
to total mortality (%) 
40.0 32.2 - 32.8 18.7 - 29.2 24.2 17.7 25.0 
 
NR denotes “not reported” and ‘-’ denotes data not available.   
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Appendix Table 5  Candidate variables and missing data in HF-REF 
 PARADIGM-HF 
(N=7156) 
ATMOSPHERE 
(N=5968) 
Demographics (N=4)   
Age -years 0 0 
Sex (male, female) 0 0 
Race (white, black, Asian, other)  0 38 (0.6%) 
Region (North America, Latin America, Western 
     Europe, Central Europe, Asia or Pacific region) 
0 0 
Clinical assessment (N=8)   
Body mass index 8 (0.1%) 16 (0.3%) 
Systolic BP -mmHg 0 2 (<0.1%) 
Diastolic BP -mmHg 0 1 (<0.1%) 
Heart rate -beats/min 0 0 
LVEF -% 1 (<0.1%) 0 
NYHA class (I, II, III, IV) 11 (0.2%) 0 
Aetiology (ischaemic, non-ischaemic) 0 0 
HF duration (within 1 year, >1-5 years, >5 years) 0 4 (0.1%) 
Medical history (N=14)   
Current smoking  0 0 
Previous HF hospitalisation 0 0 
Myocardial infarction  0 0 
Angina 0 0 
CABG or PCI 0 0 
Hypertension 0 0 
Diabetes 0 0 
Atrial fibrillation 0 0 
Stroke 0 0 
Cancer 0 0 
Asthma 0 0 
COPD 0 0 
AAA 0 0 
PAD 0 0 
Treatment (N=11)   
Digoxin 0 0 
Diuretic 0 0 
ACEI or ARB 0 0 
Beta-blocker 0 0 
MRA 0 0 
Any antiplatelet agent 0 0 
Aspirin 0 0 
Anticoagulant 0 0 
Statin 0 0 
Pacemaker 0 0 
CRT-P 0 0 
12-lead ECG (N=8)   
QRS duration -ms 103 (1.4%) 160 (2.7%) 
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Atrial fibrillation  0 61 (1.0%) 
Atrial flutter  0 61 (1.0%) 
Bundle branch block 0 61 (1.0%) 
Left bundle branch block 0 61 (1.0%) 
Right bundle branch block 0 61 (1.0%) 
Q wave 0 61 (1.0%) 
Left ventricular hypertrophy 0 61 (1.0%) 
Laboratory measurement (N=14)   
eGFR -ml/min/1.73 m2  0 1 (<0.1%) 
Creatinine -mg/dl 0 1 (<0.1%) 
BUN -mmol/L 138 (1.9%) 1 (<0.1%) 
Albumin -g/L 147 (2.1%) 7 (0.1%) 
Haemoglobin -g/L 229 (3.2%) 40 (0.7%) 
Potassium -mmol/L 152 (2.1%) 1 (<0.1%) 
Sodium -mmol/L 130 (1.8%) 1 (<0.1%) 
Chloride -mmol/L 125 (1.7%) 1 (<0.1%) 
Calcium -mmol/L 166 (2.3%) 8 (0.1%) 
Total cholesterol -mmol/L 161 (2.2%) 209 (3.5%) 
HDL-C -mmol/L 163 (2.3%) 210 (3.5%) 
LDL-C -mmol/L 331 (4.6%) 362 (6.1%) 
Triglyceride-mmol/L 161 (2.2%) 208 (3.5%) 
NT-proBNP -pg/ml 12 (0.2%) 560 (9.4%) 
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Appendix Table 6  Missing data in prediction variables for sudden death model and pump 
failure death model from PARADIGM-HF in ATMOSPHERE 
Sudden death model from PARADIGM-HF 
Male sex 0 
Asian race 38 (0.6%) 
Systolic BP -mmHg 2 (<0.1%) 
Ischaemic aetiology 0 
NYHA class 0 
CABG or PCI 0 
Cancer history 0 
Left ventricular hypertrophy on ECG 61 (1.0%) 
QRS duration -ms 160 (2.7%) 
NT-proBNP -pg/ml 560 (9.4%) 
Pump failure death model from PARADIGM-HF 
Systolic BP -mmHg 2 (<0.1%) 
LVEF -% 0 
NYHA class 0 
Ischaemic aetiology 0 
HF duration (>1-5 years, >5 years vs. within 1 year) 4 (0.1%) 
Bundle branch block on ECG 61 (1.0%) 
Creatinine -mg/dl 1 (<0.1%) 
Albumin -g/L 7 (0.1%) 
Chloride -mmol/L 1 (<0.1%) 
NT-proBNP -pg/ml 560 (9.4%) 
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Appendix Table 7  Missing data in prediction variables for SHFM and SPRM in PARADIGM-
HF and ATMOSPHERE  
PARADIGM-HF 
(N=7156) 
ATMOSPHERE 
(N=5968) 
Seattle Heart Failure Model (SHFM) 
Age -years 0 0 
Male sex 0 0 
LVEF -% 1 (<0.1%) 0 
NYHA class 11 (0.2%) 0 
Systolic BP -mmHg 0 2 (<0.1%) 
Ischaemic aetiology 0 0 
Weight adjusted diuretic dose 1504 (21.1%) 1362 (22.8%) 
Allopurinol 0 0 
Statins 0 0 
Sodium -mmol/L 130 (1.8%) 1 (<0.1%) 
Total cholesterol -mmol/L 161 (2.2%) 209 (3.5%) 
Haemoglobin -g/L 229 (3.2%) 40 (0.7%) 
Lymphocyte -% 356 (5.0%) 48 (0.8%) 
Uric acid -g/dl 160 (2.2%) 7 (<0.1%) 
ACEI 0 0 
ARB 0 0 
Beta-blocker 0 0 
K-Sparing diuretic 0 0 
Seattle Proportional Risk Model (SPRM) 
Age -years 0 0 
Male sex 0 0 
LVEF -% 1 (<0.1%) 0 
NYHA class 11 (0.2%) 0 
Systolic BP -mmHg 0 2 (<0.1%) 
Body mass index 8 (0.1%) 16 (0.3%) 
Diabetes 0 0 
Digoxin 0 0 
Creatinine -mg/dl 0 1 (<0.1%) 
Sodium -mmol/L 130 (1.8%) 1 (<0.1%) 
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Appendix Table 8 Design and characteristics of the clinical trials that were not eligible in 
HF-PEF  
DIG-PEF 
(N=988) 
SENOIRS-PEF 
(N=752) 
PEP-CHF 
(N=850) 
J-DHF 
(N=245) 
Comparison Digoxin Nebivolol  Perindopril  Carvedilol  
 
Placebo Placebo Placebo Placebo 
Study period 1991-1995 2000-2003 2000-2003 2004-2011 
Duration of follow-up mean 37 
months 
NA mean 2.1 years mean 3.2 years 
Site distribution 302 centres in 
the US and 
Canada 
11 European 
countries 
53 centres in 8 
countries 
Multicentre in Japan 
Inclusion criteria 
 
 
  
Age -years ≥21 ≥70 ≥70 ≥20 
NYHA class - - - - 
LVEF-% >45 >35 >40 >40 
HF hospitalisation - HF Hospitalisation 
within prior 12 
months if without 
a documented 
LVEF ≤35% within 
previous 6 months 
Hospitalisation for 
a CV reason 
within previous 6 
months 
- 
Exclusion criteria 
 
 
  
BP -mmHg - systolic BP <90 systolic BP <100 symptomatic 
hypotension 
Renal function serum 
creatinine >3.0 
mg/dl 
significant renal 
dysfunction 
serum creatinine 
>200 umol/L  
serum creatinine >3.0 
mg/dl or creatinine 
clearance ≤30 ml/min 
Potassium -mmol/L <3.2 or >5.5 - >5.4 >5.5 
Others - heart rate <60 
beats/min 
intolerant of 
ACEIs  
- 
Baseline treatment (%) 
 
 
  
ACEI 86 86 NA 23 
ARB NR 6 NR 54 
ACEI or ARB NR NR NR 71 
Beta-blocker NR NA 54 NA 
MRA 8 6 10 23 
CRT NR NR NR NR 
Mortality events  
 
 
  
All-cause death  231 107 109 39 
CV death  162 72 78 15 
Sudden death NR 27 NR NR 
Pump failure death 64 NR NR NR 
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Appendix Table 9 Candidate variables and missing data in HF-PEF  
Derivation cohort Validation cohorts 
 I-PRESERVE 
(N=4116) 
CHARM-
Preserved 
(N=2556) 
TOPCAT 
(N=3401) 
Demographics (N=3)    
Age -years 0 0 0 
Sex (male, female) 0 0 0 
Race (white, black, Asian, other) 0 0 0 
Clinical assessment (N=8)    
Body mass index 19 (0.5%) 8 (0.3%) 10 (0.3%) 
Systolic BP -mmHg 0 1 (<0.1%) 4 (0.1%) 
Diastolic BP -mmHg 0 1 (<0.1%) 4 (0.1%) 
Heart rate -beats/min 4 (0.1%) 1 (<0.1%) 3 (0.1%) 
LVEF -% 3 (0.1%) 0 1 (<0.1%) 
NYHA class (I-II, III-IV) 0 0 0 
Aetiology (ischaemic, hypertensive, other) 0 0 NA 
HF duration (≤1 year, >1-5 years, >5 years) 4 (0.1%) 1 (<0.1%) NA 
Medical history (N=13)    
Current smoking NA 0 4 (0.1%) 
Previous HF hospitalization within 6 months 0 0 0 
Myocardial infarction  0 0 3 (0.1%) 
Angina  0 0 3 (0.1%) 
CABG or PCI 0 0 3 (0.1%) 
Coronary artery disease 0 0 3 (0.1%) 
Hypertension 0 0 3 (0.1%) 
Diabetes 0 0 3 (0.1%) 
Atrial fibrillation 0 0 3 (0.1%) 
Stroke  0 0 3 (0.1%) 
Pacemaker 0 0 3 (0.1%) 
COPD or asthma 0 NA 3 (0.1%) 
Dyslipidaemia 0 NA 3 (0.1%) 
Treatment (N=12)    
Digitalis 3 (0.1%) 0 8 (0.2%) 
Diuretic 3 (0.1%) 0 8 (0.2%) 
Loop diuretic 3 (0.1%) 0 8 (0.2%) 
Thiazide diuretic 3 (0.1%) 0 8 (0.2%) 
ACEI or ARB 0 0 8 (0.2%) 
Beta-blocker 3 (0.1%) 0 8 (0.2%) 
MRA 3 (0.1%) 0 8 (0.2%) 
Calcium channel blocker 3 (0.1%) 0 8 (0.2%) 
Antiarrhythmic agent 3 (0.1%) 0 8 (0.2%) 
Antiplatelet 3 (0.1%) 0 8 (0.2%) 
Aspirin 3 (0.1%) 0 8 (0.2%) 
Lipid lowering agent 3 (0.1%) 0 8 (0.2%) 
ECG (N=6)    
QRS duration -ms 143 (3.5%) NA 93 (2.7%) 
Atrial fibrillation or flutter 0 12 (0.5%) 19 (0.6%) 
Bundle branch block  0 12 (0.5%) 19 (0.6%) 
Left bundle branch block 0 NA NA 
Right bundle branch block 0 NA NA 
Left ventricular hypertrophy  0 12 (0.5%) 19 (0.6%) 
Laboratory tests (N=15)    
Albumin -g/L 92 (2.2%) NA 178 (5.2%) 
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Aspartate aminotransferase -U/L 92 (2.2%) NA 46 (1.4%) 
Alanine aminotransferase -U/L 92 (2.2%) NA 41 (1.2%) 
Bilirubin -mg/dl 92 (2.2%) NA 61 (1.8%) 
Potassium -mmol/L 117 (2.8%) NA 4 (0.1%) 
Sodium -mmol/L 92 (2.2%) NA 6 (0.2%) 
Haemoglobin -g/L 140 (3.4%) NA 23 (0.7%) 
Haematocrit -% 140 (3.4%) NA 27 (0.8%) 
Leukocyte -109/L 140 (3.4%) NA 24 (0.7%) 
Neutrophil -109/L 164 (4.0%) NA NA 
Platelet -109/L 147 (3.6%) NA 35 (1.0%) 
Blood urea nitrogen -mg/dl 92 (2.2%) NA 771 (22.7%) 
Creatinine -mg/dl 89 (2.2%) 1634 (63.9%) 2 (0.1%) 
eGFR -ml/min/1.73m2 89 (2.2%) 1634 (63.9%) 2 (0.1%) 
NT-proBNP -pg/ml 646 (15.7%) NA 2786 (81.9%) 
NA denotes not available, referring to data being not collected. 
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